Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1 value | Author stringclasses 1 value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
35600.0 | 2023-07-21 00:00:00 UTC | Emergent's (EBS) Cyfendus Anthrax Vaccine Gets FDA Nod | ACAD | https://www.nasdaq.com/articles/emergents-ebs-cyfendus-anthrax-vaccine-gets-fda-nod | nan | nan | Emergent’s EBS shares were up more than 16% in after-market hours on Thursday, as the FDA approved Cyfendus, its anthrax vaccine for people aged between 18 and 65, who may have been exposed to bacillus anthracis, a harmful germ.
The vaccine, previously known as AV7909, has been approved for post-exposure prophylaxis of disease following suspected or confirmed exposure to the germ, Bacillus anthracis. It is taken with recommended antibacterial medications.
Since 2019, Emergent has been supplying AV7909 to the U.S. Department of Health and Human Services with pre-emergency use authorization status. The company plans to maintain its collaboration with the U.S. government to facilitate the shift toward post-approval procurement.
The biologics license application seeking approval for AV7909 was accepted for review by the FDA in April 2022. The regulatory approval of the Cyfendus vaccine was based on comprehensive data gathered from a couple of mid-late-stage studies conducted by EBS, supported and funded by the U.S. government.
A non-clinical study was also conducted to assess the vaccine's protective efficacy against lethal anthrax spore challenges and identify neutralizing antibody levels associated with disease protection.
Shares of Emergent have nosedived 40.2% year to date compared with the industry’s 8.6% decline.
Image Source: Zacks Investment Research
Cyfendus vaccine consists of anthrax vaccine, adsorbed along with an additional adjuvant, which has been shown to elicit protective levels of immune response when administered in two doses over 14 days. This rapid immune response can be particularly crucial in addressing large-scale public health emergencies involving anthrax.
In addition to Cyfendus, Emergent's anthrax franchise includes the BioThrax vaccine, licensed by the FDA for the general use prophylaxis and post-exposure prophylaxis of anthrax disease, and two treatments — Anthrasil (anthrax immune globulin intravenous - human), a polyclonal antibody therapeutic, and Raxibacumab, a monoclonal antibody therapeutic.
In May, the company completed the sale of its travel health business to Denmark’s biotechnology company, Bavarian Nordic. Per the agreement, Bavarian Nordic acquired rights to the drugs, Vaxchora and Vivotif, and the development-stage chikungunya vaccine candidate, CHIKV VLP, for a cash purchase price of $270 million.
Emergent Biosolutions Inc. Price and Consensus
Emergent Biosolutions Inc. price-consensus-chart | Emergent Biosolutions Inc. Quote
Zacks Rank and Stocks to Consider
Emergent currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks in the same industry are ADC Therapeutics ADCT, Acadia Pharmaceuticals ACAD and Akoya Biosciences AKYA, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 90 days, the Zacks Consensus Estimate for ADC Therapeutics has widened from a loss of $2.58 per share to a loss of $2.61 for 2023. The consensus estimate has narrowed from a loss of $2.72 per share to a loss of $2.45 for 2024 during the same time frame. Shares of the company have lost 60.9% year to date.
ADCT’s earnings beat estimates in three of the trailing four quarters and missed the mark in one, delivering an average surprise of 10.70%.
In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals has narrowed from a loss of 58 cents per share to a loss of 31 cents for 2023. Shares of the company have rallied 96.4% year to date.
ACAD’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average negative earnings surprise of 2.75%.
In the past 90 days, the Zacks Consensus Estimate for Akoya Biosciences has narrowed from a loss of $1.80 per share to a loss of $1.71 for 2023. The consensus estimate for Akoya Biosciences has narrowed from a loss of $1.57 per share to a loss of $1.33 for 2024 during the same time frame. Shares of the company have lost 27% year to date.
AKYA’s earnings missed estimates in each of the trailing four quarters, delivering an average negative surprise of 21.05%.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ADC Therapeutics SA (ADCT) : Free Stock Analysis Report
Emergent Biosolutions Inc. (EBS) : Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report
Akoya Biosciences, Inc. (AKYA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the same industry are ADC Therapeutics ADCT, Acadia Pharmaceuticals ACAD and Akoya Biosciences AKYA, each carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals has narrowed from a loss of 58 cents per share to a loss of 31 cents for 2023. ACAD’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average negative earnings surprise of 2.75%. | Some better-ranked stocks in the same industry are ADC Therapeutics ADCT, Acadia Pharmaceuticals ACAD and Akoya Biosciences AKYA, each carrying a Zacks Rank #2 (Buy) at present. Click to get this free report ADC Therapeutics SA (ADCT) : Free Stock Analysis Report Emergent Biosolutions Inc. (EBS) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Akoya Biosciences, Inc. (AKYA) : Free Stock Analysis Report To read this article on Zacks.com click here. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals has narrowed from a loss of 58 cents per share to a loss of 31 cents for 2023. | Click to get this free report ADC Therapeutics SA (ADCT) : Free Stock Analysis Report Emergent Biosolutions Inc. (EBS) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Akoya Biosciences, Inc. (AKYA) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the same industry are ADC Therapeutics ADCT, Acadia Pharmaceuticals ACAD and Akoya Biosciences AKYA, each carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals has narrowed from a loss of 58 cents per share to a loss of 31 cents for 2023. | Some better-ranked stocks in the same industry are ADC Therapeutics ADCT, Acadia Pharmaceuticals ACAD and Akoya Biosciences AKYA, each carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals has narrowed from a loss of 58 cents per share to a loss of 31 cents for 2023. ACAD’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average negative earnings surprise of 2.75%. |
35601.0 | 2023-07-21 00:00:00 UTC | Astria (ATXS) Rises 5% on Fast Track Tag for Angioedema Drug | ACAD | https://www.nasdaq.com/articles/astria-atxs-rises-5-on-fast-track-tag-for-angioedema-drug | nan | nan | Astria Therapeutics, Inc. ATXS announced that the FDA has granted fast track designation to its lead developmental candidate, STAR-0215, for the treatment of hereditary angioedema (HAE). Notably, HAE is characterized as a rare genetic disorder that causes severe unpredictable attacks of swelling throughout the body.
STAR-0215 is Astria’s monoclonal antibody, plasma kallikrein inhibitor, which is currently being evaluated in a phase Ib/II ALPHA-STAR study in HAE patients. Per the company, STAR-0215 has the potential to become the first-choice preventative treatment for people with HAE dosed once every three or six months. Treatment with STAR-0215 could benefit patients by improving their quality of life, thereby catering to a significant unmet medical need.
The stock of the company increased about 5% on Thursday in response to the encouraging regulatory update. Year to date, shares of Astria have plunged 33.8% compared with the industry’s 8.6% decline.
Image Source: Zacks Investment Research
The FDA’s fast track designations intend to expedite development and review timelines when preliminary nonclinical and clinical evidence indicates the drug may demonstrate substantial improvement over available therapies to address unmet medical needs for serious or life-threatening conditions. The fast track tag enables close communication between the FDA and sponsor to improve the efficiency of product development to get new therapeutics to patients faster.
Usually, companies, that receive the FDA’s fast track designation for a product candidate, can submit new drug application for such candidate on a rolling basis, which grants a faster review process of the application by the regulatory body. Additionally, drugs that receive fast track designation may be eligible for a priority review if certain criteria are met.
ATXS announced initiating the phase Ib/II ALPHA-STAR in February 2023. The study is enrolling patients with HAE types I and II. The early-mid-stage study will evaluate the safety and tolerability, changes in HAE attack rate, pharmacokinetics, pharmacodynamics and quality-of-life assessments, upon treatment with STAR-0215. Proof-of-concept results from the study are expected in mid-2024.
Per Astria, preliminary results from the phase Ia study in healthy subjects were coherent with STAR-0215’s target profile of being a long-acting preventative therapy, best-in-class pharmacokinetics profile and dosing once every three months or less frequently. Based on these encouraging results, the company plans to evaluate the potential for six-month administration of STAR-0215 in additional cohorts in the phase Ia study.
Preliminary data from the phase Ia additional cohorts are expected in the fourth quarter of 2023.
Astria Therapeutics, Inc. Price and Consensus
Astria Therapeutics, Inc. price-consensus-chart | Astria Therapeutics, Inc. Quote
Zacks Rank and Stocks to Consider
Astria currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks in the same industry are ADC Therapeutics ADCT, Acadia Pharmaceuticals ACAD and Akoya Biosciences AKYA, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 90 days, the Zacks Consensus Estimate for ADC Therapeutics’ 2023 loss per share has widened from $2.58 to $2.61. During the same period, the estimate for ADC Therapeutics’ 2024 loss per share narrowed from $2.72 to $2.45. In the past week, shares of ADCT have lost 36.7%.
ADCT beat estimates in three of the trailing four quarters, missing the mark on one occasion, delivering an average earnings surprise of 10.70%.
In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 58 cents to 31 cents. The estimate for Acadia Pharmaceuticals’ 2024 earnings per share is pegged at 47 cents. In the past week, shares of ACAD have risen 33.2%.
ACAD beat estimates in two of the trailing four quarters, missing the mark on other two occasions, delivering an average negative earnings surprise of 2.75%.
In the past 90 days, the Zacks Consensus Estimate for Akoya Biosciences’ 2023 loss per share has narrowed from $1.80 to $1.71. During the same period, the estimate for Akoya Biosciences’ 2024 loss per share narrowed from $1.57 to $1.33. In the past week, shares of AKYA have lost 1.1%.
AKYA missed estimates in each of the trailing four quarters, delivering an average negative earnings surprise of 21.05%.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How To Profit From Trillions On Spending For Infrastructure >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ADC Therapeutics SA (ADCT) : Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report
Akoya Biosciences, Inc. (AKYA) : Free Stock Analysis Report
Astria Therapeutics, Inc. (ATXS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the same industry are ADC Therapeutics ADCT, Acadia Pharmaceuticals ACAD and Akoya Biosciences AKYA, each carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 58 cents to 31 cents. The estimate for Acadia Pharmaceuticals’ 2024 earnings per share is pegged at 47 cents. | Some better-ranked stocks in the same industry are ADC Therapeutics ADCT, Acadia Pharmaceuticals ACAD and Akoya Biosciences AKYA, each carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 58 cents to 31 cents. Click to get this free report ADC Therapeutics SA (ADCT) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Akoya Biosciences, Inc. (AKYA) : Free Stock Analysis Report Astria Therapeutics, Inc. (ATXS) : Free Stock Analysis Report To read this article on Zacks.com click here. | In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 58 cents to 31 cents. Click to get this free report ADC Therapeutics SA (ADCT) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Akoya Biosciences, Inc. (AKYA) : Free Stock Analysis Report Astria Therapeutics, Inc. (ATXS) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the same industry are ADC Therapeutics ADCT, Acadia Pharmaceuticals ACAD and Akoya Biosciences AKYA, each carrying a Zacks Rank #2 (Buy) at present. | Some better-ranked stocks in the same industry are ADC Therapeutics ADCT, Acadia Pharmaceuticals ACAD and Akoya Biosciences AKYA, each carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 58 cents to 31 cents. The estimate for Acadia Pharmaceuticals’ 2024 earnings per share is pegged at 47 cents. |
35602.0 | 2023-07-19 00:00:00 UTC | Adial (ADIL) Shares Up 43% in the Past Week: Here's Why | ACAD | https://www.nasdaq.com/articles/adial-adil-shares-up-43-in-the-past-week%3A-heres-why | nan | nan | In the past week, shares of Adial Pharmaceuticals ADIL have gained 43.4% compared with the industry’s 1.6% rise.
Image Source: Zacks Investment Research
The steep rise in the stock price was observed after the company provided a summary of positive feedback received from respective regulatory bodies in the United States and EU regarding Adial’s propped phase III confirmatory study for AD04 in treating alcohol use disorder (AUD). Additionally, based on the feedback received, ADIL also elaborated on its current clinical development plan for AD04.
AD04 is a genetically targeted, serotonin-3 receptor antagonist, which is currently under development for treating patients with AUD. The positive feedback from the regulatory bodies signifies agreement regarding the importance of ongoing research in the AUD therapeutic area as a persistent high unmet need.
An agreement was also reached regarding the primary endpoint of the confirmatory study based on the percentage of no heavy drinking days. This primary endpoint will be determined by making use of a responder analysis of patients who reduced their alcohol consumption to zero heavy drinking days in the last two months of a six-month study.
The regulatory bodies also acknowledged the promising nature of Adial’s post hoc analysis results from its phase II and phase III studies of AD04 in the treatment of AUD. It was observed that patients with a specific genetic subtype achieved statistical significance of responder analysis in both the phase II and phase III studies. Additionally, patients averaging more than 17 heavy drinking days per month at the start of the study achieved under three average heavy drinking days per month at study completion.
These post hoc analysis data reportedly played a pivotal role in planning future studies of AD04. The safety profile of the drug in the late-stage ONWARD study of AD04 to treat AUD was also found to be acceptable by the authorities.
However, the regulatory authorities recommended that Adial identifies a patient subgroup where a relevant treatment effect and compelling evidence of a favorable risk-benefit profile can be assessed.
The feedback from the regulatory bodies also encompassed efficacy and safety requirements for the developmental candidate. The efficacy issue stated that the data from one single phase III confirmatory study may not be sufficient for approval of the drug candidate. Hence, Adial has agreed to conduct two studies of AD04 simultaneously. One of the studies will compare patients treated with AD04 against treatment with placebo. On the other hand, a second study may include a biomarker-negative patient arm to satisfy any ongoing questions from the regulators regarding efficacy parameters.
Per ADIL, conducting two simultaneous studies is the best strategy to minimize risk, optimize timing and costs, as well as improve the probability of regulatory authority acceptance and approval in the United Statues and Europe. The company is currently in the process of confirming its clinical development plan and pathwayto satisfy both the U.S. and EU AD04 submission requirements.
Adial also plans to add a long-term safety follow-up to the planned phase III study, which will expose more than 100 patients to treat with AD04 for a year. This will provide the company with sufficient safety data to satisfy the regulatory authorities.
Subject to the success of the two simultaneous studies, ADIL expects to file a new drug application with the FDA in the third quarter of 2025. Adial anticipates the total cost of the development plan around $25 million. The company is actively looking for potential commercial partners to support the planned late-stage studies of AD04 and advance its commercialization in both the U.S. and European markets.
Adial Pharmaceuticals, Inc. Price and Consensus
Adial Pharmaceuticals, Inc. price-consensus-chart | Adial Pharmaceuticals, Inc. Quote
Zacks Rank and Stocks to Consider
Adial currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks in the same industry are ADC Therapeutics ADCT, Acadia Pharmaceuticals ACAD and Akoya Biosciences AKYA, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 90 days, the Zacks Consensus Estimate for ADC Therapeutics’ 2023 loss per share has widened from $2.58 to $2.61. During the same period, the estimate for ADC Therapeutics’ 2024 loss per share narrowed from $2.72 to $2.45. In the past week, shares of ADCT have lost 36.7%.
ADCT beat estimates in three of the trailing four quarters, missing the mark on one occasion, delivering an average earnings surprise of 10.70%.
In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 57 cents to 33 cents. The estimate for Acadia Pharmaceuticals’ 2024 earnings per share is pegged at 21 cents. In the past week, shares of ACAD have risen 33.2%.
ACAD beat estimates in two of the trailing four quarters, missing the mark on other two occasions, delivering an average negative earnings surprise of 2.75%.
In the past 90 days, the Zacks Consensus Estimate for Akoya Biosciences’ 2023 loss per share has narrowed from $1.80 to $1.71. During the same period, the estimate for Akoya Biosciences’ 2024 loss per share narrowed from $1.57 to $1.33. In the past week, shares of AKYA have lost 1.1%.
AKYA missed estimates in each of the trailing four quarters, delivering an average negative earnings surprise of 21.05%.
Top 5 ChatGPT Stocks Revealed
Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
Today you can invest in the wave of the future, an automation that answers follow-up questions … admits mistakes … challenges incorrect premises … rejects inappropriate requests. As one of the selected companies puts it, “Automation frees people from the mundane so they can accomplish the miraculous.”
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ADC Therapeutics SA (ADCT) : Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report
Adial Pharmaceuticals, Inc. (ADIL) : Free Stock Analysis Report
Akoya Biosciences, Inc. (AKYA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the same industry are ADC Therapeutics ADCT, Acadia Pharmaceuticals ACAD and Akoya Biosciences AKYA, each carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 57 cents to 33 cents. The estimate for Acadia Pharmaceuticals’ 2024 earnings per share is pegged at 21 cents. | Some better-ranked stocks in the same industry are ADC Therapeutics ADCT, Acadia Pharmaceuticals ACAD and Akoya Biosciences AKYA, each carrying a Zacks Rank #2 (Buy) at present. Click to get this free report ADC Therapeutics SA (ADCT) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Adial Pharmaceuticals, Inc. (ADIL) : Free Stock Analysis Report Akoya Biosciences, Inc. (AKYA) : Free Stock Analysis Report To read this article on Zacks.com click here. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 57 cents to 33 cents. | Click to get this free report ADC Therapeutics SA (ADCT) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Adial Pharmaceuticals, Inc. (ADIL) : Free Stock Analysis Report Akoya Biosciences, Inc. (AKYA) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the same industry are ADC Therapeutics ADCT, Acadia Pharmaceuticals ACAD and Akoya Biosciences AKYA, each carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 57 cents to 33 cents. | Some better-ranked stocks in the same industry are ADC Therapeutics ADCT, Acadia Pharmaceuticals ACAD and Akoya Biosciences AKYA, each carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 57 cents to 33 cents. The estimate for Acadia Pharmaceuticals’ 2024 earnings per share is pegged at 21 cents. |
35603.0 | 2023-07-18 00:00:00 UTC | Ligand (LGND) Offers $15M in Cash to Acquire All Novan Assets | ACAD | https://www.nasdaq.com/articles/ligand-lgnd-offers-%2415m-in-cash-to-acquire-all-novan-assets | nan | nan | Ligand Pharmaceuticals, Inc. LGND has made an offer to acquire the assets of Novan, Inc. for $15 million in cash and provide an additional up to $15 million in debtor-in-possession (DIP) financing to Novan inclusive of a $3 million bridge financing loan already funded.
The offer was made after Novan filed for Chapter 11 reorganization of the U.S. Bankruptcy Code. With this filing, Novan is looking to stay in business and restructure its debts, assets and operations with court approval.
Ligand reported that the proposed transaction is designed in a way that will preserve and maximize the value of Novan’s commercial business and berdazimer gel development assets. Novan currently has a filed new drug application with the FDA to seek approval for berdazimer gel in the treatment of molluscum contagiosum infection. A decision from the regulatory body is expected on Jan 5, 2024.
We would like to remind the investors that Ligand had previously acquired milestone and royalty rights to berdazimer gel in 2019. The company will acquire all of Novan’s assets only if its bid is the successful bid in the anticipated bankruptcy sale and auction process. However, coherent with LGND’s business strategy, the company will most likely seek to out-license or sell the existing development programs and commercial business assets of Novan.
Year to date, shares of Ligand have gained 2.9% against the industry’s 10% decline.
Image Source: Zacks Investment Research
Novan announced entering into a stalking horse acquisition agreement with Ligand, which insinuates that LGND made the initial bid for all assets of Novan, knowing that other potential buyers will make competing bids.
Per the terms of the proposed transaction, Ligand’s $15 million bid to acquire all the assets of Novan is inclusive of berdazimer gel, all other programs in development, the Nitricil drug delivery technology and the commercial assets of its EPI Health business. Novan acquired EPI Health LLC in March 2022 for an upfront cash payment of $27.5 million, which added berdazimer gel to its portfolio.
Berdazimer gel is the first self-application topical treatment for molluscum contagiosum infection, a highly contagious viral skin disease. LGND believes in the potential of berdazimer gel to get approved by the FDA. At present, there are currently no FDA-approved prescription drug treatment options for molluscum contagiosum infection, representing a serious unmet medical need.
Subject to court approval, the proposed transaction will also allow Novan to make withdrawals from the $15 million secured DIP loan to finance its bankruptcy cases. This amount will be repaid to Ligand through the sale of Novan’s assets.
If the court accepts a bid from a different party, Ligand’s DIP loan will be repaid. In such a situation, LGND also expects that its milestone and royalty rights to berdazimer gel will be preserved. The company anticipates the closure of the transaction in the third quarter of 2023.
Ligand Pharmaceuticals Incorporated Price and Consensus
Ligand Pharmaceuticals Incorporated price-consensus-chart | Ligand Pharmaceuticals Incorporated Quote
Zacks Rank and Stocks to Consider
Ligand currently has a Zacks Rank #5 (Strong Sell).
Some better-ranked stocks in the same industry are ADC Therapeutics ADCT, Acadia Pharmaceuticals ACAD and Akoya Biosciences AKYA, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 90 days, the Zacks Consensus Estimate for ADC Therapeutics’ 2023 loss per share has widened from $2.58 to $2.61. During the same period, the estimate for ADC Therapeutics’ 2024 loss per share narrowed from $2.72 to $2.45. Year to date, shares of ADCT have lost 60.7%.
ADCT beat estimates in three of the trailing four quarters, missing the mark on one occasion, delivering an average earnings surprise of 10.70%.
In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 57 cents to 33 cents. The estimate for Acadia Pharmaceuticals’ 2024 earnings per share is pegged at 21 cents. Year to date, shares of ACAD have fallen by 2.2%.
ACAD beat estimates in two of the trailing four quarters, missing the mark on other two occasions, delivering an average negative earnings surprise of 2.75%.
In the past 90 days, the Zacks Consensus Estimate for Akoya Biosciences’ 2023 loss per share has narrowed from $1.80 to $1.71. During the same period, the estimate for Akoya Biosciences’ 2024 loss per share narrowed from $1.57 to $1.33. Year to date, shares of AKYA have lost 16.9%.
AKYA missed estimates in each of the trailing four quarters, delivering an average negative earnings surprise of 21.05%.
The New Gold Rush: How Lithium Batteries Will Make Millionaires
As the electric vehicle revolution expands, investors have a chance to target huge gains. Millions of lithium batteries are being made & demand is expected to increase 889%.
Download the brand-new FREE report revealing 5 EV battery stocks set to soar.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ADC Therapeutics SA (ADCT) : Free Stock Analysis Report
Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report
Akoya Biosciences, Inc. (AKYA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the same industry are ADC Therapeutics ADCT, Acadia Pharmaceuticals ACAD and Akoya Biosciences AKYA, each carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 57 cents to 33 cents. The estimate for Acadia Pharmaceuticals’ 2024 earnings per share is pegged at 21 cents. | Some better-ranked stocks in the same industry are ADC Therapeutics ADCT, Acadia Pharmaceuticals ACAD and Akoya Biosciences AKYA, each carrying a Zacks Rank #2 (Buy) at present. Click to get this free report ADC Therapeutics SA (ADCT) : Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Akoya Biosciences, Inc. (AKYA) : Free Stock Analysis Report To read this article on Zacks.com click here. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 57 cents to 33 cents. | Click to get this free report ADC Therapeutics SA (ADCT) : Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Akoya Biosciences, Inc. (AKYA) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the same industry are ADC Therapeutics ADCT, Acadia Pharmaceuticals ACAD and Akoya Biosciences AKYA, each carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 57 cents to 33 cents. | Some better-ranked stocks in the same industry are ADC Therapeutics ADCT, Acadia Pharmaceuticals ACAD and Akoya Biosciences AKYA, each carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 57 cents to 33 cents. The estimate for Acadia Pharmaceuticals’ 2024 earnings per share is pegged at 21 cents. |
35604.0 | 2023-07-17 00:00:00 UTC | Acadia (ACAD) Soars 24.7%: Is Further Upside Left in the Stock? | ACAD | https://www.nasdaq.com/articles/acadia-acad-soars-24.7%3A-is-further-upside-left-in-the-stock | nan | nan | Acadia Pharmaceuticals (ACAD) shares ended the last trading session 24.7% higher at $32.18. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 5.8% gain over the past four weeks.
The sudden surge in the stock price was observed after Acadia announced that it is expanding its current licensing agreement for trofinetide with Neuren Pharmaceuticals. Under the agreement, the company has now acquired rights to market trofinetide outside North America along with exclusive global rights to Neuren’s development candidate, NNZ-2591, in Rett syndrome and Fragile X syndrome. Neuren is entitled to receive an upfront payment of $100 million from Acadia. Neuren is also eligible to receive royalty payments and milestone payments from ACAD separately, upon the achievement of certain pre-specified revenue milestones. Additionally, Neuren will receive tiered royalty payments from Acadia, ranging from mid-teens to low-twenties percent of trofinetide net sales outside of North America.
This drugmaker is expected to post quarterly loss of $0.22 per share in its upcoming report, which represents a year-over-year change of -4.8%. Revenues are expected to be $138.56 million, up 3% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Acadia, the consensus EPS estimate for the quarter has been revised 7.7% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on ACAD going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Acadia is part of the Zacks Medical - Biomedical and Genetics industry. Tango Therapeutics, Inc. (TNGX), another stock in the same industry, closed the last trading session 0.6% lower at $3.43. TNGX has returned -4.4% in the past month.
For Tango Therapeutics, Inc., the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.35. This represents a change of -25% from what the company reported a year ago. Tango Therapeutics, Inc. currently has a Zacks Rank of #3 (Hold).
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2023. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report
Tango Therapeutics, Inc. (TNGX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The sudden surge in the stock price was observed after Acadia announced that it is expanding its current licensing agreement for trofinetide with Neuren Pharmaceuticals. Additionally, Neuren will receive tiered royalty payments from Acadia, ranging from mid-teens to low-twenties percent of trofinetide net sales outside of North America. Acadia Pharmaceuticals (ACAD) shares ended the last trading session 24.7% higher at $32.18. | Acadia Pharmaceuticals (ACAD) shares ended the last trading session 24.7% higher at $32.18. Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Tango Therapeutics, Inc. (TNGX) : Free Stock Analysis Report To read this article on Zacks.com click here. The sudden surge in the stock price was observed after Acadia announced that it is expanding its current licensing agreement for trofinetide with Neuren Pharmaceuticals. | You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Acadia is part of the Zacks Medical - Biomedical and Genetics industry. Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Tango Therapeutics, Inc. (TNGX) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals (ACAD) shares ended the last trading session 24.7% higher at $32.18. | For Acadia, the consensus EPS estimate for the quarter has been revised 7.7% higher over the last 30 days to the current level. Acadia Pharmaceuticals (ACAD) shares ended the last trading session 24.7% higher at $32.18. The sudden surge in the stock price was observed after Acadia announced that it is expanding its current licensing agreement for trofinetide with Neuren Pharmaceuticals. |
35605.0 | 2023-07-17 00:00:00 UTC | Cantor Fitzgerald Maintains Acadia Pharmaceuticals (ACAD) Overweight Recommendation | ACAD | https://www.nasdaq.com/articles/cantor-fitzgerald-maintains-acadia-pharmaceuticals-acad-overweight-recommendation | nan | nan | Fintel reports that on July 17, 2023, Cantor Fitzgerald maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Overweight recommendation.
Analyst Price Forecast Suggests 24.48% Downside
As of July 6, 2023, the average one-year price target for Acadia Pharmaceuticals is 25.27. The forecasts range from a low of 12.12 to a high of $37.80. The average price target represents a decrease of 24.48% from its latest reported closing price of 33.46.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Acadia Pharmaceuticals is 597MM, an increase of 14.76%. The projected annual non-GAAP EPS is -0.80.
For more in-depth coverage of Acadia Pharmaceuticals, view the free, crowd-sourced company research report on Finpedia.
What is the Fund Sentiment?
There are 507 funds or institutions reporting positions in Acadia Pharmaceuticals. This is an increase of 28 owner(s) or 5.85% in the last quarter. Average portfolio weight of all funds dedicated to ACAD is 0.20%, an increase of 7.08%. Total shares owned by institutions decreased in the last three months by 0.20% to 164,141K shares.
The put/call ratio of ACAD is 0.39, indicating a bullish outlook.
What are Other Shareholders Doing?
Baker Bros. Advisors holds 41,938K shares representing 25.79% ownership of the company. In it's prior filing, the firm reported owning 41,923K shares, representing an increase of 0.04%. The firm increased its portfolio allocation in ACAD by 7.14% over the last quarter.
Rtw Investments holds 8,243K shares representing 5.07% ownership of the company. In it's prior filing, the firm reported owning 3,671K shares, representing an increase of 55.47%. The firm increased its portfolio allocation in ACAD by 170.78% over the last quarter.
EcoR1 Capital holds 5,991K shares representing 3.68% ownership of the company. No change in the last quarter.
D. E. Shaw holds 4,901K shares representing 3.01% ownership of the company. In it's prior filing, the firm reported owning 4,219K shares, representing an increase of 13.90%. The firm increased its portfolio allocation in ACAD by 4.72% over the last quarter.
Price T Rowe Associates holds 4,551K shares representing 2.80% ownership of the company. In it's prior filing, the firm reported owning 4,279K shares, representing an increase of 5.97%. The firm increased its portfolio allocation in ACAD by 17.00% over the last quarter.
Acadia Pharmaceuticals Background Information
(This description is provided by the company.)
Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years it has been working at the forefront of healthcare to bring vital solutions to people who need them most. It developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson's disease psychosis. Its late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research it is exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders.
Additional reading:
Loan Agreement Between Baker Brothers Life Sciences, L.P., 667, L.P. and Baker Bros. Advisors LP
PROCEEDS AGREEMENT
Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatr
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview - Full year 2022 net sales of $517.2 million, an increase of 7% over 2021 - Prescription Drug User Fee Act (PDUFA) action date set for March 12,
Employment Offer Letter, dated December 19, 2022, between the Registrant and Doug Williamson.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Fintel reports that on July 17, 2023, Cantor Fitzgerald maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Overweight recommendation. For more in-depth coverage of Acadia Pharmaceuticals, view the free, crowd-sourced company research report on Finpedia. Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatr Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview - Full year 2022 net sales of $517.2 million, an increase of 7% over 2021 - Prescription Drug User Fee Act (PDUFA) action date set for March 12, Employment Offer Letter, dated December 19, 2022, between the Registrant and Doug Williamson. | Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatr Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview - Full year 2022 net sales of $517.2 million, an increase of 7% over 2021 - Prescription Drug User Fee Act (PDUFA) action date set for March 12, Employment Offer Letter, dated December 19, 2022, between the Registrant and Doug Williamson. Fintel reports that on July 17, 2023, Cantor Fitzgerald maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Overweight recommendation. Analyst Price Forecast Suggests 24.48% Downside As of July 6, 2023, the average one-year price target for Acadia Pharmaceuticals is 25.27. | Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatr Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview - Full year 2022 net sales of $517.2 million, an increase of 7% over 2021 - Prescription Drug User Fee Act (PDUFA) action date set for March 12, Employment Offer Letter, dated December 19, 2022, between the Registrant and Doug Williamson. Fintel reports that on July 17, 2023, Cantor Fitzgerald maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Overweight recommendation. Analyst Price Forecast Suggests 24.48% Downside As of July 6, 2023, the average one-year price target for Acadia Pharmaceuticals is 25.27. | For more in-depth coverage of Acadia Pharmaceuticals, view the free, crowd-sourced company research report on Finpedia. There are 507 funds or institutions reporting positions in Acadia Pharmaceuticals. Fintel reports that on July 17, 2023, Cantor Fitzgerald maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Overweight recommendation. |
35606.0 | 2023-07-17 00:00:00 UTC | Acadia Pharmaceuticals Rights Deal and Bullish Outlook Sends Shares Surging 16%. Here’s What To Expect | ACAD | https://www.nasdaq.com/articles/acadia-pharmaceuticals-rights-deal-and-bullish-outlook-sends-shares-surging-16.-heres-what | nan | nan | In a stunning two-day rally, shares of Acadia Pharmaceuticals (US:ACAD) have seen a 16% surge following the announcement of the company's acquisition of expanded commercial rights for the groundbreaking Rett syndrome drug, trofinetide. This growth was further fueled by upgraded projections for the fiscal year, painting a promising future for the company.
Management's pre-announcement of the 2023 Daybue sales sent shockwaves through the market, projecting sales of $21-23 million, shattering the modest consensus of $2.3 million. Furthermore, their guidance for 2023 predicts a remarkable $45-55 million, compared to the humble consensus forecast of $7.3 million.
These developments coupled with Acadia's acquisition of ex-North American rights to trofinetide and global rights to NNZ-2591 for Rett and Fragile X syndromes from Neuren Pharmaceuticals propelled the stock's value upward.
Rett syndrome, a rare genetic disorder primarily affecting females, has found a beacon of hope in trofinetide. Marketed under the brand name Daybue, the drug has shown encouraging early results. Over 90% of the eligible patients converted from clinical trial, and its sales have been well distributed across high-volume institutions, community-based centers, and Centers of Excellence.
Sales Get Necessity Boost
The management attributes the above-consensus sales to accelerated adoption driven by disease education and medical necessity. They reported an encouraging mix of patient demographics with young female patients representing the primary beneficiaries.
Acadia's acquisition of additional rights to trofinetide, together with the acquisition of global rights to NNZ-2591, signifies strategic expansion. This move provides the company with robust growth opportunities, adding another promising drug to their portfolio. The terms of the agreement involve an upfront payment of $100 million, potential milestone payments, and future royalties.
With Daybue's remarkable initial sales and promising guidance for the next quarter, Acadia is making a significant impact in the field of rare neuro diseases. The company is now preparing to engage with regulatory authorities, including those in Europe, to secure trofinetide's approval. Meanwhile, Neuren has completed a Phase 1 trial for NNZ-2591, paving the way for Phase 2.
The leap in Acadia's stock price reflects investors' optimism in the company's trajectory. As the firm strengthens its grip on the Rett syndrome and Fragile X syndrome markets with Daybue and NNZ-2591, it is poised to transform the lives of countless patients around the world.
Broker Thought
TD Cowen analyst Ritu Baral said that she continues to be surprised by Daybue’s early sales and expects the product to continue to outperform expectations. Baral said there is likely to be even further additional upside to their 12-month target price valuation that was bumped from $28 to $35 a share following the update.
The analyst thinks there is still potential for Daybue to be successful in other markets outside the US further down the line and maintains an ‘outperform’ call on the stock.
Fintel’s consensus valuation of $25.27 tells us that before the announcement, the market thinks the stock was trading around fair value. We expect the consensus target to trickle higher with the updated guidance in the coming weeks.
The dispersion of recommendations is shown below from all brokers in the street.
One area of concern:
While the news has brought a positive movement on the stock, research on the Fintel on ACAD’s insider trading data revealed five net insiders have sold stock in the last 90 days. The analysis includes every unplanned, open-market insider sale made.
These insiders have sold stock equating to 0.7% of the total share capital on issue with the bulk of sales occurring in June and July. These insiders likely sold stock following its recovery rally in the first half of 2023 after losing a significant amount of value in recent years.
The chart below shows the planned vs unplanned trades by insiders of the stock. You can find other stocks that have higher insider sentiment on Fintel’s quant leaderboard.
The optimism around Acadia's stock has pushed year-to-date returns above 80%. The journey, however, is far from over. As the company navigates the complexities of commercial launch, pricing strategy, and regulatory hurdles, the world watches in anticipation, hopeful for a future where Rett syndrome and Fragile X syndrome are no longer without viable treatments.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In a stunning two-day rally, shares of Acadia Pharmaceuticals (US:ACAD) have seen a 16% surge following the announcement of the company's acquisition of expanded commercial rights for the groundbreaking Rett syndrome drug, trofinetide. With Daybue's remarkable initial sales and promising guidance for the next quarter, Acadia is making a significant impact in the field of rare neuro diseases. These developments coupled with Acadia's acquisition of ex-North American rights to trofinetide and global rights to NNZ-2591 for Rett and Fragile X syndromes from Neuren Pharmaceuticals propelled the stock's value upward. | In a stunning two-day rally, shares of Acadia Pharmaceuticals (US:ACAD) have seen a 16% surge following the announcement of the company's acquisition of expanded commercial rights for the groundbreaking Rett syndrome drug, trofinetide. These developments coupled with Acadia's acquisition of ex-North American rights to trofinetide and global rights to NNZ-2591 for Rett and Fragile X syndromes from Neuren Pharmaceuticals propelled the stock's value upward. Acadia's acquisition of additional rights to trofinetide, together with the acquisition of global rights to NNZ-2591, signifies strategic expansion. | These developments coupled with Acadia's acquisition of ex-North American rights to trofinetide and global rights to NNZ-2591 for Rett and Fragile X syndromes from Neuren Pharmaceuticals propelled the stock's value upward. One area of concern: While the news has brought a positive movement on the stock, research on the Fintel on ACAD’s insider trading data revealed five net insiders have sold stock in the last 90 days. In a stunning two-day rally, shares of Acadia Pharmaceuticals (US:ACAD) have seen a 16% surge following the announcement of the company's acquisition of expanded commercial rights for the groundbreaking Rett syndrome drug, trofinetide. | These developments coupled with Acadia's acquisition of ex-North American rights to trofinetide and global rights to NNZ-2591 for Rett and Fragile X syndromes from Neuren Pharmaceuticals propelled the stock's value upward. One area of concern: While the news has brought a positive movement on the stock, research on the Fintel on ACAD’s insider trading data revealed five net insiders have sold stock in the last 90 days. In a stunning two-day rally, shares of Acadia Pharmaceuticals (US:ACAD) have seen a 16% surge following the announcement of the company's acquisition of expanded commercial rights for the groundbreaking Rett syndrome drug, trofinetide. |
35607.0 | 2023-07-14 00:00:00 UTC | Citigroup Maintains Acadia Pharmaceuticals (ACAD) Neutral Recommendation | ACAD | https://www.nasdaq.com/articles/citigroup-maintains-acadia-pharmaceuticals-acad-neutral-recommendation-0 | nan | nan | Fintel reports that on July 14, 2023, Citigroup maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Neutral recommendation.
Analyst Price Forecast Suggests 2.06% Downside
As of July 6, 2023, the average one-year price target for Acadia Pharmaceuticals is 25.27. The forecasts range from a low of 12.12 to a high of $37.80. The average price target represents a decrease of 2.06% from its latest reported closing price of 25.80.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Acadia Pharmaceuticals is 597MM, an increase of 14.76%. The projected annual non-GAAP EPS is -0.80.
For more in-depth coverage of Acadia Pharmaceuticals, view the free, crowd-sourced company research report on Finpedia.
What is the Fund Sentiment?
There are 507 funds or institutions reporting positions in Acadia Pharmaceuticals. This is an increase of 28 owner(s) or 5.85% in the last quarter. Average portfolio weight of all funds dedicated to ACAD is 0.20%, an increase of 7.29%. Total shares owned by institutions decreased in the last three months by 0.20% to 164,141K shares.
The put/call ratio of ACAD is 0.39, indicating a bullish outlook.
What are Other Shareholders Doing?
Baker Bros. Advisors holds 41,938K shares representing 25.79% ownership of the company. In it's prior filing, the firm reported owning 41,923K shares, representing an increase of 0.04%. The firm increased its portfolio allocation in ACAD by 7.14% over the last quarter.
Rtw Investments holds 8,243K shares representing 5.07% ownership of the company. In it's prior filing, the firm reported owning 3,671K shares, representing an increase of 55.47%. The firm increased its portfolio allocation in ACAD by 170.78% over the last quarter.
EcoR1 Capital holds 5,991K shares representing 3.68% ownership of the company. No change in the last quarter.
D. E. Shaw holds 4,901K shares representing 3.01% ownership of the company. In it's prior filing, the firm reported owning 4,219K shares, representing an increase of 13.90%. The firm increased its portfolio allocation in ACAD by 4.72% over the last quarter.
Price T Rowe Associates holds 4,551K shares representing 2.80% ownership of the company. In it's prior filing, the firm reported owning 4,279K shares, representing an increase of 5.97%. The firm increased its portfolio allocation in ACAD by 17.00% over the last quarter.
Acadia Pharmaceuticals Background Information
(This description is provided by the company.)
Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years it has been working at the forefront of healthcare to bring vital solutions to people who need them most. It developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson's disease psychosis. Its late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research it is exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders.
Additional reading:
Loan Agreement Between Baker Brothers Life Sciences, L.P., 667, L.P. and Baker Bros. Advisors LP
PROCEEDS AGREEMENT
Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatr
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview - Full year 2022 net sales of $517.2 million, an increase of 7% over 2021 - Prescription Drug User Fee Act (PDUFA) action date set for March 12,
Employment Offer Letter, dated December 19, 2022, between the Registrant and Doug Williamson.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Fintel reports that on July 14, 2023, Citigroup maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Neutral recommendation. For more in-depth coverage of Acadia Pharmaceuticals, view the free, crowd-sourced company research report on Finpedia. Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatr Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview - Full year 2022 net sales of $517.2 million, an increase of 7% over 2021 - Prescription Drug User Fee Act (PDUFA) action date set for March 12, Employment Offer Letter, dated December 19, 2022, between the Registrant and Doug Williamson. | Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatr Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview - Full year 2022 net sales of $517.2 million, an increase of 7% over 2021 - Prescription Drug User Fee Act (PDUFA) action date set for March 12, Employment Offer Letter, dated December 19, 2022, between the Registrant and Doug Williamson. Fintel reports that on July 14, 2023, Citigroup maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Neutral recommendation. Analyst Price Forecast Suggests 2.06% Downside As of July 6, 2023, the average one-year price target for Acadia Pharmaceuticals is 25.27. | Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatr Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview - Full year 2022 net sales of $517.2 million, an increase of 7% over 2021 - Prescription Drug User Fee Act (PDUFA) action date set for March 12, Employment Offer Letter, dated December 19, 2022, between the Registrant and Doug Williamson. Fintel reports that on July 14, 2023, Citigroup maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Neutral recommendation. Analyst Price Forecast Suggests 2.06% Downside As of July 6, 2023, the average one-year price target for Acadia Pharmaceuticals is 25.27. | The projected annual revenue for Acadia Pharmaceuticals is 597MM, an increase of 14.76%. For more in-depth coverage of Acadia Pharmaceuticals, view the free, crowd-sourced company research report on Finpedia. There are 507 funds or institutions reporting positions in Acadia Pharmaceuticals. |
35608.0 | 2023-07-14 00:00:00 UTC | HC Wainwright & Co. Maintains Acadia Pharmaceuticals (ACAD) Buy Recommendation | ACAD | https://www.nasdaq.com/articles/hc-wainwright-co.-maintains-acadia-pharmaceuticals-acad-buy-recommendation | nan | nan | Fintel reports that on July 14, 2023, HC Wainwright & Co. maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Buy recommendation.
Analyst Price Forecast Suggests 2.06% Downside
As of July 6, 2023, the average one-year price target for Acadia Pharmaceuticals is 25.27. The forecasts range from a low of 12.12 to a high of $37.80. The average price target represents a decrease of 2.06% from its latest reported closing price of 25.80.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Acadia Pharmaceuticals is 597MM, an increase of 14.76%. The projected annual non-GAAP EPS is -0.80.
For more in-depth coverage of Acadia Pharmaceuticals, view the free, crowd-sourced company research report on Finpedia.
What is the Fund Sentiment?
There are 507 funds or institutions reporting positions in Acadia Pharmaceuticals. This is an increase of 28 owner(s) or 5.85% in the last quarter. Average portfolio weight of all funds dedicated to ACAD is 0.20%, an increase of 7.29%. Total shares owned by institutions decreased in the last three months by 0.20% to 164,141K shares.
The put/call ratio of ACAD is 0.39, indicating a bullish outlook.
What are Other Shareholders Doing?
Baker Bros. Advisors holds 41,938K shares representing 25.79% ownership of the company. In it's prior filing, the firm reported owning 41,923K shares, representing an increase of 0.04%. The firm increased its portfolio allocation in ACAD by 7.14% over the last quarter.
Rtw Investments holds 8,243K shares representing 5.07% ownership of the company. In it's prior filing, the firm reported owning 3,671K shares, representing an increase of 55.47%. The firm increased its portfolio allocation in ACAD by 170.78% over the last quarter.
EcoR1 Capital holds 5,991K shares representing 3.68% ownership of the company. No change in the last quarter.
D. E. Shaw holds 4,901K shares representing 3.01% ownership of the company. In it's prior filing, the firm reported owning 4,219K shares, representing an increase of 13.90%. The firm increased its portfolio allocation in ACAD by 4.72% over the last quarter.
Price T Rowe Associates holds 4,551K shares representing 2.80% ownership of the company. In it's prior filing, the firm reported owning 4,279K shares, representing an increase of 5.97%. The firm increased its portfolio allocation in ACAD by 17.00% over the last quarter.
Acadia Pharmaceuticals Background Information
(This description is provided by the company.)
Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years it has been working at the forefront of healthcare to bring vital solutions to people who need them most. It developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson's disease psychosis. Its late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research it is exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders.
Additional reading:
Loan Agreement Between Baker Brothers Life Sciences, L.P., 667, L.P. and Baker Bros. Advisors LP
PROCEEDS AGREEMENT
Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatr
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview - Full year 2022 net sales of $517.2 million, an increase of 7% over 2021 - Prescription Drug User Fee Act (PDUFA) action date set for March 12,
Employment Offer Letter, dated December 19, 2022, between the Registrant and Doug Williamson.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Fintel reports that on July 14, 2023, HC Wainwright & Co. maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Buy recommendation. For more in-depth coverage of Acadia Pharmaceuticals, view the free, crowd-sourced company research report on Finpedia. Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatr Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview - Full year 2022 net sales of $517.2 million, an increase of 7% over 2021 - Prescription Drug User Fee Act (PDUFA) action date set for March 12, Employment Offer Letter, dated December 19, 2022, between the Registrant and Doug Williamson. | Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatr Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview - Full year 2022 net sales of $517.2 million, an increase of 7% over 2021 - Prescription Drug User Fee Act (PDUFA) action date set for March 12, Employment Offer Letter, dated December 19, 2022, between the Registrant and Doug Williamson. Fintel reports that on July 14, 2023, HC Wainwright & Co. maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Buy recommendation. Analyst Price Forecast Suggests 2.06% Downside As of July 6, 2023, the average one-year price target for Acadia Pharmaceuticals is 25.27. | Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatr Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview - Full year 2022 net sales of $517.2 million, an increase of 7% over 2021 - Prescription Drug User Fee Act (PDUFA) action date set for March 12, Employment Offer Letter, dated December 19, 2022, between the Registrant and Doug Williamson. Fintel reports that on July 14, 2023, HC Wainwright & Co. maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Buy recommendation. Analyst Price Forecast Suggests 2.06% Downside As of July 6, 2023, the average one-year price target for Acadia Pharmaceuticals is 25.27. | For more in-depth coverage of Acadia Pharmaceuticals, view the free, crowd-sourced company research report on Finpedia. There are 507 funds or institutions reporting positions in Acadia Pharmaceuticals. Fintel reports that on July 14, 2023, HC Wainwright & Co. maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Buy recommendation. |
35609.0 | 2023-07-14 00:00:00 UTC | JMP Securities Maintains Acadia Pharmaceuticals (ACAD) Market Outperform Recommendation | ACAD | https://www.nasdaq.com/articles/jmp-securities-maintains-acadia-pharmaceuticals-acad-market-outperform-recommendation | nan | nan | Fintel reports that on July 14, 2023, JMP Securities maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Market Outperform recommendation.
Analyst Price Forecast Suggests 2.06% Downside
As of July 6, 2023, the average one-year price target for Acadia Pharmaceuticals is 25.27. The forecasts range from a low of 12.12 to a high of $37.80. The average price target represents a decrease of 2.06% from its latest reported closing price of 25.80.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Acadia Pharmaceuticals is 597MM, an increase of 14.76%. The projected annual non-GAAP EPS is -0.80.
For more in-depth coverage of Acadia Pharmaceuticals, view the free, crowd-sourced company research report on Finpedia.
What is the Fund Sentiment?
There are 507 funds or institutions reporting positions in Acadia Pharmaceuticals. This is an increase of 28 owner(s) or 5.85% in the last quarter. Average portfolio weight of all funds dedicated to ACAD is 0.20%, an increase of 7.29%. Total shares owned by institutions decreased in the last three months by 0.20% to 164,141K shares.
The put/call ratio of ACAD is 0.39, indicating a bullish outlook.
What are Other Shareholders Doing?
Baker Bros. Advisors holds 41,938K shares representing 25.79% ownership of the company. In it's prior filing, the firm reported owning 41,923K shares, representing an increase of 0.04%. The firm increased its portfolio allocation in ACAD by 7.14% over the last quarter.
Rtw Investments holds 8,243K shares representing 5.07% ownership of the company. In it's prior filing, the firm reported owning 3,671K shares, representing an increase of 55.47%. The firm increased its portfolio allocation in ACAD by 170.78% over the last quarter.
EcoR1 Capital holds 5,991K shares representing 3.68% ownership of the company. No change in the last quarter.
D. E. Shaw holds 4,901K shares representing 3.01% ownership of the company. In it's prior filing, the firm reported owning 4,219K shares, representing an increase of 13.90%. The firm increased its portfolio allocation in ACAD by 4.72% over the last quarter.
Price T Rowe Associates holds 4,551K shares representing 2.80% ownership of the company. In it's prior filing, the firm reported owning 4,279K shares, representing an increase of 5.97%. The firm increased its portfolio allocation in ACAD by 17.00% over the last quarter.
Acadia Pharmaceuticals Background Information
(This description is provided by the company.)
Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years it has been working at the forefront of healthcare to bring vital solutions to people who need them most. It developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson's disease psychosis. Its late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research it is exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders.
Additional reading:
Loan Agreement Between Baker Brothers Life Sciences, L.P., 667, L.P. and Baker Bros. Advisors LP
PROCEEDS AGREEMENT
Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatr
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview - Full year 2022 net sales of $517.2 million, an increase of 7% over 2021 - Prescription Drug User Fee Act (PDUFA) action date set for March 12,
Employment Offer Letter, dated December 19, 2022, between the Registrant and Doug Williamson.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Fintel reports that on July 14, 2023, JMP Securities maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Market Outperform recommendation. For more in-depth coverage of Acadia Pharmaceuticals, view the free, crowd-sourced company research report on Finpedia. Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatr Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview - Full year 2022 net sales of $517.2 million, an increase of 7% over 2021 - Prescription Drug User Fee Act (PDUFA) action date set for March 12, Employment Offer Letter, dated December 19, 2022, between the Registrant and Doug Williamson. | Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatr Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview - Full year 2022 net sales of $517.2 million, an increase of 7% over 2021 - Prescription Drug User Fee Act (PDUFA) action date set for March 12, Employment Offer Letter, dated December 19, 2022, between the Registrant and Doug Williamson. Fintel reports that on July 14, 2023, JMP Securities maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Market Outperform recommendation. Analyst Price Forecast Suggests 2.06% Downside As of July 6, 2023, the average one-year price target for Acadia Pharmaceuticals is 25.27. | Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatr Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview - Full year 2022 net sales of $517.2 million, an increase of 7% over 2021 - Prescription Drug User Fee Act (PDUFA) action date set for March 12, Employment Offer Letter, dated December 19, 2022, between the Registrant and Doug Williamson. Fintel reports that on July 14, 2023, JMP Securities maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Market Outperform recommendation. Analyst Price Forecast Suggests 2.06% Downside As of July 6, 2023, the average one-year price target for Acadia Pharmaceuticals is 25.27. | For more in-depth coverage of Acadia Pharmaceuticals, view the free, crowd-sourced company research report on Finpedia. There are 507 funds or institutions reporting positions in Acadia Pharmaceuticals. Fintel reports that on July 14, 2023, JMP Securities maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Market Outperform recommendation. |
35610.0 | 2023-07-14 00:00:00 UTC | Morgan Stanley Maintains Acadia Pharmaceuticals (ACAD) Equal-Weight Recommendation | ACAD | https://www.nasdaq.com/articles/morgan-stanley-maintains-acadia-pharmaceuticals-acad-equal-weight-recommendation-0 | nan | nan | Fintel reports that on July 14, 2023, Morgan Stanley maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Equal-Weight recommendation.
Analyst Price Forecast Suggests 2.06% Downside
As of July 6, 2023, the average one-year price target for Acadia Pharmaceuticals is 25.27. The forecasts range from a low of 12.12 to a high of $37.80. The average price target represents a decrease of 2.06% from its latest reported closing price of 25.80.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Acadia Pharmaceuticals is 597MM, an increase of 14.76%. The projected annual non-GAAP EPS is -0.80.
For more in-depth coverage of Acadia Pharmaceuticals, view the free, crowd-sourced company research report on Finpedia.
What is the Fund Sentiment?
There are 507 funds or institutions reporting positions in Acadia Pharmaceuticals. This is an increase of 28 owner(s) or 5.85% in the last quarter. Average portfolio weight of all funds dedicated to ACAD is 0.20%, an increase of 7.29%. Total shares owned by institutions decreased in the last three months by 0.20% to 164,141K shares.
The put/call ratio of ACAD is 0.39, indicating a bullish outlook.
What are Other Shareholders Doing?
Baker Bros. Advisors holds 41,938K shares representing 25.79% ownership of the company. In it's prior filing, the firm reported owning 41,923K shares, representing an increase of 0.04%. The firm increased its portfolio allocation in ACAD by 7.14% over the last quarter.
Rtw Investments holds 8,243K shares representing 5.07% ownership of the company. In it's prior filing, the firm reported owning 3,671K shares, representing an increase of 55.47%. The firm increased its portfolio allocation in ACAD by 170.78% over the last quarter.
EcoR1 Capital holds 5,991K shares representing 3.68% ownership of the company. No change in the last quarter.
D. E. Shaw holds 4,901K shares representing 3.01% ownership of the company. In it's prior filing, the firm reported owning 4,219K shares, representing an increase of 13.90%. The firm increased its portfolio allocation in ACAD by 4.72% over the last quarter.
Price T Rowe Associates holds 4,551K shares representing 2.80% ownership of the company. In it's prior filing, the firm reported owning 4,279K shares, representing an increase of 5.97%. The firm increased its portfolio allocation in ACAD by 17.00% over the last quarter.
Acadia Pharmaceuticals Background Information
(This description is provided by the company.)
Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years it has been working at the forefront of healthcare to bring vital solutions to people who need them most. It developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson's disease psychosis. Its late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research it is exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders.
Additional reading:
Loan Agreement Between Baker Brothers Life Sciences, L.P., 667, L.P. and Baker Bros. Advisors LP
PROCEEDS AGREEMENT
Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatr
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview - Full year 2022 net sales of $517.2 million, an increase of 7% over 2021 - Prescription Drug User Fee Act (PDUFA) action date set for March 12,
Employment Offer Letter, dated December 19, 2022, between the Registrant and Doug Williamson.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Fintel reports that on July 14, 2023, Morgan Stanley maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Equal-Weight recommendation. For more in-depth coverage of Acadia Pharmaceuticals, view the free, crowd-sourced company research report on Finpedia. Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatr Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview - Full year 2022 net sales of $517.2 million, an increase of 7% over 2021 - Prescription Drug User Fee Act (PDUFA) action date set for March 12, Employment Offer Letter, dated December 19, 2022, between the Registrant and Doug Williamson. | Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatr Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview - Full year 2022 net sales of $517.2 million, an increase of 7% over 2021 - Prescription Drug User Fee Act (PDUFA) action date set for March 12, Employment Offer Letter, dated December 19, 2022, between the Registrant and Doug Williamson. Fintel reports that on July 14, 2023, Morgan Stanley maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Equal-Weight recommendation. Analyst Price Forecast Suggests 2.06% Downside As of July 6, 2023, the average one-year price target for Acadia Pharmaceuticals is 25.27. | Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatr Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview - Full year 2022 net sales of $517.2 million, an increase of 7% over 2021 - Prescription Drug User Fee Act (PDUFA) action date set for March 12, Employment Offer Letter, dated December 19, 2022, between the Registrant and Doug Williamson. Fintel reports that on July 14, 2023, Morgan Stanley maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Equal-Weight recommendation. Analyst Price Forecast Suggests 2.06% Downside As of July 6, 2023, the average one-year price target for Acadia Pharmaceuticals is 25.27. | For more in-depth coverage of Acadia Pharmaceuticals, view the free, crowd-sourced company research report on Finpedia. There are 507 funds or institutions reporting positions in Acadia Pharmaceuticals. Fintel reports that on July 14, 2023, Morgan Stanley maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Equal-Weight recommendation. |
35611.0 | 2023-07-14 00:00:00 UTC | RBC Capital Maintains Acadia Pharmaceuticals (ACAD) Outperform Recommendation | ACAD | https://www.nasdaq.com/articles/rbc-capital-maintains-acadia-pharmaceuticals-acad-outperform-recommendation | nan | nan | Fintel reports that on July 14, 2023, RBC Capital maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Outperform recommendation.
Analyst Price Forecast Suggests 2.06% Downside
As of July 6, 2023, the average one-year price target for Acadia Pharmaceuticals is 25.27. The forecasts range from a low of 12.12 to a high of $37.80. The average price target represents a decrease of 2.06% from its latest reported closing price of 25.80.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Acadia Pharmaceuticals is 597MM, an increase of 14.76%. The projected annual non-GAAP EPS is -0.80.
For more in-depth coverage of Acadia Pharmaceuticals, view the free, crowd-sourced company research report on Finpedia.
What is the Fund Sentiment?
There are 507 funds or institutions reporting positions in Acadia Pharmaceuticals. This is an increase of 28 owner(s) or 5.85% in the last quarter. Average portfolio weight of all funds dedicated to ACAD is 0.20%, an increase of 7.29%. Total shares owned by institutions decreased in the last three months by 0.20% to 164,141K shares.
The put/call ratio of ACAD is 0.39, indicating a bullish outlook.
What are Other Shareholders Doing?
Baker Bros. Advisors holds 41,938K shares representing 25.79% ownership of the company. In it's prior filing, the firm reported owning 41,923K shares, representing an increase of 0.04%. The firm increased its portfolio allocation in ACAD by 7.14% over the last quarter.
Rtw Investments holds 8,243K shares representing 5.07% ownership of the company. In it's prior filing, the firm reported owning 3,671K shares, representing an increase of 55.47%. The firm increased its portfolio allocation in ACAD by 170.78% over the last quarter.
EcoR1 Capital holds 5,991K shares representing 3.68% ownership of the company. No change in the last quarter.
D. E. Shaw holds 4,901K shares representing 3.01% ownership of the company. In it's prior filing, the firm reported owning 4,219K shares, representing an increase of 13.90%. The firm increased its portfolio allocation in ACAD by 4.72% over the last quarter.
Price T Rowe Associates holds 4,551K shares representing 2.80% ownership of the company. In it's prior filing, the firm reported owning 4,279K shares, representing an increase of 5.97%. The firm increased its portfolio allocation in ACAD by 17.00% over the last quarter.
Acadia Pharmaceuticals Background Information
(This description is provided by the company.)
Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years it has been working at the forefront of healthcare to bring vital solutions to people who need them most. It developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson's disease psychosis. Its late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research it is exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders.
Additional reading:
Loan Agreement Between Baker Brothers Life Sciences, L.P., 667, L.P. and Baker Bros. Advisors LP
PROCEEDS AGREEMENT
Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatr
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview - Full year 2022 net sales of $517.2 million, an increase of 7% over 2021 - Prescription Drug User Fee Act (PDUFA) action date set for March 12,
Employment Offer Letter, dated December 19, 2022, between the Registrant and Doug Williamson.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Fintel reports that on July 14, 2023, RBC Capital maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Outperform recommendation. For more in-depth coverage of Acadia Pharmaceuticals, view the free, crowd-sourced company research report on Finpedia. Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatr Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview - Full year 2022 net sales of $517.2 million, an increase of 7% over 2021 - Prescription Drug User Fee Act (PDUFA) action date set for March 12, Employment Offer Letter, dated December 19, 2022, between the Registrant and Doug Williamson. | Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatr Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview - Full year 2022 net sales of $517.2 million, an increase of 7% over 2021 - Prescription Drug User Fee Act (PDUFA) action date set for March 12, Employment Offer Letter, dated December 19, 2022, between the Registrant and Doug Williamson. Fintel reports that on July 14, 2023, RBC Capital maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Outperform recommendation. Analyst Price Forecast Suggests 2.06% Downside As of July 6, 2023, the average one-year price target for Acadia Pharmaceuticals is 25.27. | Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatr Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview - Full year 2022 net sales of $517.2 million, an increase of 7% over 2021 - Prescription Drug User Fee Act (PDUFA) action date set for March 12, Employment Offer Letter, dated December 19, 2022, between the Registrant and Doug Williamson. Fintel reports that on July 14, 2023, RBC Capital maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Outperform recommendation. Analyst Price Forecast Suggests 2.06% Downside As of July 6, 2023, the average one-year price target for Acadia Pharmaceuticals is 25.27. | For more in-depth coverage of Acadia Pharmaceuticals, view the free, crowd-sourced company research report on Finpedia. There are 507 funds or institutions reporting positions in Acadia Pharmaceuticals. Fintel reports that on July 14, 2023, RBC Capital maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Outperform recommendation. |
35612.0 | 2023-07-14 00:00:00 UTC | Why Acadia Pharmaceuticals Stock Is Soaring Today | ACAD | https://www.nasdaq.com/articles/why-acadia-pharmaceuticals-stock-is-soaring-today | nan | nan | What happened
Shares of Acadia Pharmaceuticals (NASDAQ: ACAD) were soaring 18.3% higher as of 11:03 a.m. ET on Friday. The big jump came after the drugmaker announced on Thursday that it has acquired expanded rights to two drugs.
Acadia signed an agreement with Neuren Pharmaceuticals to pick up rights to trofinetide outside of North America. It launched the drug under the brand name Daybue in the U.S. earlier this year as a treatment for Rett syndrome, a rare genetic neurological disorder.
The company also acquired global rights for Neuren's NNZ-2591. This experimental drug is being evaluated in clinical trials targeting Rett syndrome and Fragile X syndrome, another rare genetic disorder.
In addition, Acadia provided an update giving a sneak peek at its second-quarter revenue. The company expects to report second-quarter net sales of Daybue of between $21 million and $23 million and net sales of Parkinson's disease psychosis drug Nuplazid of between $140 million and $144 million.
Acadia looks for third-quarter sales of Daybue in the range of $45 million to $55 million. It projects full-year sales of Nuplazid will be between $530 million and $545 million.
So what
Investors had a lot to digest -- and a lot to like -- with Acadia's latest news.
The expanded agreement with Neuren appears to be a smart move. For an up-front payment of $100 million along with potential milestone payments and royalties in the future, Acadia gets access to a much larger market for Daybue as well as a promising new program.
Acadia's preliminary second-quarter results and guidance were also encouraging. Daybue's U.S. launch seems to be going well. Nuplazid's sales jumped close to 20% from the previous quarter.
Now what
Investors will learn the exact sales figures for Daybue and Nuplazid when Acadia provides its second-quarter update, which should be sometime in August. The company also plans to file for approval of trofinetide in Canada within the next 18 months. Acadia expects to announce its plans for pursuing approvals of the drug in Europe, Asia, and other regions later.
10 stocks we like better than Acadia Pharmaceuticals
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Acadia Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of July 10, 2023
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia signed an agreement with Neuren Pharmaceuticals to pick up rights to trofinetide outside of North America. Now what Investors will learn the exact sales figures for Daybue and Nuplazid when Acadia provides its second-quarter update, which should be sometime in August. What happened Shares of Acadia Pharmaceuticals (NASDAQ: ACAD) were soaring 18.3% higher as of 11:03 a.m. | * They just revealed what they believe are the ten best stocks for investors to buy right now... and Acadia Pharmaceuticals wasn't one of them! What happened Shares of Acadia Pharmaceuticals (NASDAQ: ACAD) were soaring 18.3% higher as of 11:03 a.m. Acadia signed an agreement with Neuren Pharmaceuticals to pick up rights to trofinetide outside of North America. | Acadia looks for third-quarter sales of Daybue in the range of $45 million to $55 million. 10 stocks we like better than Acadia Pharmaceuticals When our analyst team has a stock tip, it can pay to listen. What happened Shares of Acadia Pharmaceuticals (NASDAQ: ACAD) were soaring 18.3% higher as of 11:03 a.m. | Now what Investors will learn the exact sales figures for Daybue and Nuplazid when Acadia provides its second-quarter update, which should be sometime in August. * They just revealed what they believe are the ten best stocks for investors to buy right now... and Acadia Pharmaceuticals wasn't one of them! What happened Shares of Acadia Pharmaceuticals (NASDAQ: ACAD) were soaring 18.3% higher as of 11:03 a.m. |
35613.0 | 2023-07-14 00:00:00 UTC | Health Care Sector Update for 07/14/2023: ACAD, ELAN, UNH, XLV, IBB | ACAD | https://www.nasdaq.com/articles/health-care-sector-update-for-07-14-2023%3A-acad-elan-unh-xlv-ibb | nan | nan | Health care stocks were gaining pre-bell Friday, as the Health Care Select Sector SPDR Fund (XLV) was 0.7% higher and the iShares Biotechnology ETF (IBB) was recently up 0.5%.
UnitedHealth Group (UNH) was more than 3% higher after it reported Q2 adjusted earnings of $6.14 per diluted share, up from $5.57 a year earlier. Analysts polled by Capital IQ expected $5.98.
ACADIA Pharmaceuticals (ACAD) was climbing past 12% after saying it expanded its current licensing agreement for trofinetide, a treatment for Rett syndrome, with Neuren Pharmaceuticals to acquire ex-North American rights to the drug.
Elanco Animal Health (ELAN) was gaining more than 8% in value after saying the US Environmental Protection Agency has affirmed the safety profile of its Seresto flea and tick collar.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals (ACAD) was climbing past 12% after saying it expanded its current licensing agreement for trofinetide, a treatment for Rett syndrome, with Neuren Pharmaceuticals to acquire ex-North American rights to the drug. UnitedHealth Group (UNH) was more than 3% higher after it reported Q2 adjusted earnings of $6.14 per diluted share, up from $5.57 a year earlier. Elanco Animal Health (ELAN) was gaining more than 8% in value after saying the US Environmental Protection Agency has affirmed the safety profile of its Seresto flea and tick collar. | ACADIA Pharmaceuticals (ACAD) was climbing past 12% after saying it expanded its current licensing agreement for trofinetide, a treatment for Rett syndrome, with Neuren Pharmaceuticals to acquire ex-North American rights to the drug. Health care stocks were gaining pre-bell Friday, as the Health Care Select Sector SPDR Fund (XLV) was 0.7% higher and the iShares Biotechnology ETF (IBB) was recently up 0.5%. Elanco Animal Health (ELAN) was gaining more than 8% in value after saying the US Environmental Protection Agency has affirmed the safety profile of its Seresto flea and tick collar. | ACADIA Pharmaceuticals (ACAD) was climbing past 12% after saying it expanded its current licensing agreement for trofinetide, a treatment for Rett syndrome, with Neuren Pharmaceuticals to acquire ex-North American rights to the drug. Health care stocks were gaining pre-bell Friday, as the Health Care Select Sector SPDR Fund (XLV) was 0.7% higher and the iShares Biotechnology ETF (IBB) was recently up 0.5%. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals (ACAD) was climbing past 12% after saying it expanded its current licensing agreement for trofinetide, a treatment for Rett syndrome, with Neuren Pharmaceuticals to acquire ex-North American rights to the drug. Health care stocks were gaining pre-bell Friday, as the Health Care Select Sector SPDR Fund (XLV) was 0.7% higher and the iShares Biotechnology ETF (IBB) was recently up 0.5%. UnitedHealth Group (UNH) was more than 3% higher after it reported Q2 adjusted earnings of $6.14 per diluted share, up from $5.57 a year earlier. |
35614.0 | 2023-07-14 00:00:00 UTC | Acadia (ACAD) Expands Existing Licensing Deal With Neuren | ACAD | https://www.nasdaq.com/articles/acadia-acad-expands-existing-licensing-deal-with-neuren | nan | nan | Acadia Pharmaceuticals Inc. ACAD announced that it is expanding its current licensing agreement for trofinetide with Neuren Pharmaceuticals. Under the agreement, ACAD has now acquired rights to market trofinetide outside North America along with exclusive global rights to Neuren’s development candidate, NNZ-2591, in Rett syndrome and Fragile X syndrome.
In March 2023, trofinetide received FDA approval for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. The drug was launched in the United States in April under the brand name, Daybue. Per Acadia, Daybue currently stands as the first and only drug approved for the treatment of Rett syndrome.
The stock of the company climbed about 23% in the after-market hours on Thursday, following the positive news. Year to date, shares of Acadia have shot up 62.1% against the industry’s 10% decline.
Image Source: Zacks Investment Research
NNZ-2591, Neuren’s investigational candidate, is currently under development in four other rare neurodevelopmental syndromes, barringRett syndrome and Fragile X syndrome. By acquiring global rights for this candidate, ACAD is looking to further advance the global potential of its current development portfolio.
Per the terms of the licensing agreement, Neuren is entitled to receive an upfront payment of $100 million from Acadia. Neuren is also eligible to receive royalty payments and milestone payments from ACAD separately, upon the achievement of certain pre-specified revenue milestones. Additionally, Neuren will receive tiered royalty payments from Acadia which will range from the mid-teens to low-twenties percent of trofinetide net sales outside of North America.
In North America, the arrangement for all royalties and milestone payments for trofinetide remains unchanged from the existing North American license agreement between Acadia and Neuren. ACAD also stated that all future payments to Neuren, related to the successful development and approval of NNZ-2591 in Rett syndrome and Fragile X syndrome, will be identical to the payments for trofinetide in both inside and outside North America.
Rett syndrome is a rare, complex genetic neurodevelopmentaldisorder that may occur over four stages, affecting approximately 6,000-9,000 patients in the United States annually. Currently, approximately 4,500 patients are diagnosed with Rett syndrome according to an analysis of healthcare claims data. Rett syndrome is characterized by progressive loss of motor skills and language and it primarily affects females.
In the same press release, the company also reported its preliminary net sales of $21 million to $23 million for Daybue in the second quarter of 2023. On the other hand, Nuplazid’s preliminary net sales for the second quarter of 2023 is expected between $140 million and $144 million.
For the full year, Acadia expects to generate revenues in the range of $140-$144 million from the sales of Nuplazid. For Daybue, the company expects total sales in the band of $45-$55 million in the third quarter of 2023.
ACADIA Pharmaceuticals Inc. Price and Consensus
ACADIA Pharmaceuticals Inc. price-consensus-chart | ACADIA Pharmaceuticals Inc. Quote
Zacks Rank and Stocks to Consider
Acadia currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks in the same industry are ADC Therapeutics ADCT, Anixa Biosciences ANIX and Akero Therapeutics AKRO, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 90 days, the Zacks Consensus Estimate for ADC Therapeutics’ 2023 loss per share has widened from $2.58 to $2.61. During the same period, the estimate for ADC Therapeutics’ 2024 loss per share narrowed from $2.72 to $2.45. Year to date, shares of ADCT have lost 59.7%.
ADCT beat estimates in three of the trailing four quarters, missing the mark on one occasion, delivering an average earnings surprise of 10.70%.
In the past 90 days, the Zacks Consensus Estimate for Anixa Biosciences’ 2023 loss per share has narrowed from 43 cents to 39 cents. During the same period, the estimate for Anixa Biosciences’ 2024 loss per share has narrowed from 46 cents to 38 cents. Year to date, shares of ANIX have lost 25.2%.
ANIX beat estimates in each of the trailing four quarters, delivering an average earnings surprise of 31.21%.
In the past 90 days, the Zacks Consensus Estimate for Akero Therapeutics’ 2023 loss per share has narrowed from $2.97 to $2.80. During the same period, the estimate for AKRO’s 2024 loss per share narrowed from $3.40 to $3.27. Year to date, shares of AKRO have lost 17.3%.
AKRO beat estimates in three of the trailing four quarters, missing the mark on one occasion, delivering an average earnings surprise of 7.96%.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ADC Therapeutics SA (ADCT) : Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report
ANIXA BIOSCIENCES INC (ANIX) : Free Stock Analysis Report
Akero Therapeutics, Inc. (AKRO) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Additionally, Neuren will receive tiered royalty payments from Acadia which will range from the mid-teens to low-twenties percent of trofinetide net sales outside of North America. Acadia Pharmaceuticals Inc. ACAD announced that it is expanding its current licensing agreement for trofinetide with Neuren Pharmaceuticals. Under the agreement, ACAD has now acquired rights to market trofinetide outside North America along with exclusive global rights to Neuren’s development candidate, NNZ-2591, in Rett syndrome and Fragile X syndrome. | Under the agreement, ACAD has now acquired rights to market trofinetide outside North America along with exclusive global rights to Neuren’s development candidate, NNZ-2591, in Rett syndrome and Fragile X syndrome. Click to get this free report ADC Therapeutics SA (ADCT) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report ANIXA BIOSCIENCES INC (ANIX) : Free Stock Analysis Report Akero Therapeutics, Inc. (AKRO) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals Inc. ACAD announced that it is expanding its current licensing agreement for trofinetide with Neuren Pharmaceuticals. | ACAD also stated that all future payments to Neuren, related to the successful development and approval of NNZ-2591 in Rett syndrome and Fragile X syndrome, will be identical to the payments for trofinetide in both inside and outside North America. ACADIA Pharmaceuticals Inc. Price and Consensus ACADIA Pharmaceuticals Inc. price-consensus-chart | ACADIA Pharmaceuticals Inc. Quote Zacks Rank and Stocks to Consider Acadia currently has a Zacks Rank #3 (Hold). Click to get this free report ADC Therapeutics SA (ADCT) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report ANIXA BIOSCIENCES INC (ANIX) : Free Stock Analysis Report Akero Therapeutics, Inc. (AKRO) : Free Stock Analysis Report To read this article on Zacks.com click here. | Acadia Pharmaceuticals Inc. ACAD announced that it is expanding its current licensing agreement for trofinetide with Neuren Pharmaceuticals. Under the agreement, ACAD has now acquired rights to market trofinetide outside North America along with exclusive global rights to Neuren’s development candidate, NNZ-2591, in Rett syndrome and Fragile X syndrome. Per Acadia, Daybue currently stands as the first and only drug approved for the treatment of Rett syndrome. |
35615.0 | 2023-07-14 00:00:00 UTC | Pre-market Movers: ARBB, THRX, LESL, EDTX, LUNR, ACAD… | ACAD | https://www.nasdaq.com/articles/pre-market-movers%3A-arbb-thrx-lesl-edtx-lunr-acad... | nan | nan | (RTTNews) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 06.45 A.M. ET).
In the Green
ARB IOT Group Limited (ARBB) is up over 86% at $6.09. Intuitive Machines, Inc. (LUNR) is up over 23% at $10.58. ACADIA Pharmaceuticals Inc. (ACAD) is up over 18% at $30.51. Nikola Corporation (NKLA) is up over 15% at $2.56. MicroCloud Hologram Inc. (HOLO) is up over 14% at $3.85. Sentage Holdings Inc. (SNTG) is up over 13% at $2.75. LiveWire Group, Inc. (LVWR) is up over 12% at $13. Glaukos Corporation (GKOS) is up over 6% at $76.10.
In the Red
Theseus Pharmaceuticals, Inc. (THRX) is down over 65% at $3.26. Leslie's, Inc. (LESL) is down over 29% at $6.72. EdtechX Holdings Acquisition Corp. II (EDTX) is down over 23% at $33.13. Petros Pharmaceuticals, Inc. (PTPI) is down over 13% at $3.07. Humacyte, Inc. (HUMA) is down over 10% at $2.86. Nokia Oyj (NOK) is down over 8% at $4.00. Ault Alliance, Inc. (AULT) is down over 7% at $3.88. Strong Global Entertainment, Inc. (SGE) is down over 6% at $3.12.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals Inc. (ACAD) is up over 18% at $30.51. (RTTNews) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 06.45 A.M. In the Green ARB IOT Group Limited (ARBB) is up over 86% at $6.09. | ACADIA Pharmaceuticals Inc. (ACAD) is up over 18% at $30.51. (RTTNews) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 06.45 A.M. Ault Alliance, Inc. (AULT) is down over 7% at $3.88. | ACADIA Pharmaceuticals Inc. (ACAD) is up over 18% at $30.51. In the Green ARB IOT Group Limited (ARBB) is up over 86% at $6.09. In the Red Theseus Pharmaceuticals, Inc. (THRX) is down over 65% at $3.26. | ACADIA Pharmaceuticals Inc. (ACAD) is up over 18% at $30.51. (RTTNews) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 06.45 A.M. In the Green ARB IOT Group Limited (ARBB) is up over 86% at $6.09. |
35616.0 | 2023-07-14 00:00:00 UTC | Miners help Australian shares notch fourth day of gains | ACAD | https://www.nasdaq.com/articles/miners-help-australian-shares-notch-fourth-day-of-gains | nan | nan | By Ayushman Ojha
July 14 (Reuters) - Australian shares extended a winning run for the fourth consecutive session on Friday, logging their sharpest weekly jump this year, as bets that the Federal Reserve could pause rate hikes after this month boosted sentiment.
The S&P/ASX 200 index .AXJO ended 0.8% higher at 7,303.1, led by gains in resources stocks. The benchmark is up 3.7% this week.
The mining sub-index .AXMM was up 1.4%, underpinned by a sharp jump in iron ore prices. The sub-index notched its best week since late March. IRONORE/
Sector-majors BHP Group BHP.AX and Rio Tinto RIO.AX advanced 1.8% and 1.6%, respectively.
In the United States, overnight data showed the smallest increase in U.S. producer prices in nearly three years, a day after the CPI report showed cooling inflation.
"The CPI data in U.S. probably won't shift the RBA's position too much (but it shows) that tightening that has already been done by central banks is clearly beginning to have its desired effect," said Josh Gilbert, market analyst at eToro.
Gilbert sees one more hike by the Reserve Bank of Australia (RBA) in August, before an end to its tightening cycle.
Meanwhile, Australia has appointed Michele Bullock as the first female head of its central bank, having chosen not to reappoint Governor Philip Lowe for a second term, amid a public backlash over steeply rising interest rates.
Among individual stocks, Neuren Pharmaceuticals NEU.AX closed 16.8% higher after expanding exclusive license deal with Acadia Pharmaceuticals ACAD.O.
Energy stocks .AXEJ were up 1.3%, with Woodside Energy WDS.AX and Santos STO.AX rising 1.5% and 0.4% respectively. The sub-index logged its best week since early March.
Tech stocks .AXIJ gained 1.7%, while gold stocks .AXGD added 0.8%. Gold stocks marked their best week this year.
In New Zealand, the benchmark S&P/NZX 50 index .NZ50 rose 0.9% to 12,013.43.
(Reporting by Ayushman Ojha; Editing by Nivedita Bhattacharjee)
((Ayushman.Ojha@thomsonreuters.com))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among individual stocks, Neuren Pharmaceuticals NEU.AX closed 16.8% higher after expanding exclusive license deal with Acadia Pharmaceuticals ACAD.O. By Ayushman Ojha July 14 (Reuters) - Australian shares extended a winning run for the fourth consecutive session on Friday, logging their sharpest weekly jump this year, as bets that the Federal Reserve could pause rate hikes after this month boosted sentiment. "The CPI data in U.S. probably won't shift the RBA's position too much (but it shows) that tightening that has already been done by central banks is clearly beginning to have its desired effect," said Josh Gilbert, market analyst at eToro. | Among individual stocks, Neuren Pharmaceuticals NEU.AX closed 16.8% higher after expanding exclusive license deal with Acadia Pharmaceuticals ACAD.O. In the United States, overnight data showed the smallest increase in U.S. producer prices in nearly three years, a day after the CPI report showed cooling inflation. Gilbert sees one more hike by the Reserve Bank of Australia (RBA) in August, before an end to its tightening cycle. | Among individual stocks, Neuren Pharmaceuticals NEU.AX closed 16.8% higher after expanding exclusive license deal with Acadia Pharmaceuticals ACAD.O. By Ayushman Ojha July 14 (Reuters) - Australian shares extended a winning run for the fourth consecutive session on Friday, logging their sharpest weekly jump this year, as bets that the Federal Reserve could pause rate hikes after this month boosted sentiment. Tech stocks .AXIJ gained 1.7%, while gold stocks .AXGD added 0.8%. | Among individual stocks, Neuren Pharmaceuticals NEU.AX closed 16.8% higher after expanding exclusive license deal with Acadia Pharmaceuticals ACAD.O. The S&P/ASX 200 index .AXJO ended 0.8% higher at 7,303.1, led by gains in resources stocks. The benchmark is up 3.7% this week. |
35617.0 | 2023-07-13 00:00:00 UTC | Why These 2 Biotech Stocks Made Big Moves Late Thursday | ACAD | https://www.nasdaq.com/articles/why-these-2-biotech-stocks-made-big-moves-late-thursday | nan | nan | The bull run continued on Wall Street, as the Nasdaq Composite (NASDAQINDEX: ^IXIC) once again had the biggest gains following an encouraging start to earnings season. Gains for the Dow Jones Industrial Average (DJINDICES: ^DJI) were minimal, while the S&P 500 (SNPINDEX: ^GSPC) largely split the difference with solid gains.
INDEX
DAILY PERCENTAGE CHANGE
DAILY POINT CHANGE
Dow
+0.14%
+48
S&P 500
+0.85%
+38
Nasdaq
+1.58%
+220
Data source: Yahoo! Finance.
After the closing bell, biotech stocks were in the news. Acadia Pharmaceuticals (NASDAQ: ACAD) soared on a strategic deal that could be extremely lucrative for the company, but Theseus Pharmaceuticals (NASDAQ: THRX) suffered a catastrophic loss on discouraging news regarding a clinical trial.
Here are all the details you need to know.
Acadia makes a deal
Shares of Acadia Pharmaceuticals jumped 23% in after-hours trading on Wall Street. The biotech company made a strategic move that could help it grow its business over the long haul.
Acadia entered into a deal with Australia's Neuren Pharmaceuticals that expanded its previous licensing agreement for its Rett syndrome treatment trofinetide, also known as Daybue. The expansion gives Acadia the rights to the drug for marketing outside North America. Daybue was the first treatment for Rett syndrome to receive U.S. Food and Drug Administration approval for treating the core symptoms of the disease.
In addition, the two parties broadened the scope of the licensing agreement to include global rights for another Neuren candidate treatment. Acadia will now have the rights to NNZ-2591, which is also a treatment for patients with Rett syndrome, as well as those suffering from Fragile X syndrome.
Under the deal, Neuren will get a $100 million payment up front. In addition, additional milestone payments of up to $427 million are available for both trofinetide and NNZ-2591, as well as potential royalty payments.
Acadia also released preliminary sales and guidance figures that show it generating $575 million to $600 million in revenue from Daybue and its Nuplazid treatment in 2023. That's well above what most investors were expecting, and it shows that Acadia is making progress toward reaching its growth goals.
Theseus gives up on THE-630
Moving the other way, shares of Theseus Pharmaceuticals plunged 70% in after-hours trading late Thursday. The biotech company took an extreme step with one of its candidate treatments, prompting the move lower.
Theseus announced that it would discontinue enrollment in its phase 1/2 study of gastrointestinal stromal tumor (GIST) candidate treatment THE-630. A pair of patients in the study experienced hand-foot skin reactions upon having their doses of the drug increased under the parameters of the study, which triggered the determination that the higher dosage exceeded the maximum tolerated dose.
The problem, though, is that Theseus doesn't believe that lower dosages will be adequate to show meaningful improvement, as it would provide exposure well below the target level Theseus had set. As a result, the company has terminated development of the candidate treatment for GIST patients.
That's not the end of Theseus, as the company hopes that it might be able to use lower dosages of the treatment in fighting mutations of the KIT gene. Accordingly, the company expects to choose a development candidate among potential KIT inhibitors in the first half of next year.
Theseus has enough cash on hand to fund operations until 2026 based on its current plans. However, the setback with THE-630 was significant, and investors now have to hope that other pipeline candidates will fare better.
10 stocks we like better than Acadia Pharmaceuticals
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Acadia Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of July 10, 2023
Dan Caplinger has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia entered into a deal with Australia's Neuren Pharmaceuticals that expanded its previous licensing agreement for its Rett syndrome treatment trofinetide, also known as Daybue. Acadia Pharmaceuticals (NASDAQ: ACAD) soared on a strategic deal that could be extremely lucrative for the company, but Theseus Pharmaceuticals (NASDAQ: THRX) suffered a catastrophic loss on discouraging news regarding a clinical trial. Acadia makes a deal Shares of Acadia Pharmaceuticals jumped 23% in after-hours trading on Wall Street. | Acadia makes a deal Shares of Acadia Pharmaceuticals jumped 23% in after-hours trading on Wall Street. Acadia entered into a deal with Australia's Neuren Pharmaceuticals that expanded its previous licensing agreement for its Rett syndrome treatment trofinetide, also known as Daybue. * They just revealed what they believe are the ten best stocks for investors to buy right now... and Acadia Pharmaceuticals wasn't one of them! | Acadia Pharmaceuticals (NASDAQ: ACAD) soared on a strategic deal that could be extremely lucrative for the company, but Theseus Pharmaceuticals (NASDAQ: THRX) suffered a catastrophic loss on discouraging news regarding a clinical trial. Acadia entered into a deal with Australia's Neuren Pharmaceuticals that expanded its previous licensing agreement for its Rett syndrome treatment trofinetide, also known as Daybue. 10 stocks we like better than Acadia Pharmaceuticals When our analyst team has a stock tip, it can pay to listen. | Acadia makes a deal Shares of Acadia Pharmaceuticals jumped 23% in after-hours trading on Wall Street. Acadia will now have the rights to NNZ-2591, which is also a treatment for patients with Rett syndrome, as well as those suffering from Fragile X syndrome. Acadia Pharmaceuticals (NASDAQ: ACAD) soared on a strategic deal that could be extremely lucrative for the company, but Theseus Pharmaceuticals (NASDAQ: THRX) suffered a catastrophic loss on discouraging news regarding a clinical trial. |
35618.0 | 2023-07-06 00:00:00 UTC | Acadia Pharmaceuticals (ACAD) Price Target Increased by 6.95% to 25.27 | ACAD | https://www.nasdaq.com/articles/acadia-pharmaceuticals-acad-price-target-increased-by-6.95-to-25.27 | nan | nan | The average one-year price target for Acadia Pharmaceuticals (NASDAQ:ACAD) has been revised to 25.27 / share. This is an increase of 6.95% from the prior estimate of 23.63 dated June 1, 2023.
The price target is an average of many targets provided by analysts. The latest targets range from a low of 12.12 to a high of 37.80 / share. The average price target represents an increase of 4.59% from the latest reported closing price of 24.16 / share.
For more in-depth coverage of Acadia Pharmaceuticals, view the free, crowd-sourced company research report on Finpedia.
What is the Fund Sentiment?
There are 505 funds or institutions reporting positions in Acadia Pharmaceuticals. This is an increase of 23 owner(s) or 4.77% in the last quarter. Average portfolio weight of all funds dedicated to ACAD is 0.20%, an increase of 19.97%. Total shares owned by institutions decreased in the last three months by 0.08% to 164,250K shares.
The put/call ratio of ACAD is 0.41, indicating a bullish outlook.
What are Other Shareholders Doing?
Baker Bros. Advisors holds 41,938K shares representing 25.79% ownership of the company. In it's prior filing, the firm reported owning 41,923K shares, representing an increase of 0.04%. The firm increased its portfolio allocation in ACAD by 7.14% over the last quarter.
Rtw Investments holds 8,243K shares representing 5.07% ownership of the company. In it's prior filing, the firm reported owning 3,671K shares, representing an increase of 55.47%. The firm increased its portfolio allocation in ACAD by 170.78% over the last quarter.
EcoR1 Capital holds 5,991K shares representing 3.68% ownership of the company. No change in the last quarter.
D. E. Shaw holds 4,901K shares representing 3.01% ownership of the company. In it's prior filing, the firm reported owning 4,219K shares, representing an increase of 13.90%. The firm increased its portfolio allocation in ACAD by 4.72% over the last quarter.
Price T Rowe Associates holds 4,551K shares representing 2.80% ownership of the company. In it's prior filing, the firm reported owning 4,279K shares, representing an increase of 5.97%. The firm increased its portfolio allocation in ACAD by 17.00% over the last quarter.
Acadia Pharmaceuticals Background Information
(This description is provided by the company.)
Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years it has been working at the forefront of healthcare to bring vital solutions to people who need them most. It developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson's disease psychosis. Its late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research it is exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders.
Additional reading:
Loan Agreement Between Baker Brothers Life Sciences, L.P., 667, L.P. and Baker Bros. Advisors LP
PROCEEDS AGREEMENT
Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatr
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview - Full year 2022 net sales of $517.2 million, an increase of 7% over 2021 - Prescription Drug User Fee Act (PDUFA) action date set for March 12,
Employment Offer Letter, dated December 19, 2022, between the Registrant and Doug Williamson.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | For more in-depth coverage of Acadia Pharmaceuticals, view the free, crowd-sourced company research report on Finpedia. Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatr Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview - Full year 2022 net sales of $517.2 million, an increase of 7% over 2021 - Prescription Drug User Fee Act (PDUFA) action date set for March 12, Employment Offer Letter, dated December 19, 2022, between the Registrant and Doug Williamson. The average one-year price target for Acadia Pharmaceuticals (NASDAQ:ACAD) has been revised to 25.27 / share. | Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatr Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview - Full year 2022 net sales of $517.2 million, an increase of 7% over 2021 - Prescription Drug User Fee Act (PDUFA) action date set for March 12, Employment Offer Letter, dated December 19, 2022, between the Registrant and Doug Williamson. The average one-year price target for Acadia Pharmaceuticals (NASDAQ:ACAD) has been revised to 25.27 / share. For more in-depth coverage of Acadia Pharmaceuticals, view the free, crowd-sourced company research report on Finpedia. | Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatr Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview - Full year 2022 net sales of $517.2 million, an increase of 7% over 2021 - Prescription Drug User Fee Act (PDUFA) action date set for March 12, Employment Offer Letter, dated December 19, 2022, between the Registrant and Doug Williamson. The average one-year price target for Acadia Pharmaceuticals (NASDAQ:ACAD) has been revised to 25.27 / share. For more in-depth coverage of Acadia Pharmaceuticals, view the free, crowd-sourced company research report on Finpedia. | There are 505 funds or institutions reporting positions in Acadia Pharmaceuticals. The average one-year price target for Acadia Pharmaceuticals (NASDAQ:ACAD) has been revised to 25.27 / share. For more in-depth coverage of Acadia Pharmaceuticals, view the free, crowd-sourced company research report on Finpedia. |
35619.0 | 2023-07-03 00:00:00 UTC | After Hours Most Active for Jul 3, 2023 : LCID, GT, TSLA, RIVN, ATUS, TAL, JPM, ACAD, AMZN, OUT, CHPT, T | ACAD | https://www.nasdaq.com/articles/after-hours-most-active-for-jul-3-2023-%3A-lcid-gt-tsla-rivn-atus-tal-jpm-acad-amzn-out-chpt | nan | nan | The NASDAQ 100 After Hours Indicator is down -9.05 to 15,199.64. The total After hours volume is currently 41,090,446 shares traded.
The following are the most active stocks for the after hours session:
Lucid Group, Inc. (LCID) is -0.05 at $7.34, with 1,726,368 shares traded. LCID's current last sale is 73.4% of the target price of $10.
The Goodyear Tire & Rubber Company (GT) is unchanged at $13.72, with 1,673,979 shares traded. GT's current last sale is 105.54% of the target price of $13.
Tesla, Inc. (TSLA) is -1.09 at $278.73, with 1,530,195 shares traded. TSLA's current last sale is 125.84% of the target price of $221.5.
Rivian Automotive, Inc. (RIVN) is -0.0241 at $19.54, with 1,440,185 shares traded. As reported by Zacks, the current mean recommendation for RIVN is in the "buy range".
Altice USA, Inc. (ATUS) is unchanged at $3.19, with 1,437,490 shares traded. ATUS's current last sale is 67.16% of the target price of $4.75.
TAL Education Group (TAL) is unchanged at $6.09, with 1,333,491 shares traded. TAL's current last sale is 98.23% of the target price of $6.2.
J P Morgan Chase & Co (JPM) is +0.24 at $146.85, with 1,170,610 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Jun 2023. The consensus EPS forecast is $3.67. , following a 52-week high recorded in today's regular session.
ACADIA Pharmaceuticals Inc. (ACAD) is unchanged at $24.00, with 1,137,133 shares traded. As reported in the last short interest update the days to cover for ACAD is 7.945539; this calculation is based on the average trading volume of the stock.
Amazon.com, Inc. (AMZN) is +0.25 at $130.47, with 1,058,578 shares traded. As reported by Zacks, the current mean recommendation for AMZN is in the "buy range".
OUTFRONT Media Inc. (OUT) is unchanged at $15.85, with 986,933 shares traded. As reported by Zacks, the current mean recommendation for OUT is in the "buy range".
ChargePoint Holdings, Inc. (CHPT) is +0.02 at $8.72, with 816,725 shares traded. As reported by Zacks, the current mean recommendation for CHPT is in the "buy range".
AT&T Inc. (T) is +0.03 at $16.15, with 769,753 shares traded. As reported by Zacks, the current mean recommendation for T is in the "buy range".
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | As reported in the last short interest update the days to cover for ACAD is 7.945539; this calculation is based on the average trading volume of the stock. ACADIA Pharmaceuticals Inc. (ACAD) is unchanged at $24.00, with 1,137,133 shares traded. The Goodyear Tire & Rubber Company (GT) is unchanged at $13.72, with 1,673,979 shares traded. | ACADIA Pharmaceuticals Inc. (ACAD) is unchanged at $24.00, with 1,137,133 shares traded. As reported in the last short interest update the days to cover for ACAD is 7.945539; this calculation is based on the average trading volume of the stock. The total After hours volume is currently 41,090,446 shares traded. | ACADIA Pharmaceuticals Inc. (ACAD) is unchanged at $24.00, with 1,137,133 shares traded. As reported in the last short interest update the days to cover for ACAD is 7.945539; this calculation is based on the average trading volume of the stock. The total After hours volume is currently 41,090,446 shares traded. | ACADIA Pharmaceuticals Inc. (ACAD) is unchanged at $24.00, with 1,137,133 shares traded. As reported in the last short interest update the days to cover for ACAD is 7.945539; this calculation is based on the average trading volume of the stock. The following are the most active stocks for the after hours session: |
35620.0 | 2023-06-28 00:00:00 UTC | Acadia Pharmaceuticals Reaches Analyst Target Price | ACAD | https://www.nasdaq.com/articles/acadia-pharmaceuticals-reaches-analyst-target-price-1 | nan | nan | In recent trading, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) have crossed above the average analyst 12-month target price of $24.09, changing hands for $24.22/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher — if things are looking up for the company, perhaps it is time for that target price to be raised.
There are 17 different analyst targets within the Zacks coverage universe contributing to that average for Acadia Pharmaceuticals Inc, but the average is just that — a mathematical average. There are analysts with lower targets than the average, including one looking for a price of $12.00. And then on the other side of the spectrum one analyst has a target as high as $36.00. The standard deviation is $5.818.
But the whole reason to look at the average ACAD price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with ACAD crossing above that average target price of $24.09/share, investors in ACAD have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $24.09 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover Acadia Pharmaceuticals Inc:
RECENT ACAD ANALYST RATINGS BREAKDOWN
» Current 1 Month Ago 2 Month Ago 3 Month Ago
Strong buy ratings: 6 6 5 5
Buy ratings: 1 1 1 1
Hold ratings: 9 9 10 10
Sell ratings: 0 1 1 1
Strong sell ratings: 1 1 1 1
Average rating: 2.35 2.44 2.56 2.56
The average rating presented in the last row of the above table above is from 1 to 5 where 1 is Strong Buy and 5 is Strong Sell. This article used data provided by Zacks Investment Research via Quandl.com. Get the latest Zacks research report on ACAD — FREE.
The Top 25 Broker Analyst Picks of the S&P 500 »
Also see:
OPGN Historical Stock Prices
Regions Financial Average Annual Return
ILTB Average Annual Return
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In recent trading, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) have crossed above the average analyst 12-month target price of $24.09, changing hands for $24.22/share. And so with ACAD crossing above that average target price of $24.09/share, investors in ACAD have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $24.09 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? There are 17 different analyst targets within the Zacks coverage universe contributing to that average for Acadia Pharmaceuticals Inc, but the average is just that — a mathematical average. | In recent trading, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) have crossed above the average analyst 12-month target price of $24.09, changing hands for $24.22/share. There are 17 different analyst targets within the Zacks coverage universe contributing to that average for Acadia Pharmaceuticals Inc, but the average is just that — a mathematical average. But the whole reason to look at the average ACAD price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. | There are 17 different analyst targets within the Zacks coverage universe contributing to that average for Acadia Pharmaceuticals Inc, but the average is just that — a mathematical average. And so with ACAD crossing above that average target price of $24.09/share, investors in ACAD have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $24.09 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? In recent trading, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) have crossed above the average analyst 12-month target price of $24.09, changing hands for $24.22/share. | In recent trading, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) have crossed above the average analyst 12-month target price of $24.09, changing hands for $24.22/share. There are 17 different analyst targets within the Zacks coverage universe contributing to that average for Acadia Pharmaceuticals Inc, but the average is just that — a mathematical average. But the whole reason to look at the average ACAD price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. |
35621.0 | 2023-06-21 00:00:00 UTC | ACAD Factor-Based Stock Analysis | ACAD | https://www.nasdaq.com/articles/acad-factor-based-stock-analysis | nan | nan | Below is Validea's guru fundamental report for ACADIA PHARMACEUTICALS INC (ACAD). Of the 22 guru strategies we follow, ACAD rates highest using our Twin Momentum Investor model based on the published strategy of Dashan Huang. This momentum model looks for a combination of fundamental momentum and price momentum.
ACADIA PHARMACEUTICALS INC (ACAD) is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 83% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
FUNDAMENTAL MOMENTUM: PASS
TWELVE MINUS ONE MOMENTUM: PASS
FINAL RANK: FAIL
Detailed Analysis of ACADIA PHARMACEUTICALS INC
ACAD Guru Analysis
ACAD Fundamental Analysis
More Information on Dashan Huang
Dashan Huang Portfolio
About Dashan Huang: Dashan Huang is an Assistant Professor of Finance at the Lee Kong Chian School of Business at Singapore Management University. His paper "Twin Momentum" looked at combining traditional price momentum with improving fundamentals to generate market outperformance. In the paper, he identified seven fundamental variables (earnings, return on equity, return on assets, accrual operating profitability to equity, cash operating profitability to assets, gross profit to assets and net payout ratio) that he combined into a single fundamental momentum measure. He showed that stocks in the top 20% of the universe according to that measure outperformed the market going forward. When he combined that measure with price momentum, he was able to double its outperformance.
Additional Research Links
Top Large-Cap Growth Stocks
Factor-Based Stock Portfolios
High Momentum Stocks
Dividend Aristocrats 2023
High Insider Ownership Stocks
Top S&P 500 Stocks
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA PHARMACEUTICALS INC (ACAD) is a mid-cap growth stock in the Biotechnology & Drugs industry. Below is Validea's guru fundamental report for ACADIA PHARMACEUTICALS INC (ACAD). Of the 22 guru strategies we follow, ACAD rates highest using our Twin Momentum Investor model based on the published strategy of Dashan Huang. | Detailed Analysis of ACADIA PHARMACEUTICALS INC ACAD Guru Analysis ACAD Fundamental Analysis More Information on Dashan Huang Dashan Huang Portfolio About Dashan Huang: Dashan Huang is an Assistant Professor of Finance at the Lee Kong Chian School of Business at Singapore Management University. Below is Validea's guru fundamental report for ACADIA PHARMACEUTICALS INC (ACAD). Of the 22 guru strategies we follow, ACAD rates highest using our Twin Momentum Investor model based on the published strategy of Dashan Huang. | Detailed Analysis of ACADIA PHARMACEUTICALS INC ACAD Guru Analysis ACAD Fundamental Analysis More Information on Dashan Huang Dashan Huang Portfolio About Dashan Huang: Dashan Huang is an Assistant Professor of Finance at the Lee Kong Chian School of Business at Singapore Management University. Below is Validea's guru fundamental report for ACADIA PHARMACEUTICALS INC (ACAD). Of the 22 guru strategies we follow, ACAD rates highest using our Twin Momentum Investor model based on the published strategy of Dashan Huang. | Of the 22 guru strategies we follow, ACAD rates highest using our Twin Momentum Investor model based on the published strategy of Dashan Huang. Below is Validea's guru fundamental report for ACADIA PHARMACEUTICALS INC (ACAD). ACADIA PHARMACEUTICALS INC (ACAD) is a mid-cap growth stock in the Biotechnology & Drugs industry. |
35622.0 | 2023-06-14 00:00:00 UTC | Acadia (ACAD) to Begin Study on ACP-101 for Hyperphagia in PWS | ACAD | https://www.nasdaq.com/articles/acadia-acad-to-begin-study-on-acp-101-for-hyperphagia-in-pws | nan | nan | Acadia Pharmaceuticals ACAD announced adding a new phase III development candidate, ACP-101, to its rare disease portfolio. The investigational, intranasal formulation of ACP-101 is set to be evaluated for the treatment of hyperphagia in Prader-Willi syndrome (PWS).
We would like to remind the investors that Acadia had previously acquired worldwide rights to develop and commercialize ACP-101 with the acquisition of Levo Therapeutics in June 2022.
Year to date, shares of Acadia have gained 57.2% against the industry’s 6.3% fall.
Image Source: Zacks Investment Research
PWS is a rare neurobehavioral genetic disorder that affects approximately 8,000 to 10,000 patients in the United States. PWS affects the functioning of the hypothalamus and other aspects of the brain giving rise to a variety of behavioral problems among different individuals.
The most common symptom of PWS is hyperphagia. Notably, Hyperphagia is described as a false and unrelenting state of starvation, which is a characteristic of PWS. There is currently no FDA-approved treatment for the hyperphagia associated with PWS, constituting a serious unmet medical need.
Prior to this acquisition, Levo had conducted a phase III study to evaluate two doses of ACP-101, 3.2 mg and 9.6 mg, versus placebo three times daily. The study comprised three equally distributed cohorts of patients who received either of the two doses of ACP-101 or placebo thrice daily.
Top-line results from the phase III study conducted by Levo showed that ACP-101 was safe and overall well-tolerated, demonstrating nominally statistically significant efficacy at the 3.2 mg dose.
Acadia reported recently meeting with the FDA, reaching alignment to further evaluate the 3.2 mg dose of ACP-101 in a pivotal phase III study. If the phase III study becomes successful, Acadia plans to submit a new drug application for the treatment of hyperphagia in PWS to the FDA.
ACADIA Pharmaceuticals Inc. Price and Consensus
ACADIA Pharmaceuticals Inc. price-consensus-chart | ACADIA Pharmaceuticals Inc. Quote
Zacks Rank and Stocks to Consider
Acadia currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Adaptimmune Therapeutics ADAP, Akero Therapeutics AKRO and ADMA Biologics, Inc. ADMA, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 90 days, the Zacks Consensus Estimate for Adaptimmune Therapeutics’ 2023 loss per share has remained stable at 46 cents. During the same period, the estimate for Adaptimmune Therapeutics’ 2024 loss per share has narrowed from 74 cents to 56 cents. Year to date, shares of ADAP have fallen by 30.9%.
ADAP beat estimates in each of the trailing four quarters, delivering an average earnings surprise of 36.89%.
In the past 90 days, the Zacks Consensus Estimate for Akero Therapeutics’ 2023 loss per share has narrowed from $3.46 to $2.80. During the same period, the estimate for Akero Therapeutics’ 2024 loss per share has narrowed from $3.66 to $3.27. Year to date, shares of AKRO have gained by 3.8%.
AKRO beat estimates in three of the trailing four quarters, missing the mark on one occasion, delivering an average earnings surprise of 7.96%.
In the past 90 days, the Zacks Consensus Estimate for ADMA Biologics’ 2023 loss per share has narrowed from 19 cents to 9 cents. The consensus estimate for 2024 earnings is currently pegged at 7 cents per share. Year to date, shares of ADMA have gained by 3.1%.
ADMA beat estimates in each of the trailing four quarters, delivering an average earnings surprise of 19.13%.
Zacks Reveals ChatGPT "Sleeper" Stock
One little-known company is at the heart of an especially brilliant Artificial Intelligence sector. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
As a service to readers, Zacks is providing a bonus report that names and explains this explosive growth stock and 4 other "must buys." Plus more.
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ADMA Biologics Inc (ADMA) : Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report
Adaptimmune Therapeutics PLC (ADAP) : Free Stock Analysis Report
Akero Therapeutics, Inc. (AKRO) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia reported recently meeting with the FDA, reaching alignment to further evaluate the 3.2 mg dose of ACP-101 in a pivotal phase III study. Acadia Pharmaceuticals ACAD announced adding a new phase III development candidate, ACP-101, to its rare disease portfolio. We would like to remind the investors that Acadia had previously acquired worldwide rights to develop and commercialize ACP-101 with the acquisition of Levo Therapeutics in June 2022. | Click to get this free report ADMA Biologics Inc (ADMA) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Adaptimmune Therapeutics PLC (ADAP) : Free Stock Analysis Report Akero Therapeutics, Inc. (AKRO) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals ACAD announced adding a new phase III development candidate, ACP-101, to its rare disease portfolio. We would like to remind the investors that Acadia had previously acquired worldwide rights to develop and commercialize ACP-101 with the acquisition of Levo Therapeutics in June 2022. | ACADIA Pharmaceuticals Inc. Price and Consensus ACADIA Pharmaceuticals Inc. price-consensus-chart | ACADIA Pharmaceuticals Inc. Quote Zacks Rank and Stocks to Consider Acadia currently has a Zacks Rank #3 (Hold). Click to get this free report ADMA Biologics Inc (ADMA) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Adaptimmune Therapeutics PLC (ADAP) : Free Stock Analysis Report Akero Therapeutics, Inc. (AKRO) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals ACAD announced adding a new phase III development candidate, ACP-101, to its rare disease portfolio. | If the phase III study becomes successful, Acadia plans to submit a new drug application for the treatment of hyperphagia in PWS to the FDA. Acadia Pharmaceuticals ACAD announced adding a new phase III development candidate, ACP-101, to its rare disease portfolio. We would like to remind the investors that Acadia had previously acquired worldwide rights to develop and commercialize ACP-101 with the acquisition of Levo Therapeutics in June 2022. |
35623.0 | 2023-06-08 00:00:00 UTC | Why Is Iovance Biotherapeutics (IOVA) Up 7.9% Since Last Earnings Report? | ACAD | https://www.nasdaq.com/articles/why-is-iovance-biotherapeutics-iova-up-7.9-since-last-earnings-report | nan | nan | It has been about a month since the last earnings report for Iovance Biotherapeutics (IOVA). Shares have added about 7.9% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Iovance Biotherapeutics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Posts Narrower-Than-Expected Loss in Q1
Iovance incurred a loss of 50 cents per share in first-quarter 2023, narrower than the Zacks Consensus Estimate of a loss of 84 cents. In the year-ago quarter, the company reported a loss of 58 cents.
Without any marketed product and revenue-generating collaboration, the company did not record any revenues during the quarter.
Quarter in Detail
Research & development expenses were $82.7 million, up 21.1% from the year-ago quarter’s levels, primarily due to increased related personnel costs and facility building costs.
General and administrative expenses increased 20.1% from the prior-year quarter’s figure to $28.1 million due to an increase in related personnel costs and fees to support the Proleukin acquisition.
The company had $632.7 million in cash, cash equivalents, short-term investments and restricted cash as of Mar 31, 2023, compared with $478.3 million on Dec 31, 2022. During the quarter, Iovance raised $260.1 in net proceeds from ATM equity financing. Based on the cash position, management expects to fund the company’s current and planned operations in second-half 2024.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed an upward trend in estimates revision.
The consensus estimate has shifted 10.26% due to these changes.
VGM Scores
At this time, Iovance Biotherapeutics has an average Growth Score of C, however its Momentum Score is doing a lot better with an A. However, the stock was allocated a grade of F on the value side, putting it in the fifth quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Iovance Biotherapeutics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Iovance Biotherapeutics is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Acadia Pharmaceuticals (ACAD), a stock from the same industry, has gained 13.8%. The company reported its results for the quarter ended March 2023 more than a month ago.
Acadia reported revenues of $118.46 million in the last reported quarter, representing a year-over-year change of +2.6%. EPS of -$0.27 for the same period compares with -$0.70 a year ago.
Acadia is expected to post a loss of $0.21 per share for the current quarter, representing no change from the year-ago quarter. Over the last 30 days, the Zacks Consensus Estimate has changed +3.3%.
Acadia has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of D.
Just Released: Free Report Reveals Little-Known Strategies to Help Profit from the $30 Trillion Metaverse Boom
It's undeniable. The metaverse is gaining steam every day. Just follow the money. Google. Microsoft. Adobe. Nike. Facebook even rebranded itself as Meta because Mark Zuckerberg believes the metaverse is the next iteration of the internet. The inevitable result? Many investors will get rich as the metaverse evolves. What do they know that you don't? They’re aware of the companies best poised to grow as the metaverse does. And in a new FREE report, Zacks is revealing those stocks to you. This week, you can download, The Metaverse - What is it? And How to Profit with These 5 Pioneering Stocks. It reveals specific stocks set to skyrocket as this emerging technology develops and expands. Don't miss your chance to access it for free with no obligation.
>>Show me how I could profit from the metaverse!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Iovance Biotherapeutics, Inc. (IOVA) : Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Over the past month, Acadia Pharmaceuticals (ACAD), a stock from the same industry, has gained 13.8%. Acadia reported revenues of $118.46 million in the last reported quarter, representing a year-over-year change of +2.6%. Acadia is expected to post a loss of $0.21 per share for the current quarter, representing no change from the year-ago quarter. | Acadia is expected to post a loss of $0.21 per share for the current quarter, representing no change from the year-ago quarter. Click to get this free report Iovance Biotherapeutics, Inc. (IOVA) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. Over the past month, Acadia Pharmaceuticals (ACAD), a stock from the same industry, has gained 13.8%. | Click to get this free report Iovance Biotherapeutics, Inc. (IOVA) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. Over the past month, Acadia Pharmaceuticals (ACAD), a stock from the same industry, has gained 13.8%. Acadia reported revenues of $118.46 million in the last reported quarter, representing a year-over-year change of +2.6%. | Over the past month, Acadia Pharmaceuticals (ACAD), a stock from the same industry, has gained 13.8%. Acadia reported revenues of $118.46 million in the last reported quarter, representing a year-over-year change of +2.6%. Acadia is expected to post a loss of $0.21 per share for the current quarter, representing no change from the year-ago quarter. |
35624.0 | 2023-06-07 00:00:00 UTC | Acadia (ACAD) Up 12% Since Last Earnings Report: Can It Continue? | ACAD | https://www.nasdaq.com/articles/acadia-acad-up-12-since-last-earnings-report%3A-can-it-continue | nan | nan | It has been about a month since the last earnings report for Acadia Pharmaceuticals (ACAD). Shares have added about 12% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Acadia due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
Acadia Pharmaceuticals Q1 Earnings & Sales Miss Estimates
Acadia Pharmaceuticals Inc. reported first-quarter 2023 loss of 27 cents per share, wider than the Zacks Consensus Estimate of a loss of 21 cents and our estimate of a loss of 26 cents per share. In the year-ago quarter, the company incurred a loss of 70 cents per share.
Total revenues comprised net sales of Nuplazid (pimavanserin) in the first quarter as Acadia’s second-marketed drug, Daybue (trofinetide) was launched in April 2023 in the U.S. market. Revenues from Nuplazid sales increased 3% year over year to $118.5 million in the first quarter, missing the Zacks Consensus Estimate of $122 million. Nuplazid sales decreased by 13.2% sequentially in the first quarter.
Nuplazid sales in the first quarter were driven by an increase in new patient starts across both specialty pharmacy and specialty distribution channels. Year-over-year demand was up approximately 2% in the reported quarter.
Total revenues were lower than our estimate of $121.7 million in the reported quarter.
Nuplazid is an FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis (PDP).
Quarter in Detail
Research and development (R&D) expenses in the quarter were $69.1 million, down 46.4% year over year, owing to a $60 million upfront payment made for collaboration with Stoke Therapeutics, which was recorded in the first quarter of 2022.
Selling, general and administrative (SG&A) expenses were $101.2 million, up 4.7% year over year. The expense remained relatively steady year over year due to a reduction in spending in the PDP commercial franchise, which was offset by investments in the Daybue launch.
Acadia had cash, cash equivalents and investments worth $402.9 million as of Mar 31, 2023 compared with $416.8 million as of Dec 31, 2022.
2023 Financial Guidance Reaffirmed
Acadia expects Nuplazid net sales in the range of $520-$550 million for 2023.
The company expects R&D expenses in the $235-$255 million range, while SG&A expenses are expected to be in the range of $360-$380 million in 2023.
How Have Estimates Been Moving Since Then?
It turns out, estimates review flatlined during the past month.
The consensus estimate has shifted 6.15% due to these changes.
VGM Scores
Currently, Acadia has an average Growth Score of C, however its Momentum Score is doing a lot better with an A. However, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Acadia has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Acadia is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Karuna Therapeutics, Inc. (KRTX), a stock from the same industry, has gained 8.4%. The company reported its results for the quarter ended March 2023 more than a month ago.
Karuna Therapeutics, Inc. reported revenues of $0.65 million in the last reported quarter, representing a year-over-year change of
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How To Profit From Trillions On Spending For Infrastructure >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report
Karuna Therapeutics, Inc. (KRTX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Total revenues comprised net sales of Nuplazid (pimavanserin) in the first quarter as Acadia’s second-marketed drug, Daybue (trofinetide) was launched in April 2023 in the U.S. market. It has been about a month since the last earnings report for Acadia Pharmaceuticals (ACAD). Will the recent positive trend continue leading up to its next earnings release, or is Acadia due for a pullback? | Acadia Pharmaceuticals Q1 Earnings & Sales Miss Estimates Acadia Pharmaceuticals Inc. reported first-quarter 2023 loss of 27 cents per share, wider than the Zacks Consensus Estimate of a loss of 21 cents and our estimate of a loss of 26 cents per share. Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Karuna Therapeutics, Inc. (KRTX) : Free Stock Analysis Report To read this article on Zacks.com click here. It has been about a month since the last earnings report for Acadia Pharmaceuticals (ACAD). | Acadia Pharmaceuticals Q1 Earnings & Sales Miss Estimates Acadia Pharmaceuticals Inc. reported first-quarter 2023 loss of 27 cents per share, wider than the Zacks Consensus Estimate of a loss of 21 cents and our estimate of a loss of 26 cents per share. Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Karuna Therapeutics, Inc. (KRTX) : Free Stock Analysis Report To read this article on Zacks.com click here. It has been about a month since the last earnings report for Acadia Pharmaceuticals (ACAD). | It has been about a month since the last earnings report for Acadia Pharmaceuticals (ACAD). Will the recent positive trend continue leading up to its next earnings release, or is Acadia due for a pullback? Acadia Pharmaceuticals Q1 Earnings & Sales Miss Estimates Acadia Pharmaceuticals Inc. reported first-quarter 2023 loss of 27 cents per share, wider than the Zacks Consensus Estimate of a loss of 21 cents and our estimate of a loss of 26 cents per share. |
35625.0 | 2023-05-23 00:00:00 UTC | SGEN, ACAD & BMEA Drove Baker Brothers Advisors' Q1 Returns as ASND and HZNP Were Culled | ACAD | https://www.nasdaq.com/articles/sgen-acad-bmea-drove-baker-brothers-advisors-q1-returns-as-asnd-and-hznp-were-culled | nan | nan | The biotech-focused New York-based investment firm, Baker Brothers Advisors filed it first quarter investment update with the Securities and Exchange Commission last week, revealing several new positions as well as further investment into high conviction investments.
Julian and Felix Baker, the formidable duo behind the privately owned hedge fund, have emerged as influential players on the financial scene. Their disciplined approach and keen eye for promising biotechnology ventures have yielded extraordinary results, earning them the admiration and respect of both Wall Street insiders and industry experts alike. Bloomberg reported that the Chicago-born duo have built one of the largest biotech investment firms after they made a reported $1.4 billion over a two-week period on sector purchases.
The brothers saw their portfolio's value grow 10.4% during the quarter, to $18.38 billion, as they captured the broader recovery of equity markets during the period. During the same period, the total number of portfolio holdings was reduced from 113 to 105 positions.
The rise in the funds' value has snapped the downward trend of losses since peaking during the pandemic in 2020. The chart below displays the value of the fund each quarter for the last 10 years.
The top five positions in the fund currently by size are Seagen Inc (US:GEN), Incyte Corp. (US:INCY), BeiGene Ltd - ADR (US:BGNE), Acadia Pharmaceuticals Inc (US:ACAD) and Madrigal Pharmaceuticals Inc (US:MDGL).
A heat map has also been provided below from Fintel which gives a snapshot of the total portfolio and the relative weight of each position.
Biggest Buys
The hedge fund made several noteworthy trades during the quarter, with changes in portfolio allocation serving as a meaningful metric to gauge their investment decisions.
The fund’s most significant exposure in Seagen was concentrated further as the stock rallied more than 40% during the quarter on a takeover deal from pharma giant Pfizer (US:PFE). The portfolio allocation increased by 15.47% to 51.68% of the fund, with the stake worth $9.5 billion by the close of March.
Another noteworthy addition was Acadia Pharmaceuticals, which saw a marginal increase in portfolio allocation of 0.29%, driven mainly by share price gains. Despite a comparatively smaller market value of $789.28 million, ACAD stock accounted for 4.2943% of the portfolio, showcasing the fund's diversification strategy.
Revolution Medicines Inc (US:RVMD), with a market value of $58.30 million, witnessed a modest boost in portfolio allocation by 0.29% to 0.32% of the fund. The position was small at the beginning of the quarter and increased significantly in weight as the Baker brothers bought more than 2 million shares.
A relatively small position in Biomea Fusion Inc (US:BMEA) made the top five net increases as BMEA stock's share price more than doubled during the quarter. The position size grew to $65.4 million, equating to 0.36% of the portfolio from the minisule starting position. Since the quarter ended, the stock has continued its rally with the year-to-date gain approaching 300%.
Holdings of Roivant Sciences Ltd (US:ROIV) ended the quarter with a market value of $35.26 million as the fund purchased more than 4 million shares. Despite its relatively smaller presence, the ROIV stock position grew by 0.16% of the portfolio, ending with an allocation of 0.19%.
Other meaningful allocation increases during the quarter included: SpringWorks Therapeutics (US:SWTX), FibroGen Inc (US:FGEN), Blueprint Medicines (US:BPMC) and Allogene Therapeutics (US:ALLO).
Significant Sales
The Baker Brothers completely cut stakes in Ascendis Pharma (US:ASND) and Horizon Therapeutics (US:HZNP) during the quarter, selling ~5 million and ~1 million shares. respectively. Although Horizon is currently undergoing a takeover offer from Amgen (US:AMGN), the deal is currently under threat with the Federal Trade Commission suing to block the transaction.
There was a sizeable reduction in exposure to the Incyte Corp (US:INCY), with the total allocation declining by 3.22% to 14.22% of the fund, worth $2.61 billion. This was driven by share price weakness.
The fund sold half of its position in Biomarin Pharmaceutical (US:BMRN), keeping 3.81 million shares worth $370.51 million or 2% of the fund.
BeiGene (US:BGNE) made the list with a 1.73% allocation decrease to 13.68% of the fund. The significant decrease was driven by a large exposure to the stock, coupled with share price weakness as the fund kept hold of all of its shares.
Other notable allocation decreases during the quarter included stocks: Madrigal Pharmaceuticals, Rhythm Pharmaceuticals (US:RYTM), Replimune Group (US:REPL) and Biocryst Pharmaceuticals (US:BCRX).
Lastly, newly added positions in the fund included: Blueprint Medicines Corp (US:BPMC), Prime Medicine Inc (US:PRME), Allogene Therapeutics Inc (US:ALLO), Mersana Therapeutics Inc (US:MRSN) and Sana Biotechnology Inc (US:SANA).
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top five positions in the fund currently by size are Seagen Inc (US:GEN), Incyte Corp. (US:INCY), BeiGene Ltd - ADR (US:BGNE), Acadia Pharmaceuticals Inc (US:ACAD) and Madrigal Pharmaceuticals Inc (US:MDGL). Another noteworthy addition was Acadia Pharmaceuticals, which saw a marginal increase in portfolio allocation of 0.29%, driven mainly by share price gains. Despite a comparatively smaller market value of $789.28 million, ACAD stock accounted for 4.2943% of the portfolio, showcasing the fund's diversification strategy. | The top five positions in the fund currently by size are Seagen Inc (US:GEN), Incyte Corp. (US:INCY), BeiGene Ltd - ADR (US:BGNE), Acadia Pharmaceuticals Inc (US:ACAD) and Madrigal Pharmaceuticals Inc (US:MDGL). Another noteworthy addition was Acadia Pharmaceuticals, which saw a marginal increase in portfolio allocation of 0.29%, driven mainly by share price gains. Despite a comparatively smaller market value of $789.28 million, ACAD stock accounted for 4.2943% of the portfolio, showcasing the fund's diversification strategy. | The top five positions in the fund currently by size are Seagen Inc (US:GEN), Incyte Corp. (US:INCY), BeiGene Ltd - ADR (US:BGNE), Acadia Pharmaceuticals Inc (US:ACAD) and Madrigal Pharmaceuticals Inc (US:MDGL). Another noteworthy addition was Acadia Pharmaceuticals, which saw a marginal increase in portfolio allocation of 0.29%, driven mainly by share price gains. Despite a comparatively smaller market value of $789.28 million, ACAD stock accounted for 4.2943% of the portfolio, showcasing the fund's diversification strategy. | Another noteworthy addition was Acadia Pharmaceuticals, which saw a marginal increase in portfolio allocation of 0.29%, driven mainly by share price gains. The top five positions in the fund currently by size are Seagen Inc (US:GEN), Incyte Corp. (US:INCY), BeiGene Ltd - ADR (US:BGNE), Acadia Pharmaceuticals Inc (US:ACAD) and Madrigal Pharmaceuticals Inc (US:MDGL). Despite a comparatively smaller market value of $789.28 million, ACAD stock accounted for 4.2943% of the portfolio, showcasing the fund's diversification strategy. |
35626.0 | 2023-05-22 00:00:00 UTC | Guru Fundamental Report for ACAD | ACAD | https://www.nasdaq.com/articles/guru-fundamental-report-for-acad | nan | nan | Below is Validea's guru fundamental report for ACADIA PHARMACEUTICALS INC (ACAD). Of the 22 guru strategies we follow, ACAD rates highest using our Twin Momentum Investor model based on the published strategy of Dashan Huang. This momentum model looks for a combination of fundamental momentum and price momentum.
ACADIA PHARMACEUTICALS INC (ACAD) is a mid-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 83% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
FUNDAMENTAL MOMENTUM: PASS
TWELVE MINUS ONE MOMENTUM: PASS
FINAL RANK: FAIL
Detailed Analysis of ACADIA PHARMACEUTICALS INC
ACAD Guru Analysis
ACAD Fundamental Analysis
More Information on Dashan Huang
Dashan Huang Portfolio
About Dashan Huang: Dashan Huang is an Assistant Professor of Finance at the Lee Kong Chian School of Business at Singapore Management University. His paper "Twin Momentum" looked at combining traditional price momentum with improving fundamentals to generate market outperformance. In the paper, he identified seven fundamental variables (earnings, return on equity, return on assets, accrual operating profitability to equity, cash operating profitability to assets, gross profit to assets and net payout ratio) that he combined into a single fundamental momentum measure. He showed that stocks in the top 20% of the universe according to that measure outperformed the market going forward. When he combined that measure with price momentum, he was able to double its outperformance.
Additional Research Links
Factor-Based Stock Portfolios
Factor-Based ETF Portfolios
Harry Browne Permanent Portfolio
Ray Dalio All Weather Portfolio
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA PHARMACEUTICALS INC (ACAD) is a mid-cap value stock in the Biotechnology & Drugs industry. Below is Validea's guru fundamental report for ACADIA PHARMACEUTICALS INC (ACAD). Of the 22 guru strategies we follow, ACAD rates highest using our Twin Momentum Investor model based on the published strategy of Dashan Huang. | Of the 22 guru strategies we follow, ACAD rates highest using our Twin Momentum Investor model based on the published strategy of Dashan Huang. Detailed Analysis of ACADIA PHARMACEUTICALS INC ACAD Guru Analysis ACAD Fundamental Analysis More Information on Dashan Huang Dashan Huang Portfolio About Dashan Huang: Dashan Huang is an Assistant Professor of Finance at the Lee Kong Chian School of Business at Singapore Management University. Below is Validea's guru fundamental report for ACADIA PHARMACEUTICALS INC (ACAD). | Detailed Analysis of ACADIA PHARMACEUTICALS INC ACAD Guru Analysis ACAD Fundamental Analysis More Information on Dashan Huang Dashan Huang Portfolio About Dashan Huang: Dashan Huang is an Assistant Professor of Finance at the Lee Kong Chian School of Business at Singapore Management University. Below is Validea's guru fundamental report for ACADIA PHARMACEUTICALS INC (ACAD). Of the 22 guru strategies we follow, ACAD rates highest using our Twin Momentum Investor model based on the published strategy of Dashan Huang. | Of the 22 guru strategies we follow, ACAD rates highest using our Twin Momentum Investor model based on the published strategy of Dashan Huang. Below is Validea's guru fundamental report for ACADIA PHARMACEUTICALS INC (ACAD). ACADIA PHARMACEUTICALS INC (ACAD) is a mid-cap value stock in the Biotechnology & Drugs industry. |
35627.0 | 2023-05-22 00:00:00 UTC | B of A Securities Maintains Acadia Pharmaceuticals (ACAD) Neutral Recommendation | ACAD | https://www.nasdaq.com/articles/b-of-a-securities-maintains-acadia-pharmaceuticals-acad-neutral-recommendation | nan | nan | Fintel reports that on May 22, 2023, B of A Securities maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Neutral recommendation.
Analyst Price Forecast Suggests 3.60% Downside
As of May 11, 2023, the average one-year price target for Acadia Pharmaceuticals is 23.43. The forecasts range from a low of 12.12 to a high of $34.65. The average price target represents a decrease of 3.60% from its latest reported closing price of 24.31.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Acadia Pharmaceuticals is 597MM, an increase of 14.76%. The projected annual non-GAAP EPS is -0.80.
For more in-depth coverage of Acadia Pharmaceuticals, view the free, crowd-sourced company research report on Finpedia.
What is the Fund Sentiment?
There are 490 funds or institutions reporting positions in Acadia Pharmaceuticals. This is a decrease of 2 owner(s) or 0.41% in the last quarter. Average portfolio weight of all funds dedicated to ACAD is 0.19%, an increase of 10.71%. Total shares owned by institutions increased in the last three months by 1.03% to 164,255K shares.
The put/call ratio of ACAD is 0.32, indicating a bullish outlook.
What are Other Shareholders Doing?
Baker Bros. Advisors holds 41,938K shares representing 25.79% ownership of the company. In it's prior filing, the firm reported owning 41,923K shares, representing an increase of 0.04%. The firm increased its portfolio allocation in ACAD by 7.14% over the last quarter.
Rtw Investments holds 8,243K shares representing 5.07% ownership of the company. In it's prior filing, the firm reported owning 3,671K shares, representing an increase of 55.47%. The firm increased its portfolio allocation in ACAD by 170.78% over the last quarter.
EcoR1 Capital holds 5,991K shares representing 3.68% ownership of the company. No change in the last quarter.
XBI - SPDR(R) S&P(R) Biotech ETF holds 5,376K shares representing 3.31% ownership of the company. In it's prior filing, the firm reported owning 4,369K shares, representing an increase of 18.72%. The firm increased its portfolio allocation in ACAD by 1.90% over the last quarter.
D. E. Shaw holds 4,901K shares representing 3.01% ownership of the company. In it's prior filing, the firm reported owning 4,219K shares, representing an increase of 13.90%. The firm increased its portfolio allocation in ACAD by 4.72% over the last quarter.
Acadia Pharmaceuticals Background Information
(This description is provided by the company.)
Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years it has been working at the forefront of healthcare to bring vital solutions to people who need them most. It developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson's disease psychosis. Its late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research it is exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders.
Key filings for this company:
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Fintel reports that on May 22, 2023, B of A Securities maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Neutral recommendation. For more in-depth coverage of Acadia Pharmaceuticals, view the free, crowd-sourced company research report on Finpedia. Analyst Price Forecast Suggests 3.60% Downside As of May 11, 2023, the average one-year price target for Acadia Pharmaceuticals is 23.43. | Fintel reports that on May 22, 2023, B of A Securities maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Neutral recommendation. Analyst Price Forecast Suggests 3.60% Downside As of May 11, 2023, the average one-year price target for Acadia Pharmaceuticals is 23.43. The projected annual revenue for Acadia Pharmaceuticals is 597MM, an increase of 14.76%. | Fintel reports that on May 22, 2023, B of A Securities maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Neutral recommendation. Analyst Price Forecast Suggests 3.60% Downside As of May 11, 2023, the average one-year price target for Acadia Pharmaceuticals is 23.43. The projected annual revenue for Acadia Pharmaceuticals is 597MM, an increase of 14.76%. | Analyst Price Forecast Suggests 3.60% Downside As of May 11, 2023, the average one-year price target for Acadia Pharmaceuticals is 23.43. The projected annual revenue for Acadia Pharmaceuticals is 597MM, an increase of 14.76%. There are 490 funds or institutions reporting positions in Acadia Pharmaceuticals. |
35628.0 | 2023-05-19 00:00:00 UTC | Friday's ETF Movers: FBT, KRE | ACAD | https://www.nasdaq.com/articles/fridays-etf-movers%3A-fbt-kre | nan | nan | In trading on Friday, the First Trust NYSE Arca Biotechnology Index Fund ETF is outperforming other ETFs, up about 1.1% on the day. Components of that ETF showing particular strength include shares of Ionis Pharmaceuticals, up about 7% and shares of Acadia Pharmaceuticals, up about 4.4% on the day.
And underperforming other ETFs today is the SPDR S&P Regional Banking ETF, down about 2% in Friday afternoon trading. Among components of that ETF with the weakest showing on Friday were shares of First Foundation, lower by about 8.1%, and shares of Valley National Bancorp, lower by about 5.7% on the day.
VIDEO: Friday's ETF Movers: FBT, KRE
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Components of that ETF showing particular strength include shares of Ionis Pharmaceuticals, up about 7% and shares of Acadia Pharmaceuticals, up about 4.4% on the day. Among components of that ETF with the weakest showing on Friday were shares of First Foundation, lower by about 8.1%, and shares of Valley National Bancorp, lower by about 5.7% on the day. VIDEO: Friday's ETF Movers: FBT, KRE The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Components of that ETF showing particular strength include shares of Ionis Pharmaceuticals, up about 7% and shares of Acadia Pharmaceuticals, up about 4.4% on the day. Among components of that ETF with the weakest showing on Friday were shares of First Foundation, lower by about 8.1%, and shares of Valley National Bancorp, lower by about 5.7% on the day. VIDEO: Friday's ETF Movers: FBT, KRE The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Components of that ETF showing particular strength include shares of Ionis Pharmaceuticals, up about 7% and shares of Acadia Pharmaceuticals, up about 4.4% on the day. In trading on Friday, the First Trust NYSE Arca Biotechnology Index Fund ETF is outperforming other ETFs, up about 1.1% on the day. Among components of that ETF with the weakest showing on Friday were shares of First Foundation, lower by about 8.1%, and shares of Valley National Bancorp, lower by about 5.7% on the day. | Components of that ETF showing particular strength include shares of Ionis Pharmaceuticals, up about 7% and shares of Acadia Pharmaceuticals, up about 4.4% on the day. In trading on Friday, the First Trust NYSE Arca Biotechnology Index Fund ETF is outperforming other ETFs, up about 1.1% on the day. And underperforming other ETFs today is the SPDR S&P Regional Banking ETF, down about 2% in Friday afternoon trading. |
35629.0 | 2023-05-18 00:00:00 UTC | Acadia Pharmaceuticals Reaches Analyst Target Price | ACAD | https://www.nasdaq.com/articles/acadia-pharmaceuticals-reaches-analyst-target-price-0 | nan | nan | In recent trading, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) have crossed above the average analyst 12-month target price of $22.42, changing hands for $22.68/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher — if things are looking up for the company, perhaps it is time for that target price to be raised.
There are 18 different analyst targets within the Zacks coverage universe contributing to that average for Acadia Pharmaceuticals Inc, but the average is just that — a mathematical average. There are analysts with lower targets than the average, including one looking for a price of $12.00. And then on the other side of the spectrum one analyst has a target as high as $33.00. The standard deviation is $5.011.
But the whole reason to look at the average ACAD price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with ACAD crossing above that average target price of $22.42/share, investors in ACAD have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $22.42 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover Acadia Pharmaceuticals Inc:
RECENT ACAD ANALYST RATINGS BREAKDOWN
» Current 1 Month Ago 2 Month Ago 3 Month Ago
Strong buy ratings: 6 5 6 6
Buy ratings: 1 1 1 1
Hold ratings: 9 10 10 9
Sell ratings: 1 1 1 1
Strong sell ratings: 1 1 1 1
Average rating: 2.44 2.56 2.47 2.44
The average rating presented in the last row of the above table above is from 1 to 5 where 1 is Strong Buy and 5 is Strong Sell. This article used data provided by Zacks Investment Research via Quandl.com. Get the latest Zacks research report on ACAD — FREE.
The Top 25 Broker Analyst Picks of the S&P 500 »
Also see:
Top Broker Analyst Picks
TRHC market cap history
SLGG Past Earnings
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In recent trading, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) have crossed above the average analyst 12-month target price of $22.42, changing hands for $22.68/share. And so with ACAD crossing above that average target price of $22.42/share, investors in ACAD have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $22.42 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? There are 18 different analyst targets within the Zacks coverage universe contributing to that average for Acadia Pharmaceuticals Inc, but the average is just that — a mathematical average. | In recent trading, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) have crossed above the average analyst 12-month target price of $22.42, changing hands for $22.68/share. But the whole reason to look at the average ACAD price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. There are 18 different analyst targets within the Zacks coverage universe contributing to that average for Acadia Pharmaceuticals Inc, but the average is just that — a mathematical average. | There are 18 different analyst targets within the Zacks coverage universe contributing to that average for Acadia Pharmaceuticals Inc, but the average is just that — a mathematical average. And so with ACAD crossing above that average target price of $22.42/share, investors in ACAD have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $22.42 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? In recent trading, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) have crossed above the average analyst 12-month target price of $22.42, changing hands for $22.68/share. | In recent trading, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) have crossed above the average analyst 12-month target price of $22.42, changing hands for $22.68/share. There are 18 different analyst targets within the Zacks coverage universe contributing to that average for Acadia Pharmaceuticals Inc, but the average is just that — a mathematical average. But the whole reason to look at the average ACAD price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. |
35630.0 | 2023-05-14 00:00:00 UTC | These Biotech Stocks Hit New Highs Last Week - Were You Ahead Of The Game? | ACAD | https://www.nasdaq.com/articles/these-biotech-stocks-hit-new-highs-last-week-were-you-ahead-of-the-game | nan | nan | (RTTNews) - Several of the biotech stocks featured on our site hit new highs last week, and the following are some of them.
TICKER
PUBLISHED DATE
PUBLISHED PRICE
MAXIMUM PRICE SINCE PUBLICATION
LAST CLOSING PRICE
MAXIMUM GAIN %
Nano-X Imaging Ltd. (NNOX)
May 1, 2023
$8.81
$21.50
$19.27
144%
MoonLake Immunotherapeutics (MLTX)
Oct.19, 2022
$8.28
$29.59
$27.72
257%
Augmedix, Inc. (AUGX
May 8, 2023
$3.65
$4.29
$3.21
17%
MiMedx Group, Inc. (MDXG)
Aug.3, 2022
$3.57
$6.42
$6.14
79%
RxSight, Inc. (RXST)
Aug.10, 2022
$15.45
$23.79
$22.96
53%
Viking Therapeutics, Inc. (VKTX)
Jan.24, 2023
$8.44
$23.50
$22.53
178%
Axsome Therapeutics, Inc. (AXSM)
Apr.17, 2023
$68.99
$82.85
$79.01
20%
Morphic Holding, Inc. (MORF)
Nov.17, 2022
$28.42
$59.54
$57.34
109%
Harrow Health Inc. (HROW)
Sep.21, 2022
$8.35
$28.25
$22.04
238%
Reata Pharmaceuticals, Inc. (RETA)
Mar.1, 2023
$87.84
$106.69
$85.63
21%
Vaxcyte Inc. (PCVX)
Oct.24, 2022
$35.15
$54.84
$49.48
56%
ACADIA Pharmaceuticals Inc. (ACAD)
Apr.18, 2023
$19.49
$22.12
$21.47
13%
Marinus Pharmaceuticals, Inc. (MRNS)
Mar.15, 2023
$6.88
$9.82
$8.78
42%
Revance Therapeutics, Inc. (RVNC)
Aug.19, 2022
$22.00
$37.98
$35.18
72%
Achieve Life Sciences, Inc. (ACHV)
Feb.13, 2023
$5.45
$10.00
$8.22
83%
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Nano-X Imaging Ltd. (NNOX) May 1, 2023 $8.81 $21.50 $19.27 144% MoonLake Immunotherapeutics (MLTX) Oct.19, 2022 $8.28 $29.59 $27.72 257% Augmedix, Inc. (AUGX May 8, 2023 $3.65 $4.29 $3.21 17% MiMedx Group, Inc. (MDXG) Aug.3, 2022 $3.57 $6.42 $6.14 79% RxSight, Inc. (RXST) Aug.10, 2022 $15.45 $23.79 $22.96 53% Viking Therapeutics, Inc. (VKTX) Jan.24, 2023 $8.44 $23.50 $22.53 178% Axsome Therapeutics, Inc. (AXSM) Apr.17, 2023 $68.99 $82.85 $79.01 20% Morphic Holding, Inc. (MORF) Nov.17, 2022 $28.42 $59.54 $57.34 109% Harrow Health Inc. (HROW) Sep.21, 2022 $8.35 $28.25 $22.04 238% Reata Pharmaceuticals, Inc. (RETA) Mar.1, 2023 $87.84 $106.69 $85.63 21% Vaxcyte Inc. (PCVX) Oct.24, 2022 $35.15 $54.84 $49.48 56% ACADIA Pharmaceuticals Inc. (ACAD) Apr.18, 2023 $19.49 $22.12 $21.47 13% Marinus Pharmaceuticals, Inc. (MRNS) Mar.15, 2023 $6.88 $9.82 $8.78 42% Revance Therapeutics, Inc. (RVNC) Aug.19, 2022 $22.00 $37.98 $35.18 72% Achieve Life Sciences, Inc. (ACHV) Feb.13, 2023 $5.45 $10.00 $8.22 83% The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - Several of the biotech stocks featured on our site hit new highs last week, and the following are some of them. | Nano-X Imaging Ltd. (NNOX) May 1, 2023 $8.81 $21.50 $19.27 144% MoonLake Immunotherapeutics (MLTX) Oct.19, 2022 $8.28 $29.59 $27.72 257% Augmedix, Inc. (AUGX May 8, 2023 $3.65 $4.29 $3.21 17% MiMedx Group, Inc. (MDXG) Aug.3, 2022 $3.57 $6.42 $6.14 79% RxSight, Inc. (RXST) Aug.10, 2022 $15.45 $23.79 $22.96 53% Viking Therapeutics, Inc. (VKTX) Jan.24, 2023 $8.44 $23.50 $22.53 178% Axsome Therapeutics, Inc. (AXSM) Apr.17, 2023 $68.99 $82.85 $79.01 20% Morphic Holding, Inc. (MORF) Nov.17, 2022 $28.42 $59.54 $57.34 109% Harrow Health Inc. (HROW) Sep.21, 2022 $8.35 $28.25 $22.04 238% Reata Pharmaceuticals, Inc. (RETA) Mar.1, 2023 $87.84 $106.69 $85.63 21% Vaxcyte Inc. (PCVX) Oct.24, 2022 $35.15 $54.84 $49.48 56% ACADIA Pharmaceuticals Inc. (ACAD) Apr.18, 2023 $19.49 $22.12 $21.47 13% Marinus Pharmaceuticals, Inc. (MRNS) Mar.15, 2023 $6.88 $9.82 $8.78 42% Revance Therapeutics, Inc. (RVNC) Aug.19, 2022 $22.00 $37.98 $35.18 72% Achieve Life Sciences, Inc. (ACHV) Feb.13, 2023 $5.45 $10.00 $8.22 83% The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - Several of the biotech stocks featured on our site hit new highs last week, and the following are some of them. | Nano-X Imaging Ltd. (NNOX) May 1, 2023 $8.81 $21.50 $19.27 144% MoonLake Immunotherapeutics (MLTX) Oct.19, 2022 $8.28 $29.59 $27.72 257% Augmedix, Inc. (AUGX May 8, 2023 $3.65 $4.29 $3.21 17% MiMedx Group, Inc. (MDXG) Aug.3, 2022 $3.57 $6.42 $6.14 79% RxSight, Inc. (RXST) Aug.10, 2022 $15.45 $23.79 $22.96 53% Viking Therapeutics, Inc. (VKTX) Jan.24, 2023 $8.44 $23.50 $22.53 178% Axsome Therapeutics, Inc. (AXSM) Apr.17, 2023 $68.99 $82.85 $79.01 20% Morphic Holding, Inc. (MORF) Nov.17, 2022 $28.42 $59.54 $57.34 109% Harrow Health Inc. (HROW) Sep.21, 2022 $8.35 $28.25 $22.04 238% Reata Pharmaceuticals, Inc. (RETA) Mar.1, 2023 $87.84 $106.69 $85.63 21% Vaxcyte Inc. (PCVX) Oct.24, 2022 $35.15 $54.84 $49.48 56% ACADIA Pharmaceuticals Inc. (ACAD) Apr.18, 2023 $19.49 $22.12 $21.47 13% Marinus Pharmaceuticals, Inc. (MRNS) Mar.15, 2023 $6.88 $9.82 $8.78 42% Revance Therapeutics, Inc. (RVNC) Aug.19, 2022 $22.00 $37.98 $35.18 72% Achieve Life Sciences, Inc. (ACHV) Feb.13, 2023 $5.45 $10.00 $8.22 83% The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - Several of the biotech stocks featured on our site hit new highs last week, and the following are some of them. | Nano-X Imaging Ltd. (NNOX) May 1, 2023 $8.81 $21.50 $19.27 144% MoonLake Immunotherapeutics (MLTX) Oct.19, 2022 $8.28 $29.59 $27.72 257% Augmedix, Inc. (AUGX May 8, 2023 $3.65 $4.29 $3.21 17% MiMedx Group, Inc. (MDXG) Aug.3, 2022 $3.57 $6.42 $6.14 79% RxSight, Inc. (RXST) Aug.10, 2022 $15.45 $23.79 $22.96 53% Viking Therapeutics, Inc. (VKTX) Jan.24, 2023 $8.44 $23.50 $22.53 178% Axsome Therapeutics, Inc. (AXSM) Apr.17, 2023 $68.99 $82.85 $79.01 20% Morphic Holding, Inc. (MORF) Nov.17, 2022 $28.42 $59.54 $57.34 109% Harrow Health Inc. (HROW) Sep.21, 2022 $8.35 $28.25 $22.04 238% Reata Pharmaceuticals, Inc. (RETA) Mar.1, 2023 $87.84 $106.69 $85.63 21% Vaxcyte Inc. (PCVX) Oct.24, 2022 $35.15 $54.84 $49.48 56% ACADIA Pharmaceuticals Inc. (ACAD) Apr.18, 2023 $19.49 $22.12 $21.47 13% Marinus Pharmaceuticals, Inc. (MRNS) Mar.15, 2023 $6.88 $9.82 $8.78 42% Revance Therapeutics, Inc. (RVNC) Aug.19, 2022 $22.00 $37.98 $35.18 72% Achieve Life Sciences, Inc. (ACHV) Feb.13, 2023 $5.45 $10.00 $8.22 83% The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - Several of the biotech stocks featured on our site hit new highs last week, and the following are some of them. |
35631.0 | 2023-05-09 00:00:00 UTC | Cantor Fitzgerald Reiterates Acadia Pharmaceuticals (ACAD) Overweight Recommendation | ACAD | https://www.nasdaq.com/articles/cantor-fitzgerald-reiterates-acadia-pharmaceuticals-acad-overweight-recommendation | nan | nan | Fintel reports that on May 9, 2023, Cantor Fitzgerald reiterated coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Overweight recommendation.
Analyst Price Forecast Suggests 6.50% Upside
As of April 24, 2023, the average one-year price target for Acadia Pharmaceuticals is 22.95. The forecasts range from a low of 12.12 to a high of $34.65. The average price target represents an increase of 6.50% from its latest reported closing price of 21.55.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Acadia Pharmaceuticals is 597MM, an increase of 14.76%. The projected annual non-GAAP EPS is -0.80.
For more in-depth coverage of Acadia Pharmaceuticals, view the free, crowd-sourced company research report on Finpedia.
What is the Fund Sentiment?
There are 476 funds or institutions reporting positions in Acadia Pharmaceuticals. This is a decrease of 21 owner(s) or 4.23% in the last quarter. Average portfolio weight of all funds dedicated to ACAD is 0.20%, an increase of 18.41%. Total shares owned by institutions increased in the last three months by 2.13% to 165,076K shares.
The put/call ratio of ACAD is 0.38, indicating a bullish outlook.
What are Other Shareholders Doing?
Baker Bros. Advisors holds 41,923K shares representing 25.84% ownership of the company. No change in the last quarter.
EcoR1 Capital holds 5,991K shares representing 3.69% ownership of the company. No change in the last quarter.
XBI - SPDR(R) S&P(R) Biotech ETF holds 5,376K shares representing 3.31% ownership of the company. In it's prior filing, the firm reported owning 4,369K shares, representing an increase of 18.72%. The firm increased its portfolio allocation in ACAD by 1.90% over the last quarter.
Price T Rowe Associates holds 4,279K shares representing 2.64% ownership of the company. In it's prior filing, the firm reported owning 4,891K shares, representing a decrease of 14.30%. The firm decreased its portfolio allocation in ACAD by 16.41% over the last quarter.
D. E. Shaw holds 4,219K shares representing 2.60% ownership of the company. In it's prior filing, the firm reported owning 4,712K shares, representing a decrease of 11.68%. The firm decreased its portfolio allocation in ACAD by 19.37% over the last quarter.
Acadia Pharmaceuticals Background Information
(This description is provided by the company.)
Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years it has been working at the forefront of healthcare to bring vital solutions to people who need them most. It developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson's disease psychosis. Its late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research it is exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders.
See all Acadia Pharmaceuticals regulatory filings.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Fintel reports that on May 9, 2023, Cantor Fitzgerald reiterated coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Overweight recommendation. For more in-depth coverage of Acadia Pharmaceuticals, view the free, crowd-sourced company research report on Finpedia. Analyst Price Forecast Suggests 6.50% Upside As of April 24, 2023, the average one-year price target for Acadia Pharmaceuticals is 22.95. | Fintel reports that on May 9, 2023, Cantor Fitzgerald reiterated coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Overweight recommendation. Analyst Price Forecast Suggests 6.50% Upside As of April 24, 2023, the average one-year price target for Acadia Pharmaceuticals is 22.95. The projected annual revenue for Acadia Pharmaceuticals is 597MM, an increase of 14.76%. | Fintel reports that on May 9, 2023, Cantor Fitzgerald reiterated coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Overweight recommendation. Analyst Price Forecast Suggests 6.50% Upside As of April 24, 2023, the average one-year price target for Acadia Pharmaceuticals is 22.95. The projected annual revenue for Acadia Pharmaceuticals is 597MM, an increase of 14.76%. | There are 476 funds or institutions reporting positions in Acadia Pharmaceuticals. The firm increased its portfolio allocation in ACAD by 1.90% over the last quarter. Fintel reports that on May 9, 2023, Cantor Fitzgerald reiterated coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Overweight recommendation. |
35632.0 | 2023-05-09 00:00:00 UTC | JMP Securities Maintains Acadia Pharmaceuticals (ACAD) Outperform Recommendation | ACAD | https://www.nasdaq.com/articles/jmp-securities-maintains-acadia-pharmaceuticals-acad-outperform-recommendation | nan | nan | Fintel reports that on May 9, 2023, JMP Securities maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Outperform recommendation.
Analyst Price Forecast Suggests 6.50% Upside
As of April 24, 2023, the average one-year price target for Acadia Pharmaceuticals is 22.95. The forecasts range from a low of 12.12 to a high of $34.65. The average price target represents an increase of 6.50% from its latest reported closing price of 21.55.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Acadia Pharmaceuticals is 597MM, an increase of 14.76%. The projected annual non-GAAP EPS is -0.80.
For more in-depth coverage of Acadia Pharmaceuticals, view the free, crowd-sourced company research report on Finpedia.
What is the Fund Sentiment?
There are 476 funds or institutions reporting positions in Acadia Pharmaceuticals. This is a decrease of 21 owner(s) or 4.23% in the last quarter. Average portfolio weight of all funds dedicated to ACAD is 0.20%, an increase of 18.41%. Total shares owned by institutions increased in the last three months by 2.13% to 165,076K shares.
The put/call ratio of ACAD is 0.38, indicating a bullish outlook.
What are Other Shareholders Doing?
Baker Bros. Advisors holds 41,923K shares representing 25.84% ownership of the company. No change in the last quarter.
EcoR1 Capital holds 5,991K shares representing 3.69% ownership of the company. No change in the last quarter.
XBI - SPDR(R) S&P(R) Biotech ETF holds 5,376K shares representing 3.31% ownership of the company. In it's prior filing, the firm reported owning 4,369K shares, representing an increase of 18.72%. The firm increased its portfolio allocation in ACAD by 1.90% over the last quarter.
Price T Rowe Associates holds 4,279K shares representing 2.64% ownership of the company. In it's prior filing, the firm reported owning 4,891K shares, representing a decrease of 14.30%. The firm decreased its portfolio allocation in ACAD by 16.41% over the last quarter.
D. E. Shaw holds 4,219K shares representing 2.60% ownership of the company. In it's prior filing, the firm reported owning 4,712K shares, representing a decrease of 11.68%. The firm decreased its portfolio allocation in ACAD by 19.37% over the last quarter.
Acadia Pharmaceuticals Background Information
(This description is provided by the company.)
Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years it has been working at the forefront of healthcare to bring vital solutions to people who need them most. It developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson's disease psychosis. Its late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research it is exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders.
See all Acadia Pharmaceuticals regulatory filings.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Fintel reports that on May 9, 2023, JMP Securities maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Outperform recommendation. For more in-depth coverage of Acadia Pharmaceuticals, view the free, crowd-sourced company research report on Finpedia. Analyst Price Forecast Suggests 6.50% Upside As of April 24, 2023, the average one-year price target for Acadia Pharmaceuticals is 22.95. | Fintel reports that on May 9, 2023, JMP Securities maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Outperform recommendation. Analyst Price Forecast Suggests 6.50% Upside As of April 24, 2023, the average one-year price target for Acadia Pharmaceuticals is 22.95. The projected annual revenue for Acadia Pharmaceuticals is 597MM, an increase of 14.76%. | Fintel reports that on May 9, 2023, JMP Securities maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Outperform recommendation. Analyst Price Forecast Suggests 6.50% Upside As of April 24, 2023, the average one-year price target for Acadia Pharmaceuticals is 22.95. The projected annual revenue for Acadia Pharmaceuticals is 597MM, an increase of 14.76%. | There are 476 funds or institutions reporting positions in Acadia Pharmaceuticals. The firm increased its portfolio allocation in ACAD by 1.90% over the last quarter. Fintel reports that on May 9, 2023, JMP Securities maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Outperform recommendation. |
35633.0 | 2023-05-09 00:00:00 UTC | HC Wainwright & Co. Reiterates Acadia Pharmaceuticals (ACAD) Buy Recommendation | ACAD | https://www.nasdaq.com/articles/hc-wainwright-co.-reiterates-acadia-pharmaceuticals-acad-buy-recommendation | nan | nan | Fintel reports that on May 9, 2023, HC Wainwright & Co. reiterated coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Buy recommendation.
Analyst Price Forecast Suggests 6.50% Upside
As of April 24, 2023, the average one-year price target for Acadia Pharmaceuticals is 22.95. The forecasts range from a low of 12.12 to a high of $34.65. The average price target represents an increase of 6.50% from its latest reported closing price of 21.55.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Acadia Pharmaceuticals is 597MM, an increase of 14.76%. The projected annual non-GAAP EPS is -0.80.
For more in-depth coverage of Acadia Pharmaceuticals, view the free, crowd-sourced company research report on Finpedia.
What is the Fund Sentiment?
There are 476 funds or institutions reporting positions in Acadia Pharmaceuticals. This is a decrease of 21 owner(s) or 4.23% in the last quarter. Average portfolio weight of all funds dedicated to ACAD is 0.20%, an increase of 18.41%. Total shares owned by institutions increased in the last three months by 2.13% to 165,076K shares.
The put/call ratio of ACAD is 0.38, indicating a bullish outlook.
What are Other Shareholders Doing?
Baker Bros. Advisors holds 41,923K shares representing 25.84% ownership of the company. No change in the last quarter.
EcoR1 Capital holds 5,991K shares representing 3.69% ownership of the company. No change in the last quarter.
XBI - SPDR(R) S&P(R) Biotech ETF holds 5,376K shares representing 3.31% ownership of the company. In it's prior filing, the firm reported owning 4,369K shares, representing an increase of 18.72%. The firm increased its portfolio allocation in ACAD by 1.90% over the last quarter.
Price T Rowe Associates holds 4,279K shares representing 2.64% ownership of the company. In it's prior filing, the firm reported owning 4,891K shares, representing a decrease of 14.30%. The firm decreased its portfolio allocation in ACAD by 16.41% over the last quarter.
D. E. Shaw holds 4,219K shares representing 2.60% ownership of the company. In it's prior filing, the firm reported owning 4,712K shares, representing a decrease of 11.68%. The firm decreased its portfolio allocation in ACAD by 19.37% over the last quarter.
Acadia Pharmaceuticals Background Information
(This description is provided by the company.)
Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years it has been working at the forefront of healthcare to bring vital solutions to people who need them most. It developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson's disease psychosis. Its late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research it is exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders.
See all Acadia Pharmaceuticals regulatory filings.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Fintel reports that on May 9, 2023, HC Wainwright & Co. reiterated coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Buy recommendation. For more in-depth coverage of Acadia Pharmaceuticals, view the free, crowd-sourced company research report on Finpedia. Analyst Price Forecast Suggests 6.50% Upside As of April 24, 2023, the average one-year price target for Acadia Pharmaceuticals is 22.95. | Fintel reports that on May 9, 2023, HC Wainwright & Co. reiterated coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Buy recommendation. Analyst Price Forecast Suggests 6.50% Upside As of April 24, 2023, the average one-year price target for Acadia Pharmaceuticals is 22.95. The projected annual revenue for Acadia Pharmaceuticals is 597MM, an increase of 14.76%. | Fintel reports that on May 9, 2023, HC Wainwright & Co. reiterated coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Buy recommendation. Analyst Price Forecast Suggests 6.50% Upside As of April 24, 2023, the average one-year price target for Acadia Pharmaceuticals is 22.95. The projected annual revenue for Acadia Pharmaceuticals is 597MM, an increase of 14.76%. | There are 476 funds or institutions reporting positions in Acadia Pharmaceuticals. The firm increased its portfolio allocation in ACAD by 1.90% over the last quarter. Fintel reports that on May 9, 2023, HC Wainwright & Co. reiterated coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Buy recommendation. |
35634.0 | 2023-05-09 00:00:00 UTC | Acadia Pharmaceuticals (ACAD) Q1 Earnings & Sales Miss Estimates | ACAD | https://www.nasdaq.com/articles/acadia-pharmaceuticals-acad-q1-earnings-sales-miss-estimates | nan | nan | Acadia Pharmaceuticals Inc. ACAD reported a first-quarter 2023 loss of 27 cents per share, wider than the Zacks Consensus Estimate of a loss of 21 cents and our estimate of a loss of 26 cents per share. In the year-ago quarter, the company incurred a loss of 70 cents per share.
Total revenues comprised net sales of Nuplazid (pimavanserin) in the first quarter as Acadia’s second-marketed drug, Daybue (trofinetide) was launched in April 2023 in the U.S. market. Revenues from Nuplazid sales increased 3% year over year to $118.5 million in the first quarter, missing the Zacks Consensus Estimate of $122 million. Nuplazid sales decreased 13.2% sequentially in the first quarter.
Nuplazid sales in the first quarter were driven by an increase in new patient starts across both specialty pharmacy and specialty distribution channels. Year-over-year demand was up approximately 2% in the reported quarter.
Total revenues were lower than our estimate of $121.7 million in the reported quarter.
Nuplazid is an FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis (PDP).
Shares of Acadia have shot up 28% in the past year compared with the industry’s 0.2% rise.
Image Source: Zacks Investment Research
Quarter in Detail
Research and development (R&D) expenses in the quarter were $69.1 million, down 46.4% year over year, owing to a $60 million upfront payment made for collaboration with Stoke Therapeutics, which was recorded in the first quarter of 2022.
Selling, general and administrative (SG&A) expenses were $101.2 million, up 4.7% year over year. The expense remained relatively steady year over year due to a reduction in spending in the PDP commercial franchise, which was offset by investments in the Daybue launch.
Acadia had cash, cash equivalents and investments worth $402.9 million as of Mar 31, 2023 compared with $416.8 million as of Dec 31, 2022.
2023 Financial Guidance Reaffirmed
Acadia expects Nuplazid net sales in the range of $520-$550 million for 2023.
The company expects R&D expenses in the $235-$255 million range, while SG&A expenses are expected to be in the range of $360-$380 million in 2023.
Pipeline Updates
Acadia’s second product, Daybue, was approved by the FDA in March 2023 for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. Acadia also received a Rare Pediatric Disease Priority Review Voucher from the FDA, along with the approval of Daybue, which can be used to obtain priority review for a subsequent application.
Daybue was made available in the U.S. market in April 2023.
Acadia is currently evaluating pimavanserin in the phase III ADVANCE-2 study for treating negative symptoms of schizophrenia. The company expects to complete enrollment in the study around mid-year, announcing top-line results from the same in early 2024.
Acadia is also developing ACP-204 as a potential treatment for Alzheimer’s disease psychosis. In the reported quarter, the company completed phase I development of ACP-204, witnessing a favorable safety and tolerability profile. Acadia was also able to identify the doses to be evaluated in the phase II study of ACP-204. The company is currently planning to meet with the FDA to discuss further clinical development plans for the candidate.
ACADIA Pharmaceuticals Inc. Price, Consensus and EPS Surprise
ACADIA Pharmaceuticals Inc. price-consensus-eps-surprise-chart | ACADIA Pharmaceuticals Inc. Quote
Zacks Rank and Stocks to Consider
Acadia currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Allogene Therapeutics ALLO, Anixa Biosciences ANIX and ADMA Biologics, Inc. ADMA, all carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 90 days, the Zacks Consensus Estimate for Allogene Therapeutics’ 2023 loss per share has narrowed from $2.83 to $2.32. In the past year, shares of Allogene Therapeutics have fallen by 17.6%.
ALLO beat estimates in three of the trailing four quarters, missing the mark on one occasion, delivering an average earnings surprise of 5.08%.
In the past 90 days, the Zacks Consensus Estimate for Anixa Therapeutics’ 2023 loss per share has narrowed from 62 cents to 43 cents. In the past year, shares of Anixa Therapeutics have increased by 20.7%.
ANIX beat estimates in each of the trailing four quarters, delivering an average earnings surprise of 24.04%.
In the past 90 days, the Zacks Consensus Estimate for ADMA Biologics’ 2023 loss per share has narrowed from 19 cents to 14 cents. In the past year, shares of ADMA Biologics have increased by 117.4%.
ADMA beat estimates in three out of the trailing four quarters, missing the mark on one occasion, delivering an average earnings surprise of 2.88%.
The New Gold Rush: How Lithium Batteries Will Make Millionaires
As the electric vehicle revolution expands, investors have a chance to target huge gains. Millions of lithium batteries are being made & demand is expected to increase 889%.
Download the brand-new FREE report revealing 5 EV battery stocks set to soar.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ADMA Biologics Inc (ADMA) : Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report
ANIXA BIOSCIENCES INC (ANIX) : Free Stock Analysis Report
Allogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Total revenues comprised net sales of Nuplazid (pimavanserin) in the first quarter as Acadia’s second-marketed drug, Daybue (trofinetide) was launched in April 2023 in the U.S. market. Pipeline Updates Acadia’s second product, Daybue, was approved by the FDA in March 2023 for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. Acadia Pharmaceuticals Inc. ACAD reported a first-quarter 2023 loss of 27 cents per share, wider than the Zacks Consensus Estimate of a loss of 21 cents and our estimate of a loss of 26 cents per share. | Click to get this free report ADMA Biologics Inc (ADMA) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report ANIXA BIOSCIENCES INC (ANIX) : Free Stock Analysis Report Allogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals Inc. ACAD reported a first-quarter 2023 loss of 27 cents per share, wider than the Zacks Consensus Estimate of a loss of 21 cents and our estimate of a loss of 26 cents per share. Total revenues comprised net sales of Nuplazid (pimavanserin) in the first quarter as Acadia’s second-marketed drug, Daybue (trofinetide) was launched in April 2023 in the U.S. market. | Acadia Pharmaceuticals Inc. ACAD reported a first-quarter 2023 loss of 27 cents per share, wider than the Zacks Consensus Estimate of a loss of 21 cents and our estimate of a loss of 26 cents per share. Click to get this free report ADMA Biologics Inc (ADMA) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report ANIXA BIOSCIENCES INC (ANIX) : Free Stock Analysis Report Allogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report To read this article on Zacks.com click here. Total revenues comprised net sales of Nuplazid (pimavanserin) in the first quarter as Acadia’s second-marketed drug, Daybue (trofinetide) was launched in April 2023 in the U.S. market. | Acadia Pharmaceuticals Inc. ACAD reported a first-quarter 2023 loss of 27 cents per share, wider than the Zacks Consensus Estimate of a loss of 21 cents and our estimate of a loss of 26 cents per share. Total revenues comprised net sales of Nuplazid (pimavanserin) in the first quarter as Acadia’s second-marketed drug, Daybue (trofinetide) was launched in April 2023 in the U.S. market. Shares of Acadia have shot up 28% in the past year compared with the industry’s 0.2% rise. |
35635.0 | 2023-05-09 00:00:00 UTC | Citigroup Maintains Acadia Pharmaceuticals (ACAD) Neutral Recommendation | ACAD | https://www.nasdaq.com/articles/citigroup-maintains-acadia-pharmaceuticals-acad-neutral-recommendation | nan | nan | Fintel reports that on May 9, 2023, Citigroup maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Neutral recommendation.
Analyst Price Forecast Suggests 6.50% Upside
As of April 24, 2023, the average one-year price target for Acadia Pharmaceuticals is 22.95. The forecasts range from a low of 12.12 to a high of $34.65. The average price target represents an increase of 6.50% from its latest reported closing price of 21.55.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Acadia Pharmaceuticals is 597MM, an increase of 14.76%. The projected annual non-GAAP EPS is -0.80.
For more in-depth coverage of Acadia Pharmaceuticals, view the free, crowd-sourced company research report on Finpedia.
What is the Fund Sentiment?
There are 476 funds or institutions reporting positions in Acadia Pharmaceuticals. This is a decrease of 21 owner(s) or 4.23% in the last quarter. Average portfolio weight of all funds dedicated to ACAD is 0.20%, an increase of 18.41%. Total shares owned by institutions increased in the last three months by 2.13% to 165,076K shares.
The put/call ratio of ACAD is 0.38, indicating a bullish outlook.
What are Other Shareholders Doing?
Baker Bros. Advisors holds 41,923K shares representing 25.84% ownership of the company. No change in the last quarter.
EcoR1 Capital holds 5,991K shares representing 3.69% ownership of the company. No change in the last quarter.
XBI - SPDR(R) S&P(R) Biotech ETF holds 5,376K shares representing 3.31% ownership of the company. In it's prior filing, the firm reported owning 4,369K shares, representing an increase of 18.72%. The firm increased its portfolio allocation in ACAD by 1.90% over the last quarter.
Price T Rowe Associates holds 4,279K shares representing 2.64% ownership of the company. In it's prior filing, the firm reported owning 4,891K shares, representing a decrease of 14.30%. The firm decreased its portfolio allocation in ACAD by 16.41% over the last quarter.
D. E. Shaw holds 4,219K shares representing 2.60% ownership of the company. In it's prior filing, the firm reported owning 4,712K shares, representing a decrease of 11.68%. The firm decreased its portfolio allocation in ACAD by 19.37% over the last quarter.
Acadia Pharmaceuticals Background Information
(This description is provided by the company.)
Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years it has been working at the forefront of healthcare to bring vital solutions to people who need them most. It developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson's disease psychosis. Its late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research it is exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders.
See all Acadia Pharmaceuticals regulatory filings.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Fintel reports that on May 9, 2023, Citigroup maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Neutral recommendation. For more in-depth coverage of Acadia Pharmaceuticals, view the free, crowd-sourced company research report on Finpedia. Analyst Price Forecast Suggests 6.50% Upside As of April 24, 2023, the average one-year price target for Acadia Pharmaceuticals is 22.95. | Fintel reports that on May 9, 2023, Citigroup maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Neutral recommendation. Analyst Price Forecast Suggests 6.50% Upside As of April 24, 2023, the average one-year price target for Acadia Pharmaceuticals is 22.95. The projected annual revenue for Acadia Pharmaceuticals is 597MM, an increase of 14.76%. | Fintel reports that on May 9, 2023, Citigroup maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Neutral recommendation. Analyst Price Forecast Suggests 6.50% Upside As of April 24, 2023, the average one-year price target for Acadia Pharmaceuticals is 22.95. The projected annual revenue for Acadia Pharmaceuticals is 597MM, an increase of 14.76%. | The projected annual revenue for Acadia Pharmaceuticals is 597MM, an increase of 14.76%. The firm increased its portfolio allocation in ACAD by 1.90% over the last quarter. Fintel reports that on May 9, 2023, Citigroup maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Neutral recommendation. |
35636.0 | 2023-05-08 00:00:00 UTC | Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Lags Revenue Estimates | ACAD | https://www.nasdaq.com/articles/acadia-pharmaceuticals-acad-reports-q1-loss-lags-revenue-estimates-0 | nan | nan | Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.70 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -28.57%. A quarter ago, it was expected that this drugmaker would post a loss of $0.25 per share when it actually produced a loss of $0.26, delivering a surprise of -4%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $118.46 million for the quarter ended March 2023, missing the Zacks Consensus Estimate by 2.66%. This compares to year-ago revenues of $115.47 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Acadia shares have added about 37.8% since the beginning of the year versus the S&P 500's gain of 7.7%.
What's Next for Acadia?
While Acadia has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Acadia: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.23 on $139.22 million in revenues for the coming quarter and -$0.57 on $555.92 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Immatics (IMTX), has yet to report results for the quarter ended March 2023.
This company is expected to post quarterly loss of $0.35 per share in its upcoming report, which represents a year-over-year change of -123%. The consensus EPS estimate for the quarter has been revised 25.3% higher over the last 30 days to the current level.
Immatics' revenues are expected to be $10.29 million, down 91.1% from the year-ago quarter.
Zacks Reveals ChatGPT "Sleeper" Stock
One little-known company is at the heart of an especially brilliant Artificial Intelligence sector. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
As a service to readers, Zacks is providing a bonus report that names and explains this explosive growth stock and 4 other "must buys." Plus more.
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report
Immatics N.V. (IMTX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.21. Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $118.46 million for the quarter ended March 2023, missing the Zacks Consensus Estimate by 2.66%. Acadia shares have added about 37.8% since the beginning of the year versus the S&P 500's gain of 7.7%. | Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $118.46 million for the quarter ended March 2023, missing the Zacks Consensus Estimate by 2.66%. Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Immatics N.V. (IMTX) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.21. | Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $118.46 million for the quarter ended March 2023, missing the Zacks Consensus Estimate by 2.66%. Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Immatics N.V. (IMTX) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.21. | Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.21. Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $118.46 million for the quarter ended March 2023, missing the Zacks Consensus Estimate by 2.66%. Acadia shares have added about 37.8% since the beginning of the year versus the S&P 500's gain of 7.7%. |
35637.0 | 2023-05-04 00:00:00 UTC | Viatris (VTRS) to Report Q1 Earnings: What's in the Offing? | ACAD | https://www.nasdaq.com/articles/viatris-vtrs-to-report-q1-earnings%3A-whats-in-the-offing | nan | nan | Viatris VTRS, a global healthcare company, is scheduled to report first-quarter results on May 8. 2023.
The company beat earnings estimates in three of the trailing four quarters and met in the remaining one, the average surprise being 7.08%. In the last reported quarter, earnings were in line with the consensus estimate.
Viatris Inc. Price, Consensus and EPS Surprise
Viatris Inc. price-consensus-eps-surprise-chart | Viatris Inc. Quote
Factors to Consider
Viatris reports segment information based on markets and geography — Developed Markets, Emerging Markets, Japan, Australia and New Zealand (JANZ) and Greater China.
Branded business and new launches in the European markets have most likely driven sales in Developed markets. Loss of exclusivity for certain products and competitive headwinds for Wixela continue to impact business in North America.
Sales from Emerging Markets are likely to have increased on the strength of branded business. Sales from JANZ were down 26% in the previous quarter and the first quarter is likely to have seen a similar trend. Sales from Greater China markets are also likely to have increased.
Brands like Lipitor, Celebrex, Dymista and Yupelri, and Creon have likely maintained momentum for the company.
In November 2022, Viatris closed its transaction with Biocon Biologics Limited. Viatris had earlier announced an agreement with Biocon Biologics Limited whereby the former would sell its biosimilars portfolio to the latter. Hence, sales in the first quarter have been impacted by this sale.
Generics, which include diversified product forms such as extended-release oral solids, injectables, transdermals and topicals, performed in line with management’s expectations in the previous quarter, benefiting from the launch of lenalidomide in the United States. A similar trend is likely to have prevailed in the to-be-reported quarter.
In January, Viatris completed the acquisitions of Oyster Point Pharma and Famy LifeSciences to establish a new division - Viatris Eye Care. Incremental revenues from this division have likely boosted the top line in the first quarter.
Per management, the gross margin in the first quarter has likely been impacted due to continued competition for key products.
Share Price Performance
Viatris’ stock has lost 19.1% in the past year compared with the industry’s decline of 9.9%.
Image Source: Zacks Investment Research
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Viatris this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below.
Earnings ESP: Earnings ESP for Viatris is 0.00% as both the Most Accurate Estimate stands at 66 cents while the Zacks Consensus Estimate are pegged at 69 cents. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #4 (Sell).
Stocks to Consider
Here are a few stocks you may want to consider, as our model shows that they have the right
Oncternal Therapeutics ONCT has an Earnings ESP of +21.95% and a Zacks Rank #2.
ONCT beat estimates in three of the trailing four quarters and missed in the remaining one. It delivered an earnings surprise of 4.08%, on average.
Akero Therapeutics AKRO has an Earnings ESP of +6.45% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
AKRO topped earnings estimates in three of the last four quarters and missed in the remaining one. It has a four-quarter earnings surprise of 8.38%, on average.
Acadia Pharmaceuticals ACAD has an Earnings ESP of +14.65% and a Zacks Rank #3.
ACAD beat earnings estimates in two of the last four quarters and missed in the remaining two, the average negative surprise being 6.33%
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Top 5 ChatGPT Stocks Revealed
Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
Today you can invest in the wave of the future, an automation that answers follow-up questions … admits mistakes … challenges incorrect premises … rejects inappropriate requests. As one of the selected companies puts it, “Automation frees people from the mundane so they can accomplish the miraculous.”
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report
Oncternal Therapeutics, Inc. (ONCT) : Free Stock Analysis Report
Akero Therapeutics, Inc. (AKRO) : Free Stock Analysis Report
Viatris Inc. (VTRS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia Pharmaceuticals ACAD has an Earnings ESP of +14.65% and a Zacks Rank #3. ACAD beat earnings estimates in two of the last four quarters and missed in the remaining two, the average negative surprise being 6.33% Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Oncternal Therapeutics, Inc. (ONCT) : Free Stock Analysis Report Akero Therapeutics, Inc. (AKRO) : Free Stock Analysis Report Viatris Inc. (VTRS) : Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Oncternal Therapeutics, Inc. (ONCT) : Free Stock Analysis Report Akero Therapeutics, Inc. (AKRO) : Free Stock Analysis Report Viatris Inc. (VTRS) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals ACAD has an Earnings ESP of +14.65% and a Zacks Rank #3. ACAD beat earnings estimates in two of the last four quarters and missed in the remaining two, the average negative surprise being 6.33% Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. | ACAD beat earnings estimates in two of the last four quarters and missed in the remaining two, the average negative surprise being 6.33% Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Oncternal Therapeutics, Inc. (ONCT) : Free Stock Analysis Report Akero Therapeutics, Inc. (AKRO) : Free Stock Analysis Report Viatris Inc. (VTRS) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals ACAD has an Earnings ESP of +14.65% and a Zacks Rank #3. | Acadia Pharmaceuticals ACAD has an Earnings ESP of +14.65% and a Zacks Rank #3. ACAD beat earnings estimates in two of the last four quarters and missed in the remaining two, the average negative surprise being 6.33% Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Oncternal Therapeutics, Inc. (ONCT) : Free Stock Analysis Report Akero Therapeutics, Inc. (AKRO) : Free Stock Analysis Report Viatris Inc. (VTRS) : Free Stock Analysis Report To read this article on Zacks.com click here. |
35638.0 | 2023-05-02 00:00:00 UTC | Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Should You Buy? | ACAD | https://www.nasdaq.com/articles/stoke-therapeutics-inc.-stok-expected-to-beat-earnings-estimates%3A-should-you-buy | nan | nan | Stoke Therapeutics, Inc. (STOK) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2023. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock may move lower.
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on theearnings call it's worth handicapping the probability of a positive EPS surprise.
Zacks Consensus Estimate
This company is expected to post quarterly loss of $0.70 per share in its upcoming report, which represents a year-over-year change of -6.1%.
Revenues are expected to be $3.57 million, up 19% from the year-ago quarter.
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 5.55% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.
Earnings Whisper
Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Stoke Therapeutics, Inc.
For Stoke Therapeutics, Inc.The Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +5.49%.
On the other hand, the stock currently carries a Zacks Rank of #3.
So, this combination indicates that Stoke Therapeutics, Inc. Will most likely beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?
While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Stoke Therapeutics, Inc. Would post a loss of $0.72 per share when it actually produced a loss of $0.65, delivering a surprise of +9.72%.
Over the last four quarters, the company has beaten consensus EPS estimates three times.
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Stoke Therapeutics, Inc. Appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Expected Results of an Industry Player
Acadia Pharmaceuticals (ACAD), another stock in the Zacks Medical - Biomedical and Genetics industry, is expected to report earnings per share of $0.21 for the quarter ended March 2023. This estimate points to a year-over-year change of +70%. Revenues for the quarter are expected to be $121.69 million, up 5.4% from the year-ago quarter.
The consensus EPS estimate for Acadia has been revised 7.5% higher over the last 30 days to the current level. However, a higher Most Accurate Estimate has resulted in an Earnings ESP of 14.65%.
This Earnings ESP, combined with its Zacks Rank #3 (Hold), suggests that Acadia will most likely beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates two times.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Zacks Reveals ChatGPT "Sleeper" Stock
One little-known company is at the heart of an especially brilliant Artificial Intelligence sector. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
As a service to readers, Zacks is providing a bonus report that names and explains this explosive growth stock and 4 other "must buys." Plus more.
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Stoke Therapeutics, Inc. (STOK) : Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Expected Results of an Industry Player Acadia Pharmaceuticals (ACAD), another stock in the Zacks Medical - Biomedical and Genetics industry, is expected to report earnings per share of $0.21 for the quarter ended March 2023. The consensus EPS estimate for Acadia has been revised 7.5% higher over the last 30 days to the current level. This Earnings ESP, combined with its Zacks Rank #3 (Hold), suggests that Acadia will most likely beat the consensus EPS estimate. | Click to get this free report Stoke Therapeutics, Inc. (STOK) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. Expected Results of an Industry Player Acadia Pharmaceuticals (ACAD), another stock in the Zacks Medical - Biomedical and Genetics industry, is expected to report earnings per share of $0.21 for the quarter ended March 2023. The consensus EPS estimate for Acadia has been revised 7.5% higher over the last 30 days to the current level. | Expected Results of an Industry Player Acadia Pharmaceuticals (ACAD), another stock in the Zacks Medical - Biomedical and Genetics industry, is expected to report earnings per share of $0.21 for the quarter ended March 2023. The consensus EPS estimate for Acadia has been revised 7.5% higher over the last 30 days to the current level. This Earnings ESP, combined with its Zacks Rank #3 (Hold), suggests that Acadia will most likely beat the consensus EPS estimate. | Expected Results of an Industry Player Acadia Pharmaceuticals (ACAD), another stock in the Zacks Medical - Biomedical and Genetics industry, is expected to report earnings per share of $0.21 for the quarter ended March 2023. The consensus EPS estimate for Acadia has been revised 7.5% higher over the last 30 days to the current level. This Earnings ESP, combined with its Zacks Rank #3 (Hold), suggests that Acadia will most likely beat the consensus EPS estimate. |
35639.0 | 2023-05-01 00:00:00 UTC | Is a Beat on the Cards for Regeneron's (REGN) Q1 Earnings? | ACAD | https://www.nasdaq.com/articles/is-a-beat-on-the-cards-for-regenerons-regn-q1-earnings | nan | nan | Regeneron Pharmaceuticals, Inc. REGN is scheduled to release first-quarter 2023 results on May 4, before the opening bell.
The company has an impressive track record, beating on earnings in all the past four quarters. In the last reported quarter, it beat earnings expectations by 29.75%. It surpassed earnings estimates by 20.44%, on average, in the trailing four quarters.
Regeneron Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Regeneron Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Regeneron Pharmaceuticals, Inc. Quote
What Our Model Predicts
Our proven model predicts an earnings beat for Regeneron this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat.
Earnings ESP: Earnings ESP for REGN is +4.41% as the Zacks Consensus Estimate currently stands at $9.25 per share and the Most Accurate Estimate is currently pegged at $9.66. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3.
Factors at Play
A major chunk of Regeneron’s revenues comes from the sales of its lead drug, Eylea, which is approved for various ophthalmology indications (neovascular age-related macular degeneration, diabetic macular edema and macular edema, among others). Eylea was developed in collaboration with Bayer AG.
Regeneron records net product sales of Eylea in the United States, while Bayer records net product sales of the drug outside the country. Regeneron also records its share of profits/losses in connection with sales of Eylea outside the United States.
Eylea's sales have been strong and it has maintained momentum for the company in the past few quarters. However, sales were negatively impacted in the fourth quarter due to a short-term shift to off-label use of Avastin, a temporary closing in the fourth quarter of 2022 of a not-for-profit fund that provides patient co-pay assistance and an increase in sales-related deductions. Regeneron stated that it has substantially recovered from the issue in the fourth quarter, but Eylea’s sales in the first quarter have most likely faced competitive pressure. The Zacks Consensus Estimate for Eylea’s sales in the United States is pegged at $1.52 billion.
Apart from Eylea, investors will focus on the asthma drug Dupixent’s performance, sales of which are recorded by Sanofi SNY. Regeneron has a collaboration agreement with Sanofi for drugs like Dupixent and Kevzara. While Sanofi records sales, Regeneron records its share of profits/losses in connection with global sales of Dupixent and Kevzara. Profits from Dupixent sales have been REGN’s primary growth driver in the last few quarters.
Sales of Dupixent were up 39.7% in the first quarter, as recorded by Sanofi and hence Regeneron is likely to have recorded incremental profits in the yet-to-be-reported quarter. Dupixent has maintained its stellar performance, driven by continued strong demand in the approved indications, atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), eosinophilic esophagitis and prurigo nodularis. The label expansion of the drug in the past few months has boosted sales further and is likely to have resulted in incremental revenues for Regeneron in the first quarter.
Investors will focus on the performance of Libtayo and the PCSK9 inhibitor Praluent. Effective Jul 1, 2022, Regeneron records net product sales of Libtayo and will pay Sanofi a royalty on such sales. Increased sales of Libtayo on-label expansions have most likely boosted the top line. The Zacks Consensus Estimate for Libtayo’s sales is pegged at $166 million.
Regeneron records net product sales of Praluent in the United States. Sanofi records net product sales of the drug outside the United States and pays Regeneron a royalty on such sales. Total sales in the previous quarter witnessed a 30% increase. However, it’s mostly unlikely for the first quarter to have recorded such growth.
In January 2022, the FDA revised the authorizations for a few monoclonal antibody treatments, including Regeneron’s REGEN-COV (casirivimab and imdevimab), as data indicated that these treatments are highly unlikely to be active against the Omicron variant. REGEN-COV is a cocktail of two monoclonal antibodies (casirivimab and imdevimab, also known as REGN10933 and REGN10987, respectively). Therefore, REGEN-COV is currently unauthorized for use in U.S. states, territories or jurisdictions. Hence, this revision dented sales in 2022 from this stream and sales are likely to be negligible in the first quarter.
Recent Updates
In March 2023, the FDA approved Evzeeka (evinacumab-dgnb) as an adjunct to other lipid-lowering therapies to treat children aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH). The approval extends Evkeeza to children aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH), an inherited condition characterized by extremely high low-density lipoprotein cholesterol (LDL-C).
The European Commission (EC) approved Libtayo (cemiplimab) in combination with platinum-based chemotherapy for first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with ≥1% PD-L1 expression.
Share Price Performance
Regeneron’s shares have gained 11.1% in the year so far against the industry’s decline of 6.2%.
Image Source: Zacks Investment Research
Other Stocks to Consider
Here are some more drug/biotech stocks that you may want to consider, as our model shows that they have the right combination of elements to post an earnings beat this season.
Akero Therapeutics AKRO has an Earnings ESP of +6.45% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
AKRO beat earnings estimate in three of the last four quarters and missed in the remaining one, the average earnings surprise being 8.38%.
Acadia ACAD has an Earnings ESP of +14.65% and a Zacks Rank #3.
ACAD topped earnings estimates in two of the last four quarters and missed in the remaining two. It has a four-quarter negative earnings surprise of 6.33%, on average.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Free Report Reveals How You Could Profit from the Growing Electric Vehicle Industry
Globally, electric car sales continue their remarkable growth even after breaking records in 2021. High gas prices have fueled his demand, but so has evolving EV comfort, features and technology. So, the fervor for EVs will be around long after gas prices normalize. Not only are manufacturers seeing record-high profits, but producers of EV-related technology are raking in the dough as well. Do you know how to cash in? If not, we have the perfect report for you – and it’s FREE! Today, don't miss your chance to download Zacks' top 5 stocks for the electric vehicle revolution at no cost and with no obligation.
>>Send me my free report on the top 5 EV stocks
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report
Sanofi (SNY) : Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report
Akero Therapeutics, Inc. (AKRO) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia ACAD has an Earnings ESP of +14.65% and a Zacks Rank #3. ACAD topped earnings estimates in two of the last four quarters and missed in the remaining two. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report Sanofi (SNY) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Akero Therapeutics, Inc. (AKRO) : Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report Sanofi (SNY) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Akero Therapeutics, Inc. (AKRO) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia ACAD has an Earnings ESP of +14.65% and a Zacks Rank #3. ACAD topped earnings estimates in two of the last four quarters and missed in the remaining two. | Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report Sanofi (SNY) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Akero Therapeutics, Inc. (AKRO) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia ACAD has an Earnings ESP of +14.65% and a Zacks Rank #3. ACAD topped earnings estimates in two of the last four quarters and missed in the remaining two. | Acadia ACAD has an Earnings ESP of +14.65% and a Zacks Rank #3. ACAD topped earnings estimates in two of the last four quarters and missed in the remaining two. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report Sanofi (SNY) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Akero Therapeutics, Inc. (AKRO) : Free Stock Analysis Report To read this article on Zacks.com click here. |
35640.0 | 2023-04-24 00:00:00 UTC | 4 Pharma, Biotech Stocks Poised to Beat Q1 Earnings Estimates | ACAD | https://www.nasdaq.com/articles/4-pharma-biotech-stocks-poised-to-beat-q1-earnings-estimates | nan | nan | The earnings season has just started for the drug/biotech sector, with bellwether Johnson & Johnson JNJ reporting first-quarter 2023 results last week. Per the Zacks classification, the large-cap pharma and drug/biotech industry comes under the broader Medical sector, which comprises medical device companies as well.
Per the Earnings Trends report, as of Apr 19, only 8.8% of the companies in the Medical sector, constituting nearly 27.5% of the sector’s market capitalization, reported earnings. All the companies that have reported so far have surpassed both earnings and sales estimates. Earnings declined 2.4% year over year but revenues increased 9.8%. Overall, first-quarter earnings for the Medical sector are expected to decline 22.4% on a 1% sales increase.
A major chunk of the large-cap pharma and drug/biotech sector is scheduled to report first-quarter results in the next two weeks. Johnson & Johnson reported strong results for the first quarter, beating earnings and sales estimates on the back of strong demand trends for its products. While the risk of a recession looms large, the outlook provided by most companies in the fourth quarter is encouraging due to new drug approvals and regular pipeline updates.
Zeroing in on Winners
Almost the entire sector is yet to report results. Here we have highlighted four companies, Sanofi SNY, Amgen AMGN, Regeneron Pharmaceuticals REGN and Acadia Pharmaceuticals ACAD — using our proprietary methodology — which are expected to deliver an earnings surprise in their upcoming quarterly results.
Earnings ESP is our proprietary methodology for determining the stocks with the best chance to deliver an earnings surprise. Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Zacks Consensus Estimate.
According to the Zacks model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. The selection can be made with the help of the Zacks Stock Screener.
Our research shows that for stocks with this combination, the chance of an earnings surprise is as high as 70%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
You can see the complete list of today’s Zacks #1 Rank stocks here.
4 Pharma/Biotech Stocks That Match the Criteria
Sanofi
Sanofi focuses on major therapeutic areas such as immunology, neurology, oncology, rare disease, rare blood disorders and diabetes, among others. Sanofi has an Earnings ESP of +1.62% and a Zacks Rank #2. The Zacks Consensus Estimate for the first quarter stands at $1.08 per share.
Sanofi beat estimates in three of the last four quarters and missed in the remaining one, delivering an average earnings surprise of 7.68%. The company is scheduled to report first-quarter results on Apr 27.
Sanofi’s top-line growth is likely to have been aided by higher sales of the Specialty Care business, mainly driven by its blockbuster drug Dupixent. It witnessed strong demand for its approved indications, atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyposis indications and strong launches for new indications, eosinophilic esophagitis and prurigo nodularis.
Sanofi Price, Consensus and EPS Surprise
Sanofi price-consensus-eps-surprise-chart | Sanofi Quote
Amgen
Amgen has an Earnings ESP of +1.82% and a Zacks Rank #3. The Zacks Consensus Estimate for the first quarter stands at $3.84 per share.
Amgen is one of the largest biotech companies with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology and neuroscience markets. AMGN beat estimates in each of the last four quarters, delivering an average earnings surprise of 3.43%. Amgen is scheduled to report first-quarter results on Apr 27.
Growth products like Prolia, Xgeva, Evenity, Vectibix, Nplate and Kyprolis and Blincyto are likely to have aided the company.
Amgen Inc. Price, Consensus and EPS Surprise
Amgen Inc. price-consensus-eps-surprise-chart | Amgen Inc. Quote
Regeneron Pharmaceuticals
Biotech major Regeneron Pharmaceuticals focuses on the discovery, development and commercialization of treatments targeting serious medical conditions. Regeneron maintains momentum on Dupixent’s stellar performance with progress on launches in pediatric atopic dermatitis, eosinophilic esophagitis and prurigo nodularis. Growth in lead drugs Eylea and Dupixent through additional label expansions and a promising late-stage pipeline set the momentum for further development.
REGN has an Earnings ESP of +5.80% and a Zacks Rank #3. The Zacks Consensus Estimate for the first quarter stands at $9.44 per share. REGN beat estimates in the last four quarters, delivering an average earnings surprise of 20.44%. Regeneron is scheduled to report first-quarter results on May 4.
Regeneron Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Regeneron Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Regeneron Pharmaceuticals, Inc. Quote
Acadia Pharmaceuticals
Acadia has an Earnings ESP of +32.26% and a Zacks Rank #2. The Zacks Consensus Estimate for the first quarter is pegged at a loss of 21 cents per share. ACAD beat estimates in two of the last four quarters and missed in the other two, delivering an average negative earnings surprise of 6.33%. The company is expected to report first-quarter results in the first week of May.
Acadia’s sole marketed drug, Nuplazid, approved for Parkinson's disease psychosis, has witnessed strong uptake since its launch and the momentum is likely to have continued in the first quarter. The drug's label expansion program looks promising, with several studies currently underway.
ACADIA Pharmaceuticals Inc. Price, Consensus and EPS Surprise
ACADIA Pharmaceuticals Inc. price-consensus-eps-surprise-chart | ACADIA Pharmaceuticals Inc. Quote
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report
Sanofi (SNY) : Free Stock Analysis Report
Johnson & Johnson (JNJ) : Free Stock Analysis Report
Amgen Inc. (AMGN) : Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia’s sole marketed drug, Nuplazid, approved for Parkinson's disease psychosis, has witnessed strong uptake since its launch and the momentum is likely to have continued in the first quarter. Here we have highlighted four companies, Sanofi SNY, Amgen AMGN, Regeneron Pharmaceuticals REGN and Acadia Pharmaceuticals ACAD — using our proprietary methodology — which are expected to deliver an earnings surprise in their upcoming quarterly results. Regeneron Pharmaceuticals, Inc. Price, Consensus and EPS Surprise Regeneron Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Regeneron Pharmaceuticals, Inc. Quote Acadia Pharmaceuticals Acadia has an Earnings ESP of +32.26% and a Zacks Rank #2. | Regeneron Pharmaceuticals, Inc. Price, Consensus and EPS Surprise Regeneron Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Regeneron Pharmaceuticals, Inc. Quote Acadia Pharmaceuticals Acadia has an Earnings ESP of +32.26% and a Zacks Rank #2. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report Sanofi (SNY) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. Here we have highlighted four companies, Sanofi SNY, Amgen AMGN, Regeneron Pharmaceuticals REGN and Acadia Pharmaceuticals ACAD — using our proprietary methodology — which are expected to deliver an earnings surprise in their upcoming quarterly results. | Here we have highlighted four companies, Sanofi SNY, Amgen AMGN, Regeneron Pharmaceuticals REGN and Acadia Pharmaceuticals ACAD — using our proprietary methodology — which are expected to deliver an earnings surprise in their upcoming quarterly results. Regeneron Pharmaceuticals, Inc. Price, Consensus and EPS Surprise Regeneron Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Regeneron Pharmaceuticals, Inc. Quote Acadia Pharmaceuticals Acadia has an Earnings ESP of +32.26% and a Zacks Rank #2. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report Sanofi (SNY) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. | Here we have highlighted four companies, Sanofi SNY, Amgen AMGN, Regeneron Pharmaceuticals REGN and Acadia Pharmaceuticals ACAD — using our proprietary methodology — which are expected to deliver an earnings surprise in their upcoming quarterly results. Regeneron Pharmaceuticals, Inc. Price, Consensus and EPS Surprise Regeneron Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Regeneron Pharmaceuticals, Inc. Quote Acadia Pharmaceuticals Acadia has an Earnings ESP of +32.26% and a Zacks Rank #2. ACAD beat estimates in two of the last four quarters and missed in the other two, delivering an average negative earnings surprise of 6.33%. |
35641.0 | 2023-04-21 00:00:00 UTC | Axsome (AXSM) Focuses on Auvelity Launch to Fuel Its Growth | ACAD | https://www.nasdaq.com/articles/axsome-axsm-focuses-on-auvelity-launch-to-fuel-its-growth | nan | nan | Axsome Therapeutics AXSM is progressing well with the launch of its first product, Auvelity (AXS-05), in October 2022. The drug is aimed at treating patients with major depressive disorders. The company received FDA approval for Auvelity in August 2022.
With an encouraging early launch, the drug earned revenues of $5.2 million in the fourth quarter of 2022. Earlier this year, AXSM contacted the largest group purchasing organization (GPO) for the potential commercial coverage of Auvelity. Pharmacy benefit managers and health plans are making coverage decisions for the drug under GPO.
Axsome is also conducting several studies on AXS-05 for smoking cessation and treating other central nervous system (CNS) disorders like AD agitation. It is currently working on the ADVANCE-2 pivotal phase III study on AXS-05, which will support the NDA filing for AXS-05 for AD agitation.
The study is expected to be completed in the first half of 2024, with an NDA submission planned thereafter. The company also plans to initiate a phase II/III pivotal study for evaluating AXS-05 in smoking cessation, in collaboration with Duke University in the fourth quarter of 2023.
Axsome's shares have plunged 5% in the year-to-date period against the industry's 4.8% decline.
Image Source: Zacks Investment Research
In May 2022, the company completed its acquisition of Sunosi, a commercialized drug targeting narcolepsy, from Jazz. In February 2023, AXSM entered into a licensing agreement with Pharmanovia to market Sunosi in European and certain Middle East/North African countries. Its top line presently comprises of product revenues from Sunosi and Auvelity sales.
Axsome has an impressive portfolio of pipeline candidates, including AXS-07, AXS-09, AXS-12 and AXS-14. All of these are being developed for various CNS indications.
AXS-07 is being developed for the acute treatment of migraine. However, in April 2022, Axsome received a complete response letter for an NDA, seeking approval for AXS-07. The company intends to resubmit the NDA by the second half of 2023.
However, any regulatory setback or further developmental delay in the pipeline can hurt the stock.
Axsome faces stiff competition from other companies developing treatments for CNS disorders. ACADIA Pharmaceuticals ACAD is developing Nuplazid (pimavanserin) in several studies, targeting different CNS indications. ACAD’s Nuplazid is already approved for hallucinations and delusions associated with Parkinson’s disease. Sunosi may also face stiff competition from Jazz’s sleep disorder drugs, which currently have a robust market share.
Axsome also faces commercial launch risks for AXS-05. It may face several hurdles, such as a slow medicare coverage across the United States, which could derail the commercialization of the drug.
While there are several potential challenges ahead, the addition of Sunosi and launch of Auvelity are significant achievements for the company.
Axsome Therapeutics, Inc. Price and Consensus
Axsome Therapeutics, Inc. price-consensus-chart | Axsome Therapeutics, Inc. Quote
Zacks Rank & Stocks to Consider
Currently, Axsome has a Zacks Rank #3 (Hold).
Some better-ranked stocks for investors interested in the same sector areCRISPR Therapeutics CRSP and Allogene Therapeutics ALLO, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Loss per share estimates for CRISPR Therapeutics have narrowed from $8.21 to $7.22 for 2023 in the past 60 days.
CRSP's earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, the average surprise being 3.19%. The company's shares have plunged 22.7% in the year-to-date period.
Loss per share estimates for Allogene Therapeutics have narrowed from $2.83 to $2.44 for 2023 and from $2.69 to $2.46 for 2024 in the past 60 days.
ALLO's earnings beat estimates in each of the trailing four quarters, the average surprise being 8.33%. The company's shares have plunged 20.7% in the year-to-date period.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report
Axsome Therapeutics, Inc. (AXSM) : Free Stock Analysis Report
CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report
Allogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals ACAD is developing Nuplazid (pimavanserin) in several studies, targeting different CNS indications. ACAD’s Nuplazid is already approved for hallucinations and delusions associated with Parkinson’s disease. Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Axsome Therapeutics, Inc. (AXSM) : Free Stock Analysis Report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report Allogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Axsome Therapeutics, Inc. (AXSM) : Free Stock Analysis Report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report Allogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals ACAD is developing Nuplazid (pimavanserin) in several studies, targeting different CNS indications. ACAD’s Nuplazid is already approved for hallucinations and delusions associated with Parkinson’s disease. | Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Axsome Therapeutics, Inc. (AXSM) : Free Stock Analysis Report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report Allogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals ACAD is developing Nuplazid (pimavanserin) in several studies, targeting different CNS indications. ACAD’s Nuplazid is already approved for hallucinations and delusions associated with Parkinson’s disease. | ACADIA Pharmaceuticals ACAD is developing Nuplazid (pimavanserin) in several studies, targeting different CNS indications. ACAD’s Nuplazid is already approved for hallucinations and delusions associated with Parkinson’s disease. Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Axsome Therapeutics, Inc. (AXSM) : Free Stock Analysis Report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report Allogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report To read this article on Zacks.com click here. |
35642.0 | 2023-04-21 00:00:00 UTC | Intra-Cellular's (ITCI) Caplyta Aids Sales, Overreliance a Woe | ACAD | https://www.nasdaq.com/articles/intra-cellulars-itci-caplyta-aids-sales-overreliance-a-woe | nan | nan | Intra-Cellular Therapies ITCI, a biopharmaceutical company, is focused on discovering, developing and commercializing small-molecule drugs for treating neuropsychiatric and neurological disorders.
Intra-Cellular’s only marketed drug, Caplyta (lumateperone), was approved by the FDA in December 2019, for the treatment of schizophrenia in adults. The drug was commercially launched in the United States in March 2020 and quickly gained traction in the market. In December 2021, Caplyta was also approved for depressive episodes associated with bipolar I or II disorder in adults as monotherapy and adjunctive therapy with lithium or valproate.
In April 2022, the FDA approved two new dosage strengths of Caplyta, 10.5 mg and 21 mg, for patients concomitantly taking strong or moderate CYP3A4 inhibitors and 21 mg for patients with moderate or severe hepatic impairment. These new dosage strengths have expanded the eligible patient population for Caplyta.
Post these approvals, Caplyta’s sales skyrocketed, clocking growth of 243% year over year at $87.4 million in the last reported quarter from the year-ago quarter’s reported figure. Per management, Caplyta’s total and new prescriptions increased by 193% and 220%, respectively, year over year in the reported quarter from the year-ago quarter’s levels. Net product sales of Caplyta as of December end, were $249.1 million, up 205% year over year.
In the past year, shares of Intra-Cellular have gained 16% against the industry’s 8.2% decline.
Image Source: Zacks Investment Research
Intra-Cellular is also evaluating Caplyta in several other indications.Currently, the company is evaluating lumateperone in several label-expanding late-stage studies. The company is currently enrolling patients in its global phase III studies 501 and 502, evaluating 42 mg of lumateperone as a treatment for major depressive disorder (MDD). Intra-Cellular intends to file a supplemental new drug application seeking approval for lumateperone as adjunctive therapy to antidepressants for the treatment of MDD with the FDA in 2024.
In March 2023, Intra-Cellular announced positive top-line results from another label-expanding study on lumateperone. The phase III Study 403 evaluated 42 mg of lumateperone as monotherapy in the treatment of major depressive episodes,associated withbipolar I and bipolar II disorder, in patients with MDD with mixed features and patients with bipolar depression with mixed features. The study met both its primary and key secondary endpoints with statistical significance compared with treatment with placebo. These data provide proof of concept in the patient populations of the study, validating lumateperone’s broad potential in mood disorders. The company plans to discuss these results with the FDA to determine its step forward.
A potential approval is anticipated to boost Intra-Cellular’s top line.
Intra-Cellular is also developing a deuterated form of lumateperone, ITI-1248-ODT-SL, for treating behavioral disturbance in dementia patients, dementia-related psychosis and certain depressive disorders in the elderly. phase I single and multiple ascending dose studies have been completed. Based on these results, Intra-Cellular expects to begin phase II clinical studies in agitation in patients with probable Alzheimer’s disease, dementia-related psychosis and certain depressive disorders in the elderly in 2023.
Additionally, Intra-Cellular is working on long-acting injectable formulations in patients with stable symptoms of schizophrenia.
Despite label-expansion efforts, Intra-Cellular’s high dependence on just Caplyta sales for revenues is a concern. It needs growth opportunities apart from Caplyta.
Other than Caplyta, Intra-Cellular also has other pipeline candidates in early-stage studies. Lenrispodun (ITI-214) is being developed for Parkinson’s disease and ITI-333 is being developed as a potential treatment for substance use disorders, pain and psychiatric comorbidities, including depression and anxiety. ITI-1020 is being developed as a novel cancer immunotherapy and falls under Intra-Cellular’s PDE 1 program. However, all these are several years away from commercialization.
Competition also remains a concern for Intra-Cellular Therapies. Upon lumateperone’s approval for the treatment of MDD, Intra-Cellular is bound to face stiff competition from Axsome Therapeutics AXSM. In August 2022, Axsome received FDA approval for its lead pipeline candidate AXS-05, with the trade name of Auvelity, for the treatment of adults with MDD, making it the first approved drug in its portfolio. Axsome launched Auvelity as an MDD therapy in the United States in October 2022. Axsome’s AXS-05 is also currently being evaluated for several CNS disorders.
Nonetheless, a consistent increase in Caplyta sales, successful label expansion of the drug and relatively less competition in its target market are likely to keep the stock afloat in the long term.
Intra-Cellular Therapies Inc. Price and Consensus
Intra-Cellular Therapies Inc. price-consensus-chart | Intra-Cellular Therapies Inc. Quote
Zacks Rank and Stocks to Consider
Intra-Cellular currently has a Zacks Rank #3 (Hold).
A couple of top-ranked stocks in the same industry are Aptinyx APTX and Acadia Pharmaceuticals ACAD, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 90 days, the Zacks Consensus Estimate for Aptinyx’s 2023 loss per share has narrowed from 77 cents to 47 cents. In the past year, shares of Aptinyx have fallen by 86.8%.
APTX beat estimates in each of the trailing four quarters, delivering an average earnings surprise of 6.56%.
In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 87 cents to 57 cents. In the past year, shares of Acadia Pharmaceuticals have fallen by 2.2%.
ACAD beat estimates in two of the trailing four quarters, missing the mark on other two occasions, delivering an average negative earnings surprise of 6.33%.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Intra-Cellular Therapies Inc. (ITCI) : Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report
Axsome Therapeutics, Inc. (AXSM) : Free Stock Analysis Report
Aptinyx Inc. (APTX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A couple of top-ranked stocks in the same industry are Aptinyx APTX and Acadia Pharmaceuticals ACAD, both carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 87 cents to 57 cents. In the past year, shares of Acadia Pharmaceuticals have fallen by 2.2%. | In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 87 cents to 57 cents. Click to get this free report Intra-Cellular Therapies Inc. (ITCI) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Axsome Therapeutics, Inc. (AXSM) : Free Stock Analysis Report Aptinyx Inc. (APTX) : Free Stock Analysis Report To read this article on Zacks.com click here. A couple of top-ranked stocks in the same industry are Aptinyx APTX and Acadia Pharmaceuticals ACAD, both carrying a Zacks Rank #2 (Buy) at present. | Click to get this free report Intra-Cellular Therapies Inc. (ITCI) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Axsome Therapeutics, Inc. (AXSM) : Free Stock Analysis Report Aptinyx Inc. (APTX) : Free Stock Analysis Report To read this article on Zacks.com click here. A couple of top-ranked stocks in the same industry are Aptinyx APTX and Acadia Pharmaceuticals ACAD, both carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 87 cents to 57 cents. | A couple of top-ranked stocks in the same industry are Aptinyx APTX and Acadia Pharmaceuticals ACAD, both carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 87 cents to 57 cents. In the past year, shares of Acadia Pharmaceuticals have fallen by 2.2%. |
35643.0 | 2023-04-21 00:00:00 UTC | Is OraSure Technologies (OSUR) Outperforming Other Medical Stocks This Year? | ACAD | https://www.nasdaq.com/articles/is-orasure-technologies-osur-outperforming-other-medical-stocks-this-year | nan | nan | For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is OraSure Technologies (OSUR) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
OraSure Technologies is one of 1150 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. OraSure Technologies is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for OSUR's full-year earnings has moved 195.9% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, OSUR has returned 45.4% so far this year. Meanwhile, stocks in the Medical group have lost about 0.9% on average. This means that OraSure Technologies is outperforming the sector as a whole this year.
Acadia Pharmaceuticals (ACAD) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 25.4%.
Over the past three months, Acadia Pharmaceuticals' consensus EPS estimate for the current year has increased 34.3%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, OraSure Technologies belongs to the Medical - Products industry, a group that includes 101 individual stocks and currently sits at #153 in the Zacks Industry Rank. This group has gained an average of 6% so far this year, so OSUR is performing better in this area.
Acadia Pharmaceuticals, however, belongs to the Medical - Biomedical and Genetics industry. Currently, this 554-stock industry is ranked #80. The industry has moved -4.4% so far this year.
Going forward, investors interested in Medical stocks should continue to pay close attention to OraSure Technologies and Acadia Pharmaceuticals as they could maintain their solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
OraSure Technologies, Inc. (OSUR) : Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Going forward, investors interested in Medical stocks should continue to pay close attention to OraSure Technologies and Acadia Pharmaceuticals as they could maintain their solid performance. Acadia Pharmaceuticals (ACAD) is another Medical stock that has outperformed the sector so far this year. Over the past three months, Acadia Pharmaceuticals' consensus EPS estimate for the current year has increased 34.3%. | Click to get this free report OraSure Technologies, Inc. (OSUR) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals (ACAD) is another Medical stock that has outperformed the sector so far this year. Over the past three months, Acadia Pharmaceuticals' consensus EPS estimate for the current year has increased 34.3%. | Click to get this free report OraSure Technologies, Inc. (OSUR) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals (ACAD) is another Medical stock that has outperformed the sector so far this year. Over the past three months, Acadia Pharmaceuticals' consensus EPS estimate for the current year has increased 34.3%. | Acadia Pharmaceuticals (ACAD) is another Medical stock that has outperformed the sector so far this year. Over the past three months, Acadia Pharmaceuticals' consensus EPS estimate for the current year has increased 34.3%. Acadia Pharmaceuticals, however, belongs to the Medical - Biomedical and Genetics industry. |
35644.0 | 2023-04-19 00:00:00 UTC | Validea's Top 5 Health Care Stocks Based On Peter Lynch - 4/19/2023 | ACAD | https://www.nasdaq.com/articles/valideas-top-5-health-care-stocks-based-on-peter-lynch-4-19-2023 | nan | nan | The following are the top rated Health Care stocks according to Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ACADIA PHARMACEUTICALS INC (ACAD) is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Peter Lynch is 0% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare dis | ACADIA PHARMACEUTICALS INC (ACAD) is a mid-cap growth stock in the Biotechnology & Drugs industry. Company Description: Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The following are the top rated Health Care stocks according to Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. | ACADIA PHARMACEUTICALS INC (ACAD) is a mid-cap growth stock in the Biotechnology & Drugs industry. Company Description: Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The following are the top rated Health Care stocks according to Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. | ACADIA PHARMACEUTICALS INC (ACAD) is a mid-cap growth stock in the Biotechnology & Drugs industry. Company Description: Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The following are the top rated Health Care stocks according to Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. | Company Description: Acadia Pharmaceuticals Inc. is a biopharmaceutical company. ACADIA PHARMACEUTICALS INC (ACAD) is a mid-cap growth stock in the Biotechnology & Drugs industry. The following are the top rated Health Care stocks according to Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. |
35645.0 | 2023-04-19 00:00:00 UTC | Bellus Health (BLU) Stock Up 99% on $2B Buyout Offer From GSK | ACAD | https://www.nasdaq.com/articles/bellus-health-blu-stock-up-99-on-%242b-buyout-offer-from-gsk | nan | nan | Bellus Health BLU and GSK plc GSK announced that the former got an offer to be acquired by the latter for $14.75 per share of common stock in cash, representing an approximate total equity value of $2 billion (£1.6 billion). Bellus’ stock skyrocketed 98.9% on Tuesday, following the acquisition agreement.
The per-share price represents a premium of approximately 103.2% to Bellus’ closing stock price on Apr 17, 2023, and a premium of approximately 101% to its volume-weighted average price over the last 30 trading days.
In the past year, shares of Bellus have rallied 67.5% against the industry’s 11.6% decline.
Image Source: Zacks Investment Research
The successful acquisition of Bellus will add its refractory chronic cough (RCC) candidate, camlipixant, to GSK’s portfolio of drugs. Camlipixant, a potential best-in-class and highly selective P2X3 antagonist, is currently in phase III development for the first-line treatment of adult patients with RCC.
Notably, RCC is a condition that is observed most in adults aged 50-60 years. Severe forms of RCC can cause 900 coughs daily, resulting in degraded quality of life. Currently, there are no approved medicines for RCC in the United States and European Union, representing a serious unmet medical need.
In the past year, shares of GSK have plunged 36.8% compared with the industry’s 8% decline.
Image Source: Zacks Investment Research
Per the agreement, the acquisition of Bellus Health by GSK will be carried out through a Plan of Arrangement under the Canada Business Corporations Act. The execution of the agreement is contingent on certain customary conditions, which include, approval by some regulatory authorities and shareholders' approval.
Both parties expect to successfully close the acquisition deal in the third quarter of 2023 or earlier.
We would like to remind the investors that in December 2021, Bellus reported positive top-line data from its phase IIb SOOTHE study of the 50 mg and 200 mg twice-daily doses of camlipixant. The study achieved its statistically significant primary endpoint with a 34% placebo-adjusted reduction in 24-hour cough frequency observed at day 28 of the study. The candidate was overall well-tolerated with low rates of taste-related adverse events reported (≤6.5%) at all doses.
Based on the encouraging phase IIb results, Bellus initiated its CALM phase III development program consisting of the CALM-1 and CALM-2 studies evaluating camlipixant. Data from the CALM-1 and CALM-2 studies is expected in the second half of 2024 and 2025, respectively. BLU is also currently evaluating a once-daily formulation for camlipixant for the same indication in a phase I study.
The acquisition of Bellus is expected to immensely complement GSK’s expertise in respiratory medicines. It shall grant Bellus access to GSK’s state-of-the-art research and development, manufacturing and commercialization capabilities for the development and commercialization of camlipixant.
GSK expects the acquisition to be accretive to adjusted EPS from 2027, the expected first full year of camlipixant’s sales, assuming the anticipated regulatory approval and launch in 2026. GSK also believes that camlipixant has the potential to deliver significant sales through 2031 and beyond.
The acquisition agreement resulted in no change in GSK’s full-year 2023 guidance, its medium-term outlook for 2021-2026 of more than 5% sales and 10% adjusted operating profit CAGR at constant exchange rate.
Bellus Health Inc. Price and Consensus
Bellus Health Inc. price-consensus-chart | Bellus Health Inc. Quote
Zacks Rank and Stocks to Consider
Currently, both Bellus Health and GSK have a Zacks Rank #3 (Hold).
Some better-ranked stocks from the same industry are Aptinyx APTX and Acadia Pharmaceuticals ACAD, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 90 days, the Zacks Consensus Estimate for Aptinyx’s 2023 loss per share has narrowed from 77 cents to 47 cents. In the past year, shares of Aptinyx have fallen by 88%.
APTX beat estimates in each of the trailing four quarters, delivering an average earnings surprise of 6.56%.
In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 87 cents to 57 cents. In the past year, shares of Acadia Pharmaceuticals have fallen by 11.6%.
ACAD beat estimates in two of the trailing four quarters, missing the mark on other two occasions, delivering an average negative earnings surprise of 6.33%.
GSK PLC Sponsored ADR Price and Consensus
GSK PLC Sponsored ADR price-consensus-chart | GSK PLC Sponsored ADR Quote
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.8% per year. So be sure to give these hand-picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report
Aptinyx Inc. (APTX) : Free Stock Analysis Report
Bellus Health Inc. (BLU) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks from the same industry are Aptinyx APTX and Acadia Pharmaceuticals ACAD, both carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 87 cents to 57 cents. In the past year, shares of Acadia Pharmaceuticals have fallen by 11.6%. | Click to get this free report GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Aptinyx Inc. (APTX) : Free Stock Analysis Report Bellus Health Inc. (BLU) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks from the same industry are Aptinyx APTX and Acadia Pharmaceuticals ACAD, both carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 87 cents to 57 cents. | Click to get this free report GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Aptinyx Inc. (APTX) : Free Stock Analysis Report Bellus Health Inc. (BLU) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks from the same industry are Aptinyx APTX and Acadia Pharmaceuticals ACAD, both carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 87 cents to 57 cents. | Some better-ranked stocks from the same industry are Aptinyx APTX and Acadia Pharmaceuticals ACAD, both carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 87 cents to 57 cents. In the past year, shares of Acadia Pharmaceuticals have fallen by 11.6%. |
35646.0 | 2023-04-18 00:00:00 UTC | Agenus (AGEN) Rises on Fast Track Tag for Cancer Combo Drug | ACAD | https://www.nasdaq.com/articles/agenus-agen-rises-on-fast-track-tag-for-cancer-combo-drug | nan | nan | Agenus Inc. AGEN announced that the FDA has granted Fast Track Designation to the experimental combination of botensilimab (AGEN1181) and balstilimab (AGEN2034). The designation is for patients with non-microsatellite instability-high (MSI-H)/deficient mismatch repair metastatic colorectal cancer with no active liver involvement. The stock of the company jumped 15.9% on Monday following the news.
In the past year, shares of Agenus have lost 27% compared with the industry’s 11.9% decline.
Image Source: Zacks Investment Research
Botensilimab is Agenus’ proprietary, novel and multifunctional CTLA-4 investigational antibody to treat “cold” tumors that have not historically responded to standard-of-care or investigational therapies. Botensilimab is being studied either alone or in combination with Agenus’ PD-1 antibody, balstilimab, in a phase Ib study of more than 350 patients. It displayed clinical responses in nine, previously intestinal obstruction unresponsive, solid tumor cancers.
Per the press release, the patient group targeted with this designation includes those who are heavily pretreated, resistant or intolerant to fluoropyrimidine, oxaliplatin and irinotecan, and those who have also received a VEGF inhibitor, an EGFR inhibitor and/or a BRAF inhibitor, if indicated. This represents a huge unmet medical need. Agenus is conducting a global phase II study of botensilimab in combination with balstilimab compared with the standard of care in non-MSI-H colorectal cancer patients.
The designation, granted by the FDA, was based on positive and statistically significant results from Agenus’ ongoing studies of the botensilimab/balstilimab combination in patients with non-MSI-H colorectal cancer. Results from the combination therapy showed an overall response rate of 23% and a 12-month survival rate of 63% compared with a 1-2% overall response rate and a 25% 12-month survival rate reported for the standard of care.
Agenus is also currently conducting phase II studies in pancreatic cancer and melanoma, besides non-MSI-H colorectal cancer as part of its ACTIVATE trial programs.
Management is keen on utilizing the important benefits that the Fast Track designation offers, along with the potential eligibility for a Priority Review.
Agenus expects to launch a global phase III study of the botensilimab/balstilimab combination in non-MSI-H colorectal cancer in 2023.
Agenus Inc. Price and Consensus
Agenus Inc. price-consensus-chart | Agenus Inc. Quote
Zacks Rank and Stocks to Consider
Agenus currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks in the same industry are Aptinyx APTX, Acadia Pharmaceuticals ACAD and ADMA Biologics ADMA, all carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 90 days, the Zacks Consensus Estimate for Aptinyx’s 2023 loss per share has narrowed from 77 cents to 47 cents. In the past year, shares of Aptinyx have fallen by 87.2%.
APTX beat estimates in each of the trailing four quarters, delivering an average earnings surprise of 6.56%.
In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 87 cents to 57 cents. In the past year, shares of Acadia Pharmaceuticals have fallen by 10.8%.
ACAD beat estimates in two of the trailing four quarters, missing the mark on the other two occasions, delivering an average negative earnings surprise of 6.33%.
In the past 90 days, the consensus estimate for ADMA Biologics’ 2023 loss per share has narrowed from 19 cents to 14 cents. In the past year, shares of ADMA Biologics have increased by 63%.
ADMA beat estimates in three out of the trailing four quarters, delivering an average earnings surprise of 2.88%.
Free Report: Must-See Hydrogen Stocks
Hydrogen fuel cells are already used to provide efficient, ultra-clean energy to buses, ships and even hospitals. This technology is on the verge of a massive breakthrough, one that could make hydrogen a major source of America's power. It could even totally revolutionize the EV industry.
Zacks has released a special report revealing the 4 stocks experts believe will deliver the biggest gains.
Download Cashing In on Cleaner Energy today, absolutely free.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Agenus Inc. (AGEN) : Free Stock Analysis Report
ADMA Biologics Inc (ADMA) : Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report
Aptinyx Inc. (APTX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the same industry are Aptinyx APTX, Acadia Pharmaceuticals ACAD and ADMA Biologics ADMA, all carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 87 cents to 57 cents. In the past year, shares of Acadia Pharmaceuticals have fallen by 10.8%. | Some better-ranked stocks in the same industry are Aptinyx APTX, Acadia Pharmaceuticals ACAD and ADMA Biologics ADMA, all carrying a Zacks Rank #2 (Buy) at present. Click to get this free report Agenus Inc. (AGEN) : Free Stock Analysis Report ADMA Biologics Inc (ADMA) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Aptinyx Inc. (APTX) : Free Stock Analysis Report To read this article on Zacks.com click here. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 87 cents to 57 cents. | Some better-ranked stocks in the same industry are Aptinyx APTX, Acadia Pharmaceuticals ACAD and ADMA Biologics ADMA, all carrying a Zacks Rank #2 (Buy) at present. Click to get this free report Agenus Inc. (AGEN) : Free Stock Analysis Report ADMA Biologics Inc (ADMA) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Aptinyx Inc. (APTX) : Free Stock Analysis Report To read this article on Zacks.com click here. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 87 cents to 57 cents. | Some better-ranked stocks in the same industry are Aptinyx APTX, Acadia Pharmaceuticals ACAD and ADMA Biologics ADMA, all carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 87 cents to 57 cents. In the past year, shares of Acadia Pharmaceuticals have fallen by 10.8%. |
35647.0 | 2023-04-14 00:00:00 UTC | Mizuho Reiterates ACADIA Pharmaceuticals (ACAD) Neutral Recommendation | ACAD | https://www.nasdaq.com/articles/mizuho-reiterates-acadia-pharmaceuticals-acad-neutral-recommendation | nan | nan | Fintel reports that on April 14, 2023, Mizuho reiterated coverage of ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral recommendation.
Analyst Price Forecast Suggests 23.92% Upside
As of April 6, 2023, the average one-year price target for ACADIA Pharmaceuticals is $22.95. The forecasts range from a low of $12.12 to a high of $34.65. The average price target represents an increase of 23.92% from its latest reported closing price of $18.52.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for ACADIA Pharmaceuticals is $597MM, an increase of 15.43%. The projected annual non-GAAP EPS is -$0.80.
For more in-depth coverage of ACADIA Pharmaceuticals, view the free, crowd-sourced company research report on Finpedia.
What are Other Shareholders Doing?
Steward Financial Group holds 0K shares representing 0.00% ownership of the company.
DEUTSCHE DWS INVESTMENTS VIT FUNDS - DWS Small Cap Index VIP holds 18K shares representing 0.01% ownership of the company. In it's prior filing, the firm reported owning 18K shares, representing an increase of 1.78%. The firm decreased its portfolio allocation in ACAD by 9.04% over the last quarter.
SBIO - ALPS Medical Breakthroughs ETF holds 102K shares representing 0.06% ownership of the company. In it's prior filing, the firm reported owning 95K shares, representing an increase of 6.71%. The firm decreased its portfolio allocation in ACAD by 1.36% over the last quarter.
PNASX - SmallCap Growth Fund I R-1 holds 363K shares representing 0.22% ownership of the company. In it's prior filing, the firm reported owning 366K shares, representing a decrease of 0.91%. The firm increased its portfolio allocation in ACAD by 12.11% over the last quarter.
GCSIX - Goldman Sachs Small Cap Equity Insights Fund Institutional holds 34K shares representing 0.02% ownership of the company. In it's prior filing, the firm reported owning 53K shares, representing a decrease of 53.98%. The firm decreased its portfolio allocation in ACAD by 18.64% over the last quarter.
What is the Fund Sentiment?
There are 479 funds or institutions reporting positions in ACADIA Pharmaceuticals. This is a decrease of 16 owner(s) or 3.23% in the last quarter. Average portfolio weight of all funds dedicated to ACAD is 0.19%, an increase of 13.12%. Total shares owned by institutions increased in the last three months by 2.18% to 164,476K shares.
The put/call ratio of ACAD is 0.36, indicating a bullish outlook.
Acadia Pharmaceuticals Background Information
(This description is provided by the company.)
Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years it has been working at the forefront of healthcare to bring vital solutions to people who need them most. It developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson's disease psychosis. Its late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research it is exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders.
See all ACADIA Pharmaceuticals regulatory filings.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Fintel reports that on April 14, 2023, Mizuho reiterated coverage of ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral recommendation. For more in-depth coverage of ACADIA Pharmaceuticals, view the free, crowd-sourced company research report on Finpedia. Analyst Price Forecast Suggests 23.92% Upside As of April 6, 2023, the average one-year price target for ACADIA Pharmaceuticals is $22.95. | Fintel reports that on April 14, 2023, Mizuho reiterated coverage of ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral recommendation. Analyst Price Forecast Suggests 23.92% Upside As of April 6, 2023, the average one-year price target for ACADIA Pharmaceuticals is $22.95. The projected annual revenue for ACADIA Pharmaceuticals is $597MM, an increase of 15.43%. | Fintel reports that on April 14, 2023, Mizuho reiterated coverage of ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral recommendation. Analyst Price Forecast Suggests 23.92% Upside As of April 6, 2023, the average one-year price target for ACADIA Pharmaceuticals is $22.95. The projected annual revenue for ACADIA Pharmaceuticals is $597MM, an increase of 15.43%. | Analyst Price Forecast Suggests 23.92% Upside As of April 6, 2023, the average one-year price target for ACADIA Pharmaceuticals is $22.95. There are 479 funds or institutions reporting positions in ACADIA Pharmaceuticals. Fintel reports that on April 14, 2023, Mizuho reiterated coverage of ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral recommendation. |
35648.0 | 2023-04-13 00:00:00 UTC | Aeglea (AGLE) Plunges 26% After Rare Disorder Drug Study Fails | ACAD | https://www.nasdaq.com/articles/aeglea-agle-plunges-26-after-rare-disorder-drug-study-fails | nan | nan | Aeglea BioTherapeutics AGLE announced data from the interim analysis of a phase I/II study of pegtarviliase for the treatment of cystathionine beta synthase deficiency, also known as Classical Homocystinuria. The stock nosedived 26.21% on Wednesday after the company reported that the study failed to achieve its objectives.
The candidate, pegtarviliase, is a novel recombinant human enzyme engineered to reduce elevated levels of total homocysteine in patients with Classical Homocystinuria. It is a rare inherited disorder of methionine metabolism that leads to elevated levels of total homocysteine.
In the past year, shares of Aeglea have plummeted 90.4% compared with the industry’s 14.2% fall.
Image Source: Zacks Investment Research
The total patient population in the ongoing phase I/II dose escalation study of pegtarviliase has been divided into three cohorts. Participants in each cohort received pegtarviliase once a week for four weeks to assess safety and tolerability as well as to gather data on efficacy and optimum dose levels.
The study enrolled a total of 13 patients out of which 11 participants completed dosing and were considered evaluable. One participant withdrew from the study due to personal reasons.
Per the interim results of the study, data from the first two cohorts (0.15 mg/kg and 0.45 mg/kg, respectively) showed that treatment with pegtarviliase lowered total homocysteine levels in participants when compared with baseline values. However, in the third cohort (1.35 mg/kg), a consistent reduction in total homocysteine levels compared with baseline was not observed.
Further analysis of the data showed that anti-drug antibodies were found in the participants belonging to the third cohort. Experts speculated that this could have impacted the pharmacokinetics and reduced the effect of pegtarviliase in reducing total homocysteine levels.
All things considered, Aeglea concluded that the available data suggest exploration of higher doses or dosing of longer duration might be necessary to better determine the potential efficacy of pegtarviliase in lowering total homocysteine.
The candidate was overall well tolerated during the study, with most adverse events being mild-to-moderate injection site reactions and hypersensitivity reactions. There was one serious adverse event which was assessed as unrelated to treatment. No participants withdrew from the study or had a dose reduction due to an adverse event.
Management remains confident of the potential of its Homocystinuria treatment candidate, but unfortunately does not have compelling data to support immediate dialogue with regulatory bodies on a pivotal study design.
In the same press release, Aeglea confirmed entering the process of exploring strategic alternatives. This will include but are not limited to, an acquisition, merger, reverse merger, other business combination, sales of assets or other strategic transactions. The company further reiterates that this is not a guarantee of any transaction.
Aeglea has also not provided a date of completion of this strategic review, withholding a comment on the status of this process, for the time being. The company has slashed its workforce, including members from upper management, retaining approximately 10 employees required to support the process and continue ongoing value-creating activities.
Aeglea BioTherapeutics, Inc. Price and Consensus
Aeglea BioTherapeutics, Inc. price-consensus-chart | Aeglea BioTherapeutics, Inc. Quote
Zacks Rank and Stocks to Consider
Aeglea currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks in the same industry are Aptinyx APTX, Acadia Pharmaceuticals ACAD and ADMA Biologics ADMA, all carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 90 days, the Zacks Consensus Estimate for Aptinyx’s 2023 loss per share has narrowed from 77 cents to 47 cents. In the past year, shares of Aptinyx have fallen by 88.1%.
APTX beat estimates in each of the trailing four quarters, delivering an average earnings surprise of 6.56%.
In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 87 cents to 56 cents. In the past year, shares of Acadia Pharmaceuticals have fallen by 21.9%.
ACAD beat estimates in two of the trailing four quarters, missing the mark on other two occasions, delivering an average negative earnings surprise of 6.33%.
In the past 90 days, the consensus estimate for ADMA Biologics’ 2023 loss per share has narrowed from 19 cents to 14 cents. In the past year, shares of ADMA Biologics have increased by 55.2%.
ADMA beat estimates in three out of the trailing four quarters, delivering an average earnings surprise of 2.88%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ADMA Biologics Inc (ADMA) : Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report
Aeglea BioTherapeutics, Inc. (AGLE) : Free Stock Analysis Report
Aptinyx Inc. (APTX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the same industry are Aptinyx APTX, Acadia Pharmaceuticals ACAD and ADMA Biologics ADMA, all carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 87 cents to 56 cents. In the past year, shares of Acadia Pharmaceuticals have fallen by 21.9%. | Some better-ranked stocks in the same industry are Aptinyx APTX, Acadia Pharmaceuticals ACAD and ADMA Biologics ADMA, all carrying a Zacks Rank #2 (Buy) at present. Click to get this free report ADMA Biologics Inc (ADMA) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Aeglea BioTherapeutics, Inc. (AGLE) : Free Stock Analysis Report Aptinyx Inc. (APTX) : Free Stock Analysis Report To read this article on Zacks.com click here. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 87 cents to 56 cents. | Click to get this free report ADMA Biologics Inc (ADMA) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Aeglea BioTherapeutics, Inc. (AGLE) : Free Stock Analysis Report Aptinyx Inc. (APTX) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the same industry are Aptinyx APTX, Acadia Pharmaceuticals ACAD and ADMA Biologics ADMA, all carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 87 cents to 56 cents. | Some better-ranked stocks in the same industry are Aptinyx APTX, Acadia Pharmaceuticals ACAD and ADMA Biologics ADMA, all carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 87 cents to 56 cents. In the past year, shares of Acadia Pharmaceuticals have fallen by 21.9%. |
35649.0 | 2023-04-06 00:00:00 UTC | Here's Why You Should Add Acadia (ACAD) Stock to Your Portfolio | ACAD | https://www.nasdaq.com/articles/heres-why-you-should-add-acadia-acad-stock-to-your-portfolio | nan | nan | Acadia Pharmaceuticals Inc. ACAD is a San Diego, CA-based biopharmaceutical company, focused on developing innovative medicines to address unmet medical needs in central nervous system (CNS) disorders.
The company’s sole marketed drug, Nuplazid (pimavanserin), is the first and the only FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis. The drug was launched in May 2016.
Acadia’s top line mainly comprises U.S. sales of Nuplazid. The company recognized revenues worth $517.2 million in 2022 compared with $484.1 million in 2021.
Let’s delve deeper to discuss four reasons why adding Acadia stock to your portfolio may prove beneficial in 2023.
Good Rank & Rising Estimates: In the past year, shares of Acadia dropped 32.4% compared with the industry’s 16.6% decline.
Image Source: Zacks Investment Research
Despite the poor price performance, Acadia carries a Zacks Rank #2 (Buy) at present.
Our estimates for revenues from Nuplazid sales suggest a CAGR growth of 7.2% over the next three years.
Nuplazid Sales Strong; Label Expansion Studies Ongoing: Sales of Nuplazid have improved steadily since its launch in May 2016. Nuplazid’s net sales for 2022 were $517.2 million, witnessing year-over-year growth of 7%.
Several additional studies on Nuplazid targeting different types of neurological and psychiatric disorders are presently ongoing. Studies on Nuplazid include schizophrenia-negative symptoms (phase III ADVANCE study). Acadia is currently evaluating Nuplazid in a phase III ADVANCE-2 study to evaluate its efficacy in patients with predominantly negative symptoms of schizophrenia who have achieved adequate control of positive symptoms with the existing antipsychotic treatment. Enrollment in the study is expected to be completed in the current year, reporting top-line results in early 2024. The company is also developing Nuplazid to treat other neuropsychiatric conditions.
A potential approval for any of the above indications will be a significant boost to the company.
Approval of Trofinetide, a Boost: On Mar 10, 2023, the FDA approved trofinetide for the treatment of Rett syndrome in adults and pediatric patients aged two years and older. The drug is to be marketed under the brand name Daybue and is expected to be made available in the United States by the end of April 2023.
Acadia’s partner Neuren Pharmaceuticals, per the exclusive license agreement, will pursue the development and commercialization of trofinetide for the treatment of Rett syndrome and other indications in North America. Currently, there are no approved medicines for treating Rett syndrome. The FDA has granted Rare Pediatric Disease designation to trofinetide for the given indication. The FDA has also issued Acadia, a Rare Pediatric Disease Priority Review Voucher, which can be used to obtain priority review for a subsequent application.
The approval will add an incremental stream of revenues to the top line.
Acadia faces competition from Anavex Life Sciences Corp. AVXL, currently conducting studies on possible treatment candidates for Rett syndrome. Anavex is currently evaluating Anavex 2-73 (blarcamesine), a small-molecule activator of the sigma-1 receptor, for the treatment of Rett syndrome in a phase II/III EXCELLENCE (Anavex 2-73-RS-003) study, among other neurological indications.
Last month, Anavex announced the completion of enrollment of 92 patients in its phase II/III EXCELLENCE study for the treatment of Rett Syndrome in patients aged 5 to 17 years. The company anticipates announcing top-line data from the study in the second half of 2023.
Despite the competition, Acadia enjoys a strong foothold in the CNS disorders market with Nuplazid and the newly approved Daybue. Nuplazid and Daybue together are expected to drive up revenues in the upcoming quarters. This is expected to give Acadia a comfortable edge over its competitors.
ACADIA Pharmaceuticals Inc. Price and Consensus
ACADIA Pharmaceuticals Inc. price-consensus-chart | ACADIA Pharmaceuticals Inc. Quote
Other Stocks to Consider
Some other top-ranked stocks in the same industry are Aptinyx APTX and ADMA Biologics ADMA, both carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 90 days, the Zacks Consensus Estimate for Aptinyx’s 2023 loss per share has narrowed from 77 cents to 44 cents. In the past year, shares of Aptinyx have fallen by 89.9%.
APTX beat estimates in each of the trailing four quarters, delivering an average earnings surprise of 6.56%.
In the past 90 days, the consensus estimate for ADMA’s 2023 loss per share has narrowed from 19 cents to 14 cents. In the past year, shares of ADMA have increased by 49.6%.
ADMA beat estimates in three out of the trailing four quarters, missing the mark on one occasion, delivering an average earnings surprise of 2.88%.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ADMA Biologics Inc (ADMA) : Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report
Anavex Life Sciences Corp. (AVXL) : Free Stock Analysis Report
Aptinyx Inc. (APTX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia Pharmaceuticals Inc. ACAD is a San Diego, CA-based biopharmaceutical company, focused on developing innovative medicines to address unmet medical needs in central nervous system (CNS) disorders. Acadia’s partner Neuren Pharmaceuticals, per the exclusive license agreement, will pursue the development and commercialization of trofinetide for the treatment of Rett syndrome and other indications in North America. Acadia faces competition from Anavex Life Sciences Corp. AVXL, currently conducting studies on possible treatment candidates for Rett syndrome. | Click to get this free report ADMA Biologics Inc (ADMA) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Anavex Life Sciences Corp. (AVXL) : Free Stock Analysis Report Aptinyx Inc. (APTX) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals Inc. ACAD is a San Diego, CA-based biopharmaceutical company, focused on developing innovative medicines to address unmet medical needs in central nervous system (CNS) disorders. Acadia’s top line mainly comprises U.S. sales of Nuplazid. | Acadia is currently evaluating Nuplazid in a phase III ADVANCE-2 study to evaluate its efficacy in patients with predominantly negative symptoms of schizophrenia who have achieved adequate control of positive symptoms with the existing antipsychotic treatment. ACADIA Pharmaceuticals Inc. Price and Consensus ACADIA Pharmaceuticals Inc. price-consensus-chart | ACADIA Pharmaceuticals Inc. Quote Other Stocks to Consider Some other top-ranked stocks in the same industry are Aptinyx APTX and ADMA Biologics ADMA, both carrying a Zacks Rank #2 at present. Click to get this free report ADMA Biologics Inc (ADMA) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Anavex Life Sciences Corp. (AVXL) : Free Stock Analysis Report Aptinyx Inc. (APTX) : Free Stock Analysis Report To read this article on Zacks.com click here. | ACADIA Pharmaceuticals Inc. Price and Consensus ACADIA Pharmaceuticals Inc. price-consensus-chart | ACADIA Pharmaceuticals Inc. Quote Other Stocks to Consider Some other top-ranked stocks in the same industry are Aptinyx APTX and ADMA Biologics ADMA, both carrying a Zacks Rank #2 at present. Acadia Pharmaceuticals Inc. ACAD is a San Diego, CA-based biopharmaceutical company, focused on developing innovative medicines to address unmet medical needs in central nervous system (CNS) disorders. Acadia’s top line mainly comprises U.S. sales of Nuplazid. |
35650.0 | 2023-04-06 00:00:00 UTC | Aeterna (AEZS) Falls 5% on US Sales Halt of Growth Hormone Drug | ACAD | https://www.nasdaq.com/articles/aeterna-aezs-falls-5-on-us-sales-halt-of-growth-hormone-drug | nan | nan | Aeterna Zentaris AEZS stock dropped 4.8% on Wednesday after the company announced that sales of Macrilen (macimorelin) will be temporarily halted in the United States, effective May 23, 2023. This halt is currently for an indefinite period until the company finds an alternate commercialization partner for Macrilen’s re-launch. The stock price drop signifies investors’ anticipation of a severe blow to Aeterna’s revenues in the upcoming quarters.
Aeterna’s former commercialization partner, Novo Nordisk NVO, severed ties for Aeterna’s adult growth hormone deficiency (AGHD) diagnosis drug, Macrilen. Novo Nordisk exercised its right to terminate the licensing agreement in August 2022. Aeterna is scheduled to regain all rights to Macrilen from Novo Nordisk in the United States and Canada on May 23, 2023, at the end of the 270-day notice period.
In the past year, shares of Aeterna have plunged 72% compared with the industry’s 16.6% fall.
Image Source: Zacks Investment Research
Aeterna reaffirmed in the press release that it is committed to finding alternate development and commercialization partners for Macrilen in the United States and other territories that are yet to be ventured. Management stated that the temporary decision to discontinue sales of Macrilen in the U.S. market will not impact the sales and commercialization efforts of the drug in the UK and European Economic Area (EEA).
Macrilen is marketed under the brand name Ghryvelin in UK and EEA. Last month, the company announced entering into an exclusive licensing agreement to commercialize Ghryvelin in the UK and EEA with Pharmanovia. The exclusive right to commercialize Aeterna’s Ghryvelin was shifted from its former EEA and UK partner, Consilient Health, to Pharmanovia.
In the same press release, Aeterna announced that the United States Patent and Trademark Office has issued a Notice of Allowance in its favor to use Macimorelin in assessing growth hormone deficiency in children. The company expects the issue of the formal registration of this U.S. patent application in the coming months.
Aeterna further reiterated the advancement of its pivotal phase III DETECT study to expand the current indication for macimorelin to include the childhood-onset growth hormone deficiency diagnosis, under its label. The possible approval of the drug for this indication will enable the diagnosis of growth hormone deficiency in pediatric patients in the United States, UK and EEA.
We would like to remind the investors that macimorelin was approved by the FDA for the diagnosis of AGHD in 2017. Subsequently, the drug also received approval from the European Medicine Agency in 2019 for the same indication. Both approvals were based on results from a phase III study showing that oral macimorelin provides accuracy comparable to standard insulin tolerance testing (ITT) while portraying a better safety profile than ITT. Oral macimorelin also reduces false positive test results, helping avoid unnecessary treatment of patients.
AEterna Zentaris Inc. Price and Consensus
AEterna Zentaris Inc. price-consensus-chart | AEterna Zentaris Inc. Quote
Zacks Rank and Stocks to Consider
Aeterna currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks in the same industry are Aptinyx APTX and ACADIA Pharmaceuticals ACAD, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 90 days, the Zacks Consensus Estimate for Aptinyx’s 2023 loss per share has narrowed from 77 cents to 44 cents. In the past year, shares of Aptinyx have fallen by 89.9%.
APTX beat estimates in each of the trailing four quarters, delivering an average earnings surprise of 6.56%.
In the past 90 days, the Zacks Consensus Estimate for ACADIA’s 2023 loss per share has narrowed from 87 cents to 56 cents. In the past year, shares of ACADIA have fallen by 32.4%.
ACAD beat estimates in two of the trailing four quarters, missing the mark on other two occasions, delivering an average negative earnings surprise of 6.33%.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Novo Nordisk A/S (NVO) : Free Stock Analysis Report
AEterna Zentaris Inc. (AEZS) : Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report
Aptinyx Inc. (APTX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the same industry are Aptinyx APTX and ACADIA Pharmaceuticals ACAD, both carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for ACADIA’s 2023 loss per share has narrowed from 87 cents to 56 cents. In the past year, shares of ACADIA have fallen by 32.4%. | Click to get this free report Novo Nordisk A/S (NVO) : Free Stock Analysis Report AEterna Zentaris Inc. (AEZS) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Aptinyx Inc. (APTX) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the same industry are Aptinyx APTX and ACADIA Pharmaceuticals ACAD, both carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for ACADIA’s 2023 loss per share has narrowed from 87 cents to 56 cents. | Click to get this free report Novo Nordisk A/S (NVO) : Free Stock Analysis Report AEterna Zentaris Inc. (AEZS) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Aptinyx Inc. (APTX) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the same industry are Aptinyx APTX and ACADIA Pharmaceuticals ACAD, both carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for ACADIA’s 2023 loss per share has narrowed from 87 cents to 56 cents. | Some better-ranked stocks in the same industry are Aptinyx APTX and ACADIA Pharmaceuticals ACAD, both carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for ACADIA’s 2023 loss per share has narrowed from 87 cents to 56 cents. In the past year, shares of ACADIA have fallen by 32.4%. |
35651.0 | 2023-04-05 00:00:00 UTC | Phathom (PHAT) Up 8% on Erosive Esophagitis Drug's CRL Update | ACAD | https://www.nasdaq.com/articles/phathom-phat-up-8-on-erosive-esophagitis-drugs-crl-update | nan | nan | Phathom Pharmaceuticals PHAT stock jumped 8.42% on Tuesday after the company announced a positive outcome from a recent meeting with the FDA regarding the resubmission of its new drug application (NDA) for vonoprazan for the treatment of erosive esophagitis and H. pylori infection indications. Vonoprazan is under review for the treatment of erosive esophagitis, while Voquesna Tripple PAK and Voquezna Dual PAK are approved for the treatment of adults with H. pylori infection.
Phathom’s meeting with the FDA was regarding the complete response letters (CRLs) for Phathom’s erosive esophagitis NDA and H. pylori post-approval supplement to Voquezna Triple PAK and Voquezna Dual PAK NDAs. The company further affirmed that the higher-than-acceptable level of N-nitroso-vonoprazan (NVP) impurity was the sole cause of both CRLs.
In the past year, shares of Phathom have plunged 48.1% compared with the industry’s 15.4% decline.
Image Source: Zacks Investment Research
Phathom had previously submitted an NDA to the FDA for the use of vonoprazan as a treatment for adults for the healing of all grades of erosive esophagitis in March 2022, with a decision expected in January 2023. In May 2022, Phathom received FDA approval for Voquesna Tripple PAK and Voquezna Dual PAK for the treatment of H. pylori infection in adults under priority review. It had also been previously granted as a qualified infectious disease product by the FDA.
However, after the commercial launch of Voquesna Tripple PAK and Voquezna Dual PAK in the third quarter of 2022, the FDA found unacceptable levels of NVP in commercial batches. Following this, the FDA issued CRLs to both the vonoprazan NDA and the approved products, Voquesna Tripple PAK and Voquezna Dual PAK.
As an initial response to the CRL, Phathom met with the FDA to obtain approval for a proposed acceptable daily intake limit, test method and controls to address this impurity before releasing vonoprazan-based products to the market. The acceptable daily intake limit was established at 96 ng/day by the FDA while requesting additional stability data demonstrating levels of NVP remain below that limit throughout the proposed shelf life of the product from Phathom.
In Tuesday’s press release, Phathom reported conducting extensive root cause investigations and implementing mitigation measures, including a minor tablet reformulation, to inhibit the growth of NVP since first detecting trace levels of NVP. The company has presented these stability data to the FDA on the reformulation.
The FDA has reportedly provided feedback on the resubmission requirements, including the expected stability data requirements. Based on the feedback, the company expects to resubmit the NDA for erosive esophagitis in the second quarter of 2023. Subject to approval, this could lead to a combined commercial launch of vonoprazan for the erosive esophagitis and H. pylori indications in the fourth quarter of 2023.
Phathom Pharmaceuticals, Inc. Price and Consensus
Phathom Pharmaceuticals, Inc. price-consensus-chart | Phathom Pharmaceuticals, Inc. Quote
Zacks Rank and Other Stocks to Consider
Phathom currently has a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the same industry are Aptinyx APTX, ACADIA Pharmaceuticals ACAD and ADMA Biologics ADMA, all carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 90 days, the Zacks Consensus Estimate for Aptinyx’s 2023 loss per share has narrowed from 77 cents to 56 cents. In the past year, shares of Aptinyx have fallen by 94.9%.
APTX beat estimates in each of the trailing four quarters, delivering an average earnings surprise of 6.56%.
In the past 90 days, the Zacks Consensus Estimate for ACADIA’s 2023 loss per share has narrowed from 87 cents to 44 cents. In the past year, shares of ACADIA have fallen by 32.1%.
ACAD beat estimates in two of the trailing four quarters, missing the mark on other two occasions, delivering an average earnings negative surprise of 6.33%.
In the past 90 days, the consensus estimate for ADMA’s 2023 loss per share has narrowed from 20 cents to 14 cents. In the past year, shares of ADMA have increased by 66.4%.
ADMA beat estimates in three out of the trailing four quarters, delivering an average earnings surprise of 2.88%.
Free Report Reveals How You Could Profit from the Growing Electric Vehicle Industry
Globally, electric car sales continue their remarkable growth even after breaking records in 2021. High gas prices have fueled his demand, but so has evolving EV comfort, features and technology. So, the fervor for EVs will be around long after gas prices normalize. Not only are manufacturers seeing record-high profits, but producers of EV-related technology are raking in the dough as well. Do you know how to cash in? If not, we have the perfect report for you – and it’s FREE! Today, don't miss your chance to download Zacks' top 5 stocks for the electric vehicle revolution at no cost and with no obligation.
>>Send me my free report on the top 5 EV stocks
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ADMA Biologics Inc (ADMA) : Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report
Aptinyx Inc. (APTX) : Free Stock Analysis Report
Phathom Pharmaceuticals, Inc. (PHAT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some other top-ranked stocks in the same industry are Aptinyx APTX, ACADIA Pharmaceuticals ACAD and ADMA Biologics ADMA, all carrying a Zacks Rank #2 at present. In the past 90 days, the Zacks Consensus Estimate for ACADIA’s 2023 loss per share has narrowed from 87 cents to 44 cents. In the past year, shares of ACADIA have fallen by 32.1%. | Click to get this free report ADMA Biologics Inc (ADMA) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Aptinyx Inc. (APTX) : Free Stock Analysis Report Phathom Pharmaceuticals, Inc. (PHAT) : Free Stock Analysis Report To read this article on Zacks.com click here. Some other top-ranked stocks in the same industry are Aptinyx APTX, ACADIA Pharmaceuticals ACAD and ADMA Biologics ADMA, all carrying a Zacks Rank #2 at present. In the past 90 days, the Zacks Consensus Estimate for ACADIA’s 2023 loss per share has narrowed from 87 cents to 44 cents. | Click to get this free report ADMA Biologics Inc (ADMA) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Aptinyx Inc. (APTX) : Free Stock Analysis Report Phathom Pharmaceuticals, Inc. (PHAT) : Free Stock Analysis Report To read this article on Zacks.com click here. Some other top-ranked stocks in the same industry are Aptinyx APTX, ACADIA Pharmaceuticals ACAD and ADMA Biologics ADMA, all carrying a Zacks Rank #2 at present. In the past 90 days, the Zacks Consensus Estimate for ACADIA’s 2023 loss per share has narrowed from 87 cents to 44 cents. | Some other top-ranked stocks in the same industry are Aptinyx APTX, ACADIA Pharmaceuticals ACAD and ADMA Biologics ADMA, all carrying a Zacks Rank #2 at present. In the past 90 days, the Zacks Consensus Estimate for ACADIA’s 2023 loss per share has narrowed from 87 cents to 44 cents. In the past year, shares of ACADIA have fallen by 32.1%. |
35652.0 | 2023-03-29 00:00:00 UTC | Acadia (ACAD) Down 10.9% Since Last Earnings Report: Can It Rebound? | ACAD | https://www.nasdaq.com/articles/acadia-acad-down-10.9-since-last-earnings-report%3A-can-it-rebound | nan | nan | It has been about a month since the last earnings report for Acadia Pharmaceuticals (ACAD). Shares have lost about 10.9% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Acadia due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
Acadia Q4 Earnings Miss, Nuplazid Sales Boost Revenues
Acadia Pharmaceuticals Inc. reported a fourth-quarter 2022 loss of 26 cents per share, just missing the Zacks Consensus Estimate of a loss of 25 cents. The loss was on par with our estimate of a loss of 26 cents per share. In the year-ago quarter, the company incurred a loss of 27 cents per share.
Total revenues, comprising net sales of Acadia's only marketed drug, Nuplazid (pimavanserin), increased 4% year over year to $136.5 million in the fourth quarter, beating the Zacks Consensus Estimate of $134 million. Nuplazid sales increased by 3.8% sequentially in the fourth quarter.
Nuplazid sales in | Will the recent negative trend continue leading up to its next earnings release, or is Acadia due for a breakout? Acadia Q4 Earnings Miss, Nuplazid Sales Boost Revenues Acadia Pharmaceuticals Inc. reported a fourth-quarter 2022 loss of 26 cents per share, just missing the Zacks Consensus Estimate of a loss of 25 cents. It has been about a month since the last earnings report for Acadia Pharmaceuticals (ACAD). | It has been about a month since the last earnings report for Acadia Pharmaceuticals (ACAD). Acadia Q4 Earnings Miss, Nuplazid Sales Boost Revenues Acadia Pharmaceuticals Inc. reported a fourth-quarter 2022 loss of 26 cents per share, just missing the Zacks Consensus Estimate of a loss of 25 cents. Total revenues, comprising net sales of Acadia's only marketed drug, Nuplazid (pimavanserin), increased 4% year over year to $136.5 million in the fourth quarter, beating the Zacks Consensus Estimate of $134 million. | Acadia Q4 Earnings Miss, Nuplazid Sales Boost Revenues Acadia Pharmaceuticals Inc. reported a fourth-quarter 2022 loss of 26 cents per share, just missing the Zacks Consensus Estimate of a loss of 25 cents. Total revenues, comprising net sales of Acadia's only marketed drug, Nuplazid (pimavanserin), increased 4% year over year to $136.5 million in the fourth quarter, beating the Zacks Consensus Estimate of $134 million. It has been about a month since the last earnings report for Acadia Pharmaceuticals (ACAD). | Will the recent negative trend continue leading up to its next earnings release, or is Acadia due for a breakout? Acadia Q4 Earnings Miss, Nuplazid Sales Boost Revenues Acadia Pharmaceuticals Inc. reported a fourth-quarter 2022 loss of 26 cents per share, just missing the Zacks Consensus Estimate of a loss of 25 cents. It has been about a month since the last earnings report for Acadia Pharmaceuticals (ACAD). |
35653.0 | 2023-03-19 00:00:00 UTC | Validea's Top Ten Healthcare Stocks Based On Kenneth Fisher - 3/19/2023 | ACAD | https://www.nasdaq.com/articles/valideas-top-ten-healthcare-stocks-based-on-kenneth-fisher-3-19-2023 | nan | nan | The following are the top rated Healthcare stocks according to Validea's Price/Sales Investor model based on the published strategy of Kenneth Fisher. This value strategy rewards stocks with low P/S ratios, long-term profit growth, strong free cash flow and consistent profit margins.
USANA HEALTH SCIENCES, INC. (USNA) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Kenneth Fisher is 50% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: USANA Health Sciences, Inc. develops and manufactures nutritional supplements, functional foods, and personal care products. The Company's product line includes USANA Nutritionals Essentials/CellSentials, optimizers, foods, skincare, and all other. It also manufactures and sells protein bars. It provides a personal development framework that helps individuals create a life of balance, growth, and purpose. Its USANA Nutritionals Essentials/CellSentials includes vitamin and mineral supplements that provides a total body nutrition for every age group beginning with children 13 months of age. Its optimizers include supplements designed to meet individual health and nutritional needs. Its food product line includes meal replacement shakes, snack bars, and other related products that provide macro-nutrition. Its all-other product line includes materials and online tools that are designed to assist its associates in building their businesses and in marketing its products.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
PRICE/SALES RATIO: PASS
TOTAL DEBT/EQUITY RATIO: PASS
PRICE/RESEARCH RATIO: FAIL
PRICE/SALES RATIO: FAIL
LONG-TERM EPS GROWTH RATE: FAIL
FREE CASH PER SHARE: PASS
THREE YEAR AVERAGE NET PROFIT MARGIN: PASS
Detailed Analysis of USANA HEALTH SCIENCES, INC.
USNA Guru Analysis
USNA Fundamental Analysis
APOLLO MEDICAL HOLDINGS INC (AMEH) is a mid-cap growth stock in the Healthcare Facilities industry. The rating according to our strategy based on Kenneth Fisher is 48% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Apollo Medical Holdings, Inc. is a healthcare company. The Company provides care coordination services to each constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The Company's physician network consists of primary care physicians, specialist physicians, physician and specialist extenders, and hospitalists. The Company operates an integrated healthcare delivery platform that enables providers to participate successfully in value-based care arrangements. To implement a patient-centered, physician-centric experience, the Company also have other integrated and synergistic operations, including management service organizations (MSOs) that provide management and other services to its affiliated independent practice associations (IPAs), outpatient clinics, and hospitalists that coordinate the care of patients in hospitals.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
PRICE/SALES RATIO: FAIL
TOTAL DEBT/EQUITY RATIO: PASS
PRICE/RESEARCH RATIO: FAIL
PRICE/SALES RATIO: FAIL
LONG-TERM EPS GROWTH RATE: PASS
FREE CASH PER SHARE: PASS
THREE YEAR AVERAGE NET PROFIT MARGIN: PASS
Detailed Analysis of APOLLO MEDICAL HOLDINGS INC
AMEH Guru Analysis
AMEH Fundamental Analysis
ALTIMMUNE INC (ALT) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Kenneth Fisher is 40% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Altimmune, Inc. is a clinical-stage biopharmaceutical company that is focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis (NASH). It is also developing HepTcell, an immunotherapeutic agent designed to achieve a functional cure for chronic hepatitis B. The Company has initiated a Phase II clinical trial of HepTcell and are in Phase II and Phase I clinical development with pemvidutide for multiple indications. It is conducting its Phase II clinical trial of HepTcell in the United States, United Kingdom, Canada, Germany and Spain, and conducting Its pemvidutide Phase I clinical trial in Australia. Its wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
PRICE/SALES RATIO: FAIL
TOTAL DEBT/EQUITY RATIO: PASS
PRICE/RESEARCH RATIO: PASS
LONG-TERM EPS GROWTH RATE: FAIL
FREE CASH PER SHARE: FAIL
THREE YEAR AVERAGE NET PROFIT MARGIN: FAIL
Detailed Analysis of ALTIMMUNE INC
ALT Guru Analysis
ALT Fundamental Analysis
ALLOGENE THERAPEUTICS INC (ALLO) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Kenneth Fisher is 40% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Allogene Therapeutics, Inc. is a clinical stage immuno-oncology company. The Company is focused on the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. It is engaged in developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced T cell manufacturing technologies. Its advanced product candidates, ALLO-501 and ALLO-501A, are engineered allogeneic CAR T cell therapies that target CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is also developing engineered allogeneic CAR T cell product candidates for multiple myeloma, clear cell renal cell carcinoma (ccRCC), and other blood cancers and solid tumors. Its lead product candidates include ALLO-501, ALLO-501A, ALLO-715, ALLO-715 plus nirogacestat, ALLO-605, ALLO-316, and ALLO-647.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
PRICE/SALES RATIO: FAIL
TOTAL DEBT/EQUITY RATIO: PASS
PRICE/RESEARCH RATIO: PASS
PRICE/SALES RATIO: FAIL
LONG-TERM EPS GROWTH RATE: FAIL
FREE CASH PER SHARE: FAIL
THREE YEAR AVERAGE NET PROFIT MARGIN: FAIL
Detailed Analysis of ALLOGENE THERAPEUTICS INC
ALLO Guru Analysis
ALLO Fundamental Analysis
ALKERMES PLC (ALKS) is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Kenneth Fisher is 40% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Alkermes Public Limited Company is an integrated biopharmaceutical company. It is engaged in researching, developing and commercializing pharmaceutical products that are designed to address unmet medical needs of patients in the fields of neuroscience and oncology. Its portfolio of commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Its products include ARISTADA, ARISTADA INITIO, LYBALVI and VIVITROL. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder. VIVITROL is a non-narcotic, injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
PRICE/SALES RATIO: FAIL
TOTAL DEBT/EQUITY RATIO: PASS
PRICE/RESEARCH RATIO: PASS
PRICE/SALES RATIO: FAIL
LONG-TERM EPS GROWTH RATE: FAIL
FREE CASH PER SHARE: FAIL
THREE YEAR AVERAGE NET PROFIT MARGIN: FAIL
Detailed Analysis of ALKERMES PLC
ALKS Guru Analysis
ALKS Fundamental Analysis
ALECTOR INC (ALEC) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Kenneth Fisher is 40% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Alector, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on immuno-neurology, a therapeutic approach for the treatment of neurodegeneration. The Company is engaged in developing therapies designed to counteract these pathologies by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. The Company has advanced four product candidates, AL001, AL002, AL003, and AL101, into clinical development. Its first product candidate, AL001, is a humanized recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of frontotemporal dementia carrying a progranulin (FTD-GRN) patients. Its AL002 targets triggering receptor expressed on myeloid cells 2 (TREM2) to increase the functionality of TREM2 signaling and enhance microglia cell activation.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
PRICE/SALES RATIO: FAIL
TOTAL DEBT/EQUITY RATIO: PASS
PRICE/RESEARCH RATIO: PASS
PRICE/SALES RATIO: FAIL
LONG-TERM EPS GROWTH RATE: FAIL
FREE CASH PER SHARE: FAIL
THREE YEAR AVERAGE NET PROFIT MARGIN: FAIL
Detailed Analysis of ALECTOR INC
ALEC Guru Analysis
ALEC Fundamental Analysis
ACADIA PHARMACEUTICALS INC (ACAD) is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Kenneth Fisher is 40% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Acadia Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops and commercializes novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The Company's pipeline product candidates in CNS areas includes NUPLAZID (pimavanser), Trofinetide, ACP-044 and ACP-319. NUPLAZID (pimavanserin) is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). ACP-044, is an orally administered, non-opioid analgesic being evaluated for the treatment of pain. The Company has initiated a Phase II study evaluating ACP-044 for the treatment of postoperative pain following bunionectomy surgery. The Company also initiated an additional Phase II study evaluating ACP-044 for the treatment of pain associated with osteoarthritis. ACP-319 is a positive allosteric modulator of the muscarinic receptor targeting M1 (M1 PAM).
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
PRICE/SALES RATIO: FAIL
TOTAL DEBT/EQUITY RATIO: PASS
PRICE/RESEARCH RATIO: PASS
PRICE/SALES RATIO: FAIL
LONG-TERM EPS GROWTH RATE: FAIL
FREE CASH PER SHARE: FAIL
THREE YEAR AVERAGE NET PROFIT MARGIN: FAIL
Detailed Analysis of ACADIA PHARMACEUTICALS INC
ACAD Guru Analysis
ACAD Fundamental Analysis
ANAPTYSBIO INC (ANAB) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Kenneth Fisher is 40% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: AnaptysBio, Inc. is a clinical-stage biotechnology company developing immunology therapeutic product. The Company is focused on the immune control mechanisms applicable to inflammation and immuno-oncology indications. It develops products using antibody discovery technology platform, which is based upon a natural process of antibody generation, known as somatic hypermutation, and replicates this natural process of antibody generation in vitro. Its advanced antibody programs include: Imsidolimab is an antibody that inhibits the interleukin-36 receptor, for the treatment of inflammatory diseases called generalized pustular psoriasis and hidradenitis suppurativa; Rosnilimab is an anti-PD-1 agonist antibody program, is designed to augment PD-1 signaling through Rosnilimab treatment to suppress T-cell driven human inflammatory diseases; anti-BTLA modulator antibody, known as ANB032, is applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
PRICE/SALES RATIO: FAIL
TOTAL DEBT/EQUITY RATIO: PASS
PRICE/RESEARCH RATIO: PASS
PRICE/SALES RATIO: FAIL
LONG-TERM EPS GROWTH RATE: FAIL
FREE CASH PER SHARE: FAIL
THREE YEAR AVERAGE NET PROFIT MARGIN: FAIL
Detailed Analysis of ANAPTYSBIO INC
ANAB Guru Analysis
ANAB Fundamental Analysis
ARVINAS INC (ARVN) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Kenneth Fisher is 40% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Arvinas, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of therapies that degrade disease-causing proteins. The Company uses its proteolysis targeting chimera (PROTAC) Discovery Engine, a technology platform to engineer PROTAC targeted protein degraders that are designed to harness the body's own natural protein disposal system to selectively remove disease-causing proteins. Its three product candidates include ARV-110, ARV-471 and ARV-766. It develops ARV-110, a PROTAC protein degrader targeting the androgen receptor protein (AR), for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC). It develops ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein (ER), for the treatment of patients with locally advanced or metastatic ER-positive/HER2 negative breast cancer. The Company develops ARV-766, a PROTAC protein degrader for the treatment of men with mCRPC.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
PRICE/SALES RATIO: FAIL
TOTAL DEBT/EQUITY RATIO: PASS
PRICE/RESEARCH RATIO: PASS
PRICE/SALES RATIO: FAIL
LONG-TERM EPS GROWTH RATE: FAIL
FREE CASH PER SHARE: FAIL
THREE YEAR AVERAGE NET PROFIT MARGIN: FAIL
Detailed Analysis of ARVINAS INC
ARVN Guru Analysis
ARVN Fundamental Analysis
ARROWHEAD PHARMACEUTICALS INC (ARWR) is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Kenneth Fisher is 40% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company uses a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's pipeline includes ARO-APOC3 for hypertriglyceridemia, ARO-ANG3 for dyslipidemia, ARO-ENaC2 for cystic fibrosis, ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-COV for the coronavirus that causes COVID-19 and other possible future pulmonary-borne pathogens, ARO-C3 for complement mediated diseases, ARO-RAGE and ARO-MUC5AC for various muco-obstructive or inflammatory pulmonary conditions and ARO-MMP7 for idiopathic pulmonary fibrosis.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
PRICE/SALES RATIO: FAIL
TOTAL DEBT/EQUITY RATIO: PASS
PRICE/RESEARCH RATIO: PASS
PRICE/SALES RATIO: FAIL
LONG-TERM EPS GROWTH RATE: FAIL
FREE CASH PER SHARE: FAIL
THREE YEAR AVERAGE NET PROFIT MARGIN: FAIL
Detailed Analysis of ARROWHEAD PHARMACEUTICALS INC
ARWR Guru Analysis
ARWR Fundamental Analysis
Kenneth Fisher Portfolio
About Kenneth Fisher: The son of Philip Fisher, who is considered the "Father of Growth Investing", Kenneth Fisher is a money manager, bestselling author, and longtime Forbes columnist. The younger Fisher wowed Wall Street in the mid-1980s when his book Super Stocks first popularized the idea of using the price/sales ratio (PSR) as a means of identifying attractive stocks. According to his alma mater, Humboldt State University, Fisher is also one of the world's foremost experts on 19th century logging. Appropriately, Fisher's firm, Fisher Investments, is located in a lush forest preserve in Woodside, California, where the contrarian-minded Fisher says he and his employees can get away from Wall Street groupthink.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Detailed Analysis of ALECTOR INC ALEC Guru Analysis ALEC Fundamental Analysis ACADIA PHARMACEUTICALS INC (ACAD) is a mid-cap growth stock in the Biotechnology & Drugs industry. Company Description: Acadia Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops and commercializes novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. Detailed Analysis of ACADIA PHARMACEUTICALS INC ACAD Guru Analysis ACAD Fundamental Analysis ANAPTYSBIO INC (ANAB) is a small-cap growth stock in the Biotechnology & Drugs industry. | Detailed Analysis of ALECTOR INC ALEC Guru Analysis ALEC Fundamental Analysis ACADIA PHARMACEUTICALS INC (ACAD) is a mid-cap growth stock in the Biotechnology & Drugs industry. Company Description: Acadia Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops and commercializes novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. Detailed Analysis of ACADIA PHARMACEUTICALS INC ACAD Guru Analysis ACAD Fundamental Analysis ANAPTYSBIO INC (ANAB) is a small-cap growth stock in the Biotechnology & Drugs industry. | Detailed Analysis of ALECTOR INC ALEC Guru Analysis ALEC Fundamental Analysis ACADIA PHARMACEUTICALS INC (ACAD) is a mid-cap growth stock in the Biotechnology & Drugs industry. Company Description: Acadia Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops and commercializes novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. Detailed Analysis of ACADIA PHARMACEUTICALS INC ACAD Guru Analysis ACAD Fundamental Analysis ANAPTYSBIO INC (ANAB) is a small-cap growth stock in the Biotechnology & Drugs industry. | Detailed Analysis of ALECTOR INC ALEC Guru Analysis ALEC Fundamental Analysis ACADIA PHARMACEUTICALS INC (ACAD) is a mid-cap growth stock in the Biotechnology & Drugs industry. Company Description: Acadia Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops and commercializes novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. Detailed Analysis of ACADIA PHARMACEUTICALS INC ACAD Guru Analysis ACAD Fundamental Analysis ANAPTYSBIO INC (ANAB) is a small-cap growth stock in the Biotechnology & Drugs industry. |
35654.0 | 2023-03-16 00:00:00 UTC | Biotech Stock Roundup: ACAD's Drug Approval, SGEN to be Acquired by PFE & More | ACAD | https://www.nasdaq.com/articles/biotech-stock-roundup%3A-acads-drug-approval-sgen-to-be-acquired-by-pfe-more | nan | nan | The biotech sector was in focus with key pipeline and regulatory updates. Among these, Seagen SGEN was up on news of its acquisition by Pfizer. New drug approvals were also in the spotlight.
Recap of the Week’s Most Important Stories:
Acadia’s Drug Approval: Acadia Pharmaceuticals Inc. ACAD announced that the FDA has approved trofinetide, under the brand name Daybue, for treating Rett syndrome in adult and pediatric patients two years of age and older. The FDA approval was supported by results from the phase III LAVENDER study which evaluated the efficacy and safety of trofinetide versus placebo in 187 female patients with Rett syndrome five to 20 years of age. Data showed treatment with Daybue demonstrated statistically significant improvement compared to placebo on both co-primary efficacy endpoints, as measured by the change from baseline in Rett Syndrome Behaviour Questionnaire (RSBQ) total score (p=0.018) and the Clinical Global Impression-Improvement (CGI-I) scale score (p=0.003) at week 12. Along with the FDA approval, Acadia has received a Rare Pediatric Disease Priority Review Voucher, which can be used to obtain priority review for a subsequent application.
Acadia currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GSK’s Vaccine Data: GSK plc GSK announced positive data from a phase III study for its MenABCWY combination vaccine candidate, administered as two doses six months apart in healthy individuals aged 10-25 years. The phase III randomized, controlled, observer-blind, multi-country study is evaluating the safety, tolerability and immunogenicity of GSK’s MenABCWY vaccine candidate. MenABCWY vaccine candidate combines the antigenic components of its licensed meningococcal vaccines, Bexsero (MenB) and Menveo (MenACWY).
The study met all its primary endpoints, including the non-inferiority of the vaccine candidate for all five Neisseria meningitides serogroups (A, B, C, W, and Y) compared to licensed meningococcal vaccines Bexsero and Menveo in terms of an immune response. Per GSK, a potential approval of this 5-in-1 vaccine candidate could provide the broadest meningococcal serogroup coverage and lead to a simplified immunization schedule.
Setback for Mersana: Clinical-stage biopharmaceutical Mersana Therapeutics, Inc. MRSN announced that the phase I study of XMT-2056 has been placed on clinical hold by the FDA. Mersana voluntarily suspended the trial due to a recent Grade 5 (fatal) serious adverse event (SAE) that was deemed related to XMT-2056 and informed the FDA about the same. XMT-2056 is Mersana’s first Immunosynthen STING-agonist ADC product candidate to enter the clinic. The SAE was observed in the second patient enrolled at the initial dose level in the dose escalation portion of the phase I study in previously treated patients with HER2+ recurrent or metastatic solid tumors.
Aridis Meets Study Goals: Aridis Pharmaceuticals, Inc. ARDS announced positive preliminary top-line results from the randomized, double-blinded, placebo-controlled phase IIa study of AR-501. The study evaluated the safety and pharmacokinetics (PK) of three ascending doses of AR-501 administered as an inhaled aerosol in cystic fibrosis (CF) patients with confirmed pseudomonas aeruginosa bacterial and other potential infections. AR-501 is being developed as a once-per-week inhaled dosing regimen that is self-administered using a commercially available nebulizer device.
The study’s primary and secondary endpoints of safety and PK were met.
The study achieved high uptake of AR-501 in the respiratory tract at levels that were more than 50-fold higher than required for inhibition of the target bacteria P. aeruginosa.
Seagen to be Acquired by Pfizer: Shares of Seagen, Inc. (SGEN) surged after pharma giant Pfizer announced that it will acquire the former for $229 in cash per share for a total enterprise value of $43 billion. The news was mostly expected as last month there were reports of the same. Seagen’s portfolio includes four approved drugs, including three ADCs: Adcetris (brentuximab vedotin), Padcev (enfortumab vedotin), and Tivdak (tisotumab vedotin). The company also commercializes Tuksya (tucatinib).
Seagen expects to generate approximately $2.2 billion of revenues in 2023, up 12% year over year, with growth from its four in-line medicines, royalties and collaboration and license agreements. Pfizer believes Seagen could contribute more than $10 billion in risk-adjusted revenues in 2030, with significant potential for growth beyond 2030.
Performance
The Nasdaq Biotechnology Index has lost 0.10% in the past five trading sessions. Among the biotech giants, Moderna has gained 5.29% during the period. Over the past six months, shares of Biogen have soared 26.92%. (See the last biotech stock roundup here: Biotech Stock Roundup: PTGX Gains on Study Data, BMRN Faces Setback & More)
What's Next in Biotech?
Stay tuned for other updates.
Is THIS the Ultimate New Clean Energy Source? (4 Ways to Profit)
The world is increasingly focused on eliminating fossil fuels and ramping up use of renewable, clean energy sources. Hydrogen fuel cells, powered by the most abundant substance in the universe, could provide an unlimited amount of ultra-clean energy for multiple industries.
Our urgent special report reveals 4 hydrogen stocks primed for big gains - plus our other top clean energy stocks.
See Stocks Now
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report
Seagen Inc. (SGEN) : Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report
Mersana Therapeutics, Inc. (MRSN) : Free Stock Analysis Report
Aridis Pharmaceuticals (ARDS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Recap of the Week’s Most Important Stories: Acadia’s Drug Approval: Acadia Pharmaceuticals Inc. ACAD announced that the FDA has approved trofinetide, under the brand name Daybue, for treating Rett syndrome in adult and pediatric patients two years of age and older. Along with the FDA approval, Acadia has received a Rare Pediatric Disease Priority Review Voucher, which can be used to obtain priority review for a subsequent application. Acadia currently carries a Zacks Rank #3 (Hold). | Click to get this free report GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report Seagen Inc. (SGEN) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Mersana Therapeutics, Inc. (MRSN) : Free Stock Analysis Report Aridis Pharmaceuticals (ARDS) : Free Stock Analysis Report To read this article on Zacks.com click here. Recap of the Week’s Most Important Stories: Acadia’s Drug Approval: Acadia Pharmaceuticals Inc. ACAD announced that the FDA has approved trofinetide, under the brand name Daybue, for treating Rett syndrome in adult and pediatric patients two years of age and older. Along with the FDA approval, Acadia has received a Rare Pediatric Disease Priority Review Voucher, which can be used to obtain priority review for a subsequent application. | Click to get this free report GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report Seagen Inc. (SGEN) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Mersana Therapeutics, Inc. (MRSN) : Free Stock Analysis Report Aridis Pharmaceuticals (ARDS) : Free Stock Analysis Report To read this article on Zacks.com click here. Recap of the Week’s Most Important Stories: Acadia’s Drug Approval: Acadia Pharmaceuticals Inc. ACAD announced that the FDA has approved trofinetide, under the brand name Daybue, for treating Rett syndrome in adult and pediatric patients two years of age and older. Along with the FDA approval, Acadia has received a Rare Pediatric Disease Priority Review Voucher, which can be used to obtain priority review for a subsequent application. | Recap of the Week’s Most Important Stories: Acadia’s Drug Approval: Acadia Pharmaceuticals Inc. ACAD announced that the FDA has approved trofinetide, under the brand name Daybue, for treating Rett syndrome in adult and pediatric patients two years of age and older. Along with the FDA approval, Acadia has received a Rare Pediatric Disease Priority Review Voucher, which can be used to obtain priority review for a subsequent application. Acadia currently carries a Zacks Rank #3 (Hold). |
35655.0 | 2023-03-15 00:00:00 UTC | The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector | ACAD | https://www.nasdaq.com/articles/the-7-best-biotech-etfs-to-buy-for-exposure-to-the-healthcare-sector | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent relevance. No matter what’s going on in the economy, scientists will continue pressing forward for medical innovations. Given the practically limitless opportunities available, this sector enjoys massive pertinence.
However, it’s also a volatile arena if you’re choosing individual stocks. While one company can deliver a knockout blow during its clinical trials, many others may fail miserably. To help mitigate the feast-or-famine nature of the underlying industry, the best biotech ETFs to buy offer a broad canvas of highly compelling enterprises. This way, you’re better assured of long-term profitability.
Plus, some evidence exists that healthcare-related names can garner support through volatile market cycles. Again, the search for medical innovations never goes out of style. With that, below are the best biotech stocks to buy for exposure to the healthcare sector.
XBI SPDR S&P Biotech ETF $77.65
IBB iShares Biotechnology ETF $125.20
GNOM Global X Genomics and Biotechnology ETF $12.09
ARKG ARK Genomic Revolution ETF $28.38
IDNA iShares Genomics Immunology and Healthcare $23.25
SBIO ALPS Medical Breakthroughs ETF $28.04
CNCR Loncar Cancer Immunotherapy ETF $12.44
SPDR S&P Biotech ETF (XBI)
Source: SHUN_J / Shutterstock
One of the most popular entries among the best biotech ETFs to buy, the SPDR S&P Biotech ETF (NYSEARCA:XBI) benefits from strong volume metrics. According to data from U.S. News & World Report, XBI enjoys volume of 20.8 million shares. Further, the fund owns $6.42 billion worth of net assets. In the trailing year, the ETF declined 4%, paring in half the 8% loss that the S&P 500 index incurred during the same period.
Enticingly, SPDR S&P Biotech ETF covers a wider range of pharmaceutical firms. Its top holding is Madrigal Pharmaceuticals (NASDAQ:MDGL), which represents 3.39% of the fund’s total net assets. Next up is Natera (NASDAQ:NTRA) at 1.52% of net assets, followed by Acadia Pharmaceuticals (NASDAQ:ACAD) at 1.5%.
According to TipRanks, Wall Street analysts peg XBI as a consensus moderate buy. Further, their average price target stands at $143.11, implying 81% upside potential. Finally, XBI’s expense ratio sits at 0.35%. In contrast, the category average pings at 0.57%. Therefore, it’s an intriguing and low-cost candidate for the best biotech ETFs to buy.
iShares Biotechnology (IBB)
Source: Maxx-Studio / Shutterstock
Another popular entry among the best biotech ETFs to buy, iShares Biotechnology (NASDAQ:IBB) likewise benefits from strong volume metrics. Per U.S. News & World Report, IBB sees an average volume of nearly 2.8 million shares. At the moment, the ETF carries $7.91 billion in net assets. Since the start of the new year, IBB slipped over 2%. However, in the past 365 days, it gained nearly 5% of its equity value.
Notably, iShares Biotechnology focuses on the most well-known sector enterprises for its top holdings. Taking the pole position is Gilead Sciences (NASDAQ:GILD), which comprises 8.09% of IBB’s net assets. Slotting in second place stands Regeneron Pharmaceuticals (NASDAQ:REGN), making up 7.89% of the ETF’s net assets. In third place is Vertex Pharmaceuticals (NASDAQ:VRTX), accounting for 7.58%.
According to TipRanks, covering analysts peg IBB as a consensus moderate buy. In addition, their average price target stands at $173.08, implying over 36% capital growth potential. Lastly, IBB’s expense ratio is a bit higher at 0.44%. Still, it ranks below the category average of 0.57%. Therefore, IBB makes an interesting case for the best biotech ETFs to buy.
Global X Genomics and Biotechnology ETF (GNOM)
Source: SWKStock / Shutterstock
A lesser-known but still relatively popular among hardcore biotech enthusiasts, Global X Genomics And Biotechnology ETF (NASDAQ:GNOM) strengths lie in its focus on the exciting field of genomics. Currently, the GNOM ETF features an average volume of 45,961 shares. Since the Jan. opener, GNOM dipped 2%. In the trailing year, the fund gave up over 9% of its market value, reflecting a higher-risk, higher-reward profile.
Regarding its top holdings, coming in the first place is 10X Genomics (NASDAQ:TXG), with a 7.1% allocation of total net assets. In second place stands Sarepta Therapeutics (NASDAQ:SRPT) with a 5.52% allocation. Rounding out the top three is clinical genetic testing company Natera at 5.12%. Geographically, GNOM features modest diversity. Although 89.9% of underlying stocks hail from the U.S., 9% stem from the broader European region. The rest comes from Japan.
According to TipRanks, analysts peg GNOM as a consensus moderate buy. Their average price target stands at $19.74, implying nearly 61% upside potential. Regarding expenses, GNOM is a bit on the pricier side with an expense ratio of 0.5%. Still, if you believe in the genomics field, this could be one of the best biotech ETFs to buy.
ARK Genomic Revolution ETF (ARKG)
Source: Eviart / Shutterstock.com
If you want an alternative to the genomics industry, ARK Genomic Revolution ETF (BATS:ARKG) features some advantages. Primarily, it’s one of the larger funds among the best biotech ETFs to buy, with net assets of $1.89 billion. Also, the average volume for AKRG hits 3.9 million shares. Since the January opener, the ETF gained nearly 5% of market value. However, it’s a volatile entry, posting nearly a 27% loss during the past 365 days.
Much of this wildness centers on ARK Genomic’s high-risk, high-reward individual holdings. At the top stands Exact Sciences (NASDAQ:EXAS), commanding 11.71% of ARKG’s total net assets. Sitting in second place is Pacific Biosciences of California (NASDAQ:PACB) with a 5.12% allocation. Coming in third is Schrodinger (NASDAQ:SDGR) at 5.04%. Geographically, the U.S.-dominant ARKG features modest diversification, with companies listed in Europe, Canada, and the U.K.
According to TipRanks, analysts peg AKRG as a consensus moderate buy. Moreover, their average price target stands at $50.37, implying over 74% growth potential. However, one factor to consider for ARKG focuses on its expense ratio. At 0.75%, it’s considerably more expensive than average.
iShares Genomics Immunology and Healthcare ETF (IDNA)
Source: shutterstock.com/bangoland
For those that want to go off the beaten path with their best biotech ETFs to buy, iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) offers an attractive alternate route. To be fair, IDNA ranks on the smaller side of the ETF arena, carrying net assets of only $143.3 million. As well, the average volume sits at 24,123 shares. It’s also volatile, down 26% in the trailing year.
However, it offers a mix of established and aspiration-driven enterprises in its holdings. At the top stands Regeneron Pharmaceuticals with a 4.92% allocation of total net assets. In second place at 4.85% comes Exelixis (NASDAQ:EXEL), which focuses on genomics-based drug discovery. Rounding out the top three is Blueprint Medicines (NASDAQ:BPMC), with a 4.34% net asset allocation. Notably, IDNA offers geographic diversity, with only 61.4% of holdings based in the U.S.
Per TipRanks, covering analysts view IDNA as a consensus moderate buy. Additionally, their average price target stands at $40.94, implying over 74% upside potential. Finally, IDNA’s expense ratio pings at 0.47%. It’s not grossly expensive but it’s not necessarily cheap either.
ALPS Medical Breakthroughs ETF (SBIO)
Source: shutterstock.com/Imagentle
For greater exposure to medical innovation, speculative investors of the best biotech ETFs to buy may consider the ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO). According to U.S. News & World Report, the ETF targets small and middle-capitalization biotech enterprises that have one more drug in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
While SBIO presents higher-than-average volatility, it’s not too bad. In the past 365 days, SBIO dipped 8%, almost exactly the same performance as the S&P 500 index. Topping the individual holdings list is Roivant Sciences (NASDAQ:ROIV) at 3.85% of total net assets. In the second ping Prometheus Biosciences (NASDAQ:RXDX) at 3.36%. In third place is Alkermes (NASDAQ:ALKS) at 2.96%.
Per TipRanks, Wall Street analysts view SBIO as a consensus moderate buy. Their average price target stands at $54.62, implying almost 92% upside potential. Lastly, SBIO’s expense ratio of 0.5% comes in just under the category average of 0.57%. Still, for maximum upside potential, few might be as enticing as SBIO.
Loncar Cancer Immunotherapy ETF (CNCR)
Source: shutterstock.com/gopixa
To conclude this list of best biotech ETFs to buy, market speculators may consider Loncar Cancer Immunotherapy ETF (NASDAQ:CNCR). According to U.S. News & World Report, the Loncar Cancer ETF features approximately 30 stocks where the underlying enterprises focus on the development of drugs that harness the immune system’s power to fight cancer. As a specialty fund, it suffers from volatility, shedding over 8% of its value since the Jan. opener.
Still, for those that like to roll the dice, Loncar could be intriguing for its individual picks. Topping the list is RAPT Therapeutics (NASDAQ:RAPT), commanding 6.23% of the fund’s total net assets. Next up is Merus (NASDAQ:MRUS) with an allocation of 5.63%. Rounding out the top three sits Janux Therapeutics (NASDAQ:JANX) at 4.3%. Conspicuously, CNCR enjoys geographic diversity, with only 71.6% of the holdings hailing from the U.S.
According to TipRanks, analysts peg CNCR as a consensus moderate buy. Moreover, their average price target stands at $24.30, implying nearly 93% upside potential. Finally, CNCR’s expense ratio pings on the high side at 0.79%. Still, if a few of the underlying enterprises deliver the goods, Loncar could fly.
On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare.
The post The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Next up is Natera (NASDAQ:NTRA) at 1.52% of net assets, followed by Acadia Pharmaceuticals (NASDAQ:ACAD) at 1.5%. To help mitigate the feast-or-famine nature of the underlying industry, the best biotech ETFs to buy offer a broad canvas of highly compelling enterprises. A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. | Next up is Natera (NASDAQ:NTRA) at 1.52% of net assets, followed by Acadia Pharmaceuticals (NASDAQ:ACAD) at 1.5%. XBI SPDR S&P Biotech ETF $77.65 IBB iShares Biotechnology ETF $125.20 GNOM Global X Genomics and Biotechnology ETF $12.09 ARKG ARK Genomic Revolution ETF $28.38 IDNA iShares Genomics Immunology and Healthcare $23.25 SBIO ALPS Medical Breakthroughs ETF $28.04 CNCR Loncar Cancer Immunotherapy ETF $12.44 SPDR S&P Biotech ETF (XBI) Source: SHUN_J / Shutterstock One of the most popular entries among the best biotech ETFs to buy, the SPDR S&P Biotech ETF (NYSEARCA:XBI) benefits from strong volume metrics. iShares Biotechnology (IBB) Source: Maxx-Studio / Shutterstock Another popular entry among the best biotech ETFs to buy, iShares Biotechnology (NASDAQ:IBB) likewise benefits from strong volume metrics. | Next up is Natera (NASDAQ:NTRA) at 1.52% of net assets, followed by Acadia Pharmaceuticals (NASDAQ:ACAD) at 1.5%. XBI SPDR S&P Biotech ETF $77.65 IBB iShares Biotechnology ETF $125.20 GNOM Global X Genomics and Biotechnology ETF $12.09 ARKG ARK Genomic Revolution ETF $28.38 IDNA iShares Genomics Immunology and Healthcare $23.25 SBIO ALPS Medical Breakthroughs ETF $28.04 CNCR Loncar Cancer Immunotherapy ETF $12.44 SPDR S&P Biotech ETF (XBI) Source: SHUN_J / Shutterstock One of the most popular entries among the best biotech ETFs to buy, the SPDR S&P Biotech ETF (NYSEARCA:XBI) benefits from strong volume metrics. iShares Genomics Immunology and Healthcare ETF (IDNA) Source: shutterstock.com/bangoland For those that want to go off the beaten path with their best biotech ETFs to buy, iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) offers an attractive alternate route. | Next up is Natera (NASDAQ:NTRA) at 1.52% of net assets, followed by Acadia Pharmaceuticals (NASDAQ:ACAD) at 1.5%. XBI SPDR S&P Biotech ETF $77.65 IBB iShares Biotechnology ETF $125.20 GNOM Global X Genomics and Biotechnology ETF $12.09 ARKG ARK Genomic Revolution ETF $28.38 IDNA iShares Genomics Immunology and Healthcare $23.25 SBIO ALPS Medical Breakthroughs ETF $28.04 CNCR Loncar Cancer Immunotherapy ETF $12.44 SPDR S&P Biotech ETF (XBI) Source: SHUN_J / Shutterstock One of the most popular entries among the best biotech ETFs to buy, the SPDR S&P Biotech ETF (NYSEARCA:XBI) benefits from strong volume metrics. Regarding its top holdings, coming in the first place is 10X Genomics (NASDAQ:TXG), with a 7.1% allocation of total net assets. |
35656.0 | 2023-03-15 00:00:00 UTC | Strength Seen in Acadia (ACAD): Can Its 5.0% Jump Turn into More Strength? | ACAD | https://www.nasdaq.com/articles/strength-seen-in-acadia-acad%3A-can-its-5.0-jump-turn-into-more-strength | nan | nan | Acadia Pharmaceuticals (ACAD) shares rallied 5% in the last trading session to close at $20.38. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 1.2% gain over the past four weeks.
The sudden soaring of the stock price can be attributed to the positive momentum built around the recent FDA approval of Acadia's trofinetide for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. The drug will be marketed in the United States under the brand name, Daybue, and is expected to be made available, in the United States, by the end of April 2023. Per the company, Daybue currently stands as the first and only drug approved for the treatment of Rett syndrome.
This drugmaker is expected to post quarterly loss of $0.21 per share in its upcoming report, which represents a year-over-year change of +70%. Revenues are expected to be $123.54 million, up 7% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Acadia, the consensus EPS estimate for the quarter has been revised 25.8% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on ACAD going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Acadia is part of the Zacks Medical - Biomedical and Genetics industry. EyePoint Pharmaceuticals (EYPT), another stock in the same industry, closed the last trading session 2% lower at $2.52. EYPT has returned -37% in the past month.
For EyePoint Pharmaceuticals, the consensus EPS estimate for the upcoming report has changed +8.5% over the past month to -$0.65. This represents a change of -25% from what the company reported a year ago. EyePoint Pharmaceuticals currently has a Zacks Rank of #2 (Buy).
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report
EYEPOINT PHARMACEUTICALS, INC. (EYPT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The sudden soaring of the stock price can be attributed to the positive momentum built around the recent FDA approval of Acadia's trofinetide for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. Acadia Pharmaceuticals (ACAD) shares rallied 5% in the last trading session to close at $20.38. For Acadia, the consensus EPS estimate for the quarter has been revised 25.8% higher over the last 30 days to the current level. | You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Acadia is part of the Zacks Medical - Biomedical and Genetics industry. Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report EYEPOINT PHARMACEUTICALS, INC. (EYPT) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals (ACAD) shares rallied 5% in the last trading session to close at $20.38. | You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Acadia is part of the Zacks Medical - Biomedical and Genetics industry. Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report EYEPOINT PHARMACEUTICALS, INC. (EYPT) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals (ACAD) shares rallied 5% in the last trading session to close at $20.38. | Acadia Pharmaceuticals (ACAD) shares rallied 5% in the last trading session to close at $20.38. The sudden soaring of the stock price can be attributed to the positive momentum built around the recent FDA approval of Acadia's trofinetide for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. For Acadia, the consensus EPS estimate for the quarter has been revised 25.8% higher over the last 30 days to the current level. |
35657.0 | 2023-03-13 00:00:00 UTC | Acadia (ACAD) Gets FDA Approval for Daybue for Rett Syndrome | ACAD | https://www.nasdaq.com/articles/acadia-acad-gets-fda-approval-for-daybue-for-rett-syndrome | nan | nan | Acadia Pharmaceuticals ACAD announced that the FDA approved trofinetide for the treatment of Rett syndrome in adult and pediatric patients two years of age and older on Mar 10, 2023. The drug will be marketed in the United States under the brand name, Daybue. Per the company, Daybue currently stands as the first and only drug approved for the treatment of Rett syndrome.
In the past year, the shares of Acadia have witnessed a fall of 8.6% compared with the industry’s 11.2% decline.
Image Source: Zacks Investment Research
The approval is based on the positive and statistically significant result | Acadia Pharmaceuticals ACAD announced that the FDA approved trofinetide for the treatment of Rett syndrome in adult and pediatric patients two years of age and older on Mar 10, 2023. In the past year, the shares of Acadia have witnessed a fall of 8.6% compared with the industry’s 11.2% decline. Image Source: Zacks Investment Research The approval is based on the positive and statistically significant result | Acadia Pharmaceuticals ACAD announced that the FDA approved trofinetide for the treatment of Rett syndrome in adult and pediatric patients two years of age and older on Mar 10, 2023. In the past year, the shares of Acadia have witnessed a fall of 8.6% compared with the industry’s 11.2% decline. Per the company, Daybue currently stands as the first and only drug approved for the treatment of Rett syndrome. | Acadia Pharmaceuticals ACAD announced that the FDA approved trofinetide for the treatment of Rett syndrome in adult and pediatric patients two years of age and older on Mar 10, 2023. In the past year, the shares of Acadia have witnessed a fall of 8.6% compared with the industry’s 11.2% decline. Per the company, Daybue currently stands as the first and only drug approved for the treatment of Rett syndrome. | In the past year, the shares of Acadia have witnessed a fall of 8.6% compared with the industry’s 11.2% decline. Acadia Pharmaceuticals ACAD announced that the FDA approved trofinetide for the treatment of Rett syndrome in adult and pediatric patients two years of age and older on Mar 10, 2023. Per the company, Daybue currently stands as the first and only drug approved for the treatment of Rett syndrome. |
35658.0 | 2023-03-12 00:00:00 UTC | 3 Nasdaq Stocks on Watch This Week | ACAD | https://www.nasdaq.com/articles/3-nasdaq-stocks-on-watch-this-week | nan | nan | The SVB Financial Group (NASDAQ: SIVB) meltdown is sure to ramp up volatility in U.S. stock markets this week. The core reason is that no one knows for sure what this latest bank implosion will mean in terms of investor sentiment.
If this unexpected calamity turns out to be a localized event, for instance, the Federal Reserve could very well decide to hold off on additional rate hikes to avoid a steep correction in U.S. equity prices. Interest rate hikes, after all, were a key culprit in SVB's precipitous downfall.
Image source: Getty Images.
Then again, Federal Reserve Chairman Jerome Powell may tune out this event in his quest to tamp down historically high inflation levels. The stark contrast between these two approaches is a surefire recipe for market volatility.
Which stocks are poised to make big moves in the coming week? These three Nasdaq-listed stocks should be on investors' collective radars this week. Here's why.
1. Acadia Pharmaceuticals
After the closing bell last Friday, Acadia Pharmaceuticals (NASDAQ: ACAD) announced the Food and Drug Administration (FDA) approval of its Rett syndrome medication Daybue. Daybue is the first drug approved by the agency specifically for this rare neurological disorder. At peak, Wall Street analysts think the drug could haul in half a billion dollars annually, but there is a real chance it could generate sales in excess of $1 billion per year.
This is Acadia's second FDA approval, with the Parkinson's disease psychosis medication Nuplazid being the biopharma's inaugural commercial-stage product. These two medications ought to transform the drugmaker into a cash-flow-positive operation on a consistent basis. Even so, the initial market response to this landmark approval might underwhelm shareholders this week due to the overhang from the high-profile bank failure. A muted response, however, may represent a stellar buying opportunity.
2. Axsome Therapeutics
Axsome Therapeutics (NASDAQ: AXSM) is a central nervous system specialist with two FDA-approved medicines under its roof. The drugmaker's stock has been under heavy pressure this year due to the slow ramp of its newly approved major depressive disorder medication, Auvelity. Axsome's stock, however, might come under even more pressure in the days ahead, thanks to its exposure to SVB.
In a Securities and Exchange Commission (SEC) filing last Friday, the company revealed it has material cash deposits with the now-defunct bank. Axsome, however, didn't provide any details regarding the amount of cash in its former SVB account. The filing did note that the company expects cash held elsewhere, along with an open loan facility, ought to be sufficient to fund operations until it hits cash-flow positivity.
While this filing is overall upbeat in its message, this irrational, risk-averse market may very well ignore the all-important details of this SEC filing. However, an unwarranted drop in Axsome's shares could be a compelling buying opportunity for patient investors. Axsome's top line, after all, is forecast to rise by leaps and bounds in the years ahead.
3. Roku
Roku (NASDAQ: ROKU) is a TV streaming juggernaut. Over the next 24 months, Wall Street analysts expect the company to deliver a whopping 22% jump in annual revenue. As a result of this blistering top-line growth, Roku's shares were up by an eye-catching 47% this year. The streaming company's recent forward momentum may come to an abrupt halt on Monday, however.
ROKU data by YCharts.
On Friday, Roku revealed via an SEC filing that it had $487 million on deposit with SVB. The company highlighted in the filing that this amount represents roughly 26% of its cash and cash equivalents balance as of March 10, 2023.
Although Roku is expected to recoup some of this cash via an upcoming dividend on the uninsured portion of this deposit, this risk-averse market probably won't give the streaming giant the benefit of the doubt. The good news is that Roku does have sufficient cash on deposit at other large financial institutions to fund operations for the next 12 months and beyond. In turn, bargain hunters may want to have dry powder on hand in case this tech stock slumps meaningfully on this financial disclosure.
10 stocks we like better than Acadia Pharmaceuticals
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Acadia Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 8, 2023
SVB Financial provides credit and banking services to The Motley Fool. George Budwell has positions in Axsome Therapeutics. The Motley Fool has positions in and recommends Axsome Therapeutics, Roku, and SVB Financial. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia Pharmaceuticals After the closing bell last Friday, Acadia Pharmaceuticals (NASDAQ: ACAD) announced the Food and Drug Administration (FDA) approval of its Rett syndrome medication Daybue. This is Acadia's second FDA approval, with the Parkinson's disease psychosis medication Nuplazid being the biopharma's inaugural commercial-stage product. 10 stocks we like better than Acadia Pharmaceuticals When our award-winning analyst team has a stock tip, it can pay to listen. | Acadia Pharmaceuticals After the closing bell last Friday, Acadia Pharmaceuticals (NASDAQ: ACAD) announced the Food and Drug Administration (FDA) approval of its Rett syndrome medication Daybue. This is Acadia's second FDA approval, with the Parkinson's disease psychosis medication Nuplazid being the biopharma's inaugural commercial-stage product. 10 stocks we like better than Acadia Pharmaceuticals When our award-winning analyst team has a stock tip, it can pay to listen. | Acadia Pharmaceuticals After the closing bell last Friday, Acadia Pharmaceuticals (NASDAQ: ACAD) announced the Food and Drug Administration (FDA) approval of its Rett syndrome medication Daybue. This is Acadia's second FDA approval, with the Parkinson's disease psychosis medication Nuplazid being the biopharma's inaugural commercial-stage product. 10 stocks we like better than Acadia Pharmaceuticals When our award-winning analyst team has a stock tip, it can pay to listen. | Acadia Pharmaceuticals After the closing bell last Friday, Acadia Pharmaceuticals (NASDAQ: ACAD) announced the Food and Drug Administration (FDA) approval of its Rett syndrome medication Daybue. This is Acadia's second FDA approval, with the Parkinson's disease psychosis medication Nuplazid being the biopharma's inaugural commercial-stage product. 10 stocks we like better than Acadia Pharmaceuticals When our award-winning analyst team has a stock tip, it can pay to listen. |
35659.0 | 2023-03-10 00:00:00 UTC | U.S. FDA approves Acadia's genetic Rett syndrome drug | ACAD | https://www.nasdaq.com/articles/u.s.-fda-approves-acadias-genetic-rett-syndrome-drug | nan | nan | Adds background, comments throughout
March 10 (Reuters) - The U.S. Food and Drug Administration approved Acadia Pharmaceuticals Inc's ACAD.O drug for the treatment of Rett syndrome, a genetic brain disorder, the company said on Friday, making it the first approved drug for the condition.
The U.S. health regulator's decision allows use of the trofinetide, to be sold under the brand name Daybue, in adult and pediatric patients two years of age and older and comes with a warning of diarrhea and weight loss.
The approval comes months after the FDA declined to approve expanded use of Acadia's drug Nuplazid to treat psychosis related to Alzheimer's disease. Analysts have said approval of Daybue would help drive growth for the company in the near term.
"We have put a lot of planning into potential commercialization of trofinetide, including resources for patients to access the drug," said Acadia senior executive Kathie Bishop ahead of the approval.
Acadia said it plans to make the drug available to patients by the end of April. It did not disclose details of the price.
Before the approval, David Hoang SMBC Nikko Securities analyst estimated a list price at launch of $450,000 annually. He forecast peak U.S. trofinetide sales of $487.2 million by 2035. RBC Capital Markets analyst Gregory Renza, also writing before the approval, predicted peak U.S. sales to exceed $500 million by 2032 and an average annual launch price of about $425,000.
Acadia forecasts sales of Nuplazid - its only drug on the market - of between $520 and $550 million this year, above analysts' median expectations of $532.8 million, according to Refinitiv data. With the drugmaker facing a loss of exclusivity for Nuplazid in 2028, investors have pinned their hopes on a successful trofinetide launch.
After the FDA declined to approve the expanded use of Nuplazid, Acadia said it would not pursue that indication for Nuplazid further. The drugmaker plans to focus its resources on late-stage development of Nuplazid to treat symptoms of schizophrenia and early-stage development of another candidate, ACP-204, for Alzheimer's-related psychosis.
Rett's syndrome is a rare neurodevelopmental condition that occurs primarily in girls. According to government estimates, it affects fewer than 50,000 people in the U.S.
Shares of the California-based company closed 0.68% lower on Friday.
Acadia's drug acts as an artificial form of the insulin-like growth factor IGF-1 and helps reduces inflammation in the nervous tissue as well as aid in the transmission of nerve impulses.
Acadia's application for marketing approval was based on data from a late-stage study in which treatment with the drug showed improvement in core symptoms of the disease compared to a placebo. Improvement of symptoms was measured according to the assessment scales Rett Syndrome Behaviour Questionnaire and the Clinical Global Impression of Improvement.
The company had licensed the drug for $10 million up front payment from Australian drugmaker Neuron Pharmaceuticals NEU.AX for development and sale in North America in 2018.
(Reporting by Bhanvi Satija, Nandhini Srinivasan and Anirudh Saligrama in Bengaluru; Editing by Shailesh Kuber and William Mallard)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | "We have put a lot of planning into potential commercialization of trofinetide, including resources for patients to access the drug," said Acadia senior executive Kathie Bishop ahead of the approval. Acadia's drug acts as an artificial form of the insulin-like growth factor IGF-1 and helps reduces inflammation in the nervous tissue as well as aid in the transmission of nerve impulses. Acadia's application for marketing approval was based on data from a late-stage study in which treatment with the drug showed improvement in core symptoms of the disease compared to a placebo. | Adds background, comments throughout March 10 (Reuters) - The U.S. Food and Drug Administration approved Acadia Pharmaceuticals Inc's ACAD.O drug for the treatment of Rett syndrome, a genetic brain disorder, the company said on Friday, making it the first approved drug for the condition. The approval comes months after the FDA declined to approve expanded use of Acadia's drug Nuplazid to treat psychosis related to Alzheimer's disease. "We have put a lot of planning into potential commercialization of trofinetide, including resources for patients to access the drug," said Acadia senior executive Kathie Bishop ahead of the approval. | Adds background, comments throughout March 10 (Reuters) - The U.S. Food and Drug Administration approved Acadia Pharmaceuticals Inc's ACAD.O drug for the treatment of Rett syndrome, a genetic brain disorder, the company said on Friday, making it the first approved drug for the condition. The approval comes months after the FDA declined to approve expanded use of Acadia's drug Nuplazid to treat psychosis related to Alzheimer's disease. Acadia forecasts sales of Nuplazid - its only drug on the market - of between $520 and $550 million this year, above analysts' median expectations of $532.8 million, according to Refinitiv data. | Adds background, comments throughout March 10 (Reuters) - The U.S. Food and Drug Administration approved Acadia Pharmaceuticals Inc's ACAD.O drug for the treatment of Rett syndrome, a genetic brain disorder, the company said on Friday, making it the first approved drug for the condition. Acadia forecasts sales of Nuplazid - its only drug on the market - of between $520 and $550 million this year, above analysts' median expectations of $532.8 million, according to Refinitiv data. Acadia's application for marketing approval was based on data from a late-stage study in which treatment with the drug showed improvement in core symptoms of the disease compared to a placebo. |
35660.0 | 2023-03-07 00:00:00 UTC | 1 Top Biotech Stock to Buy in March | ACAD | https://www.nasdaq.com/articles/1-top-biotech-stock-to-buy-in-march | nan | nan | Biotech stocks had a rough 2022. Speaking to this point, the SPDR S&P Biotech ETF sank by an eye-catching 25.8% last year. Concerns about a stricter Food and Drug Administration (FDA), rising interest rates, and a growing aversion to risk weighed particularly heavily on clinical and early commercial-stage biotech stocks. The silver lining, if you can call it that, is that the small-to-mid-cap biotech landscape is now chock-full of companies trading at a steep discount relative to their long-term value proposition.
Which of these beaten-down biotech stocks is the most compelling buy in March? While there are a surfeit of candidates, Acadia Pharmaceuticals (NASDAQ: ACAD) stands out as an intriguing buy ahead of its upcoming Prescription Drug User Fee Act target action date of March 12 for the experimental Rett syndrome candidate, trofinetide.
Acadia licensed this novel synthetic analog of the amino‐terminal tripeptide of IGF-1 from the Australia-based Neuren Pharmaceuticals (ASX: NEU) in 2018. If approved, Acadia and Neuren would sport the first medication specifically designed for this rare neurological disorder.
Image source: Getty Images.
What's the value proposition?
Acadia currently has one FDA-approved drug, Nuplazid, indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Nuplazid generated net sales of $517.2 million in 2022.
Despite this hefty sum, Acadia still posted a net loss of $216 million last year due to its sizable research and development expenses. Favorable tailwinds such as an approval for trofinetide in Rett syndrome and the conclusion of other late-stage programs could transform the company into a cash flow-positive business as soon as next year.
What's trofinetide's commercial opportunity? Acadia has estimated trofinetide peak sales at approximately $500 million per year. This estimate, however, may be overly conservative. As a drug indicated for a rare condition, trofinetide will certainly garner a premium price point.
What's more, the Rett syndrome patient and healthcare provider communities are well aware of the drug's existence, a fact that bodes well for its uptake upon a potential approval. So in short, the drug's total addressable market in the Rett syndrome setting appears to stand at anywhere from $1 billion to perhaps $5 billion, depending on pricing, reimbursement status, etc.
This wide range complicates matters in terms of understanding the drug's value proposition to Acadia -- at least in the short term. Wall Street analysts, though, appear to be taking a cue from Acadia's internal estimate of roughly $500 million per year in peak annual sales. And that's what matters when it comes to where Acadia's stock might be headed in the event of an approval next week.
Right now, Acadia's stock is trading at approximately 6 times 2023 estimates sales. That's not a sky-high premium, but it is high enough to assume the market is already baking in some of this potential Rett syndrome-related upside.
So in a market that is no longer handing out ginormous premiums to biotech stocks, it's not unreasonable to assume that Acadia's stock may trade at somewhere around 4 times 2028 net Rett and PDP sales post-trofinetide approval. Under this conservative-leaning scenario, Acadia's stock would be fairly valued at $25 a share (21% implied upside potential from current levels).
Is Acadia stock worth the risk?
The cautionary part of this tale is that an approval is far from guaranteed. This latest iteration of the FDA has been exceedingly unpredictable when it comes to regulatory timelines and decisions. As such, investors should definitely consider the downside risk in the event trofinetide is rejected.
Fortunately, the downside risk calculation in this case seems fairly straightforward. Since the start of the year, Acadia's shares have jumped by 29%, with most of these gains seemingly attributable to this singular upcoming catalyst (the company didn't release any other needle-moving news since the start of the year, after all). So, overall, Acadia's stock probably has a 21% near-term upside potential following an approval, and a possible 29% downside risk upon a rejection.
Normally, this unfavorable risk-to-reward ratio would be off-putting. However, the publicly available clinical trial data seems to favor an approval in this case -- with the main question mark centering around trofinetide's side effect profile.
Moreover, there is an interesting deep-value component to this story: Trofinetide could not only help to transform Acadia into a cash flow-positive operation, but the drug's sales would undoubtedly go toward funding other value-creating activities in the years ahead.
All told, Acadia's stock ought to appeal to aggressive growth investors who are comfortable with volatile price swings.
10 stocks we like better than Acadia Pharmaceuticals
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Acadia Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of February 8, 2023
George Budwell has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Spdr Series Trust - Spdr S&p Biotech ETF. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Moreover, there is an interesting deep-value component to this story: Trofinetide could not only help to transform Acadia into a cash flow-positive operation, but the drug's sales would undoubtedly go toward funding other value-creating activities in the years ahead. While there are a surfeit of candidates, Acadia Pharmaceuticals (NASDAQ: ACAD) stands out as an intriguing buy ahead of its upcoming Prescription Drug User Fee Act target action date of March 12 for the experimental Rett syndrome candidate, trofinetide. Acadia licensed this novel synthetic analog of the amino‐terminal tripeptide of IGF-1 from the Australia-based Neuren Pharmaceuticals (ASX: NEU) in 2018. | Acadia has estimated trofinetide peak sales at approximately $500 million per year. Right now, Acadia's stock is trading at approximately 6 times 2023 estimates sales. So in a market that is no longer handing out ginormous premiums to biotech stocks, it's not unreasonable to assume that Acadia's stock may trade at somewhere around 4 times 2028 net Rett and PDP sales post-trofinetide approval. | So in a market that is no longer handing out ginormous premiums to biotech stocks, it's not unreasonable to assume that Acadia's stock may trade at somewhere around 4 times 2028 net Rett and PDP sales post-trofinetide approval. So, overall, Acadia's stock probably has a 21% near-term upside potential following an approval, and a possible 29% downside risk upon a rejection. 10 stocks we like better than Acadia Pharmaceuticals When our award-winning analyst team has a stock tip, it can pay to listen. | Acadia has estimated trofinetide peak sales at approximately $500 million per year. So, overall, Acadia's stock probably has a 21% near-term upside potential following an approval, and a possible 29% downside risk upon a rejection. While there are a surfeit of candidates, Acadia Pharmaceuticals (NASDAQ: ACAD) stands out as an intriguing buy ahead of its upcoming Prescription Drug User Fee Act target action date of March 12 for the experimental Rett syndrome candidate, trofinetide. |
35661.0 | 2023-03-01 00:00:00 UTC | This ETF Has 67% Upside Potential, According to Analysts | ACAD | https://www.nasdaq.com/articles/this-etf-has-67-upside-potential-according-to-analysts | nan | nan | Investors are always on the lookout for opportunities with considerable potential upside, and an ETF that analysts collectively view as having nearly 70% upside potential from current levels is the SPDR S&P Biotech ETF (NYSEARCA:XBI).
Analysts are Bullish
XBI is part of the popular sector SPDR ETFs from State Street Global Advisors. The fund seeks to replicate the performance of the underlying S&P Biotechnology Select Industry Index before expenses and fees.
According to the views of 3,677 analysts, XBI is a “Moderate Buy,” but the average XBI stock price target of $138.76 represents a scintillating upside potential of 66.8% from the ETF’s current price.
TipRanks utilizes proprietary technology to calibrate the analyst forecasts and price targets for ETFs based on a combination of the individual performances and price targets for the underlying assets. Using the Analyst Forecast tool, users can get an overview of the overall analyst rating, consensus analyst price target, the potential upside or downside for an ETF, and the highest and lowest analyst price targets.
TipRanks calculates a weighted average based on the combination of all the ETFs’ holdings. The average price forecast for an ETF is calculated by multiplying each individual holding’s price target by its weighting within the ETF.
Of the 1,060 analysts in our dataset for XBI, 72.9% rate this ETF a Buy, and 23.8% rate it a Hold. Just 3.3% view XBI as a Sell.
Furthermore, XBI has a "neutral" ETF Smart Score of 7 out of 10.
ETF Investing is a Great Approach for this Space
The biotech sector harbors a lot of potential, and clearly, the analyst community is bullish. Here's why using an ETF like XBI could be the right way to approach investing in this space.
There are many biotech companies out there, and many of these are early-stage pre-profit or even pre-revenue companies whose fates are reliant on the development and commercialization of a single drug or therapy. Biotech companies typically invest heavily in research and development, but this investment does not always lead to commercially viable products.
Biotech companies, especially those with smaller market caps like many of the ones featured in this fund, tend to be more volatile than the average market. Some of these companies end up fizzling out after they run out of cash or end up falling dramatically if their treatments fail to gain approval.
On the other hand, while this is clearly a high-risk part of the market, the rewards can be tremendous as well. Early-stage biotechs that become successful can provide investors with enviable returns. Some of these companies are also acquired by larger pharmaceutical players for significant premiums as their treatments advance through the clinical process.
The differences can be hard to parse through for many investors, including myself. Investing in these types of companies requires a degree of specialist, industry-specific knowledge that not all investors have.
By investing in an ETF like XBI, investors can mitigate single-stock risk and give themselves tremendous diversification right off of the bat because this ETF holds 155 biotech stocks. XBI also adds to this diversification by investing across small-cap, mid-cap, and large-cap stocks. Not only does this limit the risk of investing in one company whose drug fails, but it also gives you plenty of shots on goal as a multitude of these companies could develop blockbuster drugs and treatments.
XBI's Holdings
XBI ETF's holdings offer significant diversification. In addition to holding 155 positions, its top 10 holdings make up just 14.7% of assets. Top holding Madrigal Pharmaceuticals (NASDAQ:MDGL) makes up just a 3.5% position, and no other holding accounts for more than 1.6% of the fund.
Madrigal has climbed to this outsize weighting because the stock has surged to a phenomenal gain of 323% over the past quarter, highlighting the potential for significant capital appreciation that some of these stocks possess.
XBI rebalances on a quarterly basis, and its underlying index is modified equal weighted, so at the end of the quarter, XBI will take some profits in Madrigal, and it will again have a more equal weighting with the other holdings. As you can see, XBI spreads out its investments over many bets. Below, you’ll find a snapshot of XBI’s top 10 holdings.
Top holding Madrigal has a 'Perfect 10' Smart Score and has a Strong Buy consensus rating from analysts. Additionally, top 10 holdings like Seagen (NASDAQ:SGEN) and ACADIA Pharmaceuticals (NASDAQ:ACAD) also boast 'Perfect 10' Smart Scores.
Madrigal, the stock that has skyrocketed to a gain of 323% over the past quarter, is a clinical-stage biopharmaceutical company that develops treatments for cardiovascular, metabolic, and liver diseases. Madrigal has raced out to this incredible gain because it released positive late-stage results for its treatment for NASH.
One other positive attribute to note is that the fund’s average price-to-earnings multiple of 13.5 is lower than the S&P 500’s (SPX) average multiple of 21. Furthermore, the risk may be lower than it has been in the recent past. A well-cited figure from Janus Henderson Investors shows that in 2022, 16% of U.S.-listed biotech companies traded at valuations beneath their cash balances.
Track Record
XBI has had a fairly quiet 2023 so far, with a 1.7% gain year-to-date. The ETF is down 7% over the past year, as rising interest rates and tighter economic conditions have dampened the appetite for high-risk, high-reward sectors like biotech. Over the past 10 years, the fund is up 148%, but it's also down 9.8% over the past five years. However, zoom further out, and the fund is up over 400% since its inception in 2006.
In any case, the muted recent performance hasn't tempered the bullishness of analysts, going forward.
Looking Ahead
Given the challenges of investing in individual biotech stocks, XBI is a great ETF for investors who want to gain exposure to this exciting space while avoiding single-stock risk. Analyst sentiment is bullish, with a consensus price target nearly 70% above today's price. The recent performance of holdings like Madrigal Pharmaceuticals highlights the significant potential this ETF's holdings have. XBI also has a reasonable expense ratio of 0.35%, further enhancing its appeal to investors.
Disclosure
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Additionally, top 10 holdings like Seagen (NASDAQ:SGEN) and ACADIA Pharmaceuticals (NASDAQ:ACAD) also boast 'Perfect 10' Smart Scores. Madrigal, the stock that has skyrocketed to a gain of 323% over the past quarter, is a clinical-stage biopharmaceutical company that develops treatments for cardiovascular, metabolic, and liver diseases. The ETF is down 7% over the past year, as rising interest rates and tighter economic conditions have dampened the appetite for high-risk, high-reward sectors like biotech. | Additionally, top 10 holdings like Seagen (NASDAQ:SGEN) and ACADIA Pharmaceuticals (NASDAQ:ACAD) also boast 'Perfect 10' Smart Scores. TipRanks utilizes proprietary technology to calibrate the analyst forecasts and price targets for ETFs based on a combination of the individual performances and price targets for the underlying assets. Using the Analyst Forecast tool, users can get an overview of the overall analyst rating, consensus analyst price target, the potential upside or downside for an ETF, and the highest and lowest analyst price targets. | Additionally, top 10 holdings like Seagen (NASDAQ:SGEN) and ACADIA Pharmaceuticals (NASDAQ:ACAD) also boast 'Perfect 10' Smart Scores. Investors are always on the lookout for opportunities with considerable potential upside, and an ETF that analysts collectively view as having nearly 70% upside potential from current levels is the SPDR S&P Biotech ETF (NYSEARCA:XBI). According to the views of 3,677 analysts, XBI is a “Moderate Buy,” but the average XBI stock price target of $138.76 represents a scintillating upside potential of 66.8% from the ETF’s current price. | Additionally, top 10 holdings like Seagen (NASDAQ:SGEN) and ACADIA Pharmaceuticals (NASDAQ:ACAD) also boast 'Perfect 10' Smart Scores. Here's why using an ETF like XBI could be the right way to approach investing in this space. XBI's Holdings XBI ETF's holdings offer significant diversification. |
35662.0 | 2023-02-28 00:00:00 UTC | First Week of ACAD September 15th Options Trading | ACAD | https://www.nasdaq.com/articles/first-week-of-acad-september-15th-options-trading | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the September 15th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 199 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new September 15th contracts and identified one put and one call contract of particular interest.
The put contract at the $20.00 strike price has a current bid of $2.15. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $20.00, but will also collect the premium, putting the cost basis of the shares at $17.85 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $20.70/share today.
Because the $20.00 strike represents an approximate 3% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 64%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 10.75% return on the cash commitment, or 19.72% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $20.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $21.00 strike price has a current bid of $2.80. If an investor was to purchase shares of ACAD stock at the current price level of $20.70/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $21.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 14.98% if the stock gets called away at the September 15th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $21.00 strike highlighted in red:
Considering the fact that the $21.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 39%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 13.53% boost of extra return to the investor, or 24.82% annualized, which we refer to as the YieldBoost.
The implied volatility in the put contract example is 97%, while the implied volatility in the call contract example is 88%.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 251 trading day closing values as well as today's price of $20.70) to be 70%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
Also see:
Stock Options Channel
MOTE Videos
Top Ten Hedge Funds Holding HSAC
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $21.00 strike highlighted in red: Considering the fact that the $21.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the September 15th expiration. | Below is a chart showing ACAD's trailing twelve month trading history, with the $21.00 strike highlighted in red: Considering the fact that the $21.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the September 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new September 15th contracts and identified one put and one call contract of particular interest. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $20.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $21.00 strike price has a current bid of $2.80. Below is a chart showing ACAD's trailing twelve month trading history, with the $21.00 strike highlighted in red: Considering the fact that the $21.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the September 15th expiration. | At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new September 15th contracts and identified one put and one call contract of particular interest. Below is a chart showing ACAD's trailing twelve month trading history, with the $21.00 strike highlighted in red: Considering the fact that the $21.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the September 15th expiration. |
35663.0 | 2023-02-28 00:00:00 UTC | Acadia (ACAD) Q4 Earnings Miss, Nuplazid Sales Boost Revenues | ACAD | https://www.nasdaq.com/articles/acadia-acad-q4-earnings-miss-nuplazid-sales-boost-revenues | nan | nan | Acadia Pharmaceuticals Inc. ACAD reported fourth-quarter 2022 loss of 26 cents per share, wider than the Zacks Consensus Estimate of a loss of 25 cents. The loss was on par with our estimate of a loss of 26 cents per share. In the year-ago quarter, the company incurred a loss of 27 cents per share.
Total revenues, comprising net sales of Acadia's only marketed drug, Nuplazid (pimavanserin), increased 4% year over year to $136.5 million in the fourth quarter, beating the Zacks Consensus Estimate of $134 million. Nuplazid sales increased by 3.8% sequentially in the fourth quarter.
Nuplazid sales in the fourth quarter were driven by demand growth and growth acceleration in the long-term care channels.
Total revenues were also higher than our estimate of $134.9 million in the reported quarter.
Nuplazid is the first and the only FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis.
Shares of Acadia have decreased 23.6% in the year so far compared with the industry’s 11.8% decline.
Image Source: Zacks Investment Research
Quarter in Detail
Research and development (R&D) expenses in the quarter were $75.7 million, up 12.8% year over year, owing to a $60 million upfront payment for collaboration with Stoke Therapeutics, a $10 million milestone payment accrued to Neuren Pharmaceuticals upon acceptance of the trofinetide new drug application (NDA) filing and lastly, manufacturing and business development costs related to trofinetide.
Selling, general and administrative (SG&A) expenses were $104.4 million, down 1.3% year over year, owing to reduced advertising and promotional costs.
As of Dec 31, 2022, Acadia had cash, cash equivalents and investments worth $416.8 million compared with $436.6 million as of Sep 30, 2022.
2022 Results
Acadia clocked revenues of $517.2 million in the full-year 2022, witnessing growth of 7% year over year from $484.1 million recorded 2021 and beat the Zacks Consensus Estimate of $515.16 million. Total revenues for the year also beat our estimate of $515.6 million.
Loss per share, for the entire year 2022, was recorded at $1.34, wider than the Zacks Consensus Estimate of a loss of $1.32 per share. Loss per share for full-year 2022 was on par with our estimate of a loss of $1.34 per share.
2023 Financial Guidance
Acadia expects Nuplazid net sales in the range of $520-$550 million for 2023. The Zacks Consensus Estimate for the metric is pegged at $572.82 million.
The company expects R&D expenses in the $235-$255 million range, while SG&A expenses are expected to be in the range of $360-$380 million in 2023.
Pipeline Updates
In September 2022, the FDA accepted for review, Acadia's NDA seeking approval of its pipeline candidate, trofinetide, for the treatment of patients with Rett syndrome.
With the FDA granting priority review to the NDA, a decision from the regulatory body is expected on Mar 12, 2023. ACAD submitted the NDA for trofinetide to treat Rett Syndrome in July 2022.
Upon potential approval, trofinetide can become the second approved drug in Acadia’s portfolio of marketed drugs and lend a significant boost to the company as well as lower its sole dependence on Nuplazid for revenues.
Acadia is evaluating pimavanserin in the phase III ADVANCE-2 study for treating negative symptoms of schizophrenia. Enrollment in the study is expected to complete in mid-2023.
ACADIA Pharmaceuticals Inc. Price, Consensus and EPS Surprise
ACADIA Pharmaceuticals Inc. price-consensus-eps-surprise-chart | ACADIA Pharmaceuticals Inc. Quote
Zacks Rank and Stocks to Consider
Acadia currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the biotech sector are Allogene Therapeutics, Inc. ALLO, ADMA Biologics, Inc. ADMA and Amarin Corporation plc AMRN, all carrying a Zacks Ranks #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 90 days, the estimate for Allogene’s 2022 loss per share has been flat at a loss of $2.38. During the same period, the loss estimate per share for 2023 has narrowed from $2.85 to $2.83. In the past year, the shares of Allogene have fallen 26.3%.
ALLO’s earnings witnessed an average earnings surprise of 9.44%, beating all four estimates in the trailing four reported quarters.
In the past 90 days, the consensus estimate for ADMA Biologics’ 2022 loss per share has been flat at a loss of 33 cents. But, during the same period, the loss estimate per share for 2023 has narrowed from 20 cents to 19 cents. In the past year, the shares of ADMA Biologics have increased by 112.2%.
ADMA’s earnings beat estimates in three of the trailing four quarters, delivering an average earnings surprise of 1.81%.
In the past 90 days, the estimate for Amarin’s 2022 loss per share has been flat at a loss of 13 cents. During the same period, the loss estimate per share for 2023 has narrowed from 8 cents to 6 cents. In the past year, the shares of Amarin have fallen 42.4%.
AMRN’s earnings witnessed an average loss surprise of 14.29%, beating two out of four estimates in the trailing four reported quarters and missing the mark on the other two occasions.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.8% per year. So be sure to give these hand-picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Amarin Corporation PLC (AMRN) : Free Stock Analysis Report
ADMA Biologics Inc (ADMA) : Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report
Allogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia is evaluating pimavanserin in the phase III ADVANCE-2 study for treating negative symptoms of schizophrenia. Acadia Pharmaceuticals Inc. ACAD reported fourth-quarter 2022 loss of 26 cents per share, wider than the Zacks Consensus Estimate of a loss of 25 cents. Total revenues, comprising net sales of Acadia's only marketed drug, Nuplazid (pimavanserin), increased 4% year over year to $136.5 million in the fourth quarter, beating the Zacks Consensus Estimate of $134 million. | Total revenues, comprising net sales of Acadia's only marketed drug, Nuplazid (pimavanserin), increased 4% year over year to $136.5 million in the fourth quarter, beating the Zacks Consensus Estimate of $134 million. Click to get this free report Amarin Corporation PLC (AMRN) : Free Stock Analysis Report ADMA Biologics Inc (ADMA) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Allogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals Inc. ACAD reported fourth-quarter 2022 loss of 26 cents per share, wider than the Zacks Consensus Estimate of a loss of 25 cents. | Total revenues, comprising net sales of Acadia's only marketed drug, Nuplazid (pimavanserin), increased 4% year over year to $136.5 million in the fourth quarter, beating the Zacks Consensus Estimate of $134 million. 2022 Results Acadia clocked revenues of $517.2 million in the full-year 2022, witnessing growth of 7% year over year from $484.1 million recorded 2021 and beat the Zacks Consensus Estimate of $515.16 million. Acadia Pharmaceuticals Inc. ACAD reported fourth-quarter 2022 loss of 26 cents per share, wider than the Zacks Consensus Estimate of a loss of 25 cents. | Total revenues, comprising net sales of Acadia's only marketed drug, Nuplazid (pimavanserin), increased 4% year over year to $136.5 million in the fourth quarter, beating the Zacks Consensus Estimate of $134 million. 2022 Results Acadia clocked revenues of $517.2 million in the full-year 2022, witnessing growth of 7% year over year from $484.1 million recorded 2021 and beat the Zacks Consensus Estimate of $515.16 million. Acadia Pharmaceuticals Inc. ACAD reported fourth-quarter 2022 loss of 26 cents per share, wider than the Zacks Consensus Estimate of a loss of 25 cents. |
35664.0 | 2023-02-28 00:00:00 UTC | Biotech Stocks Facing FDA Decision In March 2023 | ACAD | https://www.nasdaq.com/articles/biotech-stocks-facing-fda-decision-in-march-2023 | nan | nan | (RTTNews) - As another month draws to a close, it is time to reflect on recent regulatory developments that have made headlines and look ahead to what's in store in March, which is observed as the National Kidney Month.
GlaxoSmithKline's Jesduvroq was approved by the FDA on February 1, becoming the first oral treatment for anemia caused by chronic kidney disease for adults on dialysis.
In order to help address the significant increase in plant-based milk alternative products that have become available in the marketplace over the past decade, the U.S. regulatory agency, on Feb.22, issued draft labeling recommendations. The draft guidance also recommends voluntary nutrient statements for the labeling of some plant-based milk alternatives.
On February 24, the FDA issued emergency use authorisation for Lucira COVID-19 & Flu Home Test, a single-use at-home test kit that provides results from self-collected nasal swab samples in roughly 30 minutes. This marks the first over-the-counter (OTC) at-home diagnostic test that can differentiate and detect both influenza A and B (commonly referred to as the flu) and SARS-CoV-2, the virus responsible for causing COVID-19.
Let's now take a look at some of the biotech stocks that are awaiting FDA decisions in March.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | GlaxoSmithKline's Jesduvroq was approved by the FDA on February 1, becoming the first oral treatment for anemia caused by chronic kidney disease for adults on dialysis. In order to help address the significant increase in plant-based milk alternative products that have become available in the marketplace over the past decade, the U.S. regulatory agency, on Feb.22, issued draft labeling recommendations. This marks the first over-the-counter (OTC) at-home diagnostic test that can differentiate and detect both influenza A and B (commonly referred to as the flu) and SARS-CoV-2, the virus responsible for causing COVID-19. | In order to help address the significant increase in plant-based milk alternative products that have become available in the marketplace over the past decade, the U.S. regulatory agency, on Feb.22, issued draft labeling recommendations. The draft guidance also recommends voluntary nutrient statements for the labeling of some plant-based milk alternatives. On February 24, the FDA issued emergency use authorisation for Lucira COVID-19 & Flu Home Test, a single-use at-home test kit that provides results from self-collected nasal swab samples in roughly 30 minutes. | (RTTNews) - As another month draws to a close, it is time to reflect on recent regulatory developments that have made headlines and look ahead to what's in store in March, which is observed as the National Kidney Month. In order to help address the significant increase in plant-based milk alternative products that have become available in the marketplace over the past decade, the U.S. regulatory agency, on Feb.22, issued draft labeling recommendations. On February 24, the FDA issued emergency use authorisation for Lucira COVID-19 & Flu Home Test, a single-use at-home test kit that provides results from self-collected nasal swab samples in roughly 30 minutes. | (RTTNews) - As another month draws to a close, it is time to reflect on recent regulatory developments that have made headlines and look ahead to what's in store in March, which is observed as the National Kidney Month. GlaxoSmithKline's Jesduvroq was approved by the FDA on February 1, becoming the first oral treatment for anemia caused by chronic kidney disease for adults on dialysis. In order to help address the significant increase in plant-based milk alternative products that have become available in the marketplace over the past decade, the U.S. regulatory agency, on Feb.22, issued draft labeling recommendations. |
35665.0 | 2023-02-27 00:00:00 UTC | Acadia Pharmaceuticals (ACAD) Reports Q4 Loss, Tops Revenue Estimates | ACAD | https://www.nasdaq.com/articles/acadia-pharmaceuticals-acad-reports-q4-loss-tops-revenue-estimates | nan | nan | Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.27 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -4%. A quarter ago, it was expected that this drugmaker would post a loss of $0.18 per share when it actually produced a loss of $0.17, delivering a surprise of 5.56%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $136.49 million for the quarter ended December 2022, surpassing the Zacks Consensus Estimate by 1.55%. This compares to year-ago revenues of $130.76 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Acadia shares have added about 18.8% since the beginning of the year versus the S&P 500's gain of 3.4%.
What's Next for Acadia?
While Acadia has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Acadia: unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.29 on $123.08 million in revenues for the coming quarter and -$0.99 on $572.82 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 38% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Telesis Bio (TBIO), is yet to report results for the quarter ended December 2022.
This synthetic biology company is expected to post quarterly loss of $0.39 per share in its upcoming report, which represents a year-over-year change of +9.3%. The consensus EPS estimate for the quarter has been revised 22.6% lower over the last 30 days to the current level.
Telesis Bio's revenues are expected to be $9 million, up 192.2% from the year-ago quarter.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report
Telesis Bio Inc. (TBIO) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.25. Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $136.49 million for the quarter ended December 2022, surpassing the Zacks Consensus Estimate by 1.55%. Acadia shares have added about 18.8% since the beginning of the year versus the S&P 500's gain of 3.4%. | Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $136.49 million for the quarter ended December 2022, surpassing the Zacks Consensus Estimate by 1.55%. Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Telesis Bio Inc. (TBIO) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.25. | Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.25. Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $136.49 million for the quarter ended December 2022, surpassing the Zacks Consensus Estimate by 1.55%. Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Telesis Bio Inc. (TBIO) : Free Stock Analysis Report To read this article on Zacks.com click here. | Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.25. Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $136.49 million for the quarter ended December 2022, surpassing the Zacks Consensus Estimate by 1.55%. Acadia shares have added about 18.8% since the beginning of the year versus the S&P 500's gain of 3.4%. |
35666.0 | 2023-02-20 00:00:00 UTC | ACAD Crosses Above Average Analyst Target | ACAD | https://www.nasdaq.com/articles/acad-crosses-above-average-analyst-target | nan | nan | In recent trading, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) have crossed above the average analyst 12-month target price of $18.88, changing hands for $19.37/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher — if things are looking up for the company, perhaps it is time for that target price to be raised.
There are 17 different analyst targets within the Zacks coverage universe contributing to that average for Acadia Pharmaceuticals Inc, but the average is just that — a mathematical average. There are analysts with lower targets than the average, including one looking for a price of $10.00. And then on the other side of the spectrum one analyst has a target as high as $27.00. The standard deviation is $4.414.
But the whole reason to look at the average ACAD price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with ACAD crossing above that average target price of $18.88/share, investors in ACAD have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $18.88 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover Acadia Pharmaceuticals Inc:
RECENT ACAD ANALYST RATINGS BREAKDOWN
» Current 1 Month Ago 2 Month Ago 3 Month Ago
Strong buy ratings: 6 7 6 7
Buy ratings: 1 1 1 1
Hold ratings: 9 8 9 9
Sell ratings: 1 1 1 1
Strong sell ratings: 1 1 1 1
Average rating: 2.44 2.33 2.44 2.37
The average rating presented in the last row of the above table above is from 1 to 5 where 1 is Strong Buy and 5 is Strong Sell. This article used data provided by Zacks Investment Research via Quandl.com. Get the latest Zacks research report on ACAD — FREE.
10 ETFs With Most Upside To Analyst Targets »
Also see:
Catalent Technical Analysis
CPK Split History
Funds Holding EVG
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In recent trading, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) have crossed above the average analyst 12-month target price of $18.88, changing hands for $19.37/share. And so with ACAD crossing above that average target price of $18.88/share, investors in ACAD have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $18.88 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? There are 17 different analyst targets within the Zacks coverage universe contributing to that average for Acadia Pharmaceuticals Inc, but the average is just that — a mathematical average. | In recent trading, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) have crossed above the average analyst 12-month target price of $18.88, changing hands for $19.37/share. But the whole reason to look at the average ACAD price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. There are 17 different analyst targets within the Zacks coverage universe contributing to that average for Acadia Pharmaceuticals Inc, but the average is just that — a mathematical average. | There are 17 different analyst targets within the Zacks coverage universe contributing to that average for Acadia Pharmaceuticals Inc, but the average is just that — a mathematical average. And so with ACAD crossing above that average target price of $18.88/share, investors in ACAD have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $18.88 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? In recent trading, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) have crossed above the average analyst 12-month target price of $18.88, changing hands for $19.37/share. | In recent trading, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) have crossed above the average analyst 12-month target price of $18.88, changing hands for $19.37/share. There are 17 different analyst targets within the Zacks coverage universe contributing to that average for Acadia Pharmaceuticals Inc, but the average is just that — a mathematical average. But the whole reason to look at the average ACAD price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. |
35667.0 | 2023-01-20 00:00:00 UTC | Acadia Pharmaceuticals Reaches Analyst Target Price | ACAD | https://www.nasdaq.com/articles/acadia-pharmaceuticals-reaches-analyst-target-price | nan | nan | In recent trading, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) have crossed above the average analyst 12-month target price of $18.47, changing hands for $18.48/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher — if things are looking up for the company, perhaps it is time for that target price to be raised.
There are 17 different analyst targets within the Zacks coverage universe contributing to that average for Acadia Pharmaceuticals Inc, but the average is just that — a mathematical average. There are analysts with lower targets than the average, including one looking for a price of $10.00. And then on the other side of the spectrum one analyst has a target as high as $25.00. The standard deviation is $4.244.
But the whole reason to look at the average ACAD price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with ACAD crossing above that average target price of $18.47/share, investors in ACAD have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $18.47 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover Acadia Pharmaceuticals Inc:
RECENT ACAD ANALYST RATINGS BREAKDOWN
» Current 1 Month Ago 2 Month Ago 3 Month Ago
Strong buy ratings: 7 6 7 6
Buy ratings: 1 1 1 1
Hold ratings: 8 9 9 9
Sell ratings: 1 1 1 1
Strong sell ratings: 1 1 1 0
Average rating: 2.33 2.44 2.37 2.29
The average rating presented in the last row of the above table above is from 1 to 5 where 1 is Strong Buy and 5 is Strong Sell. This article used data provided by Zacks Investment Research via Quandl.com. Get the latest Zacks research report on ACAD — FREE.
The Top 25 Broker Analyst Picks of the S&P 500 »
Also see:
CFG shares outstanding history
Funds Holding IWN
QEPM Videos
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In recent trading, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) have crossed above the average analyst 12-month target price of $18.47, changing hands for $18.48/share. And so with ACAD crossing above that average target price of $18.47/share, investors in ACAD have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $18.47 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? There are 17 different analyst targets within the Zacks coverage universe contributing to that average for Acadia Pharmaceuticals Inc, but the average is just that — a mathematical average. | In recent trading, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) have crossed above the average analyst 12-month target price of $18.47, changing hands for $18.48/share. But the whole reason to look at the average ACAD price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. There are 17 different analyst targets within the Zacks coverage universe contributing to that average for Acadia Pharmaceuticals Inc, but the average is just that — a mathematical average. | There are 17 different analyst targets within the Zacks coverage universe contributing to that average for Acadia Pharmaceuticals Inc, but the average is just that — a mathematical average. And so with ACAD crossing above that average target price of $18.47/share, investors in ACAD have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $18.47 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? In recent trading, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) have crossed above the average analyst 12-month target price of $18.47, changing hands for $18.48/share. | In recent trading, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) have crossed above the average analyst 12-month target price of $18.47, changing hands for $18.48/share. There are 17 different analyst targets within the Zacks coverage universe contributing to that average for Acadia Pharmaceuticals Inc, but the average is just that — a mathematical average. But the whole reason to look at the average ACAD price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. |
35668.0 | 2023-01-17 00:00:00 UTC | First Week of ACAD February 17th Options Trading | ACAD | https://www.nasdaq.com/articles/first-week-of-acad-february-17th-options-trading | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the February 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new February 17th contracts and identified one put and one call contract of particular interest.
The put contract at the $16.00 strike price has a current bid of 10 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $16.00, but will also collect the premium, putting the cost basis of the shares at $15.90 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $18.15/share today.
Because the $16.00 strike represents an approximate 12% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 76%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 0.62% return on the cash commitment, or 7.36% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $16.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $21.00 strike price has a current bid of 5 cents. If an investor was to purchase shares of ACAD stock at the current price level of $18.15/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $21.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 15.98% if the stock gets called away at the February 17th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $21.00 strike highlighted in red:
Considering the fact that the $21.00 strike represents an approximate 16% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 72%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 0.28% boost of extra return to the investor, or 3.24% annualized, which we refer to as the YieldBoost.
The implied volatility in the put contract example is 91%, while the implied volatility in the call contract example is 125%.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 250 trading day closing values as well as today's price of $18.15) to be 71%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
Also see:
STB Historical Stock Prices
OSH Options Chain
CEL-SCI Past Earnings
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $21.00 strike highlighted in red: Considering the fact that the $21.00 strike represents an approximate 16% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the February 17th expiration. | Below is a chart showing ACAD's trailing twelve month trading history, with the $21.00 strike highlighted in red: Considering the fact that the $21.00 strike represents an approximate 16% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the February 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new February 17th contracts and identified one put and one call contract of particular interest. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $16.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $21.00 strike price has a current bid of 5 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $21.00 strike highlighted in red: Considering the fact that the $21.00 strike represents an approximate 16% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the February 17th expiration. | At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new February 17th contracts and identified one put and one call contract of particular interest. Below is a chart showing ACAD's trailing twelve month trading history, with the $21.00 strike highlighted in red: Considering the fact that the $21.00 strike represents an approximate 16% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the February 17th expiration. |
35669.0 | 2023-01-05 00:00:00 UTC | Acadia Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for ACAD | ACAD | https://www.nasdaq.com/articles/acadia-pharmaceuticals-breaks-above-200-day-moving-average-bullish-for-acad | nan | nan | In trading on Thursday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed above their 200 day moving average of $17.21, changing hands as high as $17.27 per share. Acadia Pharmaceuticals Inc shares are currently trading up about 0.7% on the day. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average:
Looking at the chart above, ACAD's low point in its 52 week range is $12.24 per share, with $28.055 as the 52 week high point — that compares with a last trade of $17.22.
Click here to find out which 9 other stocks recently crossed above their 200 day moving average »
Also see:
Institutional Holders of VIRS
Funds Holding ETFS
Funds Holding LSST
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Thursday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed above their 200 day moving average of $17.21, changing hands as high as $17.27 per share. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average: Looking at the chart above, ACAD's low point in its 52 week range is $12.24 per share, with $28.055 as the 52 week high point — that compares with a last trade of $17.22. Acadia Pharmaceuticals Inc shares are currently trading up about 0.7% on the day. | In trading on Thursday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed above their 200 day moving average of $17.21, changing hands as high as $17.27 per share. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average: Looking at the chart above, ACAD's low point in its 52 week range is $12.24 per share, with $28.055 as the 52 week high point — that compares with a last trade of $17.22. Acadia Pharmaceuticals Inc shares are currently trading up about 0.7% on the day. | In trading on Thursday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed above their 200 day moving average of $17.21, changing hands as high as $17.27 per share. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average: Looking at the chart above, ACAD's low point in its 52 week range is $12.24 per share, with $28.055 as the 52 week high point — that compares with a last trade of $17.22. Acadia Pharmaceuticals Inc shares are currently trading up about 0.7% on the day. | In trading on Thursday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed above their 200 day moving average of $17.21, changing hands as high as $17.27 per share. Acadia Pharmaceuticals Inc shares are currently trading up about 0.7% on the day. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average: Looking at the chart above, ACAD's low point in its 52 week range is $12.24 per share, with $28.055 as the 52 week high point — that compares with a last trade of $17.22. |
35670.0 | 2022-12-30 00:00:00 UTC | Axsome (AXSM) Rides on New Drug Approval & Sunosi Buyout | ACAD | https://www.nasdaq.com/articles/axsome-axsm-rides-on-new-drug-approval-sunosi-buyout | nan | nan | Axsome Therapeutics, Inc. AXSM received a big boost when the FDA approved its lead pipeline candidate AXS-05, under the trade name Auvelity, for treating adults with major depressive disorder (MDD) in August, making it the first approved drug in its portfolio.
Post approval, Auvelity became the first and only oral rapid-acting drug approved for the treatment of MDD, exhibiting statistically significant antidepressant efficacy against placebo, starting at week one.
Auvelity was commercially launched in October 2022. Axsome is expected to announce the first sales of Auvelity at its fourth quarter conference call in February/March 2023.
The company is also developing AXS-05 for various central nervous system disorders.
In November 2022, AXSM announced positive data from the phase III ACCORD study evaluating AXS-05 for treating Alzheimer’s disease (AD) agitation.
Data from the same showed that treatment with AXS-05 led to statistically significant delayed time for the relapsing of AD agitation compared to placebo – the study’s primary endpoint. Treatment with AXS-05 also statistically significantly prevented relapse of AD agitation versus placebo – the secondary endpoint of the study.
The target market represents a massive opportunity. If the study progresses well, a potential label expansion of AXS-05 will majorly boost the drug’s sales.
AXS-05 is also being investigated in the phase II MERIT study to address patients with treatment-resistant depression and a candidate for smoking cessation.
Shares of Axsome have soared 102.4% in the past year against the industry’s decline of 22.6%.
Image Source: Zacks Investment Research
Axsome’s other lead candidate, AXS-07, is being developed for the acute treatment of migraine.
The company received a complete response letter from the FDA for the NDA, seeking approval for AXS-07 for the migraine indication in May. The company held a Type A meeting with the FDA to discuss Axsome’s approach to its planned resubmission of the NDA. Following the meeting, the company intends to resubmit its NDA in the third quarter of 2023. The FDA has not requested any additional safety or efficacy data for the candidate in light of the NDA resubmission.
Axsome’s other central nervous system (CNS) pipeline candidates are also progressing well.
Meanwhile, AXSM acquired Sunosi (solriamfetol) from Jazz Pharmaceuticals JAZZ in May 2022. The acquisition strengthened Axsome’s neuro portfolio and transformed the company into a revenue-generating entity before the approval of Auvelity.
JAZZ’s Sunosi is approved as a treatment to improve wakefulness and reduce excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea. Sunosi is currently marketed in the United States, Europe and several other countries.
Though Axsome is riding on the successful acquisition of Sunosi and the FDA’s approval for Auvelity, competition looms large on the company in the target market as many companies are developing treatments to address various CNS disorders. One such company is Acadia Pharmaceuticals ACAD, which is currently developing Nuplazid (pimavanserin) in several studies targeting different CNS indications.
ACAD’s Nuplazid is already approved for hallucinations and delusions associated with Parkinson’s disease psychosis. Acadia is also studying pimavanserin for the treatment of other CNS disorders,
Axsome Therapeutics, Inc. Price and Consensus
Axsome Therapeutics, Inc. price-consensus-chart | Axsome Therapeutics, Inc. Quote
Zacks Rank & Stocks to Consider
Axsome currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Syndax Pharmaceuticals, Inc. SNDX, which has a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Loss per share estimates for Syndax Pharmaceuticals have narrowed 5.9% for 2022 and 14.5% for 2023 in the past 60 days.
Earnings of Syndax Pharmaceuticals surpassed estimates in three of the trailing four quarters and met the same on the other occasion. SNDX witnessed an earnings surprise of 95.39% on average.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Jazz Pharmaceuticals PLC (JAZZ) : Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report
Syndax Pharmaceuticals, Inc. (SNDX) : Free Stock Analysis Report
Axsome Therapeutics, Inc. (AXSM) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | One such company is Acadia Pharmaceuticals ACAD, which is currently developing Nuplazid (pimavanserin) in several studies targeting different CNS indications. ACAD’s Nuplazid is already approved for hallucinations and delusions associated with Parkinson’s disease psychosis. Acadia is also studying pimavanserin for the treatment of other CNS disorders, Axsome Therapeutics, Inc. Price and Consensus Axsome Therapeutics, Inc. price-consensus-chart | Axsome Therapeutics, Inc. Quote Zacks Rank & Stocks to Consider Axsome currently carries a Zacks Rank #3 (Hold). | One such company is Acadia Pharmaceuticals ACAD, which is currently developing Nuplazid (pimavanserin) in several studies targeting different CNS indications. Acadia is also studying pimavanserin for the treatment of other CNS disorders, Axsome Therapeutics, Inc. Price and Consensus Axsome Therapeutics, Inc. price-consensus-chart | Axsome Therapeutics, Inc. Quote Zacks Rank & Stocks to Consider Axsome currently carries a Zacks Rank #3 (Hold). Click to get this free report Jazz Pharmaceuticals PLC (JAZZ) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Syndax Pharmaceuticals, Inc. (SNDX) : Free Stock Analysis Report Axsome Therapeutics, Inc. (AXSM) : Free Stock Analysis Report To read this article on Zacks.com click here. | Acadia is also studying pimavanserin for the treatment of other CNS disorders, Axsome Therapeutics, Inc. Price and Consensus Axsome Therapeutics, Inc. price-consensus-chart | Axsome Therapeutics, Inc. Quote Zacks Rank & Stocks to Consider Axsome currently carries a Zacks Rank #3 (Hold). Click to get this free report Jazz Pharmaceuticals PLC (JAZZ) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Syndax Pharmaceuticals, Inc. (SNDX) : Free Stock Analysis Report Axsome Therapeutics, Inc. (AXSM) : Free Stock Analysis Report To read this article on Zacks.com click here. One such company is Acadia Pharmaceuticals ACAD, which is currently developing Nuplazid (pimavanserin) in several studies targeting different CNS indications. | One such company is Acadia Pharmaceuticals ACAD, which is currently developing Nuplazid (pimavanserin) in several studies targeting different CNS indications. ACAD’s Nuplazid is already approved for hallucinations and delusions associated with Parkinson’s disease psychosis. Acadia is also studying pimavanserin for the treatment of other CNS disorders, Axsome Therapeutics, Inc. Price and Consensus Axsome Therapeutics, Inc. price-consensus-chart | Axsome Therapeutics, Inc. Quote Zacks Rank & Stocks to Consider Axsome currently carries a Zacks Rank #3 (Hold). |
35671.0 | 2022-12-15 00:00:00 UTC | U.S. Parkinson's disease incidence far higher than earlier estimates -study | ACAD | https://www.nasdaq.com/articles/u.s.-parkinsons-disease-incidence-far-higher-than-earlier-estimates-study | nan | nan | By Shawana Alleyne-Morris and Nancy Lapid
Dec 15 (Reuters) - The annual number of new Parkinson's disease diagnoses in the United States is likely 50% higher than estimated, based on a broad analysis of insurance claims and population growth detailed in a study published on Thursday that could help increase funding and care for the disabling illness.
Earlier, much smaller U.S. studies conducted in the mid-1980's had suggested roughly 60,000 people are diagnosed with Parkinson's disease each year. The number in 2020 was likely closer to 86,000 and will approach 90,000 this year, James Beck, chief scientific officer for the Parkinson's Foundation, said in an interview.
Parkinson's - the second-most deadly neurodegenerative disease after Alzheimer's disease - is disabling and incurable. The estimated economic cost is $52 billion annually in the United States alone, according to a report of the study published in npj Parkinson's Disease.
The researchers hope documenting the higher numbers will help the Parkinson's Foundation and other advocacy groups such as the Michael J. Fox Foundation for Parkinson's Research obtain increased funding for research and access to care.
To update the estimated number of people being diagnosed with the disease, Beck's team analyzed data from large health insurance databases and long-term health studies on more than 15 million adults across the United States and in Ontario, Canada, in 2012. That is the most recent year for which the necessary data was consistent among all the databases, Beck said.
Using computer models, the researchers adjusted the findings to reflect more recent U.S. populations.
"These updated estimates of incidence are necessary for understanding disease risk, planning healthcare delivery, and addressing care disparities," Beck said.
"We're confident that we have data sets that represent a broad swath of America."
Each year, Parkinson's disease is diagnosed in 47 to 77 of every 100,000 adults over age 45 and in 108 to 112 of every 100,000 age 65 and older, Beck's team reported
The higher rate in older people is not surprising because age is the biggest risk factor for the disease, Beck said.
A separate study by Beck's team recently put the number of U.S. patients living with Parkinson's disease at nearly 1 million, whereas earlier estimates had been closer to 650,000, he said.
The global Parkinson's disease drug market is projected to reach $8.4 billion by 2030, from $5.5 billion in 2021, according to QY Research as reported by Biospace.
Manufacturers of Parkinson's treatments include Pfizer Inc PFE.N, Roche Holding AG ROG.S, Merck & Co MRK.N, Novartis AG NOVN.S, UCB SA UCB.BR, Teva Pharmaceutical Industries Ltd VRTX.O, H Lundbeck A/S LUN.CO, Acadia Pharmaceuticals ACAD.O, Vertical Pharma Resources Ltd and Impax Laboratories.
"Because the U.S. population is aging, a lot of people are going to be entering the health system with Parkinson's disease," Beck said, "and there are only about 700 neurologists in the country who specialize in movement disorders."
(Reporting by Shawana Alleyne-Morris and Nancy Lapid; editing by Caroline Humer and Bill Berkrot)
((Shawana.Alleyne-Morris@thomsonreuters.com; Nancy.Lapid@thomsonreuters.com))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Manufacturers of Parkinson's treatments include Pfizer Inc PFE.N, Roche Holding AG ROG.S, Merck & Co MRK.N, Novartis AG NOVN.S, UCB SA UCB.BR, Teva Pharmaceutical Industries Ltd VRTX.O, H Lundbeck A/S LUN.CO, Acadia Pharmaceuticals ACAD.O, Vertical Pharma Resources Ltd and Impax Laboratories. By Shawana Alleyne-Morris and Nancy Lapid Dec 15 (Reuters) - The annual number of new Parkinson's disease diagnoses in the United States is likely 50% higher than estimated, based on a broad analysis of insurance claims and population growth detailed in a study published on Thursday that could help increase funding and care for the disabling illness. A separate study by Beck's team recently put the number of U.S. patients living with Parkinson's disease at nearly 1 million, whereas earlier estimates had been closer to 650,000, he said. | Manufacturers of Parkinson's treatments include Pfizer Inc PFE.N, Roche Holding AG ROG.S, Merck & Co MRK.N, Novartis AG NOVN.S, UCB SA UCB.BR, Teva Pharmaceutical Industries Ltd VRTX.O, H Lundbeck A/S LUN.CO, Acadia Pharmaceuticals ACAD.O, Vertical Pharma Resources Ltd and Impax Laboratories. By Shawana Alleyne-Morris and Nancy Lapid Dec 15 (Reuters) - The annual number of new Parkinson's disease diagnoses in the United States is likely 50% higher than estimated, based on a broad analysis of insurance claims and population growth detailed in a study published on Thursday that could help increase funding and care for the disabling illness. To update the estimated number of people being diagnosed with the disease, Beck's team analyzed data from large health insurance databases and long-term health studies on more than 15 million adults across the United States and in Ontario, Canada, in 2012. | Manufacturers of Parkinson's treatments include Pfizer Inc PFE.N, Roche Holding AG ROG.S, Merck & Co MRK.N, Novartis AG NOVN.S, UCB SA UCB.BR, Teva Pharmaceutical Industries Ltd VRTX.O, H Lundbeck A/S LUN.CO, Acadia Pharmaceuticals ACAD.O, Vertical Pharma Resources Ltd and Impax Laboratories. By Shawana Alleyne-Morris and Nancy Lapid Dec 15 (Reuters) - The annual number of new Parkinson's disease diagnoses in the United States is likely 50% higher than estimated, based on a broad analysis of insurance claims and population growth detailed in a study published on Thursday that could help increase funding and care for the disabling illness. To update the estimated number of people being diagnosed with the disease, Beck's team analyzed data from large health insurance databases and long-term health studies on more than 15 million adults across the United States and in Ontario, Canada, in 2012. | Manufacturers of Parkinson's treatments include Pfizer Inc PFE.N, Roche Holding AG ROG.S, Merck & Co MRK.N, Novartis AG NOVN.S, UCB SA UCB.BR, Teva Pharmaceutical Industries Ltd VRTX.O, H Lundbeck A/S LUN.CO, Acadia Pharmaceuticals ACAD.O, Vertical Pharma Resources Ltd and Impax Laboratories. By Shawana Alleyne-Morris and Nancy Lapid Dec 15 (Reuters) - The annual number of new Parkinson's disease diagnoses in the United States is likely 50% higher than estimated, based on a broad analysis of insurance claims and population growth detailed in a study published on Thursday that could help increase funding and care for the disabling illness. To update the estimated number of people being diagnosed with the disease, Beck's team analyzed data from large health insurance databases and long-term health studies on more than 15 million adults across the United States and in Ontario, Canada, in 2012. |
35672.0 | 2022-12-02 00:00:00 UTC | Acadia (ACAD) Up 3.5% Since Last Earnings Report: Can It Continue? | ACAD | https://www.nasdaq.com/articles/acadia-acad-up-3.5-since-last-earnings-report%3A-can-it-continue | nan | nan | A month has gone by since the last earnings report for Acadia Pharmaceuticals (ACAD). Shares have added about 3.5% in that time frame, underperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Acadia due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Acadia's Q3 Loss Narrower Than Expected, Revenues Miss
Acadia reported a third-quarter 2022 loss of 17 cents per share, narrower than the Zacks Consensus Estimate of a loss of 18 cents. The loss was wider than our estimate of a loss of 16 cents per share. In the year-ago quarter, the company incurred a loss of 9 cents per share.
Total revenues, comprising net sales of Acadia's only marketed drug, Nuplazid, decreased 1% year over year to $130.7 million in the third quarter, missing the Zacks Consensus Estimate of $140 million. Nuplazid sales decreased 2.9% sequentially in the third quarter.
Nuplazid sales in the third quarter were driven by sequential demand growth of 2% and growth acceleration in the long-term care channel, which was offset by a reduction of in-channel inventory of approximately $7 million.
Total revenues were also lower than our estimate of $139 million in the reported quarter.
Quarter in Detail
Research and development (R&D) expenses in the quarter were $81.3 million, up 38.7% year over year, owing to increased costs related to pipeline development activities and a $10 million milestone payment accrued to Neuren Pharmaceuticals upon the acceptance of the trofinetide NDA filing.
Selling, general and administrative (SG&A) expenses were $78.1 million, down 4.4% year over year, owing to reduced advertising and promotional costs.
As of Sep 30, 2022, Acadia had cash, cash equivalents and investments worth $436.6 million compared with $436.4 million as of Jun 30, 2022.
2022 Guidance
Acadia tightened its guidance for Nuplazid’s sales for 2022.
The company now expects Nuplazid’s net sales for 2022 in the $510-$520 million range compared with the earlier projection of $510-$540 million. The Zacks Consensus Estimate for the metric is pegged at $533.3 million.
The company now expects R&D expenses in the range of $345-$355 million compared with the $340-$360 million range expected previously. SG&A expenses are now expected to be $365-$375 million compared with $360-$380 million expected earlier.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in estimates review.
The consensus estimate has shifted -26.61% due to these changes.
VGM Scores
At this time, Acadia has a strong Growth Score of A, though it is lagging a lot on the Momentum Score front with an F. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Acadia has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Acadia belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Blueprint Medicines (BPMC), has gained 8% over the past month. More than a month has passed since the company reported results for the quarter ended September 2022.
Blueprint Medicines reported revenues of $65.98 million in the last reported quarter, representing a year-over-year change of +172.8%. EPS of -$2.23 for the same period compares with -$2 a year ago.
For the current quarter, Blueprint Medicines is expected to post a loss of $2.67 per share, indicating a change of -169.7% from the year-ago quarter. The Zacks Consensus Estimate has changed -4.3% over the last 30 days.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Blueprint Medicines. Also, the stock has a VGM Score of F.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report
Blueprint Medicines Corporation (BPMC) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A month has gone by since the last earnings report for Acadia Pharmaceuticals (ACAD). Will the recent positive trend continue leading up to its next earnings release, or is Acadia due for a pullback? Acadia's Q3 Loss Narrower Than Expected, Revenues Miss Acadia reported a third-quarter 2022 loss of 17 cents per share, narrower than the Zacks Consensus Estimate of a loss of 18 cents. | Acadia's Q3 Loss Narrower Than Expected, Revenues Miss Acadia reported a third-quarter 2022 loss of 17 cents per share, narrower than the Zacks Consensus Estimate of a loss of 18 cents. Total revenues, comprising net sales of Acadia's only marketed drug, Nuplazid, decreased 1% year over year to $130.7 million in the third quarter, missing the Zacks Consensus Estimate of $140 million. Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Blueprint Medicines Corporation (BPMC) : Free Stock Analysis Report To read this article on Zacks.com click here. | Acadia's Q3 Loss Narrower Than Expected, Revenues Miss Acadia reported a third-quarter 2022 loss of 17 cents per share, narrower than the Zacks Consensus Estimate of a loss of 18 cents. Total revenues, comprising net sales of Acadia's only marketed drug, Nuplazid, decreased 1% year over year to $130.7 million in the third quarter, missing the Zacks Consensus Estimate of $140 million. Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Blueprint Medicines Corporation (BPMC) : Free Stock Analysis Report To read this article on Zacks.com click here. | A month has gone by since the last earnings report for Acadia Pharmaceuticals (ACAD). Total revenues, comprising net sales of Acadia's only marketed drug, Nuplazid, decreased 1% year over year to $130.7 million in the third quarter, missing the Zacks Consensus Estimate of $140 million. Will the recent positive trend continue leading up to its next earnings release, or is Acadia due for a pullback? |
35673.0 | 2022-11-23 00:00:00 UTC | Analysts See 21% Upside For FBT | ACAD | https://www.nasdaq.com/articles/analysts-see-21-upside-for-fbt | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust NYSE Arca Biotechnology Index Fund ETF (Symbol: FBT), we found that the implied analyst target price for the ETF based upon its underlying holdings is $184.23 per unit.
With FBT trading at a recent price near $152.17 per unit, that means that analysts see 21.07% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of FBT's underlying holdings with notable upside to their analyst target prices are EXACT Sciences Corp. (Symbol: EXAS), Acadia Pharmaceuticals Inc (Symbol: ACAD), and Agios Pharmaceuticals Inc (Symbol: AGIO). Although EXAS has traded at a recent price of $42.23/share, the average analyst target is 46.82% higher at $62.00/share. Similarly, ACAD has 34.45% upside from the recent share price of $15.04 if the average analyst target price of $20.22/share is reached, and analysts on average are expecting AGIO to reach a target price of $38.25/share, which is 33.41% above the recent price of $28.67. Below is a twelve month price history chart comparing the stock performance of EXAS, ACAD, and AGIO:
Combined, EXAS, ACAD, and AGIO represent 10.00% of the First Trust NYSE Arca Biotechnology Index Fund ETF. Below is a summary table of the current analyst target prices discussed above:
NAME SYMBOL RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET
First Trust NYSE Arca Biotechnology Index Fund ETF FBT $152.17 $184.23 21.07%
EXACT Sciences Corp. EXAS $42.23 $62.00 46.82%
Acadia Pharmaceuticals Inc ACAD $15.04 $20.22 34.45%
Agios Pharmaceuticals Inc AGIO $28.67 $38.25 33.41%
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
Also see:
PAK Videos
LPDX Insider Buying
Top Ten Hedge Funds Holding CMN
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is a twelve month price history chart comparing the stock performance of EXAS, ACAD, and AGIO: Combined, EXAS, ACAD, and AGIO represent 10.00% of the First Trust NYSE Arca Biotechnology Index Fund ETF. First Trust NYSE Arca Biotechnology Index Fund ETF FBT $152.17 $184.23 21.07% EXACT Sciences Corp. EXAS $42.23 $62.00 46.82% Acadia Pharmaceuticals Inc ACAD $15.04 $20.22 34.45% Agios Pharmaceuticals Inc AGIO $28.67 $38.25 33.41% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of FBT's underlying holdings with notable upside to their analyst target prices are EXACT Sciences Corp. (Symbol: EXAS), Acadia Pharmaceuticals Inc (Symbol: ACAD), and Agios Pharmaceuticals Inc (Symbol: AGIO). | Three of FBT's underlying holdings with notable upside to their analyst target prices are EXACT Sciences Corp. (Symbol: EXAS), Acadia Pharmaceuticals Inc (Symbol: ACAD), and Agios Pharmaceuticals Inc (Symbol: AGIO). First Trust NYSE Arca Biotechnology Index Fund ETF FBT $152.17 $184.23 21.07% EXACT Sciences Corp. EXAS $42.23 $62.00 46.82% Acadia Pharmaceuticals Inc ACAD $15.04 $20.22 34.45% Agios Pharmaceuticals Inc AGIO $28.67 $38.25 33.41% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Similarly, ACAD has 34.45% upside from the recent share price of $15.04 if the average analyst target price of $20.22/share is reached, and analysts on average are expecting AGIO to reach a target price of $38.25/share, which is 33.41% above the recent price of $28.67. | Similarly, ACAD has 34.45% upside from the recent share price of $15.04 if the average analyst target price of $20.22/share is reached, and analysts on average are expecting AGIO to reach a target price of $38.25/share, which is 33.41% above the recent price of $28.67. Three of FBT's underlying holdings with notable upside to their analyst target prices are EXACT Sciences Corp. (Symbol: EXAS), Acadia Pharmaceuticals Inc (Symbol: ACAD), and Agios Pharmaceuticals Inc (Symbol: AGIO). Below is a twelve month price history chart comparing the stock performance of EXAS, ACAD, and AGIO: Combined, EXAS, ACAD, and AGIO represent 10.00% of the First Trust NYSE Arca Biotechnology Index Fund ETF. | Three of FBT's underlying holdings with notable upside to their analyst target prices are EXACT Sciences Corp. (Symbol: EXAS), Acadia Pharmaceuticals Inc (Symbol: ACAD), and Agios Pharmaceuticals Inc (Symbol: AGIO). Similarly, ACAD has 34.45% upside from the recent share price of $15.04 if the average analyst target price of $20.22/share is reached, and analysts on average are expecting AGIO to reach a target price of $38.25/share, which is 33.41% above the recent price of $28.67. Below is a twelve month price history chart comparing the stock performance of EXAS, ACAD, and AGIO: Combined, EXAS, ACAD, and AGIO represent 10.00% of the First Trust NYSE Arca Biotechnology Index Fund ETF. |
35674.0 | 2022-11-02 00:00:00 UTC | Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Misses Revenue Estimates | ACAD | https://www.nasdaq.com/articles/acadia-pharmaceuticals-acad-reports-q3-loss-misses-revenue-estimates | nan | nan | Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.09 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 5.56%. A quarter ago, it was expected that this drugmaker would post a loss of $0.25 per share when it actually produced a loss of $0.21, delivering a surprise of 16%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $130.71 million for the quarter ended September 2022, missing the Zacks Consensus Estimate by 6.40%. This compares to year-ago revenues of $131.61 million. The company has topped consensus revenue estimates just once over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Acadia shares have lost about 32.1% since the beginning of the year versus the S&P 500's decline of -19.1%.
What's Next for Acadia?
While Acadia has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Acadia: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.20 on $143.23 million in revenues for the coming quarter and -$1.28 on $533.28 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 20% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
vTv Therapeutics (VTVT), another stock in the same industry, has yet to report results for the quarter ended September 2022.
This biopharmaceutical company is expected to post quarterly loss of $0.05 per share in its upcoming report, which represents a year-over-year change of -150%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
vTv Therapeutics' revenues are expected to be $0.5 million, down 83.3% from the year-ago quarter.
Just Released: Zacks Unveils the Top 5 EV Stocks for 2022
For several months now, electric vehicles have been disrupting the $82 billion automotive industry. And that disruption is only getting bigger thanks to sky-high gas prices. Even titans in the financial industry including George Soros, Jeff Bezos, and Ray Dalio have invested in this unstoppable wave. You don't want to be sitting on your hands while EV stocks break out and climb to new highs. In a new free report, Zacks is revealing the top 5 EV stocks for investors. Next year, don't look back on today wishing you had taken advantage of this opportunity.
>>Send me my free report revealing the top 5 EV stocks
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
vTv Therapeutics Inc. (VTVT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.18. Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $130.71 million for the quarter ended September 2022, missing the Zacks Consensus Estimate by 6.40%. Acadia shares have lost about 32.1% since the beginning of the year versus the S&P 500's decline of -19.1%. | Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $130.71 million for the quarter ended September 2022, missing the Zacks Consensus Estimate by 6.40%. ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.18. | Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.18. Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $130.71 million for the quarter ended September 2022, missing the Zacks Consensus Estimate by 6.40%. Acadia shares have lost about 32.1% since the beginning of the year versus the S&P 500's decline of -19.1%. | Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.18. Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $130.71 million for the quarter ended September 2022, missing the Zacks Consensus Estimate by 6.40%. Acadia shares have lost about 32.1% since the beginning of the year versus the S&P 500's decline of -19.1%. |
35675.0 | 2022-11-01 00:00:00 UTC | Viatris (VTRS) to Report Q3 Earnings: What's in the Cards? | ACAD | https://www.nasdaq.com/articles/viatris-vtrs-to-report-q3-earnings%3A-whats-in-the-cards | nan | nan | Viatris VTRS, a global healthcare company, is scheduled to report third-quarter 2022 results on Nov 7.
The company was formed in 2020 through the combination of Mylan and Upjohn. It beat earnings estimates in three of the trailing four quarters and missed in one, the average surprise being 9.03%. In the last reported quarter, the company beat expectations by 8.64%.
Viatris Inc. Price, Consensus and EPS Surprise
Viatris Inc. price-consensus-eps-surprise-chart | Viatris Inc. Quote
Factors to Consider
Viatris reports segment information based on markets and geography — Developed Markets, Emerging Markets, Japan, Australia, and New Zealand (JANZ)and Greater China.
Unfavorable movements in foreign exchange rates impacted results in the second quarter and the scenario is likely to have prevailed in the third quarter.
Net sales from Developed markets were down 6% in the previous quarter. This trend is likely to have continued in the third quarter.
Sales from Emerging Markets were down 25% in the previous quarter and sales are likely to have decreased in the to-be-reported quarter as well.
Sales from JANZ were down 15% in the previous quarter and the third quarter is likely to have seen a similar trend.
Sales from Greater China markets were roughly flat. Sales in the third quarter are likely to have declined due to lockdowns.
On a segment basis, brands performed better than management expectations in the previous quarter, driven by products such as EpiPen, Norvasc, and Lipitor. A similar or better performance might have been witnessed by the company in the to-be-reported quarter.
Complex generics and biosimilars performed largely in line with expectations and grew 11% year over year on an operational basis, mainly driven by the interchangeable Semglee launch in the United States.
Generics, which includes diversified product forms such as extended-release oral solids, injectables, transdermals and topicals, performed better than expectations, driven by higher North American demand. A similar trend is likely to have prevailed in the to-be-reported quarter.
Management stated that Viatris is on track to achieve approximately $600 million in new product revenues in 2022.
Per management, SG&A and R&D were projected to increase in the second half of the year and the same is likely to have impacted margins and the bottom line in the third quarter.
An update on the U.S. launch of generic lenalidomide is also expected with the third-quarter results.
Other Updates
Viatris had earlier announced an agreement with Biocon Biologics Limited whereby the former would sell its biosimilars portfolio to the latter.
Per the terms of the agreement, Viatris will combine its biosimilars portfolio with Biocon Biologics Ltd in exchange for a pre-tax consideration of up to $3.335 billion.
Viatris will receive $3 billion in consideration in the form of a $2 billion cash payment and $1 billion of convertible preferred equity at the time of closing, which is currently expected in the second half of 2022, subject to the satisfaction of closing conditions, including certain regulatory approvals. VTRS will own a stake of at least 12.9% of Biocon Biologics on a fully diluted basis.
The transaction is on track to close in the second half of 2022.
Share Price Performance
Viatris’ stock has lost 25.1% in the year so far compared with the industry’s decline of 28.7%.
Image Source: Zacks Investment Research
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Viatris this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Earnings ESP for Viatris is 0.00% as both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at 82 cents.
Zacks Rank: The company currently carries a Zacks Rank #3.
Stocks to Consider
Here are a few stocks you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this season.
Editas Medicine EDIT has an Earnings ESP of +1.67% and a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Earnings of EDIT beat estimates in each of the trailing four quarters. It delivered an earnings surprise of 17.82%, on average.
Jazz Pharmaceuticals JAZZ has an Earnings ESP of +2.12% and a Zacks Rank #2.
JAZZ beat earnings estimates in three of the last four quarters, with the average earnings surprise being 10.94%.
Acadia Pharmaceuticals ACAD has an Earnings ESP of +6.47% and a Zacks Rank #3.
Acadia topped earnings estimates in two of the last four quarters and has a four-quarter earnings surprise of 6.83%, on average.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Jazz Pharmaceuticals PLC (JAZZ): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Editas Medicine, Inc. (EDIT): Free Stock Analysis Report
Viatris Inc. (VTRS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia Pharmaceuticals ACAD has an Earnings ESP of +6.47% and a Zacks Rank #3. Acadia topped earnings estimates in two of the last four quarters and has a four-quarter earnings surprise of 6.83%, on average. ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report | ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Acadia Pharmaceuticals ACAD has an Earnings ESP of +6.47% and a Zacks Rank #3. Acadia topped earnings estimates in two of the last four quarters and has a four-quarter earnings surprise of 6.83%, on average. | Acadia Pharmaceuticals ACAD has an Earnings ESP of +6.47% and a Zacks Rank #3. Acadia topped earnings estimates in two of the last four quarters and has a four-quarter earnings surprise of 6.83%, on average. ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report | Acadia Pharmaceuticals ACAD has an Earnings ESP of +6.47% and a Zacks Rank #3. Acadia topped earnings estimates in two of the last four quarters and has a four-quarter earnings surprise of 6.83%, on average. ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report |
35676.0 | 2022-11-01 00:00:00 UTC | Is a Surprise Coming for Acadia Pharmaceuticals (ACAD) This Earnings Season? | ACAD | https://www.nasdaq.com/articles/is-a-surprise-coming-for-acadia-pharmaceuticals-acad-this-earnings-season | nan | nan | Investors are always looking for stocks that are poised to beat at earnings season and Acadia Pharmaceuticals Inc. ACAD may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
That is because Acadia Pharmaceuticals is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for ACAD in this report.
In fact, the Most Accurate Estimate for the current quarter is currently at a loss of 17 cents per share for ACAD, compared to a broader Zacks Consensus Estimate of an earnings of 18 cents per share. This suggests that analysts have very recently bumped up their estimates for ACAD, giving the stock a Zacks Earnings ESP of +6.47% heading into earnings season.
ACADIA Pharmaceuticals Inc. Price and EPS Surprise
ACADIA Pharmaceuticals Inc. price-eps-surprise | ACADIA Pharmaceuticals Inc. Quote
Why is this Important?
A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).
Given that ACAD has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Clearly, recent earnings estimate revisions suggest that good things are ahead for Acadia Pharmaceuticals, and that a beat might be in the cards for the upcoming report.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for ACAD in this report. Clearly, recent earnings estimate revisions suggest that good things are ahead for Acadia Pharmaceuticals, and that a beat might be in the cards for the upcoming report. Investors are always looking for stocks that are poised to beat at earnings season and Acadia Pharmaceuticals Inc. ACAD may be one such company. | Clearly, recent earnings estimate revisions suggest that good things are ahead for Acadia Pharmaceuticals, and that a beat might be in the cards for the upcoming report. ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Investors are always looking for stocks that are poised to beat at earnings season and Acadia Pharmaceuticals Inc. ACAD may be one such company. | This suggests that analysts have very recently bumped up their estimates for ACAD, giving the stock a Zacks Earnings ESP of +6.47% heading into earnings season. Given that ACAD has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. Investors are always looking for stocks that are poised to beat at earnings season and Acadia Pharmaceuticals Inc. ACAD may be one such company. | Investors are always looking for stocks that are poised to beat at earnings season and Acadia Pharmaceuticals Inc. ACAD may be one such company. Given that ACAD has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report |
35677.0 | 2022-10-27 00:00:00 UTC | Incyte (INCY) to Report Q3 Earnings: What's in the Cards? | ACAD | https://www.nasdaq.com/articles/incyte-incy-to-report-q3-earnings%3A-whats-in-the-cards | nan | nan | Incyte Corporation INCY is scheduled to release its third-quarter 2022 results on Nov 1, before market open.
The company’s earnings surprise history has been dismal so far, with its earnings beating the Zacks Consensus Estimate in two of the trailing four quarters and missing on the other two occasions, the average negative surprise being 2.13%. In the last reported quarter, Incyte beat earnings by 27.8%.
Shares of Incyte have risen 0.3% in the year so far against the industry’s decline of 24.5%.
Image Source: Zacks Investment Research
Let’s see how things are shaping up for the quarter to be reported.
Factors at Play
Incyte primarily derives product revenues from sales of its lead drug, Jakafi (ruxolitinib), in the United States as well as its other marketed drugs.
Patient demand for Jakafi, a first-in-class JAK1/JAK2 inhibitor, in all approved indications (polycythemia vera, myelofibrosis and refractory acute graft-versus-host disease [GvHD]) increased 13% year over year in the second quarter. The trend is likely to have continued in the to-be-reported quarter as well. The Zacks Consensus Estimate for Jakafi’s sales stands at $617 million.
Incyte also earns product royalty revenues from Novartis AG (NVS) for the commercialization of Jakafi in ex-U.S. markets. Novartis licensed ruxolitinib from Incyte for development and commercialization outside the United States.
Jakafi is marketed by Incyte in the United States and is marketed as Jakavi by Novartis outside the country. Jakavi sales, as recorded by Novartis, were up 4% in the third quarter, and hence, Incyte is likely to have received higher royalties from NVS in the third quarter. The Zacks Consensus Estimate for the same is $96 million.
Incyte also receives royalties from the sales of Tabrecta (capmatinib), which is approved for the treatment of adult patients with metastatic non-small cell lung cancer. Novartis has exclusive worldwide development and commercialization rights to Tabrecta.
While Jakafi’s sales and royalties are key catalysts for the company’s revenue growth, Iclusig’s sales and Olumiant’s royalties from Eli Lilly are likely to have contributed to the top line. Hence, these are likely to have aided the company’s revenues in the to-be-reported quarter.
Iclusig’s net product revenues were down year over year in the previous quarter and a similar trend is likely to have been witnessed by INCY in the to-be-reported quarter.
Incremental sales from newly approved drugs like Opzelura are also likely to have added to sales in the third quarter. The adoption of other newly approved drugs like Monjuvi is also a positive and is likely to have boosted sales in the third quarter. The Zacks Consensus Estimate for Opzelura is $31 million.
Total costs and expenses increased 16.3% year over year in the second quarter and the same is likely to have increased in the third quarter due to a rise in R&D, selling, general and administrative expenses.
Key Pipeline Updates
In August 2022, the FDA approved Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. MLNs with FGFR1 rearrangement are extremely rare and aggressive blood cancers that may affect less than 1 in 100,000 people in the United States.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Incyte this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Earnings ESP for Incyte is -11.65% as the Zacks Consensus Estimate stands at 74 cents per share and the Most Accurate Estimate is currently pegged at 65 cents per share.
Zacks Rank: INCY currently carries a Zacks Rank #3.
Incyte Corporation Price, Consensus and EPS Surprise
Incyte Corporation price-consensus-eps-surprise-chart | Incyte Corporation Quote
Stocks to Consider
Here are some drug and biotech stocks you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this season.
Editas Medicine EDIT has an Earnings ESP of +3.47% and a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Earnings of EDIT beat estimates in each of the trailing four quarters. It delivered an earnings surprise of 17.82%, on average.
Jazz Pharmaceuticals JAZZ has an Earnings ESP of +2.12% and a Zacks Rank #2.
JAZZ beat earnings estimates in three of the last four quarters, with the average earnings surprise being 10.94%.
Acadia Pharmaceuticals ACAD has an Earnings ESP of +6.47% and a Zacks Rank #3.
Acadia topped earnings estimates in two of the last four quarters and has a four-quarter earnings surprise of 6.83%, on average.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
This Little-Known Semiconductor Stock Could Be Your Portfolio’s Hedge Against Inflation
Everyone uses semiconductors. But only a small number of people know what they are and what they do. If you use a smartphone, computer, microwave, digital camera or refrigerator (and that’s just the tip of the iceberg), you have a need for semiconductors. That’s why their importance can’t be overstated and their disruption in the supply chain has such a global effect. But every cloud has a silver lining. Shockwaves to the international supply chain from the global pandemic have unearthed a tremendous opportunity for investors. And today, Zacks' leading stock strategist is revealing the one semiconductor stock that stands to gain the most in a new FREE report. It's yours at no cost and with no obligation.
>>Yes, I Want to Help Protect My Portfolio During the Recession
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Incyte Corporation (INCY): Free Stock Analysis Report
Jazz Pharmaceuticals PLC (JAZZ): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Editas Medicine, Inc. (EDIT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia Pharmaceuticals ACAD has an Earnings ESP of +6.47% and a Zacks Rank #3. Acadia topped earnings estimates in two of the last four quarters and has a four-quarter earnings surprise of 6.83%, on average. ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report | ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Acadia Pharmaceuticals ACAD has an Earnings ESP of +6.47% and a Zacks Rank #3. Acadia topped earnings estimates in two of the last four quarters and has a four-quarter earnings surprise of 6.83%, on average. | Acadia Pharmaceuticals ACAD has an Earnings ESP of +6.47% and a Zacks Rank #3. Acadia topped earnings estimates in two of the last four quarters and has a four-quarter earnings surprise of 6.83%, on average. ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report | Acadia Pharmaceuticals ACAD has an Earnings ESP of +6.47% and a Zacks Rank #3. Acadia topped earnings estimates in two of the last four quarters and has a four-quarter earnings surprise of 6.83%, on average. ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report |
35678.0 | 2022-10-27 00:00:00 UTC | Analysts Estimate Moderna (MRNA) to Report a Decline in Earnings: What to Look Out for | ACAD | https://www.nasdaq.com/articles/analysts-estimate-moderna-mrna-to-report-a-decline-in-earnings%3A-what-to-look-out-for | nan | nan | Moderna (MRNA) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2022. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on November 3. On the other hand, if they miss, the stock may move lower.
While management's discussion of business conditions on theearnings callwill mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Zacks Consensus Estimate
This biotechnology company is expected to post quarterly earnings of $3.02 per share in its upcoming report, which represents a year-over-year change of -60.8%.
Revenues are expected to be $3.33 billion, down 33% from the year-ago quarter.
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 1.7% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.
Earnings Whisper
Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Moderna?
For Moderna, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -17.91%.
On the other hand, the stock currently carries a Zacks Rank of #3.
So, this combination makes it difficult to conclusively predict that Moderna will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Moderna would post earnings of $4.50 per share when it actually produced earnings of $5.24, delivering a surprise of +16.44%.
Over the last four quarters, the company has beaten consensus EPS estimates three times.
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Moderna doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Expected Results of an Industry Player
Among the stocks in the Zacks Medical - Biomedical and Genetics industry, Acadia Pharmaceuticals (ACAD) is soon expected to post loss of $0.18 per share for the quarter ended September 2022. This estimate indicates a year-over-year change of -100%. This quarter's revenue is expected to be $139.65 million, up 6.1% from the year-ago quarter.
The consensus EPS estimate for Acadia has been revised 3.7% higher over the last 30 days to the current level. However, a higher Most Accurate Estimate has resulted in an Earnings ESP of 6.47%.
When combined with a Zacks Rank of #3 (Hold), this Earnings ESP indicates that Acadia will most likely beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates two times.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
This Little-Known Semiconductor Stock Could Be Your Portfolio’s Hedge Against Inflation
Everyone uses semiconductors. But only a small number of people know what they are and what they do. If you use a smartphone, computer, microwave, digital camera or refrigerator (and that’s just the tip of the iceberg), you have a need for semiconductors. That’s why their importance can’t be overstated and their disruption in the supply chain has such a global effect. But every cloud has a silver lining. Shockwaves to the international supply chain from the global pandemic have unearthed a tremendous opportunity for investors. And today, Zacks' leading stock strategist is revealing the one semiconductor stock that stands to gain the most in a new FREE report. It's yours at no cost and with no obligation.
>>Yes, I Want to Help Protect My Portfolio During the Recession
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Moderna, Inc. (MRNA): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Expected Results of an Industry Player Among the stocks in the Zacks Medical - Biomedical and Genetics industry, Acadia Pharmaceuticals (ACAD) is soon expected to post loss of $0.18 per share for the quarter ended September 2022. The consensus EPS estimate for Acadia has been revised 3.7% higher over the last 30 days to the current level. When combined with a Zacks Rank of #3 (Hold), this Earnings ESP indicates that Acadia will most likely beat the consensus EPS estimate. | Expected Results of an Industry Player Among the stocks in the Zacks Medical - Biomedical and Genetics industry, Acadia Pharmaceuticals (ACAD) is soon expected to post loss of $0.18 per share for the quarter ended September 2022. The consensus EPS estimate for Acadia has been revised 3.7% higher over the last 30 days to the current level. When combined with a Zacks Rank of #3 (Hold), this Earnings ESP indicates that Acadia will most likely beat the consensus EPS estimate. | Expected Results of an Industry Player Among the stocks in the Zacks Medical - Biomedical and Genetics industry, Acadia Pharmaceuticals (ACAD) is soon expected to post loss of $0.18 per share for the quarter ended September 2022. The consensus EPS estimate for Acadia has been revised 3.7% higher over the last 30 days to the current level. When combined with a Zacks Rank of #3 (Hold), this Earnings ESP indicates that Acadia will most likely beat the consensus EPS estimate. | When combined with a Zacks Rank of #3 (Hold), this Earnings ESP indicates that Acadia will most likely beat the consensus EPS estimate. Expected Results of an Industry Player Among the stocks in the Zacks Medical - Biomedical and Genetics industry, Acadia Pharmaceuticals (ACAD) is soon expected to post loss of $0.18 per share for the quarter ended September 2022. The consensus EPS estimate for Acadia has been revised 3.7% higher over the last 30 days to the current level. |
35679.0 | 2022-10-26 00:00:00 UTC | Eli Lilly (LLY) to Report Q3 Earnings: What's in the Cards? | ACAD | https://www.nasdaq.com/articles/eli-lilly-lly-to-report-q3-earnings%3A-whats-in-the-cards | nan | nan | Eli Lilly & Company LLY will report third-quarter 2022 results on Nov 1, before market open. In the last reported quarter, the company delivered a negative earnings surprise of 30.56%.
This large drugmaker’s earnings performance has been rather weak, with the company missing earnings expectations in three of the last four quarters while beating in one. Lilly delivered a four-quarter negative earnings surprise of 5.11%, on average.
Eli Lilly and Company Price and EPS Surprise
Eli Lilly and Company price-eps-surprise | Eli Lilly and Company Quote
Lilly’s stock has risen 27.2% this year so far compared with an increase of 0.1% for the industry. | Eli Lilly & Company LLY will report third-quarter 2022 results on Nov 1, before market open. In the last reported quarter, the company delivered a negative earnings surprise of 30.56%. Lilly delivered a four-quarter negative earnings surprise of 5.11%, on average. | In the last reported quarter, the company delivered a negative earnings surprise of 30.56%. Lilly delivered a four-quarter negative earnings surprise of 5.11%, on average. Eli Lilly and Company Price and EPS Surprise Eli Lilly and Company price-eps-surprise | Eli Lilly and Company Quote Lilly’s stock has risen 27.2% this year so far compared with an increase of 0.1% for the industry. | In the last reported quarter, the company delivered a negative earnings surprise of 30.56%. This large drugmaker’s earnings performance has been rather weak, with the company missing earnings expectations in three of the last four quarters while beating in one. Eli Lilly and Company Price and EPS Surprise Eli Lilly and Company price-eps-surprise | Eli Lilly and Company Quote Lilly’s stock has risen 27.2% this year so far compared with an increase of 0.1% for the industry. | Eli Lilly & Company LLY will report third-quarter 2022 results on Nov 1, before market open. In the last reported quarter, the company delivered a negative earnings surprise of 30.56%. Eli Lilly and Company Price and EPS Surprise Eli Lilly and Company price-eps-surprise | Eli Lilly and Company Quote Lilly’s stock has risen 27.2% this year so far compared with an increase of 0.1% for the industry. |
35680.0 | 2022-10-26 00:00:00 UTC | Agenus (AGEN) to Report Q3 Earnings: What's in the Cards? | ACAD | https://www.nasdaq.com/articles/agenus-agen-to-report-q3-earnings%3A-whats-in-the-cards | nan | nan | We expect investors to focus on Agenus Inc.’s AGEN progress with the development of its pipeline candidates, including its lead program — botensilimab, when it reports third-quarter 2022 results on Nov 8, before market open.
AGEN’s surprise record has been mixed so far, as its earnings surpassed expectations in three of the trailing four quarters and missed the same on the remaining occasion. It has a trailing four-quarter earnings surprise of 12.02%, on average. In the last reported quarter, Agenus delivered an earnings surprise of 26.09%.
Shares of Agenus have lost 18.3% this year compared with the industry’s decline of 24.5%.
Image Source: Zacks Investment Research
Let’s see how things have shaped up for the quarter to be reported.
Factors at Play
Agenus’ revenues in the third quarter are likely to have been driven by the company’s collaboration agreements, milestones earned and revenue related to non-cash royalties earned.
AGEN’s top line comprises revenues related to royalty sales milestones, revenues related to non-cash royalties, research and development revenues, and other revenues. Revenues increased around 95% in the last reported quarter, a trend likely to have continued in the third quarter.
Per the second quarter earnings release, the company expected to receive payments in the second half of 2022 on royalties owed on Shingrix sales. It also achieved sales-based milestone related to QS-21 STIMULON in the said quarter. These are likely to have aided AGEN’s top line in the quarter under review.
The company has been developing its lead candidate, botensilimab, for treating various types of cancer indications. Phase II studies for botensilimab are expected to begin in microsatellite stable colorectal cancer (MCC CRC), melanoma and pancreatic cancer later in 2022.
AGEN has been working closely with regulatory bodies to speed up the development of botensilimab in pursuit of global registrations across multiple cancer indications.
We expect management to provide further updates on botensilimab at the upcoming investors’ call.
The activities related to the development of its pipeline candidate across various clinical studies are likely to have escalated AGEN’s operating expenses in the third quarter.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Agenus this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Agenus’ Earnings ESP is 0.00% as the Most Accurate Estimate and the Zacks Consensus Estimate currently are both pegged at a loss of 18 cents per share.
Zacks Rank: Agenus currently carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Agenus Inc. Price and EPS Surprise
Agenus Inc. price-eps-surprise | Agenus Inc. Quote
Stocks to Consider
AVEO Pharmaceuticals AVEO has an Earnings ESP of +8.16% and a Zacks Rank #3.
AVEO Pharmaceuticals' stock has surged 215.1% so far this year. AVEO topped earnings estimates in three of the last four quarters and missed the same on the other occasion. AVEO has a four-quarter earnings surprise of 13.10%, on average.
Acadia ACAD has an Earnings ESP of +6.47% and a Zacks Rank #3.
Acadia’s stock has lost 32.7% so far this year. ACAD topped earnings estimates in two of the last four quarters and missed the same on the other two occasions. ACAD has a four-quarter earnings surprise of 6.83%, on average. ACAD is scheduled to release its third-quarter 2022 results on Nov 2.
ImmunoGen IMGN has an Earnings ESP of +4.39% and a Zacks Rank #3.
The ImmunoGen stock has declined 18.4% so far this year. IMGN topped earnings estimates in three of the last four quarters and missed the same on the other occasion. ImmunoGen has a four-quarter earnings surprise of 13.53%, on average. IMGN is scheduled to release its third-quarter 2022 results on Nov 4.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ImmunoGen, Inc. (IMGN): Free Stock Analysis Report
AVEO Pharmaceuticals, Inc. (AVEO): Free Stock Analysis Report
Agenus Inc. (AGEN): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia ACAD has an Earnings ESP of +6.47% and a Zacks Rank #3. Acadia’s stock has lost 32.7% so far this year. ACAD topped earnings estimates in two of the last four quarters and missed the same on the other two occasions. | ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Acadia ACAD has an Earnings ESP of +6.47% and a Zacks Rank #3. Acadia’s stock has lost 32.7% so far this year. | Acadia ACAD has an Earnings ESP of +6.47% and a Zacks Rank #3. Acadia’s stock has lost 32.7% so far this year. ACAD topped earnings estimates in two of the last four quarters and missed the same on the other two occasions. | Acadia ACAD has an Earnings ESP of +6.47% and a Zacks Rank #3. Acadia’s stock has lost 32.7% so far this year. ACAD topped earnings estimates in two of the last four quarters and missed the same on the other two occasions. |
35681.0 | 2022-10-25 00:00:00 UTC | What's in Store for Gilead (GILD) This Earnings Season? | ACAD | https://www.nasdaq.com/articles/whats-in-store-for-gilead-gild-this-earnings-season | nan | nan | Biotech major Gilead Sciences Inc. GILD is set to report third-quarter 2022 results on Oct 27, after market close.
The company has a good track record, with earnings beating estimates in three of the last four quarters and missing in one, with the average beat being 5.90%. In the last reported quarter, the company beat expectations by 4.64%.
Gilead Sciences, Inc. Price, Consensus and EPS Surprise
Gilead Sciences, Inc. price-consensus-eps-surprise-chart | Gilead Sciences, Inc. Quote
Factors to Note
Gilead did not provide any guidance for the third quarter.
HIV franchise sales increased 7% in the last reported quarter, driven by higher demand for flagship HIV therapy Biktarvy and favorable pricing dynamics, which more than offset the decline in sales due to the loss of exclusivity of Truvada and Atripla. Biktarvy’s sales increased 28% year over year in the second quarter due to higher demand, and the trend is likely to have continued in the third quarter. Descovy’s revenues increased 6% year over year, driven by higher demand and channel mix. The momentum is likely to have continued in the third quarter.
On the second-quarterearnings call management stated that Biktarvy remains the leading regimen for new starts and switches in the United States and new starts in Europe.
The Zacks Consensus Estimate for sales of Biktarvy and Descovy is pegged at $2.6 billion and $453 million, respectively. Our estimates for the same are $2.6 billion and $427, respectively.
Hepatitis C virus product sales have been declining for quite some time now, and the second quarter saw an 18% decline due to a lower average realized price and fewer patient starts. The trend is likely to have continued in the third quarter.
Sales of Veklury (remdesivir), an antiviral treatment for COVID-19, plunged 46% in the second quarter and the third quarter is likely to have seen a significant sequential decline as the need for medications fell with a rise in general immunity to this virus. Gilead expects total Veklury sales of approximately $2.5 billion for 2022, of which $2 billion has already been recorded in the first half.
Cell Therapy product sales, which include Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel), were up 68% in the previous quarter. Sales are likely to have experienced a sequential increase, driven by label expansions of Yescarta and Tecartus. The Zacks Consensus Estimate for Cell Therapy product sales stands at $365 million and our estimate is $444 million.
Sales of Trodelvy (for breast cancer) surged 79% in the second quarter, reflecting continued uptake in the second-line setting for the treatment of metastatic triple-negative breast cancer (TNBC) in the United States and Europe, as well as metastatic urothelial cancer in the United States. The drug was added following the acquisition of Immunomedics by Gilead in 2020. Sales are likely to have registered a sequential increase on increased demand.
Hepatitis B virus and hepatitis delta virus product sales decreased 1% in the second quarter and the third quarter is likely to have seen a similar trend.
Operating expenses are likely to have increased due to higher investments in the oncology program.
Pipeline & Regulatory Updates
Apart from the regular top and bottom-line numbers, we expect investors to focus on key pipeline updates when the company reports.
Gilead’s HIV treatment Sunlenca (lenacapavir) has been approved by the European Commission for treating HIV infection, in combination with other antiretroviral(s), in adults with multi-drug resistant HIV infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.
The FDA also accepted the company’s new drug application resubmission for lenacapavir. The agency has assigned a target action date of Dec 27, 2022. Additional regulatory filings and decisions by regulatory authorities are anticipated later in 2022.
Share Price Performance
Gilead’s stock has lost 4.3% in the year so far compared with the industry's decline of 25.4%.
Image Source: Zacks Investment Research
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Gilead in this reporting cycle. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Gilead has an Earnings ESP of -2.74%. This is because the Most Accurate Estimate stands at $1.42 while the Zacks Consensus Estimate stands at $1.46;
Zacks Rank: Gilead currently carries a Zacks Rank #3.
Stocks to Consider
Here are some drug and biotech stocks you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this season.
Editas Medicine EDIT has an Earnings ESP of +3.47% and a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Earnings of EDIT beat estimates in each of the trailing four quarters. It delivered an earnings surprise of 17.82%, on average.
Acadia Pharmaceuticals ACAD has an Earnings ESP of +6.47% and a Zacks Rank #3.
Acadia topped earnings estimates in two of the last four quarters and has a four-quarter earnings surprise of 6.83%, on average.
Jazz Pharmaceuticals JAZZ has an Earnings ESP of +2.12% and a Zacks Rank #2.
JAZZ beat earnings estimate in three of the last four quarters, with the average earnings surprise being 10.94%.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Just Released: Zacks Unveils the Top 5 EV Stocks for 2022
For several months now, electric vehicles have been disrupting the $82 billion automotive industry. And that disruption is only getting bigger thanks to sky-high gas prices. Even titans in the financial industry including George Soros, Jeff Bezos, and Ray Dalio have invested in this unstoppable wave. You don't want to be sitting on your hands while EV stocks break out and climb to new highs. In a new free report, Zacks is revealing the top 5 EV stocks for investors. Next year, don't look back on today wishing you had taken advantage of this opportunity.
>>Send me my free report revealing the top 5 EV stocks
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
Jazz Pharmaceuticals PLC (JAZZ): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Editas Medicine, Inc. (EDIT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia Pharmaceuticals ACAD has an Earnings ESP of +6.47% and a Zacks Rank #3. Acadia topped earnings estimates in two of the last four quarters and has a four-quarter earnings surprise of 6.83%, on average. ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report | ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Acadia Pharmaceuticals ACAD has an Earnings ESP of +6.47% and a Zacks Rank #3. Acadia topped earnings estimates in two of the last four quarters and has a four-quarter earnings surprise of 6.83%, on average. | Acadia Pharmaceuticals ACAD has an Earnings ESP of +6.47% and a Zacks Rank #3. Acadia topped earnings estimates in two of the last four quarters and has a four-quarter earnings surprise of 6.83%, on average. ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report | Acadia Pharmaceuticals ACAD has an Earnings ESP of +6.47% and a Zacks Rank #3. Acadia topped earnings estimates in two of the last four quarters and has a four-quarter earnings surprise of 6.83%, on average. ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report |
35682.0 | 2022-10-24 00:00:00 UTC | Will Eliquis, Opdivo Fuel Bristol-Myers (BMY) Q3 Earnings? | ACAD | https://www.nasdaq.com/articles/will-eliquis-opdivo-fuel-bristol-myers-bmy-q3-earnings | nan | nan | Bristol-Myers Squibb Company BMY is scheduled to report third-quarter 2022 results on Oct 26, before market open.
The company’s shares have gained 15.8% in the year so far against the industry's decline of 26.2%.
Image Source: Zacks Investment Research
Bristol-Myers beat earnings estimates in each of the last four quarters, the average surprise being 3.65%. In the last reported quarter, the company beat earnings by 7.82%.
Factors at Play
Bristol-Myers posted 9% growth in Total In-line Product Revenues in the last reported quarter. Demand is likely to have improved in the third quarter. Blood thinner drug, Eliquis, was one of the top revenue generators in the last reported quarter and posted revenue growth of 16% year over year. The solid performance of the drug | Bristol-Myers Squibb Company BMY is scheduled to report third-quarter 2022 results on Oct 26, before market open. Image Source: Zacks Investment Research Bristol-Myers beat earnings estimates in each of the last four quarters, the average surprise being 3.65%. Factors at Play Bristol-Myers posted 9% growth in Total In-line Product Revenues in the last reported quarter. | Image Source: Zacks Investment Research Bristol-Myers beat earnings estimates in each of the last four quarters, the average surprise being 3.65%. In the last reported quarter, the company beat earnings by 7.82%. Blood thinner drug, Eliquis, was one of the top revenue generators in the last reported quarter and posted revenue growth of 16% year over year. | In the last reported quarter, the company beat earnings by 7.82%. Factors at Play Bristol-Myers posted 9% growth in Total In-line Product Revenues in the last reported quarter. Blood thinner drug, Eliquis, was one of the top revenue generators in the last reported quarter and posted revenue growth of 16% year over year. | In the last reported quarter, the company beat earnings by 7.82%. Demand is likely to have improved in the third quarter. Blood thinner drug, Eliquis, was one of the top revenue generators in the last reported quarter and posted revenue growth of 16% year over year. |
35683.0 | 2022-10-24 00:00:00 UTC | Novavax (NVAX) to Report Q3 Earnings: What's in the Cards? | ACAD | https://www.nasdaq.com/articles/novavax-nvax-to-report-q3-earnings%3A-whats-in-the-cards | nan | nan | We expect investors to focus on the sales performance of Novavax, Inc.’s NVAX protein-based COVID-19 vaccine, NVX-CoV2373, its sole marketed product, when it reports third-quarter 2022 results.
NVAX’s surprise record has been dismal so far, as its earnings missed expectations in each of the last four quarters. It has a trailing four-quarter negative earnings surprise of 232.53%, on average. In the last reported quarter, Novavax witnessed a negative earnings surprise of 218.51%.
Shares of Novavax have plunged 86.5% so far this year compared with the industry’s decline of 26.2%.
Image Source: Zacks Investment Research
Let’s see how things have shaped up for the quarter to be reported.
Factors at Play
The company’s COVID vaccine gained authorization for use as a primary two-dose regimen in several countries, including the United States, Australia, Japan, India and various European countries.
Last week, the FDA expanded the emergency use authorization granted to Novavax’s COVID-19 Vaccine, Adjuvanted (NVX-CoV2373), to allow its use as a booster dose in adults aged 18 years and older.
Novavax’s COVID-19 Vaccine, Adjuvanted, has also been endorsed by the Centers for Disease Control and Prevention for use as a booster dose in adults.
The company’s booster dose, the Nuvaxovid vaccine, was also authorized for use in New Zealand, Australia, Japan, Israel and the European Union during the third quarter.
All these authorizations are likely to aid NVAX to generate product revenues from the sale of its COVID vaccine during the reported quarter. The booster dose is likely to generate more revenues than the primary regimen as most of the population is already vaccinated.
Novavax’s top line is likely to have been aided by the sale of its COVID-19 vaccine in the third quarter. NVX-CoV2373 generated sales worth $55 million in the last reported quarter. However, vaccine sales could suffer as the impact of the pandemic is lessening and demand for vaccines is going down. Investors will be keen to get an update on the same at the upcoming earnings call.
We also expect management to provide an update on Novavax’s other pipeline candidates.
In October 2022, NVAX announced positive top-line data from a phase I/II study evaluating the safety and tolerability of its COVID-19-Influenza Combination (“CIC”) vaccine candidate. The CIC vaccine candidate proved feasible, well-tolerated and immunogenic, inducing both antibody and T-cell responses against SARS-CoV-2 and homologous and heterologous influenza strains in subjects.
Both the influenza vaccine and NVX-CoV2373 had previously demonstrated encouraging results in their separate phase III clinical studies.
Novavax also completed a phase III pivotal study on its nanoparticle seasonal influenza vaccine candidate, NanoFlu, for patients aged 65 years and above. The study met all eight primary endpoints. An update on the timeline for the regulatory filing of the vaccine is expected during the upcoming earnings call.
ResVax, Novavax’s potential respiratory syncytial virus vaccine, is being evaluated in a phase III study to protect infants by immunizing their mothers against the disease.
Activities related to the development of the portfolio of vaccine candidates are likely to have escalated NVAX’s operating expenses in the third quarter.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Novavax this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is not the case here as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Novavax’s Earnings ESP is -35.07% as the Most Accurate Estimate currently stands at $1.44 per share while the Zacks Consensus Estimate is much higher at $2.21 per share.
Zacks Rank: Novavax currently carries a Zacks Rank #5 (Strong Sell). You can see the complete list of today’s Zacks #1 Rank stocks here.
Novavax, Inc. Price and EPS Surprise
Novavax, Inc. price-eps-surprise | Novavax, Inc. Quote
Stocks to Consider
Here are a few stocks worth considering, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.
Eli Lilly LLY has an Earnings ESP of +0.58% and a Zacks Rank #3.
Lilly’s stock has risen 23.4% this year so far. Lilly missed earnings estimates in three of the last four quarters. Lilly has a four-quarter earnings negative surprise of 5.11%, on average. LLY is scheduled to release its third-quarter 2022 results on Nov 1.
Acadia ACAD has an Earnings ESP of +15.82% and a Zacks Rank #2.
Acadia’sstock has lost 32% this year so far. ACAD topped earnings estimates in two of the last four quarters. ACAD has a four-quarter earnings surprise of 6.83%, on average. ACAD is scheduled to release its third-quarter 2022 results on Nov 2.
ImmunoGen IMGN has an Earnings ESP of +4.39% and a Zacks Rank #3.
ImmunoGen stock has declined 17.2% this year so far. ImmunoGen topped earnings estimates in three of the last four quarters. IMGN has a four-quarter earnings surprise of 13.53%, on average. IMGN is scheduled to release its third-quarter 2022 results on Nov 4.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Eli Lilly and Company (LLY): Free Stock Analysis Report
Novavax, Inc. (NVAX): Free Stock Analysis Report
ImmunoGen, Inc. (IMGN): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia ACAD has an Earnings ESP of +15.82% and a Zacks Rank #2. Acadia’sstock has lost 32% this year so far. ACAD topped earnings estimates in two of the last four quarters. | Acadia ACAD has an Earnings ESP of +15.82% and a Zacks Rank #2. Acadia’sstock has lost 32% this year so far. ACAD topped earnings estimates in two of the last four quarters. | Acadia ACAD has an Earnings ESP of +15.82% and a Zacks Rank #2. Acadia’sstock has lost 32% this year so far. ACAD topped earnings estimates in two of the last four quarters. | Acadia ACAD has an Earnings ESP of +15.82% and a Zacks Rank #2. Acadia’sstock has lost 32% this year so far. ACAD topped earnings estimates in two of the last four quarters. |
35684.0 | 2022-10-21 00:00:00 UTC | Interesting ACAD Put And Call Options For June 2023 | ACAD | https://www.nasdaq.com/articles/interesting-acad-put-and-call-options-for-june-2023 | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the June 2023 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 238 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new June 2023 contracts and identified one put and one call contract of particular interest.
The put contract at the $11.00 strike price has a current bid of 50 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $11.00, but will also collect the premium, putting the cost basis of the shares at $10.50 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $15.62/share today.
Because the $11.00 strike represents an approximate 30% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 82%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 4.55% return on the cash commitment, or 6.97% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $11.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $21.00 strike price has a current bid of 60 cents. If an investor was to purchase shares of ACAD stock at the current price level of $15.62/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $21.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 38.28% if the stock gets called away at the June 2023 expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $21.00 strike highlighted in red:
Considering the fact that the $21.00 strike represents an approximate 34% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 54%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 3.84% boost of extra return to the investor, or 5.89% annualized, which we refer to as the YieldBoost.
The implied volatility in the put contract example is 177%, while the implied volatility in the call contract example is 127%.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $15.62) to be 79%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $21.00 strike highlighted in red: Considering the fact that the $21.00 strike represents an approximate 34% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the June 2023 expiration. | Below is a chart showing ACAD's trailing twelve month trading history, with the $21.00 strike highlighted in red: Considering the fact that the $21.00 strike represents an approximate 34% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the June 2023 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new June 2023 contracts and identified one put and one call contract of particular interest. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $11.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $21.00 strike price has a current bid of 60 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $21.00 strike highlighted in red: Considering the fact that the $21.00 strike represents an approximate 34% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the June 2023 expiration. | At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new June 2023 contracts and identified one put and one call contract of particular interest. Below is a chart showing ACAD's trailing twelve month trading history, with the $21.00 strike highlighted in red: Considering the fact that the $21.00 strike represents an approximate 34% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the June 2023 expiration. |
35685.0 | 2022-10-20 00:00:00 UTC | Immunovant (IMVT) Set to Develop Lead Candidate Batoclimab | ACAD | https://www.nasdaq.com/articles/immunovant-imvt-set-to-develop-lead-candidate-batoclimab | nan | nan | Immunovant, Inc. IMVT is making good progress with the development of its lead pipeline candidate, batoclimab (formerly IMVT-1401), which is being developed for treating several autoimmune diseases.
Batoclimab is a fully human, monoclonal antibody that selectively binds to and inhibits neonatal fragment crystallizable receptors (FcRn). The candidate is being developed as a subcutaneous injection for the treatment of myasthenia gravis (“MG”), warm autoimmune hemolytic anemia (“WAIHA”) and thyroid eye disease (“TED”). IMVT is making rapid progress in batoclimab’s development this year.
Shares of Immunovant have rallied 8.5% so far this year against the industry’s decline of 27.1%.
Image Source: Zacks Investment Research
Last month, IMVT announced plans to develop batoclimab for two new indications, Chronic Inflammatory Demyelinating Polyneuropathy and Graves’ Disease.
The company is looking to initiate a pivotal phase IIb study evaluating batoclimab for treating Chronic Inflammatory Demyelinating in the second half of 2022. The company also plans to start another phase II study on batoclimab for treating Graves’ Disease in early 2023.
In June 2022, Immunovant initiated a pivotal study evaluating batoclimab for the treatment of MG. Top-line data from the same is expected in the second half of 2024.
During the same period, the company also achieved alignment with the FDA’s Division of Ophthalmology to initiate two phase III studies evaluating batoclimab for treating TED. Both studies are expected to begin in the second half of 2022. Top-line data from both are expected in the first half of 2025.
The company also plans to initiate a placebo-controlled study on batoclimab as a treatment for WAIHA, contingent on discussions with the hematology division of the FDA, which is expected to take place later in 2022.
In September, Immunovant announced that it plans to begin a phase I study on its new anti-FcRn, IMVT-1402 in early 2023, contingent on IND clearance. Initial data from the same is expected in mid-2023.
The encouraging pipeline progress with batoclimab has maintained momentum for IMVT.
However, in the absence of a marketed drug, the successful development of batoclimab remains the main focus of Immunovant. Moreover, batoclimab is still in late-stage development and is still a few years away from commercialization. Any developmental setback for batoclimab will be a major setback for the company, leaving an adverse impact on its shares.
Zacks Rank & Stocks to Consider
Immunovant currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks worth considering in the biotech sector are Acadia Pharmaceuticals Inc. ACAD, ORIC Pharmaceuticals, Inc. ORIC and Aeglea BioTherapeutics, Inc. AGLE, all carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Loss per share estimates for Acadia narrowed 0.7% for 2022 and 2.9% for 2023 in the past 60 days.
Earnings of Acadia surpassed estimates in two of the trailing four quarters and missed on the remaining two occasions. ACAD delivered an earnings surprise of 6.83%, on average.
Loss per share estimates for ORIC Pharmaceuticals narrowed 5.9% for 2022 and 7.3% for 2023 in the past 60 days.
Earnings of ORIC Pharmaceuticals surpassed estimates in three of the trailing four quarters and missed on the other occasion. ORIC delivered an earnings surprise of 8.85%, on average.
Loss per share estimates for Aeglea BioTherapeutics narrowed 3.5% for 2022 and 1.2% for 2023 in the past 60 days.
Earnings of Aeglea BioTherapeutics surpassed estimates in one of the trailing four quarters and missed on the other three occasions. AGLE delivered a negative earnings surprise of 3.34%, on average.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Aeglea BioTherapeutics, Inc. (AGLE): Free Stock Analysis Report
Immunovant, Inc. (IMVT): Free Stock Analysis Report
Oric Pharmaceuticals, Inc. (ORIC): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks worth considering in the biotech sector are Acadia Pharmaceuticals Inc. ACAD, ORIC Pharmaceuticals, Inc. ORIC and Aeglea BioTherapeutics, Inc. AGLE, all carrying a Zacks Rank #2 (Buy) at present. Loss per share estimates for Acadia narrowed 0.7% for 2022 and 2.9% for 2023 in the past 60 days. Earnings of Acadia surpassed estimates in two of the trailing four quarters and missed on the remaining two occasions. | Some better-ranked stocks worth considering in the biotech sector are Acadia Pharmaceuticals Inc. ACAD, ORIC Pharmaceuticals, Inc. ORIC and Aeglea BioTherapeutics, Inc. AGLE, all carrying a Zacks Rank #2 (Buy) at present. ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Loss per share estimates for Acadia narrowed 0.7% for 2022 and 2.9% for 2023 in the past 60 days. | Some better-ranked stocks worth considering in the biotech sector are Acadia Pharmaceuticals Inc. ACAD, ORIC Pharmaceuticals, Inc. ORIC and Aeglea BioTherapeutics, Inc. AGLE, all carrying a Zacks Rank #2 (Buy) at present. Loss per share estimates for Acadia narrowed 0.7% for 2022 and 2.9% for 2023 in the past 60 days. Earnings of Acadia surpassed estimates in two of the trailing four quarters and missed on the remaining two occasions. | ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Some better-ranked stocks worth considering in the biotech sector are Acadia Pharmaceuticals Inc. ACAD, ORIC Pharmaceuticals, Inc. ORIC and Aeglea BioTherapeutics, Inc. AGLE, all carrying a Zacks Rank #2 (Buy) at present. Loss per share estimates for Acadia narrowed 0.7% for 2022 and 2.9% for 2023 in the past 60 days. |
35686.0 | 2022-10-20 00:00:00 UTC | Zymeworks (ZYME) Up on Licensing Deal With Jazz Pharmaceuticals | ACAD | https://www.nasdaq.com/articles/zymeworks-zyme-up-on-licensing-deal-with-jazz-pharmaceuticals | nan | nan | Shares of Zymeworks ZYME were up 15.86% on Oct 19 after the company announced a licensing deal with Jazz Pharmaceuticals JAZZ for the former’s HER-2 targeted bispecific antibody, zanidatamab.
However, Zymeworks’ stock has declined 60.3% in the year-to-date period compared with the industry’s fall of 24.1%.
Image Source: Zacks Investment Research
Pursuant to the deal, Jazz will acquire the rights to develop and commercialize zanidatamab across all its indications in all territories, except in Asia Pacific territories, where the drug is already licensed to BeiGene BGNE.
Zymeworks entered into a strategic collaboration with BeiGene in 2018, where the latter acquired the exclusive rights to develop and commercialize Zymeworks’ bispecific candidates zanidatamab and its second product candidate zanidatamab zovodotin (ZW49) in Asia (excluding Japan), Australia and New Zealand.
Under the terms of the Zymeworks-Jazz agreement, Jazz will make an upfront payment of $50 million to Zymeworks, once the necessary regulatory bodies approve the transaction.
Additionally, after Zymeworks reports the data from the pivotal HERIZON-BTC- study evaluating zanidatamab as a monotherapy in patients with previously treated advanced or metastatic HER2-amplified biliary tract cancer (BTC), Jazz can choose to continue with the collaboration. In case Jazz decides to continue, it will have to pay an additional $325 million to Zymeworks for the same.
Zymeworks will also be eligible to receive regulatory milestone payments of up to $525 million and up to $862.5 million on achievement of certain commercial milestones. Jazz will also be paying Zymeworks tiered royalties between 10% to 20% of the net sales if and when zanidatamab is approved and marketed. Thus, the deal has the potential to reach a total valuation of $1.76 billion, which impressed investors.
Investors must note that apart from zanidatamab, Zymeworks is also developing zanidatamab zovodotin (ZW49) for a range of HER-2 expressing cancers. The candidate is currently undergoing a phase I study to establish its safety and antitumor activity in humans.
Zymeworks Inc. Price
Zymeworks Inc. price | Zymeworks Inc. Quote
Zacks Rank and A Key Pick
Zymeworks currently has a Zacks Rank #3 (Hold).
A better-ranked stock worth considering in the same sector is ACADIA Pharmaceuticals ACAD, carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Acadia’s loss per share estimates for 2022 have narrowed down from $1.30 to $1.29 in the past 30 days. The loss per share for 2023 has also narrowed down from 67 cents to 60 cents in the same time frame.
Earnings of Acadia beat estimates in two of the trailing four quarters, while missing the same on the remaining two occasions. The average negative earnings surprise for ACAD is 6.83%.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Jazz Pharmaceuticals PLC (JAZZ): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
BeiGene, Ltd. (BGNE): Free Stock Analysis Report
Zymeworks Inc. (ZYME): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A better-ranked stock worth considering in the same sector is ACADIA Pharmaceuticals ACAD, carrying a Zacks Rank #2 (Buy). Acadia’s loss per share estimates for 2022 have narrowed down from $1.30 to $1.29 in the past 30 days. Earnings of Acadia beat estimates in two of the trailing four quarters, while missing the same on the remaining two occasions. | ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report A better-ranked stock worth considering in the same sector is ACADIA Pharmaceuticals ACAD, carrying a Zacks Rank #2 (Buy). Acadia’s loss per share estimates for 2022 have narrowed down from $1.30 to $1.29 in the past 30 days. | A better-ranked stock worth considering in the same sector is ACADIA Pharmaceuticals ACAD, carrying a Zacks Rank #2 (Buy). Acadia’s loss per share estimates for 2022 have narrowed down from $1.30 to $1.29 in the past 30 days. Earnings of Acadia beat estimates in two of the trailing four quarters, while missing the same on the remaining two occasions. | ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report A better-ranked stock worth considering in the same sector is ACADIA Pharmaceuticals ACAD, carrying a Zacks Rank #2 (Buy). Acadia’s loss per share estimates for 2022 have narrowed down from $1.30 to $1.29 in the past 30 days. |
35687.0 | 2022-10-19 00:00:00 UTC | AVEO Pharmaceuticals (AVEO) Inks Deal to be Acquired by LG Chem | ACAD | https://www.nasdaq.com/articles/aveo-pharmaceuticals-aveo-inks-deal-to-be-acquired-by-lg-chem | nan | nan | Shares of AVEO Pharmaceuticals AVEO surged 42.4% on Oct 18 after the company announced that it has entered into an agreement to be acquired by the Korean company LG Chem.
AVEO stock has surged 218.2% in the year-to-date period, compared to the industry’s decline of 25.9%.
Image Source: Zacks Investment Research
Pursuant to the agreement, LG Chem will acquire all outstanding shares of AVEO for $15.00 per share, or an approximate amount of $566 million, on a fully diluted basis, in an all-cash transaction. The offer price of $15 per share represents a premium of 43% of AVEO’s closing price on Oct 17.
The transaction has been approved by the board members of the companies and is anticipated to close early in 2023, subject to c | AVEO stock has surged 218.2% in the year-to-date period, compared to the industry’s decline of 25.9%. Image Source: Zacks Investment Research Pursuant to the agreement, LG Chem will acquire all outstanding shares of AVEO for $15.00 per share, or an approximate amount of $566 million, on a fully diluted basis, in an all-cash transaction. The transaction has been approved by the board members of the companies and is anticipated to close early in 2023, subject to c | Shares of AVEO Pharmaceuticals AVEO surged 42.4% on Oct 18 after the company announced that it has entered into an agreement to be acquired by the Korean company LG Chem. Image Source: Zacks Investment Research Pursuant to the agreement, LG Chem will acquire all outstanding shares of AVEO for $15.00 per share, or an approximate amount of $566 million, on a fully diluted basis, in an all-cash transaction. The offer price of $15 per share represents a premium of 43% of AVEO’s closing price on Oct 17. | Shares of AVEO Pharmaceuticals AVEO surged 42.4% on Oct 18 after the company announced that it has entered into an agreement to be acquired by the Korean company LG Chem. Image Source: Zacks Investment Research Pursuant to the agreement, LG Chem will acquire all outstanding shares of AVEO for $15.00 per share, or an approximate amount of $566 million, on a fully diluted basis, in an all-cash transaction. The offer price of $15 per share represents a premium of 43% of AVEO’s closing price on Oct 17. | Shares of AVEO Pharmaceuticals AVEO surged 42.4% on Oct 18 after the company announced that it has entered into an agreement to be acquired by the Korean company LG Chem. AVEO stock has surged 218.2% in the year-to-date period, compared to the industry’s decline of 25.9%. Image Source: Zacks Investment Research Pursuant to the agreement, LG Chem will acquire all outstanding shares of AVEO for $15.00 per share, or an approximate amount of $566 million, on a fully diluted basis, in an all-cash transaction. |
35688.0 | 2022-10-18 00:00:00 UTC | Milestone's (MIST) Tachycardia Study Data Fail to Impress Investors | ACAD | https://www.nasdaq.com/articles/milestones-mist-tachycardia-study-data-fail-to-impress-investors | nan | nan | Shares of Milestone Therapeutics MIST fell 21.67% during market hours on Oct 17, after rising 41% in premarket, post the company’s announcement of top-line results from a late-stage study evaluating its lead candidate, etripamil.
Milestone’s shares have returned 1.5% in the year-to-date period against the industry’s decline of 25.9%:
Image Source: Zacks Investment Research
Etripamil is a potent short-acting calcium channel blocker designed by Milestone. The company is developing it as a rapid-onset nasal spray to treat paroxysmal supraventricular tachycardia (PSVT), atrial fibrillation and other cardiovascular indications.
The phase III RAPID study evaluated the safety and efficacy of etripamil in patients with PSVT, a type of abnormal heart rhythm or arrhythmia.
However, RAPID is the second part of a study, the first part of which, NODE-301, failed to achieve its primary endpoint, as reported by Milestone Therapeutics in March 2020.
With guidance from the FDA in July 2020, Milestone altered the size and design of the NODE-301 study, which was later renamed RAPID.
The multi-center, double-blind, placebo-controlled phase III RAPID study achieved its primary endpoint of converting sinus rhythm within 30 minutes of the subject’s self-administering etripamil.
The candidates taking etripamil exhibited a statistically and clinically significant difference in time to PSVT conversion against a placebo. Among the subjects, 64.3% that were administered with etripamil converted within 30 minutes compared with 31.2% who took a placebo. Additionally, the median time for conversion for patients who took etripamil was three times faster than the subjects on placebo.
The safety and tolerability data from the RAPID study was consistent with the data observed in the prior clinical studies evaluating the potential of self-administering etripamil in PSVT patients.
The RAPID study reported a significantly better hazard ratio (HR) of 2.62 compared to the HR of 1.87 in the NODE-301 study.
Pooled data from the NODE-301 and RAPID study demonstrated that the etripamil treatment provided a statistically significant reduction in the additional use of medical interventions and visits to the emergency department for the patients.
Thus, the positive data from the RAPID study and the data from the previously completed NODE-301 study are expected to fulfill the efficacy requirement for Milestone to submit a new drug application (NDA) for etripamil in PSVT patients. The company intends to submit an NDA for etripamil by the middle of 2023.
However, Milestone’s data from the late-stage RAPID study for PSVT did not impress the investors, thereby causing a fall in the company’s share prices.
Milestone Pharmaceuticals Inc. Price
Milestone Pharmaceuticals Inc. price | Milestone Pharmaceuticals Inc. Quote
Zacks Rank and Stocks to Consider
Milestone Therapeutics currently holds a Zacks Rank #2 (Buy).
Some similar-ranked stocks worth considering in the same sector include ACADIA Pharmaceuticals ACAD, BioMarin Pharmaceuticals BMRN, and Pliant Therapeutics PLRX, each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Acadia’s loss per share estimates for 2022 have narrowed down from $1.30 to $1.29 in the past 30 days. The loss per share for 2023 has also narrowed down from 67 cents to 60 cents in the same time frame.
Earnings of Acadia beat estimates in two of the trailing four quarters, while missing the same on the remaining two occasions. The average negative earnings surprise for ACAD is 6.83%.
BioMarin’s earnings per share estimates for 2022 are down by a cent at $1.98 in the past 30 days. The same for 2023 has improved by a cent from $3.80 to $3.81 in the same time frame.
Earnings of BioMarin beat estimates in all of the trailing four quarters. The average earnings surprise for BMRN is 98.90%.
Pliant’s loss estimates for 2022 have remained steady at $3.01 over the past 30 days. The earnings estimate for 2023 also remained steady at $3.26 per share in the same time frame.
PLRX earnings were in-line in one of the trailing four quarters, beat the same in one, and missed the same in the remaining two occasions. The average earnings surprise for Pliant is 0.90%.
Just Released: Zacks Unveils the Top 5 EV Stocks for 2022
For several months now, electric vehicles have been disrupting the $82 billion automotive industry. And that disruption is only getting bigger thanks to sky-high gas prices. Even titans in the financial industry including George Soros, Jeff Bezos, and Ray Dalio have invested in this unstoppable wave. You don't want to be sitting on your hands while EV stocks break out and climb to new highs. In a new free report, Zacks is revealing the top 5 EV stocks for investors. Next year, don't look back on today wishing you had taken advantage of this opportunity.
>>Send me my free report revealing the top 5 EV stocks
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Milestone Pharmaceuticals Inc. (MIST): Free Stock Analysis Report
Pliant Therapeutics, Inc. (PLRX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some similar-ranked stocks worth considering in the same sector include ACADIA Pharmaceuticals ACAD, BioMarin Pharmaceuticals BMRN, and Pliant Therapeutics PLRX, each carrying a Zacks Rank #2 (Buy). Acadia’s loss per share estimates for 2022 have narrowed down from $1.30 to $1.29 in the past 30 days. Earnings of Acadia beat estimates in two of the trailing four quarters, while missing the same on the remaining two occasions. | Some similar-ranked stocks worth considering in the same sector include ACADIA Pharmaceuticals ACAD, BioMarin Pharmaceuticals BMRN, and Pliant Therapeutics PLRX, each carrying a Zacks Rank #2 (Buy). Acadia’s loss per share estimates for 2022 have narrowed down from $1.30 to $1.29 in the past 30 days. Earnings of Acadia beat estimates in two of the trailing four quarters, while missing the same on the remaining two occasions. | Some similar-ranked stocks worth considering in the same sector include ACADIA Pharmaceuticals ACAD, BioMarin Pharmaceuticals BMRN, and Pliant Therapeutics PLRX, each carrying a Zacks Rank #2 (Buy). Acadia’s loss per share estimates for 2022 have narrowed down from $1.30 to $1.29 in the past 30 days. Earnings of Acadia beat estimates in two of the trailing four quarters, while missing the same on the remaining two occasions. | Some similar-ranked stocks worth considering in the same sector include ACADIA Pharmaceuticals ACAD, BioMarin Pharmaceuticals BMRN, and Pliant Therapeutics PLRX, each carrying a Zacks Rank #2 (Buy). Acadia’s loss per share estimates for 2022 have narrowed down from $1.30 to $1.29 in the past 30 days. Earnings of Acadia beat estimates in two of the trailing four quarters, while missing the same on the remaining two occasions. |
35689.0 | 2022-10-18 00:00:00 UTC | Gilead's (GILD) Yescarta Gets EC Nod for New Cancer Indication | ACAD | https://www.nasdaq.com/articles/gileads-gild-yescarta-gets-ec-nod-for-new-cancer-indication | nan | nan | Gilead Sciences, Inc.’s GILD wholly owned subsidiary, Kite, announced that the European Commission (“EC”) has approved its chimeric antigen receptor (CAR) T-cell therapy, Yescarta (axicabtagene ciloleucel) for the treatment of diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) in adult patients who relapse within 12 months from the completion of or are refractory to first-line chemoimmunotherapy.
Following the EC nod, Yescarta became the first CAR T-cell therapy to be approved for patients in Europe who do not respond to first-line treatment.
The latest EC nod was based on data from the pivotal phase III ZUMA-7 study, which evaluated Yescarta versus standard of care (“SOC”) in the above-mentioned patient popu | Gilead Sciences, Inc.’s GILD wholly owned subsidiary, Kite, announced that the European Commission (“EC”) has approved its chimeric antigen receptor (CAR) T-cell therapy, Yescarta (axicabtagene ciloleucel) for the treatment of diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) in adult patients who relapse within 12 months from the completion of or are refractory to first-line chemoimmunotherapy. Following the EC nod, Yescarta became the first CAR T-cell therapy to be approved for patients in Europe who do not respond to first-line treatment. The latest EC nod was based on data from the pivotal phase III ZUMA-7 study, which evaluated Yescarta versus standard of care (“SOC”) in the above-mentioned patient popu | Gilead Sciences, Inc.’s GILD wholly owned subsidiary, Kite, announced that the European Commission (“EC”) has approved its chimeric antigen receptor (CAR) T-cell therapy, Yescarta (axicabtagene ciloleucel) for the treatment of diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) in adult patients who relapse within 12 months from the completion of or are refractory to first-line chemoimmunotherapy. Following the EC nod, Yescarta became the first CAR T-cell therapy to be approved for patients in Europe who do not respond to first-line treatment. The latest EC nod was based on data from the pivotal phase III ZUMA-7 study, which evaluated Yescarta versus standard of care (“SOC”) in the above-mentioned patient popu | Gilead Sciences, Inc.’s GILD wholly owned subsidiary, Kite, announced that the European Commission (“EC”) has approved its chimeric antigen receptor (CAR) T-cell therapy, Yescarta (axicabtagene ciloleucel) for the treatment of diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) in adult patients who relapse within 12 months from the completion of or are refractory to first-line chemoimmunotherapy. Following the EC nod, Yescarta became the first CAR T-cell therapy to be approved for patients in Europe who do not respond to first-line treatment. The latest EC nod was based on data from the pivotal phase III ZUMA-7 study, which evaluated Yescarta versus standard of care (“SOC”) in the above-mentioned patient popu | Gilead Sciences, Inc.’s GILD wholly owned subsidiary, Kite, announced that the European Commission (“EC”) has approved its chimeric antigen receptor (CAR) T-cell therapy, Yescarta (axicabtagene ciloleucel) for the treatment of diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) in adult patients who relapse within 12 months from the completion of or are refractory to first-line chemoimmunotherapy. Following the EC nod, Yescarta became the first CAR T-cell therapy to be approved for patients in Europe who do not respond to first-line treatment. The latest EC nod was based on data from the pivotal phase III ZUMA-7 study, which evaluated Yescarta versus standard of care (“SOC”) in the above-mentioned patient popu |
35690.0 | 2022-10-17 00:00:00 UTC | NeuBase (NBSE) Up on Restructuring Plan, Set to Lower Workforce | ACAD | https://www.nasdaq.com/articles/neubase-nbse-up-on-restructuring-plan-set-to-lower-workforce | nan | nan | NeuBase Therapeutics, Inc. NBSE announced that it is planning to enter a restructuring process focused on the advancement of its pipeline in gene editing.
As a part of this strategic review by its board of directors and management team, the company is looking to streamline its organization, reduce operating expenses, preserve capital and maximize shareholder value.
The company will shelve preclinical activities for its Myotonic Dystrophy Type 1 (DM1), Huntington’s Disease (HD), and KRAS programs and hold plans to file an investigational new drug application to the FDA for DM1. NBSE expects to incur total expenses related to the restructuring process of around $0.5 million while recording a significant portion of these charges in the fourth quarter of the calendar year 2022.
The company is planning to enter into partnerships with other companies for the advancement of its DM1, HD and KRAS (G12D & G12V) programs.
NeuBase is also looking to maximize its cash resource with robust cost-containment measures. The company is planning to reduce its existing workforce by approximately 60%, which is expected to extend its cash runway into the second quarter of the calendar year 2024.
Shares of NeuBase were up 11.8% in after-hours trading on Friday following the announcement of the news. The stock has plunged 90.4% so far this year compared with the industry’s decline of 26.8%.
Image Source: Zacks Investment Research
NeuBase had cash and cash equivalents worth $29.8 million as of Jun 30, 2022.
NeuBase is engaged in developing a new class of precision genetic medicines that drug the genome, which are built on its proprietary platform called PATrOL.
Strategic reviews and restructurings are often considered by companies as cost-cutting initiatives. However, it remains to be seen how this review of strategic alternatives helps NeuBase to maximize its shareholders’ value while focusing on its pipeline.
Zacks Rank & Other Stocks to Consider
NeuBase currently carries a Zacks Rank #2 (Buy). Other stocks worth considering in the biotech sector are Acadia Pharmaceuticals Inc. ACAD, ORIC Pharmaceuticals, Inc. ORIC and Aeglea BioTherapeutics, Inc. AGLE, all carrying the same Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Loss per share estimates for Acadia narrowed 0.8% for 2022 and 11.7% for 2023 in the past 60 days.
Earnings of Acadia surpassed estimates in two of the trailing four quarters and missed on the remaining two occasions. ACAD delivered an earnings surprise of 6.83%, on average.
Loss per share estimates for ORIC Pharmaceuticals narrowed 5.9% for 2022 and 7.3% for 2023 in the past 60 days.
Earnings of ORIC Pharmaceuticals surpassed estimates in three of the trailing four quarters and missed on the other occasion. ORIC delivered an earnings surprise of 8.85%, on average.
Loss per share estimates for Aeglea BioTherapeutics narrowed 3.5% for 2022 and 1.2% for 2023 in the past 60 days.
Earnings of Aeglea BioTherapeutics surpassed estimates in one of the trailing four quarters and missed on the other three occasions. AGLE delivered a negative earnings surprise of 3.34%, on average.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Aeglea BioTherapeutics, Inc. (AGLE): Free Stock Analysis Report
NeuBase Therapeutics, Inc. (NBSE): Free Stock Analysis Report
Oric Pharmaceuticals, Inc. (ORIC): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other stocks worth considering in the biotech sector are Acadia Pharmaceuticals Inc. ACAD, ORIC Pharmaceuticals, Inc. ORIC and Aeglea BioTherapeutics, Inc. AGLE, all carrying the same Zacks Rank #2 at present. Loss per share estimates for Acadia narrowed 0.8% for 2022 and 11.7% for 2023 in the past 60 days. Earnings of Acadia surpassed estimates in two of the trailing four quarters and missed on the remaining two occasions. | Other stocks worth considering in the biotech sector are Acadia Pharmaceuticals Inc. ACAD, ORIC Pharmaceuticals, Inc. ORIC and Aeglea BioTherapeutics, Inc. AGLE, all carrying the same Zacks Rank #2 at present. ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Loss per share estimates for Acadia narrowed 0.8% for 2022 and 11.7% for 2023 in the past 60 days. | Other stocks worth considering in the biotech sector are Acadia Pharmaceuticals Inc. ACAD, ORIC Pharmaceuticals, Inc. ORIC and Aeglea BioTherapeutics, Inc. AGLE, all carrying the same Zacks Rank #2 at present. Loss per share estimates for Acadia narrowed 0.8% for 2022 and 11.7% for 2023 in the past 60 days. Earnings of Acadia surpassed estimates in two of the trailing four quarters and missed on the remaining two occasions. | Other stocks worth considering in the biotech sector are Acadia Pharmaceuticals Inc. ACAD, ORIC Pharmaceuticals, Inc. ORIC and Aeglea BioTherapeutics, Inc. AGLE, all carrying the same Zacks Rank #2 at present. ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Loss per share estimates for Acadia narrowed 0.8% for 2022 and 11.7% for 2023 in the past 60 days. |
35691.0 | 2022-10-14 00:00:00 UTC | GSK's RSV Vaccine Candidate Shows High Efficacy in Older Adults | ACAD | https://www.nasdaq.com/articles/gsks-rsv-vaccine-candidate-shows-high-efficacy-in-older-adults | nan | nan | GSK plc GSK recently announced that positive data from the pivotal phase III study — AReSVi 006 — evaluating its respiratory syncytial virus (RSV) vaccine candidate for adults aged 60 years and above were presented at the IDWeek 2022.
In the study, the RSV vaccine candidate showed an overall vaccine efficacy of 82.6% against RSV lower respiratory tract disease (RSV-LRTD), thereby meeting the study’s primary endpoint.
The vaccine also demonstrated consistent high efficacy against LRTD in severe disease (94.1%). In adults aged 70-79 years vaccine efficacy was 93.8% while in adults with underlying comorbidities such as cardiorespiratory and endocrinometabolic conditions, vaccine efficacy was 94.6%. The vaccine’s efficacy against LRTD was also consistent across both RSV-A and RSV-B subtypes.
Treatment with the vaccine was generally well tolerated with a favorable safety profile.
GSK plans to file regulatory applications seeking approval of its RSV vaccine candidate for older adults in the second half of 2022.
Shares of GSK have plunged 44.4% in the year-to-date period compared with the industry’s decrease of 27.3.
Image Source: Zacks Investment Research
Currently, there are no FDA-approved vaccines against RSV infections — a disease that leads to more than 420,000 hospitalizations and 29,000 deaths worldwide each year.
A potential approval for the RSV vaccine for older adults will boost GSK’s vaccine portfolio as it may become the first FDA-approved vaccine for this patient population. However, GSK is likely to face competition from other companies that are developing their respective vaccine candidates for RSV.
Pfizer PFE is also developing its bivalent RSV vaccine candidate, RSVpreF, in a phase III study to prevent lower respiratory tract illness caused by RSV in individuals aged 60 years and above.
Pfizer plans to file a biologics license application seeking approval of the vaccine from the FDA in fall 2022.
Pfizer is also conducting a phase III study on RSVpreF in healthy pregnant women to help protect their babies from RSV after birth.
Zacks Rank & Stocks to Consider
GSK currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector are Acadia Pharmaceuticals Inc. ACAD and ORIC Pharmaceuticals, Inc. ORIC, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Loss per share estimates for Acadia narrowed 0.8% for 2022 and 11.7% for 2023 in the past 60 days.
Earnings of Acadia surpassed estimates in two of the trailing four quarters and missed on the remaining two occasions. ACAD delivered an earnings surprise of 6.83%, on average.
Loss per share estimates for ORIC Pharmaceuticals narrowed 5.9% for 2022 and 7.3% for 2023 in the past 60 days.
Earnings of ORIC Pharmaceuticals surpassed estimates in three of the trailing four quarters and missed on the other occasion. ORIC delivered an earnings surprise of 8.85%, on average.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
GSK PLC Sponsored ADR (GSK): Free Stock Analysis Report
Pfizer Inc. (PFE): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Oric Pharmaceuticals, Inc. (ORIC): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the biotech sector are Acadia Pharmaceuticals Inc. ACAD and ORIC Pharmaceuticals, Inc. ORIC, both carrying a Zacks Rank #2 (Buy) at present. Loss per share estimates for Acadia narrowed 0.8% for 2022 and 11.7% for 2023 in the past 60 days. Earnings of Acadia surpassed estimates in two of the trailing four quarters and missed on the remaining two occasions. | Some better-ranked stocks in the biotech sector are Acadia Pharmaceuticals Inc. ACAD and ORIC Pharmaceuticals, Inc. ORIC, both carrying a Zacks Rank #2 (Buy) at present. Loss per share estimates for Acadia narrowed 0.8% for 2022 and 11.7% for 2023 in the past 60 days. Earnings of Acadia surpassed estimates in two of the trailing four quarters and missed on the remaining two occasions. | Some better-ranked stocks in the biotech sector are Acadia Pharmaceuticals Inc. ACAD and ORIC Pharmaceuticals, Inc. ORIC, both carrying a Zacks Rank #2 (Buy) at present. Loss per share estimates for Acadia narrowed 0.8% for 2022 and 11.7% for 2023 in the past 60 days. Earnings of Acadia surpassed estimates in two of the trailing four quarters and missed on the remaining two occasions. | ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Some better-ranked stocks in the biotech sector are Acadia Pharmaceuticals Inc. ACAD and ORIC Pharmaceuticals, Inc. ORIC, both carrying a Zacks Rank #2 (Buy) at present. Loss per share estimates for Acadia narrowed 0.8% for 2022 and 11.7% for 2023 in the past 60 days. |
35692.0 | 2022-10-13 00:00:00 UTC | Regeneron's (REGN) Eylea sBLA Gets FDA's Priority Review | ACAD | https://www.nasdaq.com/articles/regenerons-regn-eylea-sbla-gets-fdas-priority-review | nan | nan | Regeneron Pharmaceuticals, Inc. REGN recently announced that its supplemental biologics license application (sBLA) for the ophthalmology drug, Eylea (aflibercept), has been accepted by the FDA for priority review. Eylea is a VEGF inhibitor formulated as an injection for the eye.
The sBLA is seeking label expansion of Eylea for the treatment of retinopathy of prematurity (ROP) in preterm infants.
With the FDA granting a priority review to the sBLA, a decision from the regulatory body is expected on Feb 11, 2023.
The latest sBLA was based on data from two phase III studies – FIREFLEYE and BUTTERFLEYE – which evaluated Eylea (0.4 mg) compared to laser photocoagulation (laser) in infants with ROP, a leading cause of childhood blindness in the world.
Data from both studies showed that 80% of infants treated with Eylea achieved an absence of both active ROP and unfavorable structural outcomes at 52 weeks of age.
However, both studies did not meet the primary endpoint of non-inferiority as laser demonstrated comparable levels of efficacy, which was higher than what has been historically observed in similar ROP studies.
While Regeneron is the lead sponsor of the BUTTERFLEYE study, Bayer AG BAYRY is the lead sponsor of the FIREFLEYE study.
The FDA granted orphan drug designation to Eylea for the treatment of ROP in July 2019.
Shares of Regeneron have risen 15.3% so far this year against the industry’s decline of 27.8%.
Image Source: Zacks Investment Research
Regeneron is jointly developing Eylea with Bayer.
While Regeneron records net product sales of Eylea in the United States, Bayer records net product sales of the drug outside the United States. Regeneron records its share of profits/losses in connection with sales of Eylea outside the United States.
Eylea injection (2mg) is approved for treating patients with neovascular (Wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.
Sales of Eylea in the United States came in at $3.1 billion in the first six months of 2022. Successful label expansion into additional indications should boost sales further in the days ahead.
However, stiff competition from new treatment options remains an overhang.
Zacks Rank & Other Stocks to Consider
Regeneron currently carries a Zacks Rank #2 (Buy). Other stocks worth considering in the biotech sector are Acadia Pharmaceuticals Inc. ACAD and ORIC Pharmaceuticals, Inc. ORIC, both carrying the same Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Loss per share estimates for Acadia have narrowed 0.8% for 2022 and 11.7% for 2023 in the past 60 days.
Earnings of Acadia surpassed estimates in two of the trailing four quarters and missed on the remaining two occasions. ACAD delivered an earnings surprise of 6.83%, on average.
Loss per share estimates for ORIC Pharmaceuticals have narrowed 5.9% for 2022 and 7.3% for 2023 in the past 60 days.
Earnings of ORIC Pharmaceuticals surpassed estimates in three of the trailing four quarters and missed on the other occasion. ORIC delivered an earnings surprise of 8.85%, on average.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report
Bayer Aktiengesellschaft (BAYRY): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Oric Pharmaceuticals, Inc. (ORIC): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other stocks worth considering in the biotech sector are Acadia Pharmaceuticals Inc. ACAD and ORIC Pharmaceuticals, Inc. ORIC, both carrying the same Zacks Rank #2 at present. Loss per share estimates for Acadia have narrowed 0.8% for 2022 and 11.7% for 2023 in the past 60 days. Earnings of Acadia surpassed estimates in two of the trailing four quarters and missed on the remaining two occasions. | ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Other stocks worth considering in the biotech sector are Acadia Pharmaceuticals Inc. ACAD and ORIC Pharmaceuticals, Inc. ORIC, both carrying the same Zacks Rank #2 at present. Loss per share estimates for Acadia have narrowed 0.8% for 2022 and 11.7% for 2023 in the past 60 days. | Other stocks worth considering in the biotech sector are Acadia Pharmaceuticals Inc. ACAD and ORIC Pharmaceuticals, Inc. ORIC, both carrying the same Zacks Rank #2 at present. Loss per share estimates for Acadia have narrowed 0.8% for 2022 and 11.7% for 2023 in the past 60 days. Earnings of Acadia surpassed estimates in two of the trailing four quarters and missed on the remaining two occasions. | Other stocks worth considering in the biotech sector are Acadia Pharmaceuticals Inc. ACAD and ORIC Pharmaceuticals, Inc. ORIC, both carrying the same Zacks Rank #2 at present. ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Loss per share estimates for Acadia have narrowed 0.8% for 2022 and 11.7% for 2023 in the past 60 days. |
35693.0 | 2022-10-13 00:00:00 UTC | BioMarin (BMRN) Hemophilia Gene Therapy BLA Gets FDA Acceptance | ACAD | https://www.nasdaq.com/articles/biomarin-bmrn-hemophilia-gene-therapy-bla-gets-fda-acceptance | nan | nan | BioMarin Pharmaceutical Inc. BMRN recently announced that the FDA has accepted the resubmitted biologics license application (BLA) for its investigational AAV gene therapy, valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.
A decision from the regulatory body is expected on Mar 31, 2023. Currently, the FDA is not planning to hold an advisory committee meeting.
If approved, valoctocogene roxaparvovec would become the first gene therapy for treating severe hemophilia A in the United States.
Last month, BMRN resubmitted the BLA for valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.
The resubmitted BLA was based on two-year outcomes data from the phase III study, GENEr8-1, evaluating valoctocogene roxaparvovec in patients with hemophilia A. Data from the GENEr8-1 study showed that treatment with valoctocogene roxaparvovec led to a stable and durable bleed control. Participants, who were treated with the gene therapy, achieved significantly reduced annualized bleeding rate and the mean annualized factor VIII (a blood clotting protein) infusion rate. Treatment with the gene therapy also demonstrated superiority to the current standard of care, Factor VIII prophylactic therapy.
BioMarin had submitted a BLA in 2019 for valoctocogene roxaparvovec for hemophilia A. However, the FDA issued a complete response letter to the BLA ahead of the PDUFA date in August 2020 as the FDA was not satisfied with the available data and asked for two-year follow-up data on annualized bleed rates from the ongoing phase III study to provide additional evidence of a durable effect.
Shares of BioMarin have risen 0.6% in the year-to-date period against the industry’s 27.8% decline.
Image Source: Zacks Investment Research
A one-time infusion, valoctocogene roxaparvovec is designed to enable the body to produce Factor VIII on its own. Moreover, the patients are also not required to be administered continued hemophilia prophylaxis, which is required in other marketed therapies.
In August 2022, the European Commission granted conditional approval to valoctocogene roxaparvovec for treating adult patients with severe hemophilia A. The therapy is being marketed by BioMarin under the trade name Roctavian.
Zacks Rank & Other Stocks to Consider
BioMarin currently carries a Zacks Rank #2 (Buy). Other stocks worth considering in the biotech sector are Acadia Pharmaceuticals Inc. ACAD, ORIC Pharmaceuticals, Inc. ORIC and Atara Biotherapeutics, Inc. ATRA, all carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Loss per share estimates for Acadia have narrowed 0.8% for 2022 and 11.7% for 2023 in the past 60 days.
Earnings of Acadia surpassed estimates in two of the trailing four quarters and missed on the remaining two occasions. ACAD delivered an earnings surprise of 6.83%, on average.
Loss per share estimates for ORIC Pharmaceuticals have narrowed 5.9% for 2022 and 7.3% for 2023 in the past 60 days.
Earnings of ORIC Pharmaceuticals surpassed estimates in three of the trailing four quarters and missed on the other occasion. ORIC delivered an earnings surprise of 8.85%, on average.
Loss per share estimates for Atara Biotherapeutics have narrowed 21.3% for 2022 and 8.3% for 2023 in the past 60 days.
Earnings of Atara Biotherapeutics surpassed estimates in three of the trailing four quarters and missed on the other occasion. ATRA delivered an earnings surprise of 4.83%, on average.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Atara Biotherapeutics, Inc. (ATRA): Free Stock Analysis Report
Oric Pharmaceuticals, Inc. (ORIC): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other stocks worth considering in the biotech sector are Acadia Pharmaceuticals Inc. ACAD, ORIC Pharmaceuticals, Inc. ORIC and Atara Biotherapeutics, Inc. ATRA, all carrying a Zacks Rank #2 at present. Loss per share estimates for Acadia have narrowed 0.8% for 2022 and 11.7% for 2023 in the past 60 days. Earnings of Acadia surpassed estimates in two of the trailing four quarters and missed on the remaining two occasions. | Other stocks worth considering in the biotech sector are Acadia Pharmaceuticals Inc. ACAD, ORIC Pharmaceuticals, Inc. ORIC and Atara Biotherapeutics, Inc. ATRA, all carrying a Zacks Rank #2 at present. Loss per share estimates for Acadia have narrowed 0.8% for 2022 and 11.7% for 2023 in the past 60 days. Earnings of Acadia surpassed estimates in two of the trailing four quarters and missed on the remaining two occasions. | Other stocks worth considering in the biotech sector are Acadia Pharmaceuticals Inc. ACAD, ORIC Pharmaceuticals, Inc. ORIC and Atara Biotherapeutics, Inc. ATRA, all carrying a Zacks Rank #2 at present. Loss per share estimates for Acadia have narrowed 0.8% for 2022 and 11.7% for 2023 in the past 60 days. Earnings of Acadia surpassed estimates in two of the trailing four quarters and missed on the remaining two occasions. | Other stocks worth considering in the biotech sector are Acadia Pharmaceuticals Inc. ACAD, ORIC Pharmaceuticals, Inc. ORIC and Atara Biotherapeutics, Inc. ATRA, all carrying a Zacks Rank #2 at present. Loss per share estimates for Acadia have narrowed 0.8% for 2022 and 11.7% for 2023 in the past 60 days. Earnings of Acadia surpassed estimates in two of the trailing four quarters and missed on the remaining two occasions. |
35694.0 | 2022-10-13 00:00:00 UTC | VBI Vaccine (VBIV) Inks Deal With Agenus for Brain Cancer Study | ACAD | https://www.nasdaq.com/articles/vbi-vaccine-vbiv-inks-deal-with-agenus-for-brain-cancer-study | nan | nan | VBI Vaccines VBIV stock increased almost 7% on Oct 12 after the company announced a collaboration with Agenus Inc AGEN to evaluate its cancer vaccine immunotherapeutic, VBI-1901 in combination with Agenus’ anti-PD-1 therapy balstilimab for primary glioblastoma (GBM)
Shares of VBI Vaccines have declined 70.7% in the year-to-date period compared with the industry’s fall of 26.9%.
Image Source: Zacks Investment Research
Shares of Agenus have declined 21.1% compared with the industry’s fall of 26.9% this year.
Image Source: Zacks Investment Research
GBM is among the most common and aggressive malignant primary brain tumors in humans but it still has limited treatment options.
The study, which is a part of INSIGhT adaptive platform, is expected to evaluate the efficacy of VBI-1901 in combination with balstilimab in frontline GBM patients following primary tumor resection and radiotherapy. The combination study is expected to start by the end of 2022.
As part of the agreement, VBI will be responsible for the operational execution of the combination study, while Agenus will focus on drug supply and provide scientific support.
VBI Vaccines’ VBI-1901 is a cancer vaccine immunotherapeutic used to treat multiple solid tumors, including GBM. The candidate is currently being evaluated in an ongoing phase II study in recurrent GBM patients. In the latest data reported from the study, once recurrent GBM patient remains on protocol beyond two and a half years with a sustained 93% tumor reduction relative to baseline.
Based on the latest data, VBI Vaccines also intends to initiate a randomized controlled extension study evaluating VBI-1901 in recurrent GBM patients in the fourth quarter of 2022.
Agenus’ balstilimab is a programmed death receptor-1 (PD-1) monoclonal antibody that blocks the PD-1 protein, an important barrier that prevents T-cells from attacking cancer. Agenus had submitted a biologics license application (BLA) for balstilimab as a monotherapy for treating cervical cancer. However, the company decided to withdraw the BLA for balstilimab in October 2021, following the FDA approval for Merck’s Keytruda (pembrolizumab) for the same indication. Balstilimab is currently being studied in combination with Agenus’ other pipeline candidates for treating other cancer indications.
VBI Vaccines, Inc. Price
VBI Vaccines, Inc. price | VBI Vaccines, Inc. Quote
Agenus Inc. Price
Agenus Inc. price | Agenus Inc. Quote
Zacks Rank and Stocks to Consider
VBI Vaccines currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks in the same sector include Immunocore IMCR, carrying a Zacks Rank #1 (Strong Buy), Acadia Pharmaceuticals ACAD, carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Immunocore’s loss per share estimates for 2022 narrowed down from $1.48 to $1.46 in the past 30 days. The same for 2023 has widened from $1.63 to $1.65 in the same time frame.
Earnings of Immunocore missed estimates in three of the trailing four quarters, while beating the same in the reaming occasion. The average earnings surprise for IMCR is 33.28%.
Acadia’s loss per share estimates for 2022 have narrowed from $1.30 to $1.29 in the past 30 days. The loss per share for 2023 has narrowed from 67 cents to 60 cents in the same time frame.
Earnings of Acadia beat estimates in two of the trailing four quarters, while missing the same on the remaining two occasions. The average negative earnings surprise for STSA is 6.83%.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Agenus Inc. (AGEN): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
VBI Vaccines, Inc. (VBIV): Free Stock Analysis Report
Immunocore Holdings PLC Sponsored ADR (IMCR): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the same sector include Immunocore IMCR, carrying a Zacks Rank #1 (Strong Buy), Acadia Pharmaceuticals ACAD, carrying a Zacks Rank #2 (Buy). Acadia’s loss per share estimates for 2022 have narrowed from $1.30 to $1.29 in the past 30 days. Earnings of Acadia beat estimates in two of the trailing four quarters, while missing the same on the remaining two occasions. | Some better-ranked stocks in the same sector include Immunocore IMCR, carrying a Zacks Rank #1 (Strong Buy), Acadia Pharmaceuticals ACAD, carrying a Zacks Rank #2 (Buy). Acadia’s loss per share estimates for 2022 have narrowed from $1.30 to $1.29 in the past 30 days. Earnings of Acadia beat estimates in two of the trailing four quarters, while missing the same on the remaining two occasions. | Some better-ranked stocks in the same sector include Immunocore IMCR, carrying a Zacks Rank #1 (Strong Buy), Acadia Pharmaceuticals ACAD, carrying a Zacks Rank #2 (Buy). Acadia’s loss per share estimates for 2022 have narrowed from $1.30 to $1.29 in the past 30 days. Earnings of Acadia beat estimates in two of the trailing four quarters, while missing the same on the remaining two occasions. | Some better-ranked stocks in the same sector include Immunocore IMCR, carrying a Zacks Rank #1 (Strong Buy), Acadia Pharmaceuticals ACAD, carrying a Zacks Rank #2 (Buy). Acadia’s loss per share estimates for 2022 have narrowed from $1.30 to $1.29 in the past 30 days. Earnings of Acadia beat estimates in two of the trailing four quarters, while missing the same on the remaining two occasions. |
35695.0 | 2022-10-12 00:00:00 UTC | Albireo (ALBO) Up on Results From Alagille Syndrome Study | ACAD | https://www.nasdaq.com/articles/albireo-albo-up-on-results-from-alagille-syndrome-study | nan | nan | Albireo Pharma ALBO stock increased 14.41% on Oct 11 after the company announced positive top-line results from a phase III ASSERT study evaluating the safety and efficacy of Bylvay in Alagille syndrome (ALGS) patients from birth to early adulthood.
Shares of Albireo have returned 0.6% in the year-to-date period against the industry’s decline of 27.5%.
Image Source: Zacks Investment Research
The late-stage ASSERT study met its primary and key secondary endpoint.
In the study, Bylvay demonstrated a statistically significant reduction in pruritus from baseline at the sixth month, as measured by the PRUCISION Observer-Reported Outcome scratching score compared with a placebo, which was the study’s primary endpoint.
The study also demonstrated a significant reduction in serum bile acid levels from baseline in the Bylvay, throughout the study, in comparison to the placebo arm.
The study displayed statistically significant improvements in multiple sleep parameters, starting as early as week one to four, which continued through the study period of six months. No severe adverse events were observed, except for a low incidence of drug-related diarrhea.
Alagille syndrome is a rare inherited multi-system disorder characterized by liver damage, affecting young children. Liver damage is caused by the paucity of the bile duct, which prevents the bile flow from the liver to the small intestine. Per the company, the disease affects 25,000 people worldwide, where almost 95% of the affected people suffer from chronic cholestasis and approximately 88% show symptoms of severe intractable pruritus.
Bylvay is a once-daily non-systemic ileal bile acid transport inhibitor (IBATi) and is already approved in the United States and in the European Union for the treatment of pruritus in patients with progressive familial intrahepatic cholestasis (PFIC) above three years of age.
The company intends to submit regulatory filings both in the United States and the European Union immediately.
Bylvay is also being evaluated in another phase III BOLD study to treat biliary atresia, another rare, life-threatening disease affecting children. Albireo continues to enroll patients in the BOLD study and is currently on track to complete the process by the end of 2022. It intends to report top-line data from the BOLD study in 2024.
Albireo Pharma Price
Albireo Pharma price | Albireo Pharma Quote
Zacks Rank and Stocks to Consider
Albireo currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks in the same sector include Acadia Pharmaceuticals ACAD, Aridis Pharmaceuticals ARDS, and Immunocore IMCR, each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Acadia’s loss per share estimates for 2022 have narrowed from $1.30 to $1.29 in the past 30 days. The loss per share for 2023 has narrowed from 67 cents to 60 cents in the same time frame.
Earnings of Acadia beat estimates in two of the trailing four quarters, while missing the same in the remaining two occasions. The average negative earnings surprise for STSA is 6.83%.
Aridis Pharmaceuticals' loss estimates for 2022 have remained steady at 23 cents over the past 30 days. The loss estimates for 2023 also remained steady at 53 cents per share in the same time frame.
ARDS surpassed earnings in three of the trailing four quarters, missing the same in one. The average negative earnings surprise for Aridis is 238.54%.
Immunocore’s loss per share estimates for 2022 widened from $1.34 to $1.46 in the past 30 days. The same for 2023 has narrowed from $1.78 to $1.65 in the same time frame.
Earnings of Immunocore missed estimates in three of the trailing four quarters, while beating the same in the reaming occasion. The average earnings surprise for IMCR is 33.28%.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Albireo Pharma (ALBO): Free Stock Analysis Report
Aridis Pharmaceuticals (ARDS): Free Stock Analysis Report
Immunocore Holdings PLC Sponsored ADR (IMCR): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the same sector include Acadia Pharmaceuticals ACAD, Aridis Pharmaceuticals ARDS, and Immunocore IMCR, each carrying a Zacks Rank #2 (Buy). Acadia’s loss per share estimates for 2022 have narrowed from $1.30 to $1.29 in the past 30 days. Earnings of Acadia beat estimates in two of the trailing four quarters, while missing the same in the remaining two occasions. | Some better-ranked stocks in the same sector include Acadia Pharmaceuticals ACAD, Aridis Pharmaceuticals ARDS, and Immunocore IMCR, each carrying a Zacks Rank #2 (Buy). ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Acadia’s loss per share estimates for 2022 have narrowed from $1.30 to $1.29 in the past 30 days. | Some better-ranked stocks in the same sector include Acadia Pharmaceuticals ACAD, Aridis Pharmaceuticals ARDS, and Immunocore IMCR, each carrying a Zacks Rank #2 (Buy). Acadia’s loss per share estimates for 2022 have narrowed from $1.30 to $1.29 in the past 30 days. Earnings of Acadia beat estimates in two of the trailing four quarters, while missing the same in the remaining two occasions. | Some better-ranked stocks in the same sector include Acadia Pharmaceuticals ACAD, Aridis Pharmaceuticals ARDS, and Immunocore IMCR, each carrying a Zacks Rank #2 (Buy). Acadia’s loss per share estimates for 2022 have narrowed from $1.30 to $1.29 in the past 30 days. Earnings of Acadia beat estimates in two of the trailing four quarters, while missing the same in the remaining two occasions. |
35696.0 | 2022-10-12 00:00:00 UTC | Acadia (ACAD) Thrives on Nuplazid, Overdependence a Concern | ACAD | https://www.nasdaq.com/articles/acadia-acad-thrives-on-nuplazid-overdependence-a-concern | nan | nan | Acadia Pharmaceuticals Inc. ACAD is making good progress with its sole marketed drug, Nuplazid (pimavanserin), which is approved by the FDA for treating hallucinations and delusions associated with Parkinson’s disease psychosis in the United States.
Nuplazid has witnessed a steady uptake so far. In the first six months of 2022, the drug generated sales worth $250 million, reflecting an increase of 12.7% on a year-over-year basis.
Nuplazid’s label expansion studies also look promising. However, ACAD faced a major setback when it received a complete response letter (“CRL”) from the FDA for the resubmitted supplemental new drug application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (“ADP”) in August 2022.
In June 2022, the FDA’s Psychopharmacologic Drugs Advisory Committee voted (nine-three) against the sNDA for pimavanserin for treating hallucinations and delusions associated with ADP.
The FDA first issued a CRL to the Nuplazid sNDA in April 2021.
Shares of Acadia have plunged 32% this year compared with the industry’s decrease of 28.3%.
Image Source: Zacks Investment Research
Meanwhile, in September 2022, the FDA accepted for review Acadia's new drug application (NDA) seeking approval of its pipeline candidate, trofinetide, for the treatment of patients with Rett syndrome, a rare neurological disorder for girls aged between five and 20 years.
With the FDA granting priority review to the NDA, a decision from the regulatory body is expected on Mar 12, 2023.
Upon potential approval, trofinetide can become the second approved drug in Acadia’s portfolio of marketed drugs and lend a significant boost to the company as well as lower its sole dependence on Nuplazid for revenues.
However, competition remains stiff as several other companies, including Axsome Therapeutics AXSM, are also developing treatments to address various CNS disorders.
In August, the FDA approved Axsome’s lead pipeline candidate AXS-05, with the trade name Auvelity, for the treatment of adults with major depressive disorder.
Axsome also has several other CNS product candidates, namely AXS-07, AXS-09, AXS-12 and AXS-14, which are being developed for multiple CNS indications. A prospective approval for any of these candidates is likely to induce competition for Acadia in the days ahead.
Acadia Pharmaceuticals Inc. Price and Consensus
Acadia Pharmaceuticals Inc. price-consensus-chart | Acadia Pharmaceuticals Inc. Quote
Zacks Rank & Other Stocks to Consider
Acadia currently carries a Zacks Rank #2 (Buy). Other stocks worth considering in the biotech sector are ORIC Pharmaceuticals, Inc. ORIC and Atara Biotherapeutics, Inc. ATRA, both carrying the same Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
ORIC Pharmaceuticals’ loss per share estimates narrowed 5.9% for 2022 and 7.3% for 2023 in the past 60 days.
Earnings of ORIC Pharmaceuticals surpassed estimates in three of the trailing four quarters and missed on the other occasion. ORIC delivered an earnings surprise of 8.85%, on average.
Atara Biotherapeutics’ loss per share estimates narrowed 21.3% for 2022 and 8.3% for 2023 in the past 60 days.
Earnings of Atara Biotherapeutics surpassed estimates in three of the trailing four quarters and missed on the other occasion. ATRA delivered an earnings surprise of 4.83%, on average.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Atara Biotherapeutics, Inc. (ATRA): Free Stock Analysis Report
Axsome Therapeutics, Inc. (AXSM): Free Stock Analysis Report
Oric Pharmaceuticals, Inc. (ORIC): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia Pharmaceuticals Inc. ACAD is making good progress with its sole marketed drug, Nuplazid (pimavanserin), which is approved by the FDA for treating hallucinations and delusions associated with Parkinson’s disease psychosis in the United States. However, ACAD faced a major setback when it received a complete response letter (“CRL”) from the FDA for the resubmitted supplemental new drug application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (“ADP”) in August 2022. Image Source: Zacks Investment Research Meanwhile, in September 2022, the FDA accepted for review Acadia's new drug application (NDA) seeking approval of its pipeline candidate, trofinetide, for the treatment of patients with Rett syndrome, a rare neurological disorder for girls aged between five and 20 years. | Acadia Pharmaceuticals Inc. Price and Consensus Acadia Pharmaceuticals Inc. price-consensus-chart | Acadia Pharmaceuticals Inc. Quote Zacks Rank & Other Stocks to Consider Acadia currently carries a Zacks Rank #2 (Buy). ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Acadia Pharmaceuticals Inc. ACAD is making good progress with its sole marketed drug, Nuplazid (pimavanserin), which is approved by the FDA for treating hallucinations and delusions associated with Parkinson’s disease psychosis in the United States. | Acadia Pharmaceuticals Inc. ACAD is making good progress with its sole marketed drug, Nuplazid (pimavanserin), which is approved by the FDA for treating hallucinations and delusions associated with Parkinson’s disease psychosis in the United States. Image Source: Zacks Investment Research Meanwhile, in September 2022, the FDA accepted for review Acadia's new drug application (NDA) seeking approval of its pipeline candidate, trofinetide, for the treatment of patients with Rett syndrome, a rare neurological disorder for girls aged between five and 20 years. Acadia Pharmaceuticals Inc. Price and Consensus Acadia Pharmaceuticals Inc. price-consensus-chart | Acadia Pharmaceuticals Inc. Quote Zacks Rank & Other Stocks to Consider Acadia currently carries a Zacks Rank #2 (Buy). | Image Source: Zacks Investment Research Meanwhile, in September 2022, the FDA accepted for review Acadia's new drug application (NDA) seeking approval of its pipeline candidate, trofinetide, for the treatment of patients with Rett syndrome, a rare neurological disorder for girls aged between five and 20 years. Acadia Pharmaceuticals Inc. ACAD is making good progress with its sole marketed drug, Nuplazid (pimavanserin), which is approved by the FDA for treating hallucinations and delusions associated with Parkinson’s disease psychosis in the United States. However, ACAD faced a major setback when it received a complete response letter (“CRL”) from the FDA for the resubmitted supplemental new drug application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (“ADP”) in August 2022. |
35697.0 | 2022-10-11 00:00:00 UTC | scPharmaceuticals (SCPH) Plunges Despite Furoscix's FDA Approval | ACAD | https://www.nasdaq.com/articles/scpharmaceuticals-scph-plunges-despite-furoscixs-fda-approval | nan | nan | scPharmaceuticals SCPH recently announced that the FDA approved its proprietary formulation of furosemide in 80 mg dosage delivered via an on-body infusor, marketed under the trade name Furoscix (furosemide injection) for treating congestion due to fluid overload in adults with New York Heart Association (NYHA) Class II and Class III heart failure.
This was scPharmaceuticals’ third attempt to secure FDA approval for Furoscix. The company had previously received a complete response letter (CRL) from the FDA twice, first in June 2018 and then in December 2020.
Post the approval, Furoscix becomes the first and only FDA-approved subcutaneous loop diuretic that delivers IV equivalent diuresis at home.
The company is working toward optimizing the commercialization of Furoscix to make the therapy available to patients in the first quarter of 2023 and meet the global demand in the addressable market.
However, Furoscix has not been approved for use in emergencies or patients with acute pulmonary edema.
In spite of a regulatory win, scPharmaceuticals shares dropped 19.28% on Oct 10. Shares of scPharmaceuticals have declined 19.9% in the year-to-date period compared with the industry’s fall of 28.5%.
Image Source: Zacks Investment Research
Along with the FDA approval, scPharmaceuticals also announced that it has agreed to receive financing of $100 million from Oaktree Capital Management, L.P. The company intends to use the funding to execute the launch of Furoscix and repay its debt under its existing loan and security agreement.
Pursuant to the agreement, to be signed mid-October, Oaktree will pay scPharmaceuticals $50 million instantly, while the remaining $50 million will be paid in two tranches of $25 million, upon achievement of specified commercial milestones.
Though it seems like a great deal at a glance, the loan terms say otherwise. The debt is expected to carry an interest rate equal to the three-month secured overnight financing rate (SOFR) plus 8.75%, with the interest rate capped at 11.75% per annum. If a $100 million net sale of Furoscix is achieved in the trailing 12-month period, the interest rate will be lowered to 8.25%.
Even with the interest capping, a rate of 11.75% might push the company towards a massive debt load. As of June 30, 2022, scPharmaceuticals had cash, cash equivalents, restricted cash and investments of $56 million.
This might be yet another reason for the downfall of SCPH’s stock price on Monday.
scPharmaceuticals, Inc. Price
scPharmaceuticals, Inc. price | scPharmaceuticals, Inc. Quote
Zacks Rank and Stocks to Consider
scPharmaceuticals currently holds a Zacks Rank #4 (Sell).
Some better-ranked stocks in the same sector include Acadia Pharmaceuticals ACAD, Aridis Pharmaceuticals ARDS, and Immunocore IMCR, each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Acadia’s loss per share estimates for 2022 have narrowed from $1.30 to $1.29 in the past 30 days. The loss per share for 2023 has narrowed from 67 cents to 60 cents in the same time frame.
Earnings of Acadia beat estimates in two of the trailing four quarters, while missing the same in the remaining two occasions. The average negative earnings surprise for STSA is 6.83%.
Aridis Pharmaceuticals' loss estimates for 2022 have remained steady at 23 cents over the past 30 days. The loss estimates for 2023 also remained steady at 53 cents per share in the same time frame.
ARDS surpassed earnings in three of the trailing four quarters, missing the same in one. The average negative earnings surprise for Aridis is 238.54%.
Immunocore’s loss per share estimates for 2022 widened from $1.34 to $1.46 in the past 30 days. The same for 2023 has narrowed from $1.78 to $1.65 in the same time frame.
Earnings of Immunocore missed estimates in three of the trailing four quarters, while beating the same in the reaming occasion. The average earnings surprise for IMCR is 33.28%.
Free Report Reveals How You Could Profit from the Growing Electric Vehicle Industry
Globally, electric car sales continue their remarkable growth even after breaking records in 2021. High gas prices have fueled his demand, but so has evolving EV comfort, features and technology. So, the fervor for EVs will be around long after gas prices normalize. Not only are manufacturers seeing record-high profits, but producers of EV-related technology are raking in the dough as well. Do you know how to cash in? If not, we have the perfect report for you – and it’s FREE! Today, don't miss your chance to download Zacks' top 5 stocks for the electric vehicle revolution at no cost and with no obligation.
>>Send me my free report on the top 5 EV stocks
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
scPharmaceuticals, Inc. (SCPH): Free Stock Analysis Report
Aridis Pharmaceuticals (ARDS): Free Stock Analysis Report
Immunocore Holdings PLC Sponsored ADR (IMCR): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the same sector include Acadia Pharmaceuticals ACAD, Aridis Pharmaceuticals ARDS, and Immunocore IMCR, each carrying a Zacks Rank #2 (Buy). Acadia’s loss per share estimates for 2022 have narrowed from $1.30 to $1.29 in the past 30 days. Earnings of Acadia beat estimates in two of the trailing four quarters, while missing the same in the remaining two occasions. | Some better-ranked stocks in the same sector include Acadia Pharmaceuticals ACAD, Aridis Pharmaceuticals ARDS, and Immunocore IMCR, each carrying a Zacks Rank #2 (Buy). ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Acadia’s loss per share estimates for 2022 have narrowed from $1.30 to $1.29 in the past 30 days. | Some better-ranked stocks in the same sector include Acadia Pharmaceuticals ACAD, Aridis Pharmaceuticals ARDS, and Immunocore IMCR, each carrying a Zacks Rank #2 (Buy). Acadia’s loss per share estimates for 2022 have narrowed from $1.30 to $1.29 in the past 30 days. Earnings of Acadia beat estimates in two of the trailing four quarters, while missing the same in the remaining two occasions. | Some better-ranked stocks in the same sector include Acadia Pharmaceuticals ACAD, Aridis Pharmaceuticals ARDS, and Immunocore IMCR, each carrying a Zacks Rank #2 (Buy). Acadia’s loss per share estimates for 2022 have narrowed from $1.30 to $1.29 in the past 30 days. Earnings of Acadia beat estimates in two of the trailing four quarters, while missing the same in the remaining two occasions. |
35698.0 | 2022-10-11 00:00:00 UTC | Iovance (IOVA) Doses First Patient in TIL Cancer Therapy Study | ACAD | https://www.nasdaq.com/articles/iovance-iova-doses-first-patient-in-til-cancer-therapy-study | nan | nan | Iovance Biotherapeutics IOVA recently announced that the first patient had been dosed in phase I/II IOV-GM1-201 study, evaluating the company’s genetically modified, tumor-infiltrating lymphocyte (TIL) therapy, IOV-4001 in patients with previously-treated metastatic non-small cell lung cancer (NSCLC) or advanced melanoma.
The first patient in the study has also completed the safety observation period.
IOV-4001 leverages the gene-editing TALEN technology licensed by Iovance from Cellectis CLLS to inactivate the gene coding for PD-1 protein, an important barrier that prevents T-cells from attacking cancer.
Iovance entered a research collaboration and exclusive worldwide licensing agreement with Cellectis in January 2020, allowing the former to use the latter’s Talen technology to develop TIL products to create potent cancer therapies.
In March, the FDA allowed an investigational new drug application (“IND”) to proceed with the clinical study of IOV-4001 for treating NSCLC and stage III or IV metastatic melanoma,
Post the IND approval, Iovance initiated the IOV-GM1-201 study in the first quarter of 2022 and recently dosed the first patient.
In cohort 1 of the study, Iovance intends to enroll patients with advanced melanoma who have progressed following anti-PD-1/PD-L1 blocking antibody therapy and patients with BRAF mutations after BRAF/MEK inhibitor therapy.
While in the second cohort of the study, the company will enroll patients with NSCLC who have received not more than three prior lines of therapy, with or without oncogene-driven mutations.
Presently, the company is actively enrolling adult patients in both cohorts of the study.
Shares of Iovance have declined 54.7% in the year-to-date period, compared to the industry’s fall of 27%.
Image Source: Zacks Investment Research
Without any marketed products in its portfolio, Iovance is highly dependent on its pipeline candidates’ successful development and potential commercialization. All of Iovance’s pipeline candidates target oncology indications, which have tremendous potential.
The lead candidate in Iovance’s pipeline is lifileucel, which is being developed as a monotherapy for treating metastatic melanoma and metastatic cervical cancer in two mid-stage studies. The company started a rolling submission of the biologics license application (BLA), seeking approval for lifileucel in August 2022 for melanoma. The company is also developing combination therapies of lifileucel for other oncology indications.
Iovance Biotherapeutics, Inc. Price
Iovance Biotherapeutics, Inc. price | Iovance Biotherapeutics, Inc. Quote
Zacks Rank and Stocks to Consider
Iovance currently holds a Zacks Rank #4 (Sell).
Some better-ranked stocks in the same sector include Acadia Pharmaceuticals ACAD and Aridis Pharmaceuticals ARDS, each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Acadia’s loss per share estimates for 2022 have narrowed from $1.30 to $1.29 in the past 30 days. The loss per share for 2023 has narrowed from 67 cents to 60 cents in the same time frame.
Earnings of Acadia beat estimates in two of the trailing four quarters while missing the same in the remaining two occasions. The average negative earnings surprise for STSA is 6.83%.
Aridis Pharmaceuticals' loss estimates for 2022 have remained steady at 23 cents over the past 30 days. The loss estimates for 2023 also remained steady at 53 cents per share in the same time frame.
ARDS surpassed earnings in three of the trailing four quarters, missing the same in one. The average negative earnings surprise for Aridis is 238.54%.
Free Report Reveals How You Could Profit from the Growing Electric Vehicle Industry
Globally, electric car sales continue their remarkable growth even after breaking records in 2021. High gas prices have fueled his demand, but so has evolving EV comfort, features and technology. So, the fervor for EVs will be around long after gas prices normalize. Not only are manufacturers seeing record-high profits, but producers of EV-related technology are raking in the dough as well. Do you know how to cash in? If not, we have the perfect report for you – and it’s FREE! Today, don't miss your chance to download Zacks' top 5 stocks for the electric vehicle revolution at no cost and with no obligation.
>>Send me my free report on the top 5 EV stocks
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Cellectis S.A. (CLLS): Free Stock Analysis Report
Iovance Biotherapeutics, Inc. (IOVA): Free Stock Analysis Report
Aridis Pharmaceuticals (ARDS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the same sector include Acadia Pharmaceuticals ACAD and Aridis Pharmaceuticals ARDS, each carrying a Zacks Rank #2 (Buy). Acadia’s loss per share estimates for 2022 have narrowed from $1.30 to $1.29 in the past 30 days. Earnings of Acadia beat estimates in two of the trailing four quarters while missing the same in the remaining two occasions. | ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Some better-ranked stocks in the same sector include Acadia Pharmaceuticals ACAD and Aridis Pharmaceuticals ARDS, each carrying a Zacks Rank #2 (Buy). Acadia’s loss per share estimates for 2022 have narrowed from $1.30 to $1.29 in the past 30 days. | Some better-ranked stocks in the same sector include Acadia Pharmaceuticals ACAD and Aridis Pharmaceuticals ARDS, each carrying a Zacks Rank #2 (Buy). Acadia’s loss per share estimates for 2022 have narrowed from $1.30 to $1.29 in the past 30 days. Earnings of Acadia beat estimates in two of the trailing four quarters while missing the same in the remaining two occasions. | Some better-ranked stocks in the same sector include Acadia Pharmaceuticals ACAD and Aridis Pharmaceuticals ARDS, each carrying a Zacks Rank #2 (Buy). Acadia’s loss per share estimates for 2022 have narrowed from $1.30 to $1.29 in the past 30 days. Earnings of Acadia beat estimates in two of the trailing four quarters while missing the same in the remaining two occasions. |
35699.0 | 2022-10-06 00:00:00 UTC | Acadia (ACAD) Rises More Than 14% in 3 Months: Here's Why | ACAD | https://www.nasdaq.com/articles/acadia-acad-rises-more-than-14-in-3-months%3A-heres-why | nan | nan | Shares of Acadia Pharmaceuticals Inc. ACAD have risen 14.9% in the past three months against the industry’s decrease of 8.4%.
Last month, the FDA accepted for review Acadia's new drug application (“NDA”) seeking approval of its pipeline candidate, trofinetide, for the treatment of patients with Rett syndrome.
With the FDA granting priority review to the NDA, a decision from the regulatory body is expected on Mar 12, 2023.
This might be a reason for ACAD’s shares to have witnessed an upside during this time frame.
ACAD submitted the NDA for trofinetide to treat Rett Syndrome in July 2022. Rett syndrome is a rare neurological disorder for girls aged between five and 20 years.
Image Source: Zacks Investment Research
Currently, Acadia’s top line solely comprises sales of its only marketed drug, Nuplazid (pimavanserin), in the United States. The drug is approved for treating hallucinations and delusions associated with Parkinson’s disease psychosis.
In August 2022, Acadia received a complete response letter (“CRL”) from the FDA for its resubmitted supplemental new drug application (“sNDA”) for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP).
The latest CRL was expected, as in June 2022, the FDA’s Psychopharmacologic Drugs Advisory Committee voted (nine-three) against the sNDA for pimavanserin for treating hallucinations and delusions associated with ADP.
Earlier, the FDA had asked the committee for advice and recommendations regarding the evidence that pimavanserin is effective for the given indication.
We remind investors that the FDA issued a CRL to the Nuplazid sNDA in April 2021.
Upon potential approval, trofinetide can become the second approved drug in Acadia’s portfolio of marketed drugs and lend a significant boost to the company as well as lower its sole dependence on Nuplazid for revenues.
However, competition remains stiff as several other companies, including Axsome Therapeutics AXSM, are also developing treatments to address various CNS disorders.
In August, the FDA approved Axsome’s lead pipeline candidate AXS-05, with the trade name Auvelity, for the treatment of adults with major depressive disorder.
Axsome also has several other CNS product candidates, namely, AXS-07, AXS-09, AXS-12 and AXS-14, which are being developed for multiple CNS indications. A prospective approval for any of these candidates will induce competition for Acadia and its products.
Acadia Pharmaceuticals Inc. Price
Acadia Pharmaceuticals Inc. price | Acadia Pharmaceuticals Inc. Quote
Zacks Rank & Stocks to Consider
Acadia currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector are Atara Biotherapeutics, Inc. ATRA and ORIC Pharmaceuticals, Inc. ORIC, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Estimates for Atara Biotherapeutics’ loss per share have narrowed 43.2% for 2022 and 21.3% for 2023 in the past 60 days.
Earnings of Atara Biotherapeutics surpassed estimates in three of the trailing four quarters and missed on the other occasion. ATRA delivered an earnings surprise of 4.83%, on average.
Estimates for ORIC Pharmaceuticals’ loss per share have narrowed 8.6% for 2022 and 22% for 2023 in the past 60 days.
Earnings of ORIC Pharmaceuticals surpassed estimates in three of the trailing four quarters and missed on the remaining occasion. ORIC delivered an earnings surprise of 8.85%, on average.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Atara Biotherapeutics, Inc. (ATRA): Free Stock Analysis Report
Axsome Therapeutics, Inc. (AXSM): Free Stock Analysis Report
Oric Pharmaceuticals, Inc. (ORIC): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Image Source: Zacks Investment Research Currently, Acadia’s top line solely comprises sales of its only marketed drug, Nuplazid (pimavanserin), in the United States. In August 2022, Acadia received a complete response letter (“CRL”) from the FDA for its resubmitted supplemental new drug application (“sNDA”) for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). Shares of Acadia Pharmaceuticals Inc. ACAD have risen 14.9% in the past three months against the industry’s decrease of 8.4%. | Last month, the FDA accepted for review Acadia's new drug application (“NDA”) seeking approval of its pipeline candidate, trofinetide, for the treatment of patients with Rett syndrome. Acadia Pharmaceuticals Inc. Price Acadia Pharmaceuticals Inc. price | Acadia Pharmaceuticals Inc. Quote Zacks Rank & Stocks to Consider Acadia currently carries a Zacks Rank #3 (Hold). Shares of Acadia Pharmaceuticals Inc. ACAD have risen 14.9% in the past three months against the industry’s decrease of 8.4%. | Last month, the FDA accepted for review Acadia's new drug application (“NDA”) seeking approval of its pipeline candidate, trofinetide, for the treatment of patients with Rett syndrome. Acadia Pharmaceuticals Inc. Price Acadia Pharmaceuticals Inc. price | Acadia Pharmaceuticals Inc. Quote Zacks Rank & Stocks to Consider Acadia currently carries a Zacks Rank #3 (Hold). Shares of Acadia Pharmaceuticals Inc. ACAD have risen 14.9% in the past three months against the industry’s decrease of 8.4%. | Last month, the FDA accepted for review Acadia's new drug application (“NDA”) seeking approval of its pipeline candidate, trofinetide, for the treatment of patients with Rett syndrome. Shares of Acadia Pharmaceuticals Inc. ACAD have risen 14.9% in the past three months against the industry’s decrease of 8.4%. This might be a reason for ACAD’s shares to have witnessed an upside during this time frame. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.